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ABSTRACT 
Uncoupling protein 1 (UCP1) is essential for non-shivering thermogenesis in brown 
adipose tissue (BAT) by dissipating proton-motive force to stimulate maximum 
mitochondrial respiration. cAMP-dependent protein kinase induction of UCP1, as well 
as the PPAR cŽĂĐƚŝǀĂƚŽƌ ?ɲ ?W'1ɲ), is a typical characteristic in BAT but not in white 
adipose tissue (WAT). Previous work demonstrated that the overexpression of 
d ?ŶŚĂŶĐĞƌŝŶĚŝŶŐWƌŽƚĞŝŶɴ  ? ?Wɴ )could rescue the cAMP-ŝŶĚƵĐĞĚW' ?ɲ
and UCP1 expression in white preadipocytes 3T3-L1 cell line, indicating a key 
ƌĞŐƵůĂƚŽƌǇƌŽůĞŽĨ ?WɴŝŶďƌŽǁŶĂĚŝƉŽŐĞŶĞƐŝƐ ?dŚĞŽǀĞƌĂůůĂŝŵŽĨƚŚŝƐƐƚƵĚǇǁĂƐƚŽ
ĞǆĂŵŝŶĞƚŚĞƌŽůĞŽĨ ?WɴŽǀĞƌĞǆƉƌĞƐƐŝŽŶŝŶƌĞŐƵůĂƚŝŶŐƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨhW ?ŝŶ
3T3-L1 white preadipocytes to transform them to a more brown-like cell phenotype.  
 
Tetracycline inducible (Tet on) lentiviral, adipose-specific expression vectors for 
ŽǀĞƌĞǆƉƌĞƐƐŝŶŐ  ?Wɴ  ?Žƌ ƚŚĞ ĐŽŶƚƌŽů >ƵĐŝĨĞƌĂƐĞ-GFP) gene were constructed with 
the pLenti6 lentiviral vector backbone with TRE tight and rtTA advance regulatory 
elements. In the absence of doxycycline there was low basal expression from the 
vectors and a dose-dependent, doxycycline-induced transient, adipose-specific 
overexpression was observed in 3T3-L1 preadipocytes. Transduction of the pLenti6 
positive control luciferase-Z&W ǀĞĐƚŽƌ ǁĂƐ ƐƵĐĐĞƐƐĨƵůůǇ ĂĐŚŝĞǀĞĚ ďƵƚ ƚŚĞ  ?Wɴ Žƌ
LucGFP vectors constructed failed to produce highly infectious lentiviral particles, 
possibly due to the large size of insert which challenged the limit of the pLenti6 vector 
backbone. Therefore a stable inducible, adipose-specific, 3T3-L1 line overexpressing 
 ?WɴǁĂƐŶŽƚĂĐŚŝĞǀĞĚ ?
 
dƌĂŶƐŝĞŶƚ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?Wɴ ĂŶĚ WZD ? ? ƐŝŐŶŝĨŝĐĂŶƚůǇ ŝŶĐƌĞĂƐĞĚ ƚŚĞ
transcriptional activity of UCP1 promoter in the presence of forskolin in 3T3-L1 cells 
ǁŝƚŚŽƵƚƐƚŝŵƵůĂƚŝŶŐW' ?ɲƉƌŽŵŽƚĞƌĂĐƚŝǀŝƚǇ ?ŝŵƉůǇŝŶŐĂW' ?ɲ-independent manner 
of activating UCP1 transcription in 3T3-> ?Ɛ ?  ?Wɴ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ĂůŽŶĞ ĂĐƚŝǀĂƚĞĚ
ƚŚĞW' ?ɲƉƌŽŵŽƚĞƌ ŝŶ,/-1B and Cos7 cells but not in 3T3-L1 cells, indicating the 
lack of some activators in 3T3-L1 or a potential 3T3-L1 specific repressive mechanism. 
Co-ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?Wɴ ĂŶĚ WWZɶ ŝŶ  ?d ?-> ? ŵĂƌŬĞĚůǇ ƐƚŝŵƵůĂƚĞĚ ƚŚĞ W' ?ɲ
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promoter in response to rosiglitazone and increased the UCP1 promoter activity in 
ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ƌŽƐŝŐůŝƚĂǌŽŶĞ ĂŶĚ ĨŽƌƐŬŽůŝŶ ? dŚŝƐ ƌĞƐƵůƚ ƐƵŐŐĞƐƚƐ ƚŚĂƚ WWZɶ ĐŽƵůĚ
make up for the lack of activator or release the 3T3-L1 repressive mechanism and 
ŵĞĚŝĂƚĞĚ Ă W' ?ɲ-dependent manner of activating UCP1 together with  ?Wɴ ŝŶ
3T3-L1 cells. Further studies demonstrated that both CRE and PPRE elements were 
ŝŶĚŝƐƉĞŶƐŝďůĞŝŶƚŚŝƐW' ?ɲ-dependent pathway of activating UCP1 promoter in 3T3-
> ? ĐĞůůƐ ? dŚĞ ƌĞƐƵůƚƐ ƐƵŐŐĞƐƚ ƚŚĂƚ  ?Wɴ ĂŶĚ WWZɶ ĐŽŽƉĞƌĂƚĞ ƚŽ ŝŶĚƵĐĞ hW ?
expression in 3T3-> ?ĐĞůůƐƐƚŝŵƵůĂƚĞĚďǇWWZɶĂŐŽŶŝƐƚĂŶĚĐDW ?
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1 LITERATURE REVIEW 
1.1 INTRODUCTION 
Obesity is an increasingly prevalent problem nowadays. According to the statistical 
data from World Health Organization (WHO), in 2008, more than one in ten of the 
world adult population was obese and in 2010 around 43 million children under five 
were overweight. Once considered a high-income country problem, obesity now has 
been on the rise in low- and middle-income countries, especially in urban settings 
(Flegal et al., 2005).  In addition, obesity is an important risk factor in the 
development of metabolic syndromes such as hypertension, dyslipidaemia, 
cardiovascular diseases and type II diabetes. 44% of the diabetes burden, 23% of the 
ischaemic heart disease burden and between 7% and 41% of certain cancer burdens 
are contributed to overweight and obesity (Bray, 2004). Obesity is caused by 
imbalanced energy intake and expenditure, which leads to the accumulation of 
energy in adipose tissue. The strategies to prevent and treat obesity to date have had 
limited success although advances in understanding the control of food intake, 
energy expenditure and the metabolic regulation processes, have been made. 
 
Energy is expended by obligatory and facultative thermogenesis. Obligatory 
thermogenesis is a necessary accompaniment of all metabolic processes involved in 
maintenance of the body in the living state, and occurs in all organs. It includes 
energy expenditure involved in ingesting, digesting, and processing food (thermic 
effect of food). At certain stages extra energy expenditure for growth, pregnancy, or 
lactation would also be obligatory. Facultative thermogenesis is superimposed on 
obligatory thermogenesis and can be rapidly switched on, or suppressed by the 
nervous system. It functions in two different manners, shivering thermogenesis which 
depends on the movement of muscle and non-shivering thermogenesis which occurs 
in brown adipose tissue (Himms-Hagen, 1989). Non-shivering thermogenic capacity 
can be induced either by cold exposure or high-fat diet (diet-induced thermogenesis, 
DIT) (Rothwell and Stock, 1979; Sellers et al., 1954), and is due to brown adipose 
tissue activity (Cannon and Nedergaard, 2011).  
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 As one of the two types of adipose tissues in mammals, brown adipose tissue 
functions to oxidise carbohydrate and fat fuels for producing heat, while its 
counterpart, white adipose tissue (WAT) acts to store energy in the form of 
triglycerides (Farmer, 2008). The most significant characteristic of BAT at gene 
expression level is the unique expression of uncoupling protein 1 (UCP1), a critical 
gene in the non-shivering adaptive thermogenic function of BAT (Enerback S et al., 
1997; Foster DO, 1978). Small mammals like rodents and human infants have large 
depots of BAT as to keep warm temperature (Cannon and Nedergaard, 2004), but in 
adult humans, the appearance of functional BAT was not confirmed until recently 
Yeung and colleagues identified the existence and importance of active BAT in adult 
humans using 
18
F-fluorodeoxyglucose (
18
F-FDG) positron emission tomographic and 
computed tomographic (PET WCT) scans (Nedergaard et al., 2007; Yeung et al., 2003). 
Later on, it was found that the amount of BAT is inversely correlated with body-mass 
index (BMI) (Cypess et al., 2009), indicating a potential role of BAT in counteracting 
with obesity and related diseases ?ƵĞƚŽŝƚƐĨƵŶĐƚŝŽŶŽĨ “ďƵƌŶŝŶŐ ?ĨĂƚ ?ďƌŽǁŶĂĚŝƉŽƐĞ
tissue has been recognised for its potential and demonstrated anti-obesity properties. 
In fact, a large number of genetic studies in mice have shown that experimentally-
induced increases in the amount and/or function of brown adipose tissue favour lean 
phenotypes, less weight gain, higher insulin sensitivity, lower levels of circulating free 
fatty acids and lower insulin resistance (Kopecky et al., 1995; Kopecky et al., 1996; 
Miner et al., 2001; Tsukiyama-Kohara et al., 2001; Xue et al., 2007).  
 
Several nuclear factors have been associated with the formation of brown adipocytes 
(Gesta et al., 2007). Apart from the master regulator for adipogenesis, the 
transcriptional factor peroxisome proliferator-ĂĐƚŝǀĂƚĞĚƌĞĐĞƉƚŽƌɶ ?WWZɶ )(Tontonoz 
et al., 1994c), the nuclear receptor coactivator WWZɶ ĐŽĂĐƚŝǀĂƚŽƌ- ?ɲ  ?W' ?ɲ ) ǁĂƐ
discovered as a cold-inducible regulator of UCP1 expression, capable of inducing 
UCP1 expression in fibroblasts (Puigserver et al., 1998). More recently an additional 
WWZɶ ďŝŶĚŝŶŐ ŶƵĐůĞĂƌ ĨĂĐƚŽƌ ? WZ ?-BF-1-RIZ1 Homologous Domain Containing 
Protein 16 (PRDM16), has been proposed to be the principal regulator of brown 
adipocyte differentiation (Kajimura et al., 2008). PRDM16 switches on the brown 
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adipogenic programme by forming a complex with the transcriptional factor, CCAAT 
ŶŚĂŶĐĞƌŝŶĚŝŶŐWƌŽƚĞŝŶɴ  ? ?Wɴ )(Kajimura et al., 2009). It had been previously 
ĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚ ?WɴĐŽƵůĚƌĞƉƌŽŐƌĂŵŵĞ ǁŚŝƚĞĂĚŝƉŽƐĞƚŝƐƐƵĞ ŝŶƚŽĂ  “ďƌŽǁŶ ?
lineĂŐĞ ďǇ ƌĞƐĐƵŝŶŐ ƚŚĞ ĐDW ŝŶĚƵĐŝďůĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ hW ? ĂŶĚ W' ?ɲ ŝŶ ǁŚŝƚĞ
adipocytes (Karamanlidis et al., 2007), C/Wɴ ŝƐ obviously another critical regulator 
in brown adipogenesis and hence a good target to investigate the white-brown 
transdifferentiation. Despite the importance of this gene, few studies to date have 
ĞǆĂŵŝŶĞĚ ƚŚĞ ƌĞŐƵůĂƚŝŶŐ ŵĞĐŚĂŶŝƐŵƐ ŽĨ  ?Wɴ ŽŶ hW ? ĂŶĚ W' ?ɲ ƚƌĂŶƐĐƌŝƉƚŝŽŶ
throughout the whole process of brown adipogenesis.  
Therefore, this review will critically outline the literature on the control of adipocyte 
differentiation with emphasis on the molecular mechanisms regulating brown 
adipogenesis. The aim of the review is to bring together known regulators of brown 
adipocyte development to construct a model of interacting networks, especially those 
ŝŶǀŽůǀŝŶŐ  ?Wɴ ?  ƐĞƌŝĞƐ ŽĨ ƐƚƵĚies will also be reviewed to provide an 
understanding of methods generating stable gene overexpression in mammalian cells 
and animals, which are required in investigating gene functions in adipocyte 
differentiation process.  
1.2 ADIPOSE TISSUE 
Humans, like most of the other mammals, contain essentially two types of adipose 
tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). Adipose tissue is 
composed of adipocytes, stromo-vascular cells, immune cells, nerve tissue and a 
connective tissue matrix that all together function as an integrated unit (Kershaw and 
Flier, 2004). White adipose tissue is dispersed throughout the body with major intra-
abdorminal depots around the omentum, intestine and perirenal areas, as well as 
subcutaneous depots (Gesta et al., 2007). Lipolysis in WAT releases free fatty acids 
(FFAs) into the circulation to provide energy for the other tissues such as liver, heart 
and muscle (Coppack et al., 1994). Once mainly considered as the tissue involved in 
insulation in a cold environment and the store for excess energy, white adipose tissue 
has now been  acknowledged as an important organ for metabolism as it responds to 
signals from central nervous system (CNS) and expresses and secretes different kinds 
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of adipokines, which have the potential to influence various functions including food 
intake, metabolism and cardio-metabolic function (Trayhurn and Wood, 2005). The 
potential role of brown adipose tissue in promoting energy expenditure to prevent 
and treat obesity has resulted in this becoming a hot topic in adipose tissue research 
area in recent years. Brown adipose tissue, unlike WAT, is responsive for producing 
heat, hence a mammalian adaptation that is most obvious in rodents and human 
infants (Cannon and Nedergaard, 2004), since smaller animals have larger area to 
volume ratio so have higher risk of hypothermia. Adapted to its function, brown 
adipose tissue has a very unique cellular and molecular composition.   Sharing basic 
common characteristics of adipose tissue, WAT and BAT once were considered 
originating from a common early precursor (adipoblast), which derives from 
mesenchymal stem cells (MSCs) and in turn develops into white and brown 
preadipocytes (Gesta et al., 2007). However, the different evolutionary and 
developmental features of WAT and BAT suggest that they are quite distinct tissues 
with separate origins (Farmer, 2008; Gesta et al., 2007). With the discovery that 
PRDM16- ?Wɴ ĐŽŵƉůĞǆ ĐĂŶ ŝŶŝƚŝĂƚĞ Ă ďƌŽǁŶ ĂĚŝƉŽŐĞŶŝĐ ƉƌŽŐƌĂŵŵĞ ĨƌŽŵ
myoblasts (Kajimura et al., 2009), more and more researchers are realizing that the 
relation between muscle and brown fat is even closer than that between WAT and 
BAT. The below part of the review  will summarize the basic characteristics of WAT 
and BAT in morphology, location, function and formation and will also collect some 
evidence about the origin controversies of white and brown adipose tissue. 
1.2.1 Anatomy of WAT and BAT 
WAT and BAT both contain white and brown adipocytes, respectively. These two 
types of adipocytes have distinct anatomy: white adipocytes are unilocular where the 
lipids are organised in a single lipid droplet for storage (Figure 1.1 A), while brown 
adipocytes are multilocular where lipids accumulate in many small lipid droplets 
(Figure 1.1 B). Brown adipocytes have numerous large mitochondria containing the 
uniquely expressed protein UCP1 (Figure 1.1 C and D) responsible for uncoupling of 
the oxidative phosphorylation to produce heat in these cells (Cinti, 2006). In white 
adipocytes, mitochondria are in limited number and poorly developed and most of 
the cytoplasm is compressed by the big lipid droplet to a thin rim containing a nucleus 
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and the organelles (Figure 1A)(Cinti, 2005). Apart from adipocytes, WAT and BAT are 
richly supplied with parenchymal nerve fibres and blood vessels but the density is 
considerably higher in BAT, giving it the characteristic brown colour (Cinti, 2001, 
2006).  
 
 
 
 
Figure 1.1 Anatomy of white adipocytes and brown adipocytes. 
(A) Light microscopy of haematoxylin-eosin stained human human white 
adipocytes. Objective magnification 20× (Cinti, 2005). (B) Transmission electron 
microscopy of a neonatal rat filled with numerous small lipid droplets and typical 
mitochondria packed with cristae. Go, Golgi apparatus; CAP: capillary. 
Magnification=8700. (C) High magnification of a typical brown adipocyte 
mitochondrion. L, lipid droplet; SER, smooth endoplasmic reticulum. 
Magnification= 80000 (Cinti, 2001). (D) Scanning electron microscopy of brown 
adipocyte mitochondria. Scale bar: 333 nm (Cinti, 2005).  
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Adipose tissue consists of several depots in mammals (Figure 1.2). White adipose 
tissue has a prevalent distribution with major intra-abdominal depots around 
omentum, intestines and perirenal areas, as well as in subcutaneous depots in the 
buttocks, thighs and abdomen (Cinti, 2001; Gesta et al., 2007). WAT can also be found 
in the retro- orbital space, on the face and extremities and within the bone morrow 
(Gesta et al., 2007). In contrast, brown adipose tissue is not dispersed so widely. In 
rodents, BAT is most abundant in the neonatal period and is most concentrated in the 
interscapular region, and it also can be found in WAT depot, particularly after cold 
exposure (Figure 1.3). In humans, BAT is found in axillary, cervical, perirenal and 
periadrenal regions of foetuses and newborns (Cannon and Nedergaard, 2004) but 
decreases rapidly after birth and has been traditionally considered not significant in 
adults, except in patients with pheochromocytoma, where adrenergic activity is 
extremely high (English et al., 1973), or in outdoor workers subject to prolonged cold 
exposure (Huttunen et al., 1981). However, the recent morphological and scanning 
studies using [
18
F]-2-fluoro-D-2-deoxy-D-glucose (FDG) positron emission tomography 
(PET) can successfully detect metabolically active brown fat in the cervical, 
supraclavicular, axillary and paravertibral regions in normal individuals (Nedergaard 
et al., 2007).  
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Figure 1.2 Distribution of white and brown adipose tissue in mouse and human.  
(A) The adipose organ of an adult Sv129 mouse maintained at 29°C for 10 days. 
The organ has been dissected with the aid of a surgical microscope and each 
depot has been placed on the mouse profile mimicking its anatomical position. 
The organ is made up of two subcutaneous and several visceral depots. The most 
representative visceral depots are shown. Kidneys and testes were dissected 
together with the depots. Names of single depot: A) deep cervical; B) anterior 
subcutaneous (interscapular, subsapular, axillo-toracic, superficial cervical); C) 
visceral mediastinic; D) visceral mesenteric; E) visceral retroperitoneal; F) visceral 
perirenal, periovaric, parametrial and perivescical; G) posterior subcutaneous 
(dorso-lumbar, inguinal and gluteal). White areas made up of white adipose 
tissue and vrown areas composed of brown adipose tissue are indicated by the 
scheme  (Cinti, 2005). (B) In humans, depots of white adipose tissue are found in 
areas all over the body, with subcutaneous and intra-abdominal depots 
representing the main compartments for fat storage. Brown adipose tissue is 
abundant at birth and still present in adulthood but to a lesser extent (Gesta et 
al., 2007). 
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White adipose depots in rodents and humans contain brown adipocytes which can 
dramatically increase in number, as well as the number of brown adipocytes in brown 
adipose depots, in cold-acclimated animals (Figure 1.3)(Cinti, 2001), indicating the 
striking plastic properties of adipose tissue. 
 
Figure 1.3 Gross anatomy of the adipose organs of adult mice kept at 20°C and 
4°C.  
Dissections were performed on C57BL/KS-db/+ mice aged 43 weeks. Mice were 
kept at 20°C or acclimated (several days) at low temperature (4°C). Most of the 
fat depots at 20°C have a white-yellowish colour but some areas in the upper and 
lower subcutaneous depots and the perirenal and mediastinic depots are brown 
in colour. In cold-acclimated (4°C) animals, the brown areas increase in number 
(Cinti, 2001). 
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1.2.2 Functions of adipose tissue 
The most obvious function of white adipose tissue is energy storage and release 
besides insulation and cushioning. Excess energy is stored in WAT in the form of 
triglycerides, and then hydrolysed into free fatty acids and delivered to the other 
organs to be used as fuel (Coppack et al., 1994). In BAT the stored energy is oxidised 
to produce heat via uncoupling respiration (Cannon and Nedergaard, 2004). However, 
energy storage and release is not the only function of adipose tissue. It has been 
acknowledged as an important endocrine organ, secreting varieties of factors 
regulating the energy homeostasis in the body (Kershaw and Flier, 2004). A series of 
experiments about energy metabolic function of WAT and BAT will be reviewed in the 
following few paragraphs, emphasising on the thermogenic function of BAT, followed 
by studies on the endocrine role of adipose tissue.  
Lipolysis refers to processes in which triglyceride is hydrolysed, via di- and 
monoglyceride intermediates, to fatty acids and glycerol (Renold, 1965). In WAT, 
where the majority of lipolysis occurs, free fatty acids are released into the circulation 
then absorbed and oxidized by specific tissues (e.g. liver and muscle) as fuel on 
demand (Coppack et al., 1994). So adipose tissue lipolysis is the major regulator of 
ƚŚĞďŽĚǇ ?ƐƐƵƉƉůǇŽĨĨĂƚƚǇĂĐŝĚƐĨŽƌĞŶĞƌŐǇŵĞƚĂďŽůŝƐŵ ? 
Unlike WAT, BAT has much more limited amount and locations in the body (Cannon 
and Nedergaard, 2004; Nedergaard et al., 2007) and the lipolysis in BAT provides FFAs 
for thermogenesis, as BAT mitochondria have a unique proton conductance 
mechanism that allows them to become reversibly uncoupled (Nicholls and Locke, 
1984) and thus to oxidise both endogenous and exogenous substrates at an 
extremely high rate independent of the need to phosphorylate ADP (Himms-Hagen, 
1984). This uncoupled respiration is controlled by the intracellular concentration of 
FFAs (Bukowiecki, 1984; Nicholls and Locke, 1984) and involves the specific protein 
uncoupling protein 1 (UCP1), which is also the unique marker of brown adipose tissue 
gene expression. UCP1 is located in the inner membrane of mitochondria and 
catalyzes a leak of protons from the intramembrane space into the mitochondrial 
matrix (Figure 1.4)(Klingenberg and Huang, 1999), therefore mitochondria in brown 
adipocytes are capable of high rates of lipid oxidation which is uncoupled from ATP 
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generation, so releasing the energy as heat  (Cannon and Nedergaard, 2004; Scheffler, 
1999). The resulting dissipation of the mitochondrial membrane potential, along with 
extremely high rates of mitochondrial electron transport and lipid oxidation, results in 
the generation of heat and the expenditure of huge amounts of chemical energy 
(Seale et al., 2009). BAT has been well established as a key component in non-
shivering thermogenesis. Chronic cold exposure causes an increase in brown 
adipocytes (or recruitment) and activation of uncoupled thermogenesis in rodents 
and humans (Klingenspor, 2003). When an environmental temperature below the 
lower critical temperature  is sensed by central nervous system (CNS), catecholamine 
is secreted from the sympathetic nerve terminals within the BAT (Cannon and 
Nedergaard, 2004; Klingenspor, 2003) to stimulate UCP1 expression and activate non-
shivering thermogenesis. The thermogenic function of BAT is only occurs in response 
ƚŽ ĂĚƌĞŶĞƌŐŝĐ ƐƚŝŵƵůĂƚŝŽŶ ? ƐŽ d ĐĂŶ ďĞ ĂĐƚŝǀĂƚĞĚ ďǇ ĞǆƉŽƐƵƌĞ ƚŽ ɴ-adrenergic 
agonists (Seale et al., 2009). 
 
Figure 1.4 A model of the mechanism of H
+
 transport by UCP1 and the role of 
fatty acid. 
The fatty acid acts as H
+
 donor/acceptor between resident carboxyl groups of 
UCP1. The H
+
 transport path is proposed to consist of a wider aqueous pore and a 
narrow path lined by the loops protruding from the matrix side. The inhibition of 
H
+
 transport occurs by closure of the narrow path under influence of nucleotide 
binding (Klingenberg, 1999).  
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Adipokines 
Besides energy storage and release, adipose tissue is also an important endocrine 
organ, expressing and secreting varieties of bioactive peptides, known as adipokines, 
which act at both the local (autocrine/ paracrine) and systemic (endocrine) level 
(Table 1) (Kershaw and Flier, 2004). As early as 1987, adipose tissue was identified as 
a site for metabolism of sex steroids (Siiteri, 1987) and production of an endocrine 
factor adipsin, whose expression is severely impaired in obesity (Flier et al., 1987). In 
1994, the identification and characterization of leptin demonstrated the role of 
adipose tissue as an endocrine organ (Zhang et al., 1994).  
 
 
(Kershaw and Flier, 2004) 
Leptin (from Greek leptos, meaning thin) is a 16kD polypeptide containing 167 amino 
acids with structural homology to cytokines. Adipose tissue secrets leptin in direct 
proportion to adipose tissue mass and nutritional status, and leptin secretion from 
subcutaneous adipose tissue is higher than in visceral fat depots (Fain et al., 2004; 
Wajchenberg, 2000). The expression and secretion of leptin are also regulated by 
ǀĂƌŝŽƵƐ ŽƚŚĞƌ ĨĂĐƚŽƌƐ ŝŶĐůƵĚŝŶŐ ŝŶƐƵůŝŶ ? ŐůƵĐŽĐŽƌƚŝĐŽŝĚƐ ? dE&ɲ ? ĞƐƚƌŽŐĞŶƐ ĂŶĚ
d ?ŶŚĂŶĐĞƌ ŝŶĚŝŶŐ WƌŽƚĞŝŶ ɲ  ? ?Wɲ ) ǁŚŝĐŚ ŝŶĐƌĞĂƐĞ ůĞƉƚŝŶ ůĞǀĞů ? ĂŶĚ ɴ ?-
adrenergic activitǇ ? ĂŶĚƌŽŐĞŶ ? ĨƌĞĞ ĨĂƚƚǇ ĂĐŝĚƐ ĂŶĚ WWZɶ ĂŐŽŶŝƐƚ ǁŚŝĐŚ ĚĞĐƌĞĂƐĞ ŝƚ
Table 1.1 Examples of adipocyte-derived proteins with endocrine functions 
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(Margetic et al., 2002). The primary function of leptin is to play as a metabolic signal 
of energy sufficiency rather than excess, thus viewed as an anti-obesity hormone 
(Flier, 1998).  
dƵŵŽƵƌ EĞĐƌŽƐŝƐ &ĂĐƚŽƌ ɲ  ?dE&ɲ ) ĂůƐŽ ĐĂŶ ďĞ ĞǆƉƌĞƐƐĞĚ ĂŶĚ ƐĞĐƌĞƚĞĚ ŝŶ ĂĚŝƉŽƐĞ
tissue, by both adipocytes and stromovascular cells (Fain et al., 2004). Adipocytes also 
ĞǆƉƌĞƐƐďŽƚŚƚǇƉĞƐŽĨdE&ɲƌĞĐĞƉƚŽƌƐĂƐŵĞŵďƌĂŶĞďŽƵŶĚĂŶĚƐŽůƵďůĞĨŽƌŵƐ (Ruan 
and Lodish, 2003) ?ĚŝƉŽƐĞ ƚŝƐƐƵĞ ĞǆƉƌĞƐƐŝŽŶŽĨ dE&ɲ ŝƐ ŝŶĐƌĞĂƐĞĚ ŝŶŽďĞƐĞ ƌŽĚĞŶƚƐ
and humans and is positively correlated to adiposity and insulin resistance 
(Hotamisligil, 2003; Ruan and Lodish, 2003; Seckl and Walker, 2001; Stulnig and 
Waldhausl, 2004).  
A unique adipocyte-derived hormone adiponectin was first identified (Au et al., 1999) 
in 1995 and it is highly and specifically expressed in differentiated adipocytes and 
circulates at high level in the bloodstream (Scheffler, 1999). There is a strong and 
consistent inverse association between adiponectin and both insulin resistance and 
inflammatory states (Klingenberg, 1999; Scheffler, 1999). Low adiponectin expression 
is asscoiated with insulin resistance in either obesity or lipodystrophy, and 
administration of adiponectin improves the metabolic parameters in these conditions 
(Echtay et al., 1999; Klingenberg, 1999). Another adipocyte-derived hormone is 
adipsin, which has shown positive correlation with adiposity, insulin resistance, 
dyslipidemia and cardiovascular disease in human studies (Klingenberg and Huang, 
1999).  
Around 2001, several research groups identified separately a novel gene named 
Resistin (resistance to insulin) that was induced during adipocyte differentiation but 
down-regulated by thiazolidinediones (TZDs) in vitro (Fukuda et al., 1987; Naquet et 
al., 1987; Rektor et al., 1987). In vivo studies in rodents confirmed the TZD mediated 
down-regulation and confirmed the adipose tissue-specific expression of resistin. In 
vivo treatment with recombinant resistin in rodents induces insulin resistance 
whereas immunoneutralization of resistin has the opposite effect (Fukuda et al., 
1987).  However, a clear and consistent link between resistin expression in adipose 
tissue or circulation resistin levels and adiposity or insulin resistance has not been 
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found in human epidemiological studies. Human resistin only shares 64% homology 
with murine resistin and is expressed at very low levels in human adipocytes 
(Klingenspor, 2003).  
Apart from the hormones mentioned above, adipose tissue also expresses enzymes 
involved in the metabolism of steroid hormones, such as cytochrome P450-
ĚĞƉĞŶĚĞŶƚ ĂƌŽŵĂƚĂƐĞ ?  ?ɴ-hydroxysteroid dehydrogenase (HSD) and UDP-
glucuronosyltransferases 2B15 (Shammah-Lagnado et al., 1987; Silva et al., 1987), as 
ǁĞůů ĂƐ ƚŚĞ ĞŶǌǇŵĞ  ? ?ɴ,^ ? ƚŚĂƚ ƉƌŝŵĂƌŝůǇ ĚĞƚĞƌŵŝŶĞƐ ƚŚĞ ĂĚŝƉŽƐĞ ƚŝƐƐƵĞ-specific 
glucocorticoid metabolism (Seckl and Walker, 2001; Stulnig and Waldhausl, 2004).  
The expression and secretion levels of the hormones and enzymes above are much 
higher in white adipose tissue compared with those in brown (Farmer, 2008). The 
studies of adipose tissue as an endocrine organ are still going on to identify and 
characterize more novel genes and gain further insights into the endocrine function 
of adipose tissue and the relationship between energy homeostasis and other 
physiological systems. 
1.2.3 Control of adipogenesis 
Adipogenesis, defined as the formation of adipocytes, results in growth of adipose 
tissue. During adipogenesis, precursor cells are devoid of lipid but become committed 
to the adipocyte lineage and are called preadipocytes. These cells may become 
quiescent, proliferate to increase the number of committed preadipocytes, or 
differentiate into mature adipocytes containing lipid droplets (Poulos et al., 2009). 
Preadipocytes originate from mesenchymal stem cells (MSCs); however, it is 
uncertain how many intermediate stages there are exactly from MSCs to mature 
adipocytes (Figure 1.5). Additionally, as none of the intermediate precursor cells 
possesses any unique morphological characteristics or gene expression markers, the 
differentiation process from MSCs to preadipocytes is not so well defined as the later 
stage that starts from preadipocytes (Farmer, 2006; Gesta et al., 2007). Therefore, 
the adipogenesic process reviewed here will refer to differentiation from 
preadipocytes to mature adipocytes, which is initiated by specific hormone signals 
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and involves a cascade of transcriptional events, regulated by the hormonal and 
nutritional environment.  
 
 
 
 
 
 
Figure 1.5 Development of mesenchymal/ mesodermal derivatives 
Mesenchymal stem cells (MSCs) develop from the mesoderm and then commit 
into different lineages influenced by a number of factors. Once committed, MSCs 
give rise to undifferentiated precursors (osteoblast, adipoblast/ preadipocyte, and 
myoblast), which upon the expression of key transcription factors enter a 
differentiation programme to acquire their specific functions (Gesta et al., 2007). 
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The process of adipocyte differentiation has been extensively studied in mouse 3T3-
L1 and 3T3-F442A white preadipocye cell lines and immortalized brown preadipocyte 
cell lines (Rosen and Spiegelman, 2000). Differentiation of preadipocytes can be 
induced by the adipogenic hormone cocktail containing isobutylmethylxanthine 
(IBMX), dexamethasone (Dex), insulin, triiodothyronine (T3) and foetal bovine serum 
(FBS) (Kajimura et al., 2008). Adipogenesis in confluent preadipocytes involves four 
stages: growth arrest, clonal expansion, early differentiation and terminal 
differentiation. These stages are controlled by a transcriptional cascade, in which 
WWZɶĂŶĚ ?WɲĂƌĞƚŚĞŵŽƐƚŝŵƉŽƌƚĂŶƚĨĂĐƚŽƌƐ(Farmer, 2006).  
dŚĞƌŽůĞŽĨWWZɶĂƐƚŚĞŵĂƐƚĞƌƌĞŐƵůĂƚŽƌŚĂƐďĞĞŶĨŝƌŵůǇƉƌŽǀĞĚĨƌŽŵďŽƚŚ in vitro 
and in vivo studies.  The critical early evidence of the important ƌŽůĞ ŽĨ WWZɶ ŝŶ
regulating adipogenesis was found by Spiegelman and colleagues when trying to 
elucidate the transcriptional factors regulating expression of the adipose-specific fatty 
acid binding protein aP2/FABP4. This work resulted in the identificatioŶŽĨWWZɶĂŶĚ
ŝƚƐ ŚĞƚĞƌŽĚŝŵĞƌŝĐ ƉĂƌƚŶĞƌ ZyZɲ (Tontonoz et al., 1994a; Tontonoz et al., 1994b). A 
ƐĞƌŝĞƐ ŽĨ ĞǆƉĞƌŝŵĞŶƚƐ ŝŶ ǁŚŝĐŚ WWZɶ ŝƐ ĞĐƚŽƉŝĐĂůůǇ ĞǆƉƌĞƐƐĞĚ ŝŶ ŶŽŶĂĚŝƉŽŐĞŶŝĐ
ŵŽƵƐĞ ĨŝďƌŽďůĂƐƚƐ ŚĂǀĞ ƐŚŽǁŶ ƚŚĞ ĐĂƉĂďŝůŝƚǇ ŽĨ WWZɶ ƚŽ ŝŶŝƚŝĂƚĞ ƚŚĞ ĞŶƚŝƌĞ
adipogenic program (Tontonoz et al., 1994c). PPZɶŝƐĂůƐŽƌĞƋƵŝƌĞĚƚŽŵĂŝŶƚĂŝŶƚŚĞ
terminal differentiated state of adipocytes, and expression of a dominant-negative 
WWZɶ ŝŶ ĚŝĨĨĞƌĞŶƚŝĂƚĞĚ  ?d ?-L1 cells induces differentiation with loss of lipid 
accumulation and decreased expression of adipocytes markers (Gesta et al., 2007). 
>ŝŬĞǁŝƐĞ ? ŝŶĚƵĐŝďůĞ ŬŶŽĐŬŽƵƚ ŽĨ WWZɶin vivo leads to death of brown and white 
adipocytes (Gesta et al., 2007) ?dŚĞƌĞĂƌĞƚǁŽŝƐŽĨŽƌŵƐŽĨWWZɶ ?WWZɶ ?ĂŶĚWWZɶ ? )
generated from alternative splicing and PPARɶ ? ŝƐĂĨĂƚ-ƐƉĞĐŝĨŝĐŵĂƌŬĞƌ ?WWZɶ ?ŶƵůů
mice still have some white adipose tissue but are insulin resistant, indicating that 
WWZɶ ? ĐĂŶƉĂƌƚŝĂůůǇ ĐŽŵƉĞŶƐĂƚĞ ĨŽƌ ƚŚĞ ůŽƐƐŽĨWWZɶ ? ŝŶĂĚŝƉŽŐĞŶŝĐ ĨƵŶĐƚŝŽŶ ďƵƚ
ƚŚĞ ĐĂƉĂďŝůŝƚǇ ŽĨ WWZɶ ? ŝŶ ŵĂŝŶƚĂŝŶŝŶŐ ŝŶƐƵůŝŶsensitivity is independent of its 
adipogenic ability (Zhang et al., 2004a).   
 ?WɲďĞůŽŶŐƐƚŽd ?ŶŚĂŶĐĞƌŝŶĚŝŶŐWƌŽƚĞŝŶ  ? ?W )ĨĂŵŝůǇĂŶĚĂůƐŽƉůĂǇƐĂ
ĐƌŝƚŝĐĂůƌŽůĞ ŝŶĂĚŝƉŽŐĞŶŝĐƉƌŽŐƌĂŵŵĞ ?>ŝŬĞWWZɶ ?ĞĐƚŽƉŝĐĞǆƉƌĞƐƐŝŽŶŽĨ ?WɲĐĂŶ
also induce adipogenesis in a variety of fibroblasts (Freytag et al., 1994). A tissue-
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ƐƉĞĐŝĨŝĐŬŶŽĐŬŽƵƚŽĨ ?WɲƌĞǀĞĂůĞĚƚŚĂƚ ?WɲŝƐƌĞƋƵŝƌĞĚŝŶƚŚĞĨŽƌŵĂƚŝŽŶŽĨtd
ďƵƚ ŶŽƚ ŝŶ d ? WWZɶ ĐĂŶ ŝŶĚƵĐĞ ĂĚŝƉŽŐĞŶĞƐŝƐ ŝŶ  ?Wɲ ŶƵůů ŵŽƵƐĞ ĞŵďƌǇŽŶŝĐ
ĨŝďƌŽďůĂƐƚƐ ?D&Ɛ ) ?ďƵƚ ?WɲŝƐŶŽƚĂďůĞƚŽĚƌŝǀĞƚŚ ĂĚŝƉŽŐĞŶŝĐƉƌŽŐƌĂŵŵĞŝŶƚŚĞ
ĂďƐĞŶĐĞŽĨWWZɶ (Rosen et al., 2002) ?ƐƵŐŐĞƐƚŝŶŐƚŚĂƚWWZɶĂŶĚ ?WɲƉĂƌƚŝĐŝƉĂƚĞ
ŝŶĂƐŝŶŐůĞƉĂƚŚǁĂǇŽĨĂĚŝƉŽƐĞĚĞǀĞůŽƉŵĞŶƚŝŶǁŚŝĐŚWWZɶŝƐƚŚĞĚŽŵŝŶĂŶƚĨĂĐƚŽƌ ? 
tĞůů ďĞĨŽƌĞ ƚŚĞ ĚŝƐĐŽǀĞƌǇ ŽĨ WWZɶ ĂƐ ƚŚe master regulator of adipogenesis, much 
endeavour had been taken to identify the molecular mechanism in adipogenesis and 
now it is established that a cascade of transcriptional factors eventually leads to the 
ĞǆƉƌĞƐƐŝŽŶŽĨWWZɶĂŶĚ ?Wɲ(Farmer, 2006). Work of McKnight and associates 
ŝŶĚŝĐĂƚĞĚƚŚĞŽƚŚĞƌƚǁŽŵĞŵďĞƌƐŽĨ ?WĨĂŵŝůǇ ? ?WɴĂŶĚ  ?Wɷ ?ĂƌĞĞǆƉƌĞƐƐĞĚ
ĞĂƌůŝĞƌ ƚŚĂŶ  ?Wɲ ĚƵƌŝŶŐ ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ŝŶ  ?d ?-L1 cells and responsible for 
ƌĞŐƵůĂƚŝŶŐ ?WɲĞǆƉƌĞƐƐŝŽŶ(Cao et al., 1991; Yeh et al., 1995). Ectopic expression of 
 ?Wɴ ŝŶ E/,  ?d ? ĨŝďƌŽďůĂƐƚƐ ? ĂůŽŶĞ Žƌ ĐŽŵďŝŶĞĚ ǁŝƚŚ  ?Wɷ ? ŝŶĚƵĐĞƐ ƚŚĞ
ĞǆƉƌĞƐƐŝŽŶ ŽĨ WWZɶ ? ĂŶĚ ? ĨŽůůŽǁŝŶŐ ƚŚĞ ĞǆƉŽƐƵƌĞ ƚŽ WZɶ ůŝŐĂŶĚƐ ?facilitates the 
conversion of these cells into adipocytes (Wu et al., 1996; Wu et al., 1995). However, 
ŝƚŚĂƐďĞĞŶƐŚŽǁŶƚŚĂƚĞĐƚŽƉŝĐĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴŝŶ^ǁŝƐƐĨŝďƌŽďůĂƐƚƐŝƐŝŶĐĂƉĂďůĞ
ŽĨ ŝŶĚƵĐŝŶŐ  ?Wɲ ĞǆƉƌĞƐƐŝŽŶ ƚŽ ĂŶǇ ƐŝŐŶŝĨŝĐĂŶƚ ĞǆƚĞŶƚ ǁŝƚŚŽƵƚ Ă ƉŽƚĞŶƚ WWZɶ
ůŝŐĂŶĚ ?/ŶƐƵƉƉŽƌƚŽĨƚŚŝƐƉƌŽƉŽƐĂů ?ƌĞƚƌŽǀŝƌĂůĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴŝŶWWZɶŶƵůůD&Ɛ
ĂůƐŽ ĨĂŝůƐ ƚŽ ƐƚŝŵƵůĂƚĞ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?Wɲ(Zuo et al., 2006). Therefore it 
ĂƉƉĞĂƌƐƚŚĂƚƚŚĞƉƌŝŶĐŝƉĂůƉĂƚŚǁĂǇŽĨĂĚŝƉŽŐĞŶĞƐŝƐŝŶǀŽůǀĞƐƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨ ?Wɴ
ĂŶĚ ?Wɷ ?ǁŚŝĐŚ ŝŶĚƵĐĞƐWWZɶ ĞǆƉƌĞƐƐŝŽŶ ?WWZɶĂůŽŶŐǁŝƚŚ ƚŚĞƐĞ  ?WƐ ƚŚĞŶ
ĂĐƚŝǀĂƚĞ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶŽĨ ?Wɲ  ?&ŝŐƵƌĞ  ? ? ? )(Farmer, 2005) ?^ŝŶĐĞ  ?Wɴ ŝƐ ƐŽ
ŝŵƉŽƌƚĂŶƚ ŝŶ ƌĞŐƵůĂƚŝŶŐ ƚŚĞ ĂĐƚŝǀŝƚǇ ĂƐ ǁĞůů ĂƐ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ WWZɶ ĚƵƌŝŶŐ ƚŚĞ
early phase of adipogenesis, Farmer and associates have done much work in 
ŝĚĞŶƚŝĨǇŝŶŐ ƚŚĞ ƐŝŐŶĂůůŝŶŐ ƉĂƚŚǁĂǇƐ ĐŽŶƚƌŽůůŝŶŐ  ?Wɴ ĂĐƚŝǀŝƚǇ ? dŚĞǇ ŚĂǀĞ
demonstrated that hormonal stimulation of confluent 3T3-L1 preadipocytes induces a 
rapid but transient burst of MEK/ERK signalling that coincides with the induction of 
 ?Wɴ ĞǆƉƌĞƐƐŝŽŶ(Farmer, 2005). Point mutations at a consensus MEK/GSK3 
ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ƐŝƚĞ ŝŶ ƚŚĞ ƌĞƉƌĞƐƐŽƌ ƌĞŐŝŽŶ ŽĨ  ?Wɴ ĚŝƐĂďůĞĚ ƚŚĞ ƉƌŽƚĞŝŶ ŝŶ
ĨĂĐŝůŝƚĂƚŝŶŐ WWZɶ ƚŽ ĂĐƚŝǀĂƚĞ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?WɲĂŶĚ Ă ƐĞůĞĐƚ ƐĞƚ ŽĨ  ?Wɲ
target genes most notably adiponectin (Figure 1.6 B) (Park et al., 2004). Studies from 
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Klemm and Lane suggest that cAMP regulatory element (CRE) binding protein (CREB), 
which is expressed in early stage of 3T3-L1 differentiation, participates in the 
ŝŶĚƵĐƚŝŽŶ ŽĨ  ?Wɴ ĞǆƉƌĞƐƐŝŽŶ(Zhang et al., 2004b), thus explaining the need for 
stimulating cAMP intracellular levels using IBMX in the adipogenic cocktail.  
 
 
 
 
 
 
&ŝŐƵƌĞ ? ? ?ZŽůĞŽĨ ?WɴŝŶƌĞŐƵůĂƚŝŶŐWWZɶĞǆƉƌĞƐƐŝŽŶĂŶĚĂĐƚŝǀŝƚǇ ? 
 ? )^ƚŝŵƵůĂƚŝŽŶŽĨ ?WɴŝŶƌĞƐƉŽŶƐĞƚŽĞǆƉŽƐƵƌĞŽĨƉƌĞĂĚŝƉŽĐǇƚĞƐƚŽĂĚŝƉŽŐĞŶŝĐ
ŚŽƌŵŽŶĞƐ ŝŶĚƵĐĞƐ ĞǆƉƌĞƐƐŝŽŶ ŽĨ WWZɶ ĂŶĚ ůĞĂĚƐ ƚŽ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ WWZɶ
ůŝŐĂŶĚƐ ?ĐƚŝǀĂƚĞĚWWZɶĐŽŶƚrols terminal adipogenesis by inducing expression of 
 ?Wɲ ? ǁŚŝĐŚ ŝƐ ƌĞƋƵŝƌĞĚ ĨŽƌ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ ƐƉĞĐŝĨŝĐ ĂĚŝƉŽŐĞŶŝĐ ŐĞŶĞƐ
(Farmer, 2005) ?  ? ) WŚŽƐƉŚŽƌǇůĂƚŝŽŶ ŽĨ  ?Wɴ Ăƚ Ă ĐŽŶƐĞŶƐƵƐ Z< ?'^<ƐŝƚĞ ŝƐ
ƌĞƋƵŝƌĞĚ ĨŽƌ ƚŚĞ WWZɶ-ĂƐƐŽĐŝĂƚĞĚ ŝŶĚƵĐƚŝŽŶ ŽĨ  ?Wɲ ĂŶĚ ĂĚŝƉŽŶĞĐƚŝŶ
expression (Farmer, 2005).  
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Additional factors in parallel pathways are also likely to be involved in activating 
PPAZɶ ?ĂƚĂƐƚĂŐĞĚŽǁŶƐƚƌĞĂŵŽĨ ?WɴĂŶĚ ?Wɷ ?ƐƵĐŚĂƐƚŚĞ ƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌ
sterol regulatory element binding protein 1c (SREBP1c). The expression of SREBP1c is 
significantly increased in 3T3-L1 adipocytes in response to insulin (Kim et al., 1998a). 
Ectopic expression of a dominant-negative SREBP1c inhibits preadipocyte 
differentiation, whereas the overexpression of this protein significantly enhanced the 
ĂĚŝƉŽŐĞŶŝĐĂĐƚŝǀŝƚǇŽĨWWZɶ (Kim and Spiegelman, 1996). Additional studies suggest 
that ^ZW ?Đ ĐŽŶƚƌŝďƵƚĞƐ ƚŽ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ WWZɶ ůŝŐĂŶĚƐ ? ƚŚĞƌĞĨŽƌĞ ĨĂĐŝůŝƚĂƚŝŶŐ
ƚŚĞ ĂĐƚŝǀĂƚŝŽŶ ŽĨ WWZɶ (Kim et al., 1998b). Studies on the functions of signal 
transducers and activators of transcription (STAT) proteins also provide support for 
the additional pathway regulating adipogenesis. Ectopic expression of STAT5A in non-
ĂĚŝƉŽŐĞŶŝĐ ĨŝďƌŽďůĂƐƚƐ ŝŶĚƵĐĞƐ ƉƌĞĂĚŝƉŽĐǇƚĞ ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ? ŝŶĐůƵĚŝŶŐ WWZɶ
activation and accumulation of lipid droplets (Floyd and Stephens, 2003).  
The transcription factors responsible for adipogenesis are in turn orchestrated by the 
hormonal  and neural environment (Gesta et al., 2007). In rodents, the sympathetic 
nervous system has opposing role in the recruitment and development of BAT and 
WAT. Differentiation of brown preadipocytes is significantly enhanced by adrenergic 
agents such as norepinephrine, while the proliferation and differentiation of WAT is 
stimulated by sympathetic denervation (Cousin et al., 1993). Adrenergic stimulators 
induce proliferation and differentiation of brown preadipocytes, protect mature 
brown adipocytes from apoptosis and increase thermogenic capacity via induction of 
UCP1 gene expression (Cannon and Nedergaard, 2004). Chronic cold exposure and 
feeding increase BAT activity via norepinephrine from sympathetic nervous system, 
and UCP1 expression can also be stimulated by thyroid hormone, insulin, TZD, 
ƌĞƚŝŶŽŝĐ ĂĐŝĚ  ?Z ) ? ĐDW ĂŶĚ ɴ-adrenergic agonists (Diehl and Hoek, 1999). On the 
contrary, glucocorticoids inhibit UCP1 expression in response to adrenergic 
stimulation (Soumano et al., 2000). 
1.2.4 Transdifferentiaton between WAT and BAT and the origin debate 
The term transdifferentiation has been used to define both a direct transformation 
from one cell to another with different morphology and function and to define an 
unusual differentiation fate from a stem cell that usually differentiates into a 
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different lineage (Tosh D., 2002). In vivo studies suggest that white adipocytes of the 
murine adipose organ can undergo a true reversible transdifferentiation process  to 
brown adipocytes in physiological conditions (Himms-Hagen et al., 2000). A large 
amount of evidence has also been provided that chronic cold exposure induces the 
emergence of brown adipocytes in  WAT depots in rodents (Cinti, 2001). In these 
conditions, the appearance of brown adipocytes in subcutaneous WAT is much more 
significant than that in visceral WAT (Barbatelli et al., 2010). About 17% of the 
adipocytes in all WAT depots of Sprague-Dawley rats become more brown like after 
ƚŚĞ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ɴ ?-adrenoceptor agonist CL-316, 243 for 7 days (Figure 1.2 A) 
(Cinti, 2009b) ? ŚƌŽŶŝĐ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ WWZɶ ĂŐŽŶŝƐƚ ƌŽƐŝŐůŝƚĂǌŽŶĞ ĂůƐŽ ŝŶĚƵĐĞƐ
P' ?ɲĞǆƉƌĞƐƐŝŽŶĂŶĚŵŝƚŽĐŚŽŶĚƌŝŽŐĞŶĞƐŝƐĂƐǁĞůů ĂƐŶŽƌĞƉŝŶĞƉŚƌŝŶĞ-augmentable 
UCP1 expression in epididymal WAT depots (Petrovic et al., 2009). Studies from 
Karamanlidis and associates indicate that overexpression of the transcription factor 
 ?WɴŝŶǁŚŝƚĞƉƌĞĂĚŝƉŽĐǇƚĞcell line 3T3-L1 reprograms the cells towards a brown 
fat lineage by rescuing the cAMP-ŝŶĚƵĐĞĚ ĞǆƉƌĞƐƐŝŽŶ ŽĨ W' ?ɲ ĂŶĚ hW ?
(Karamanlidis et al., 2007). Recently, PRDM16 is also shown to stimulate a select set 
ŽĨ d ŐĞŶĞƐ ǁŚĞŶ ŽǀĞƌĞǆƉƌĞƐƐĞĚ ĂŶĚ ŝŶ ĂƐƐŽĐŝĂƚŝŽŶ ǁŝƚŚ Ă W' ?ɲ ?ɴ ĐŽŵƉůĞǆ ŝŶ
white 3T3-F442A preadipocytes (Kajimura et al., 2008). Although the hypothesis of 
reversible physiological transdifferentiation (Cinti, 2009a) could at least partly explain 
the plasticity of the appearance of brow adipocytes in WAT, without signs of 
apoptosis, direct evidence using lineage tracing studies are needed.  
The observation of WAT-dĐŽŶǀĞƌƐŝŽŶĂůƐŽ ŝŵƉůŝĞƐĂ  “ĐŽŵŵŽŶŽƌŝŐŝŶ ?ŚǇƉŽƚŚĞƐŝƐ
of white and brown adipocytes. Despite the distinct morphology and functions, white 
and brown adipocytes were originally considered differentiated from common 
precursor cells (adipoblasts or preadipocytes) derived from mesenchymal stem cells 
(Figure 1.5) (Gesta et al., 2007). However, in vivo fate mapping studies showed that in 
BAT depots, brown, but not white, fat cells arise from precursors expressing Myf5, a 
gene previously thought to be expressed only in the myogenic lineage (Seale et al., 
2008). The striking discovery suggests that brown adipocytes have a closer relation 
with skeletal muscle cells other than white adipocytes.  Further studies identified that 
the PRDM16- ?Wɴ ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů ĐŽŵƉůĞǆ ŝŶŝƚŝĂƚĞƐ ƚŚĞ ƐǁŝƚĐŚ ĨƌŽŵ ŵǇŽďůĂƐƚƐ ƚŽ
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brown adipocytes (Kajimura et al., 2009), which enhanced the concept that brown fat 
and muscle share the common origin.  
The debate about the transition between WAT and BAT has spurred questions about 
the origin and molecular characteristics of the UCP1-expressing cells observed in the 
classic white adipose tissue depots under certain physiological or pharmacological 
conditions. Petrovic and colleagues suggested that although the functional 
thermogenic genes are expressed, the  brown-like cells appearing in WAT depots are 
devoid of transcripts for the novel transcription factors now associated with classic 
brown adipocytes (Zic1, Lhx8, Meox2 and characteristically PRDM16) or for myocyte-
associated genes (myogenin and muscle-specific microRNAs) and retain white fat 
characteristics such as Hoxc9 expression. Co-culture experiments verified that the 
UCP1-expressing cells from WAT, are not proliferating classic brown adipocytes, 
ŚĞŶĐĞ ĐŽŶƐƚŝƚƵƚŝŶŐ Ă ƐƵďƐĞƚ ŽĨ ĂĚŝƉŽĐǇƚĞƐ ĐĂůůĞĚ  “ďƌŝƚĞ ?  ?brown-white) with a 
developmental origin and molecular characteristics distinguishing them as a separate 
class of cells (Figure 1.7) (Petrovic et al., 2009).   
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Figure 1.7 Subtypes of adipocytes and their origins 
There are at least three distinguished types of adipocytes: the classic brown 
adipocytes (the adipomyocytes), the brite adipocytes (i.e. the brown adipocyte-
like adipocytes induced in white adipocyte cultures), and the genuine white 
adipocytes. The adipomyocytes share their origin with myocytes, whereas brite 
and white adipocytes have a different origin (Petrovic et al., 2009).  
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1.3 TRANSCRIPTIONAL CONTROL OF UCP1 AND THE REGULATION OF 
THERMOGENESIS IN BAT 
As mentioned above, the adaptive non-shivering thermogenesis in brown adipose 
tissue is mediated mainly by a brown fat marker gene UCP1. This 32kD protein was 
first identified in 1978 from hamster brown adipose tissue mitochondria (Nicholls et 
al., 1978). The regulatory promoter region of UCP1 gene has now been studied in 
several species, defining a conserved region as a strong enhancer responsible for 
tissue-specific and cAMP-dependent expression (Cassard-Doulcier et al., 1993; Kozak 
et al., 1994; Sears et al., 1996). This enhancer contains a canonical PPAR-responsive 
element (PPRE) and two putative cAMP-responsive elements (CREs), to bind with 
ǀĂƌŝŽƵƐĐĂŶĚŝĚĂƚĞƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌƐ ?ŵŽƐƚŶŽƚĂďůǇWZɶ-ZyZɲŚĞƚĞƌŽĚŝŵĞƌ ?ďĞŝŶŐ
proposed to regulate this enhancer region (Cao et al., 2001; Sears et al., 1996). 
Adaptive thermogenesis in BAT, with the most notable features of the increasing 
number of mitochondria (mitochondriogenesis) and the stimulated expression of 
UCP1, is controlled by the sympathetic nervous system (SNS) through the activation 
ŽĨɴ-adrenergic recepƚŽƌƐ ?ɴZƐ ) ?/ƚŝƐǁĞůůĞƐƚĂďůŝƐŚĞĚƚŚĂƚɴZƐĐŽƵƉůĞƚŽ'ƉƌŽƚĞŝŶƐ
and adenylyl cyclase, resulting in the elevated level of intracellular cAMP and 
activation of cAMP-dependent protein kinase A (PKA), which has been considered as 
the ultimate component activating lipolytic enzymes and expression of UCP1 and 
W' ?ɲ ? ,ŽǁĞǀĞƌ ? ďĞƐŝĚĞƐ ƚŚŝƐ ĐůĂƐƐŝĐ ƉĂƚŚǁĂǇ ? ĂĚĚŝƚŝŽŶĂů ƐŝŐŶĂůůŝŶŐ ƉĂƚŚǁĂǇƐ
ĞŵĂŶĂƚĞ ĨƌŽŵ ɴZƐ ŚĂǀĞ ĂůƐŽ ďĞĞŶ ƌĞƉŽƌƚĞĚ ? ŝŶĐůƵĚŝŶŐ ƚŚĞ Z< ĂŶĚ Ɖ ? ? ŵŝƚŽŐĞŶ-
activated protein (MAP) kinase pathways (Cao et al., 2004; Kumar et al., 2007; 
Robidoux et al., 2006) ?ĚĚŝƚŝŽŶĂůůǇ ?ƚŚĞƐǇŶƚŚĞƚŝĐdWWZɶĂŐŽŶŝƐƚƐŚĂǀĞĂlso been 
shown to play a positive regulatory role in converting adipocytes in WAT more brown 
like by activating thermogenic genes like UCP1 and promoting mitochondrial 
biogenesis (Petrovic et al., 2009), suggesting the thermogenesis programme is 
regulated by multiple signalling transduction pathways.   
In terms of gene expression regulation, there has been an explosion of information 
relating to the transcriptional control of UCP1, the hallmark gene in BAT. Several 
nuclear factors have been associated with the expression of UCP1. Until the recent 
discovery of PRDM16, the most notaďůĞǁĂƐW' ?ɲ ?ǁŚŝĐŚĂůƐŽĐĂŶďĞƐƚŝŵƵůĂƚĞĚďǇ
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chronic cold exposure and hence is a thermoregulatory gene itself. This co-activator 
ŽĨWWZŐƌĞĂƚůǇ ŝŶĐƌĞĂƐĞƐƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŽĨWWZɶĂŶĚƚŚĞƚŚǇƌŽŝĚŚŽƌŵŽŶĞ
receptor on UCP1 promoter (Puigserver et al., 1998). Since several studies have 
ƉƌŽǀĞĚ ƚŚĂƚ ĞǆƉŽƐƵƌĞ ŽĨ ǁŚŝƚĞ ĂĚŝƉŽĐǇƚĞƐ ƚŽ ƉŽƚĞŶƚ WWZɶ ůŝŐĂŶĚƐ ŝŶĚƵĐĞƐ Ă
 “ďƌŽǁŶŝŶŐ ?ŽĨƚŚĞĐĞůůƐ ?ǁŚŝĐŚŝƐůŝŬĞůǇĚƵĞƚŽĂWWZɶůŝŐĂŶĚ-associated induction of 
mitochondrial genes including UCP1 and cytochrome oxidase (Cox) (Wilson-Fritch et 
al., 2003; Wilson-Fritch et al., 2004) ? ƚŚĞ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ĨĂĐƚŽƌ WWZɶ ŝƐ ŽďǀŝŽƵƐůǇ
playing a critical role in regulating UCP1 expression as well. PRDM16, screened from a 
global expression analysis of murine transcriptional components using white and 
brown tissue RNAs, is considered as a master regulator of brown adipogenesis and 
ƚŚĞƌŵŽŐĞŶĞƐŝƐ ? ?WɴŚĂƐďĞĞŶƌĞƉŽƌƚĞĚƚŽƌĞƉƌŽŐƌĂŵŵĞ white preadipocytes into 
a brown-like phenotype (Karamanlidis et al., 2007) and to be involved in the muscle 
to brown fat cell switch (Kajimura et al., 2009), but the stimulating mechanism has 
not been clearly defined yet. Apart from the positive regulating nuclear factors, there 
are also a set of repressors which participate in the control of UCP1 transcription. 
CtBP-1 and CtBP-2 act as dimers with various sequence-specific DNA-binding 
transcriptional repressors to form complexes that recruit repressive histone 
modifying enzymes, which has a general inhibitory effect on the expression of the 
multiple genes involved in BAT adipogenesis and thermogenesis (Chinnadurai, 2007). 
RIP140 is another corepressor for nuclear receptors that suppresses a broad 
programme of metabolic genes and plays an essential role in both DNA and histone 
methylation of UCP1 gene (Kiskinis et al., 2007). Finally, the nuclear receptor Liver X 
ZĞĐĞƉƚŽƌ ɲ  ?>yZɲ ) ŝƐ ĂůƐŽ ƌĞƉŽƌƚĞĚ ĂƐ Ă ĐDW- and oxysterol- dependent 
transcriptional repressor of UCP1 (Collins et al., 2010). 
1.3.1 Signalling pathways 
The sympathetic nervous system controls adaptive thermogenesis in brown adipose 
tissue through the aĐƚŝǀĂƚŝŽŶŽĨɴ-ĂĚƌĞŶĞƌŐŝĐƌĞĐĞƉƚŽƌƐ ?ůůƚŚƌĞĞŬŶŽǁŶɴZƐƵďƚǇƉĞƐ
are expressed in adipocytes, but the main and best defined signalling pathway 
ƐƚŝŵƵůĂƚŝŶŐ ĂĚĂƉƚŝǀĞ ƚŚĞƌŵŽŐĞŶĞƐŝƐ ŝƐ ŵĞĚŝĂƚĞĚ ďǇ ɴ ?-ĂĚƌĞŶĞƌŐŝĐ ƌĞĐĞƉƚŽƌ  ?ɴ ?Z ) ?
Studies from Cao and associates ŝŶĚŝĐĂƚĞĚ ƚŚĂƚ ƚŚĞ ɴ ?Z ƐƚŝŵƵůĂƚĞƐ Ɖ ? ? ŵŝƚŽŐĞŶ-
activated protein kinase (p38 MAPK) via protein kinase A (PKA) in adipocytes and that 
25 
 
cAMP-ĚĞƉĞŶĚĞŶƚƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨƚŚĞŵŝƚŽĐŚŽŶĚƌŝĂůhW ?ƉƌŽŵŽƚĞƌďǇɴ ?ZƌĞƋƵŝƌĞƐ
Ɖ ? ? DW< ? dŚĞ ƐĞůĞĐƚŝǀĞ ɴ ?Z ĂŐŽŶŝƐƚƐ ĂĐƚivate p38 MAPK in a time- and dose- 
dependent manner and the activation can be blocked by the specific p38 MAPK 
ŝŶŚŝďŝƚŽƌĂƐǁĞůů ĂƐ ƚŚĞ W< ŝŶŚŝďŝƚŽƌƐ ? ĐŽŶĨŝƌŵŝŶŐ ƚŚĞ ŝŶǀŽůǀĞŵĞŶƚŽĨW< ŝŶɴ ?Z-
dependent p38 MAPK phosphorylation (Cao et al., 2001). The activated p38 MAPK 
ƉŚŽƐƉŚŽƌǇůĂƚĞƐĂĐƚŝǀĂƚŝŶŐƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌ  ?  ?d& ? )ĂŶĚW' ?ɲ ?ĂŶĚĐŽŶƚƌŽůƐƚŚĞ
expression of UCP1 gene through their respective interactions with a CRE and PPRE 
that both reside within a critical enhancer motif of the UCP1 gene. Activation of ATF2 
by p38 MAPK additionally serves as the cAMP sensor that increases expression of the 
W' ?ɲŐĞŶĞ ŝƚƐĞůĨ ŝŶďƌŽǁŶĂĚŝƉŽƐĞƚŝƐƐƵĞ(Cao et al., 2004; Robidoux et al., 2005). 
Therefore, p38 MAPK  plays a central role in the cAMP signalling mechanism in 
promoting brown fat adaptive thermogenic programme including up-regulation of 
UCP1 expression (Figure 1.8) (Collins et al., 2010).  
 
&ŝŐƵƌĞ ? ? ?ɴ-ĂĚƌĞŶĞƌŐŝĐƌĞĐĞƉƚŽƌ ?ɴZ ?ĂĐƚŝǀĂƚŝŽŶŽĨƉ ? ?MAP kinase in brown 
ĂĚŝƉŽĐǇƚĞƐĂĐƚŝǀĂƚĞƐƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨhW ?ĂŶĚW' ?ɲŐĞŶĞĨŽƌĂĚĂƉƚŝǀĞ
thermogenesis, mitochondrial biogenesis and fatty acid oxidation. 
ŝƌĞĐƚ ƚĂƌŐĞƚ ŽĨ Ɖ ? ? DW ŬŝŶĂƐĞ ŝŶĐůƵĚĞ ƚŚĞ W' ?ɲ ĐŽĂĐƚŝǀĂƚŽƌ ĂŶĚ ƚŚĞ
transcription factor ATF-2. The biochemical steps (dashed arrow) between PKA 
and the p38 MAP kinase model are not yet defined, but current results indicate 
ƚŚĂƚƚŚĞƉ ? ?ɲŝƐŽĨŽƌŵĂŶĚDWŬŝŶĂƐĞ-3 (MKK3) are required, together with a JIP 
scaffold (Collins et al., 2010). 
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The synthetic PPARɶ ligand rosiglitazone has been shown to have the capacity of up-
regulating UCP1 expression as well as the respiratory rate in brown adiocytes of rats 
(Teruel et al., 2005) ? /Ŷ  ? ? ? ? ? WĞƚƌŽǀŝĐ ĂŶĚ ĐŽůůĞĂŐƵĞƐ ƐƵŐŐĞƐƚĞĚ Ă WWZɶ ƉĂƚhway 
that is norepinephrine-independent but stimulates fully competent mechanism for 
BAT recruitment. They treated the brown preadipocytes with rosiglitazone 
continuously and observed an accelerated brown adipogenic process in terms of 
morphology and adipogenic marker aP2 expression, as well as the significantly 
ĞŶŚĂŶĐĞĚ ĞǆƉƌĞƐƐŝŽŶ ŽĨ hW ? ĂŶĚ W' ?ɲ ĞǀĞŶ ŝŶ ƚŚĞ ĂďƐĞŶĐĞ ŽĨ ŶŽƌĞƉŝŶĞƉŚƌŝŶĞ ?
Likewise, mitochondria biogenesis is also enhanced by rosiglitazone treatment, and 
enables brown adipocytes to respond to the addition of norepinephrine with a large 
increase of oxygen consumption in a UCP1-dependent manner (Petrovic et al., 2008). 
^ƵďƐĞƋƵĞŶƚůǇ ? ƚŚĞ ƐĂŵĞŐƌŽƵƉŽĨ ŝŶǀĞƐƚŝŐĂƚŽƌƐĚĞŵŽŶƐƚƌĂƚĞĚ ƚŚĂƚWWZɶĂĐƚŝǀĂtion 
(by rosiglitazone treatment) enables white preadipocyte cultures to acquire brown 
adipocyte-like characteristics at both morphological and molecular levels, although 
these brown-ůŝŬĞĐĞůůƐǁĞƌĞƉƌŽƉŽƐĞĚƚŽďĞĂƐĞƉĂƌĂƚĞƐĞƚŽĨĂĚŝƉŽĐǇƚĞƐ ? “ďƌŝƚĞ ?ĐĞůůs) 
different from traditionally classified brown or white adipocytes (Petrovic et al., 2009). 
dŚŝƐ WWZɶ ŵĞĚŝĂƚĞĚ ƐŝŐŶĂůůŝŶŐ ƉĂƚŚǁĂǇ ŽĨ ƐƚŝŵƵůĂƚŝŶŐ hW ? ĞǆƉƌĞƐƐŝŽŶ ĂŶĚ d
thermogenesis is not so well defined yet, but it might be the cellular explanation for 
the enigmatic BAT recruitment mechanism in prehibernation and prenatal states 
when the cAMP-dependent pathway is not functional (Petrovic et al., 2008). 
It is therefore interesting to investigate the interactions between these two pathways. 
/Ŷ ĨĂĐƚ ? ǁĞůů ďĞĨŽƌĞ ƚŚĞ WWZɶ-dependent pathway was suggested, the effects of 
ŶŽƌĞƉŝŶĞƉŚƌŝŶĞƚƌĞĂƚŵĞŶƚŽŶWWZɶŐĞŶĞĞǆƉƌĞƐƐŝŽŶŚĂĚĂůƌĞĂĚǇďĞĞŶŝŶǀĞƐƚŝŐĂƚĞĚ ?
In the brown preadipocyte cell line HIB-1Bs, both a noradrenaline-induced decrease 
(Sears et al., 1996) and a noradrenaline-induced increase (Valmaseda et al., 1999) in 
WWZɶŵZEůĞǀĞůƐŚĂǀĞďĞĞŶŶŽƚĞĚ ? ?-5 hours after stimulation), perhaps reflecting 
variability in the characteristics and phenotypic drift  in the cell line. A repressive 
ĞĨĨĞĐƚŽĨŶŽƌĞƉŝŶĞƉŚƌŝŶĞŽŶWWZɶĞǆƉƌĞƐƐŝŽŶǁĂƐĂůƐŽ ŽďƐĞƌǀĞĚ ŝŶƉƌŝŵĂƌǇďƌŽǁŶ
 ?ƉƌĞ )ĂĚŝƉŽĐǇƚĞƐ ?WWZɶŵZEůĞǀĞůƐĂƌĞĚŽǁŶ-regulated by noradrenaline treatment 
in both proliferating and differentiating primary brown (pre)adipocytes, with a 
lagtime of 1 hour and lasting up to 4 hours, after which expression gradually recovers. 
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The down-ƌĞŐƵůĂƚŝŽŶŝƐɴZŝŶĚƵĐĞĚĂŶĚŵĞĚŝĂƚĞĚǀŝĂĐDWĂŶĚW< ?ďƵƚƐƵƌƉƌŝƐŝŶŐůǇ
independent of p38 MAPK, as the addition of p38 MAPK inhibitor to the 
noradrenaline-treated culture has no significant effect on the noradrenaline-induced 
ƌĞƉƌĞƐƐŝŽŶ ŽĨ WWZɶ ĞǆƉƌĞƐƐŝŽŶ (Lindgren et al., 2004). However, in vivo studies in 
lean and ob/ob mice demonstrated that a non-dWWZɶĂŐŽŶŝƐƚ ?-(2-(4-phenoxy-2-
propylphenoxy)ethyl)indole-5-acetic acid (COOH)-pretreated mice have stronger 
ƌĞƐƉŽŶƐĞƐ ƚŽ ɴ ?Z ĂŐŽŶŝƐƚ ƐƚŝŵƵůĂƚŝŽŶ ŝŶ ƚĞƌŵƐ ŽĨ ƚŚĞƌŵŽŐĞŶĞƐŝƐ ? ƚŚƵƐ WWZɶ 
agonism increases the thermogenic potential in white and brown adipose depots in 
ďŽƚŚ ůĞĂŶ ĂŶĚ ŽďĞƐĞ ŵŝĐĞ ƵŶĚĞƌ ɴ-adrenergic stimulation (Sell et al., 2004). Also 
reflecting a positive correlation between the two mechanisms, the recent studies 
from Festuccia and colleagues indicated that the maximal UCP1 expression induced 
ďǇ WWZɶ in vivo depends on the presence of basal BAT adrenergic tone. Cold 
exposure significantly increases UCP1 mRNA levels in innervated BAT pads of 
untreated rats without affecting the already high BAT UCP1 levels of rosiglitazone 
treated animals. A similar pattern is found in denervated pads, but with markedly 
lower UCP1 expression than that in the innervated pads (Festuccia et al., 2010). 
Although the interaction between the two pathways has not been clearly elucidated, 
the current studies have implied that they are not independent of each other, but 
have some manners of cross-talking, co-ordinately regulating the adaptive 
thermogenesis in brown adipose tissue.  
1.3.2 Peroxisome Proliferator-Activated Receptors (PPARs) 
The peroxisome proliferator-activated receptors (PPARs) are lipid-activated 
transcription factors involved in the regulation of lipid metabolism and adipocyte 
ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ?ůůƚŚĞƚŚƌĞĞƐƵďƚǇƉĞƐŽĨWWZƐ ?ɲ ?ɶĂŶĚɷ )ĂƌĞĞǆƉƌĞƐƐĞĚŝŶďƌŽǁŶ
adipocytes (Valmaseda et al., 1999). PPARs are activated in a ligand-dependent way 
and once activated, heterodimerize with the retinoid X receptors (RXRs) and regulate 
the transcription of target genes after binding to specific binding sites (PPREs). The 
PPAR-RXR heterodimer is responsive to both retinoic acids and PPAR activators such 
as fatty acids, peroxisome proliferators and TZD antidiabetic agents (Keller et al., 
1993; Kliewer et al., 1992).  
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WWZɶŚĂƐďĞĞŶĚĞƐĐƌŝďĞĚĂƐƚŚĞŵĂƐƚĞƌƌĞŐƵůĂƚŽƌŝŶĂĚŝƉŽŐĞŶĞƐŝƐ ?ĂŶĚƚŚƵƐŚĂƐŚŝŐŚ
expression levels in both white and brown adipocytes. Furthermore, studies involving 
ƚŚĞƉŽƐŝƚŝǀĞƌŽůĞŽĨWWZɶĂŐŽŶŝƐƚŝŶƐƚŝŵƵůĂƚŝŶŐhW ?ĞǆƉƌĞƐƐŝŽŶ ?ĂƐĚĞƐĐƌŝďĞĚĂďŽǀĞ )
ŝŶĚŝĐĂƚĞƚŚĂƚWWZɶĂŐŽŶŝƐƚƐŶŽƚŽŶůǇƉƌŽŵŽƚĞĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶĂŶĚƚŚƵƐĞŶĂďůĞhW ?
gene expression  but also, by themselves, can induce UCP1 to the full extent 
(Villarroya et al., 2007). The ability of the UCP1 geŶĞ ƚŽ ƌĞƐƉŽŶĚ ƚŽWWZɶĂŐŽŶŝƐƚƐ
resides in the distal complex enhance of this gene. This complex includes a PPRE 
which localized at -2458 to -2485 in mouse with a similar localization in rat and 
human UCP1 enhancers (Figure 1.9) (Cannon and Nedergaard, 2004).  
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Figure 1.9 Factors controlling UCP1 gene expression. 
The top part indicates the direct pathway for norepinephrine-induced UCP1 gene 
expression; the bottom part summarizes the presence of other transcription 
factors and response elements than those involved in the direct norepinephrine 
effect. Two regulation regions have been characterized: a proximal promoter and 
a distal, complex enhancer region. The proximal promoter region contains a cAMP 
response element (CRE) and two C/EBP sites (C/E). A complex enhancer region 
exists around -2500 in rodents, containing many response elements within a short 
sequence, some of which are even overlapping. CRE, retinoic acid response 
elements (RARE), PPAR response element (PPRE) and thyroid hormone response 
element (TRE) have all been found to locate here (Cannon and Nedergaard, 2004). 
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dŚĞWWZŝŶhW ?ƉƌŽŵŽƚĞƌĐĂŶďŝŶĚƚŽďŽƚŚWWZɶĂŶĚWWZɲ ?ĂŶĚĂůƐŽďŽƚŚWWZɶ
ĂŶĚWWZɲĂŐŽŶŝƐƚƐĐĂŶŝŶĚƵĐĞhW ?ĞǆƉƌĞƐƐŝŽŶ(Barbera et al., 2001) ?WWZɲŝƐŽŶůǇ
found in brown and not in white adipocytes (Escher et al., 2001; Gorla-Bajszczak et al., 
2000), and it is first expressed when brown adipocytes are maturing (Valmaseda et al., 
1999) ? ĂƐĞĚ ŽŶ ƚŚĞ ŐĞŶĞƌĂů ĐŽŶĐĞƉƚ ŽĨ WWZɲ ĂƐ Ă ƚƌĂŶƐĐƌŝƉƚŝŽŶ ĨĂĐƚŽƌ ĨŽƌ ůŝƉŝĚ
ŵĞƚĂďŽůŝƐŵ ?ŝƚǁŽƵůĚďĞĞǆƉĞĐƚĞĚƚŚĂƚWWZɲǁĂƐƚŚĞƉƌŝŶĐŝƉĂůWWZŝƐŽŵĞƌŝŶĚƵĐŝŶŐ
hW ?ĞǆƉƌĞƐƐŝŽŶ ?ĂŶĚŶŽƚWWZɶĂƐĚŝƐĐƵƐsed above. However, these earlier studies 
in the brown preadipocyte HIB- ? ĐĞůůƐ ŝŶĚŝĐĂƚŝŶŐ WWZɶ ĂƐ ƚŚĞ ŵĂŝŶ ƌĞŐƵůĂƚŽƌ ŽĨ
UCP1 have been influenced by the fact that HIB- ? ĐĞůůƐ ĚŽ ŶŽƚ ĞǆƉƌĞƐƐ WWZɲ
(Nedergaard et al., 2005) ? &ƵƌƚŚĞƌŵŽƌĞ ? ƚŚĞ ĂĐƵƚĞ ĞĨĨĞĐƚƐ ŽĨ ŝŶũĞĐƚŝŽŶ ŽĨ WWZɲ
ĂŐŽŶŝƐƚƐƐĞĞŵůĂƌŐĞƌƚŚĂŶƚŚĂƚŽĨŝŶũĞĐƚŝŽŶŽĨWWZɶĂŐŽŶŝƐƚƐŝŶǀŝƌŐŝŶŵŝĐĞ (Pedraza 
et al., 2001) ? /Ŷ ƐƵƉƉŽƌƚ ŽĨ ƚŚĞ ŝĚĞĂ ƚŚĂƚ WWZɶ ŵĂǇ ŶŽƚ ďĞ ĂƐ ĞƐƐĞŶƚŝĂů ĨŽƌ hW ?
ĞǆƉƌĞƐƐŝŽŶ ĂƐ ŐĞŶĞƌĂůůǇ ĐŽŶƐŝĚĞƌĞĚ ŝƐ ƚŚĞ ŽďƐĞƌǀĂƚŝŽŶ ƚŚĂƚ ĂŶŝŵĂůƐ ǁŝƚŚ ŶŽ WWZɶ
expression in brown adipose tissue exhibit no decrease in UCP1 expression in 
differentiated brown adipocytes (He et al., 2003), suggesting at least in such a system, 
ƚŚĂƚWWZɶŝƐŶŽƚĞƐƐĞŶƚŝĂůĨŽƌhW ?ĞǆƉƌĞƐƐŝŽŶ ?KŶƚŚĞĐŽŶƚƌĂƌǇ ?ƚŚĞƌĞŝƐĂŶŝŵƉĂŝƌĞĚ
ĂĐƚŝǀĂƚŝŽŶ ŽĨ hW ? ŐĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ŝŶ WWZɲ-null mice in several physiological 
situations associated with cold stress (Villarroya et al., 2007). Finally, the PPAR co-
ĂĐƚŝǀĂƚŽƌ  ?ɲ  ?W' ?ɲ ? ƐĞĞ ďĞůŽǁ ) ĐĂŶ ĐŽŽƌĚŝŶĂƚĞ ďŽƚŚ WWZɶ ĂŶĚ WWZɲ ŝŶ ƚŚĞ
transcriptional control of genes in adipogenesis, thermogenesis and lipid metabolism 
in brown fat (Villarroya et al., 2007). 
 ? ? ? ? ?W' ?ɲ 
Peroxisome proliferator-activated receptor (PPAR) co-ĂĐƚŝǀĂƚŽƌ  ?ɲ  ?W' ?ɲ )ǁĂƐĨŝƌƐƚ
ŝĚĞŶƚŝĨŝĞĚ ĂƐ Ă WWZɶ-interacting protein preferentially expressed in mature brown 
adipocyte rather than white adipocytes (Puigserver et al., 1998) ?W' ?ɲĞǆƉƌĞƐƐŝŽŶŝƐ
ŚŝŐŚůǇŝŶĚƵĐĞĚĂŶĚĂĐƚŝǀĂƚĞĚŝŶďƌŽǁŶĂĚŝƉŽĐǇƚĞƐŝŶƌĞƐƉŽŶƐĞƚŽĐŽůĚĞǆƉŽƐƵƌĞŽƌɴ-
adrenergic agonist, mediated by a cAMP-PKA signalling pathway (Cao et al., 2004; 
Herzig et al., 2001) ? ĞƐŝĚĞƐ ? W' ?ɲ ĞǆƉƌĞƐƐŝŽŶ ŝŶ ĂĚŝƉŽĐǇƚĞƐ ŝƐ ĐŽŶƚƌŽůůĞĚ ďǇ ĂŶ
ĂƵƚŽƌĞŐƵůĂƚŽƌǇ ůŽŽƉ ǀŝĂ WWZɶ ĂĐƚŝǀĂƚŝŽŶ ? ^ƉĞĐŝĨŝĐĂůůǇ ? dƐ ĂŶĚ ƌĞƚŝŶŽŝĚƐ ŝŶĚƵĐĞ
PGC ?ɲĞǆƉƌĞƐƐŝŽŶĚƵĞƚŽƚŚĞƉƌĞƐĞŶĐĞŽĨĂWWZŝŶƚŚĞĚŝƐƚĂůƌĞŐŝŽŶŽĨW' ?ɲŐĞŶĞ
ƉƌŽŵŽƚĞƌ ƚŚĂƚ ďŝŶĚƐ WWZɶ ?ZyZ ŚĞƚĞƌŽĚŝŵĞƌƐ ? ĂŶĚ ƚŚĞ ĞůĞǀĂƚĞĚ W' ?ɲ ĨƵƌƚŚĞƌ
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coacitvates WWZɶ ŝŶƌĞƐƉŽŶƐĞƚŽƚŚĞdƐ ?ŚĞŶĐĞĨŽƌŵŝŶŐĂƉŽƐŝƚŝǀĞĂƵƚŽƌĞŐƵůĂƚŽƌǇ
loop controlling PG ?ɲĞǆƉƌĞƐƐŝŽŶ(Hondares et al., 2006) ?W' ?ɲŚĂƐďĞĞŶƉƌŽƉŽƐĞĚ
as the dominant regulator of mitochondrial biogenesis and oxidative metabolic 
pathways in many cell types via its co-activation of various transcription factors, 
ŶŽƚĂďůǇ WWZɲ ĂŶĚ WWZɶ(Finck and Kelly, 2006; Handschin and Spiegelman, 2006; 
Lin et al., 2005; Rosen and MacDougald, 2006) ?ĐƚŽƉŝĐĞǆƉƌĞƐƐŝŽŶŽĨW' ?ɲŝŶǁŚŝƚĞ
adipocytes induces expression of a number of mitochondrial and thermogenic genes, 
including UCP1 (Puigserver et al., 1998; Tiraby et al., 2003), therefore it is widely 
ĂĐĐĞƉƚĞĚƚŚĂƚW' ?ɲŝƐĞƐƐĞŶƚŝĂůĨŽƌďƌŽǁŶĂĚŝƉŽĐǇƚĞĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶĂŶĚŝŶĚƵĐƚŝŽŶŽĨ
the UCP1 gene.  
Several genes have been reported to influence brown fat development and function, 
ĂƚůĞĂƐƚŝŶƉĂƌƚ ?ƚŚƌŽƵŐŚƌĞŐƵůĂƚŝŶŐƚŚĞĞǆƉƌĞƐƐŝŽŶŽƌƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŽĨW' ?ɲ ?
KŶĞ ĞǆĂŵƉůĞ ŝƐ ƚŚĞ ĐŽƌĞƉƌĞƐƐŽƌ Z/W ? ? ? ? ǁŚŝĐŚ ďŝŶĚƐ W' ?ɲ ĚŝƌĞĐƚůǇ ĂŶĚ ďůŽĐŬƐ ŝƚƐ
traŶƐĐƌŝƉƚŝŽŶĂů ĂĐƚŝǀŝƚǇ ŽŶ ƐĞǀĞƌĂů ŐĞŶĞ ƉƌŽŵŽƚĞƌƐ ƐŚĂƌĞĚ ďǇ W' ?ɲ ĂŶĚ Z/W ? ? ? ?
including a brown fat selective gene CIDEA (cell-death inducing DFFA-like effector A) 
(Hallberg et al., 2008). The steroid receptor co-activator (SRC) family members, 
including SRC-1, 2 and 3, have distinct and overlapping functions in controlling energy 
metabolism and brown fat development (Louet and O'Malley, 2007). SRC-1 reinforces 
ƚŚĞĐŽĂĐƚŝǀĂƚŝŽŶŽĨW' ?ɲŽŶWWZɶ ?ƚŚĞƌĞĨŽƌĞŝƚƐĂďůĂƚŝŽŶ ŝn mice caused impaired 
thermogenesis with reduced UCP1 expression in BAT. In contrast, SRC-2 inhibits the 
ŝŶƚĞƌĂĐƚŝŽŶŽĨWWZɶǁŝƚŚW' ?ɲ ?ƐŽ ŝƚƐŬŶŽĐŬŽƵƚ ŝŶŵŝĐĞĚŝƐƉůĂǇƐ ŝŵƉƌŽǀĞĚĞŶĞƌŐǇ
expenditure and higher adaptive thermogenesis (Picard et al., 2002) ?W' ?ɲĂĐƚŝŽŶŝƐ
reduced by acetylation and, interestingly, SRC-3 induces GCN5, the major 
ĂĐĞƚǇůƚƌĂŶƐĨĞƌĂƐĞĂĐƚŝŶŐŽŶW' ?ɲƚŽƌĞƉƌĞƐƐ ŝƚƐƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇ (Lerin et al., 
2006). Ablation of SRC- ? ƌĞĚƵĐĞƐ ĂĐĞƚǇůĂƚŝŽŶ ŽĨ W' ?ɲ ? ůĞĂĚŝŶŐ ƚŽ ĂŶ ŝŶĐƌĞĂƐĞ ŝŶ
mitochondria biogenesis (Coste et al., 2008; Louet et al., 2006). Retinoblastoma 
ƉƌŽƚĞŝŶ ?ƉZď )ĂůƐŽŚĂƐďĞĞŶƐŚŽǁŶƚŽƌĞƉƌĞƐƐW' ?ɲƚƌĂŶƐĐƌŝƉƚŝŽŶďǇĚŝƌĞĐƚůǇďŝŶĚŝŶŐ
to its promoter (Scime et al., 2005), thus adipocytes from pRb-deficient fibroblasts or 
embryonic stem cells exhibit a brown fat phenotype with high mitochondrial content, 
ĂŶĚ ĞůĞǀĂƚĞĚ ĞǆƉƌĞƐƐŝŽŶ ŽĨ hW ? ? W' ?ɲ ĂŶĚ ŵŝƚŽĐŚŽŶĚƌŝĂů ŐĞŶĞƐ (Hansen et al., 
2004).  
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Taken together, ƚŚĞƐĞĚĂƚĂƐƵŐŐĞƐƚĞĚĂĚŽŵŝŶĂŶƚƌŽůĞŽĨW' ?ɲŝŶdĚĞǀĞůŽƉŵĞŶƚ
and function. In fact, both in vivo and in vitro studies have shown that genetic 
ĂďůĂƚŝŽŶŽĨW' ?ɲŐƌĞĂƚůǇƌĞĚƵĐĞƐĐĂƉĂĐŝƚǇĨŽƌĂĚĂƉƚŝǀĞƚŚĞƌŵŽŐĞŶĞƐŝƐŝŶƌĞƐƉŽŶƐĞƚŽ
cold exposure or cAMP(Lin et al., 2004; Uldry et al., 2006). However, many non-
cAMP-dependent brown adipocyte-ƐĞůĞĐƚŝǀĞ ŐĞŶĞƐ ĂƌĞ Ɛƚŝůů ĞǆƉƌĞƐƐĞĚ ŝŶ W' ?ɲ
knockout models, and the fat differentiation programme itself is not greatly altered 
(Seale et al., 2009) ? ŝŵƉůǇŝŶŐ ƚŚĂƚ ĂůƚŚŽƵŐŚ W' ?ɲ ŝƐ ĐƌƵĐŝĂů ŝŶ ƌĞŐƵůĂƚŝŶŐ ĂĚĂƉƚŝǀe 
ƚŚĞƌŵŽŐĞŶĞƐŝƐ ?ŝƚĚŽĞƐŶ ?ƚĚĞƚĞƌŵŝŶĞƚŚĞĐĞůůƵůĂƌƐƉĞĐŝĨŝĐĂƚŝŽŶŽĨďƌŽǁŶĂĚŝƉŽĐǇƚĞƐ ? 
1.3.4 PRD1-BF-1-RIZ1 Homologous Domain Containing Protein 16 (PRDM16) 
PRDM16 is a 140kD zinc finger protein originally identified at a chromosomal 
breakpoint of t(1; 3)(p36; q21)-positive human acute myeloid leukaemia cells, also 
named as MEL1 in humans (Mochizuki et al., 2000). PRDM16 is highly enriched in 
brown adipocytes compared to white adipocytes. When ectopically expressed in WAT 
preadipocytes or myoblasts, PRDM16 induces nearly complete brown adipogenic 
programme, including mitochondrial biogenesis, increased cellular respiration and 
expression of brown fat-selective genes, both the cAMP-inducible thermogenic genes 
 ?hW ? ?W' ?ɲĂŶĚĞŝŽĚŝŶĂƐĞ-d2) and those not sensitive to cAMP such as CIDEA and 
Elovl3 (Seale et al., 2007). Furthermore, transgenic expression of PRDM16 in adipose 
tissue increases the formation of multilocular brown-like fat pockets in WAT depots in 
ƌĞƐƉŽŶƐĞƚŽɴ-adrenergic agonist (Kajimura et al., 2010). 
PRDM16 was previously shown to directly bind to a specific DNA sequence through 
two sets of zinc fingers (ZF1 and ZF2 domains, Figure 1.10) in vitro (Nishikata et al., 
2003). However, abrogation of DNA binding using a point mutation did not alter the 
ability of PRDM16 to induce the brown fat phenotype compared to the wild-type 
protein, suggesting that PRDM16 was not working as a classical DNA-binding 
transcription factor. Further studies demonstrated that PRDM16, in addition to 
ŝŶĚƵĐŝŶŐW' ?ɲŐĞŶĞĞǆƉƌĞƐƐŝŽŶ ?ĚŝƌĞĐƚůǇďŝŶĚƐƚŽW' ?ɲĂŶĚW' ?ɴƚŽŝŶĐƌĞĂƐĞƚŚĞŝƌ
transcriptional activities (Seale et al., 2007). In fact, PRDM16 interacts with a number 
of DNA-ďŝŶĚŝŶŐƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌƐƐƵĐŚĂƐWWZɲ ?WWZɶ ?Ɖ ? ?ĂŶĚƐĞǀĞƌĂůŵĞŵďĞƌƐ
of the C/EBP family via one or more of PRDM16 zinc finger domains, resulting in 
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powerful coactivation of their transcriptional activities (Figure 1.11) (Kajimura et al., 
2009; Seale et al., 2008). 
 
 
 
 
 
Figure 1.11 Interaction between PRDM16 and other transcriptional regulators 
WZD ? ? ĚŝƌĞĐƚůǇ ŝŶƚĞƌĂĐƚƐ ǁŝƚŚ ĐĂŶŽŶŝĐĂů ƚƌĂŶƐĐƌŝƉƚŝŽŶ ĨĂĐƚŽƌƐ ƐƵĐŚ ĂƐ WWZɶ ?
WWZɲ ĂŶĚ  ?W ĨĂŵŝůǇ members and transcriptional co-ĂĐƚŝǀĂƚŽƌƐ W' ?ɲ ĂŶĚ
W' ?ɴƚŚƌŽƵŐŚƚŚĞƚǁŽƐĞƚƐŽĨǌŝŶĐĨŝŶŐĞƌĚŽŵĂŝŶƐ ?& ?ĂŶĚ& ? ) ?WZD ? ?ŝƐĂůƐŽ
associated with the co-repressor CtBP-1/2 through its PLDLS motif (Kajimura et al., 
2010).  
Figure 1.10 structure of human MEL1 (PRDM16) gene 
PRD indicates PR domain; DBD1, DNA-binding domain 1 (zinc finger 1, ZF1); PRD, 
proline rich domain; RD, repressor domain; DBD2, DNA-binding domain 2 (ZF2); 
AD, acidic domain (Nishikata et al., 2003). 
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PRDM16 represses the expression of white fat-selective genes by forming a 
transcriptional holocomplex with the well-known co-repressor proteins C-terminal-
binding-protein-1 (CtBP-1) and CtBP-2. The repression occurs through recruiting the 
PRDM16/CtBP complex onto the promoters of white fat-specific genes such as 
resistin, and is abolished in the genetic absence of CtBP-1 and CtBP- ? ? W' ?ɲ ĂŶĚ
W' ?ɴ ĐŽŵƉĞƚĞ ǁŝƚŚ ƚW-1/2 for binding to PRDM16 and once bound the 
PRDM16/PGC1ɲ ?ɴĐŽŵƉůĞǆĐĂŶƉŽǁĞƌĨƵůůǇĂĐƚŝǀĂƚĞďƌŽǁŶ ĨĂƚŐĞŶĞƐƐƵĐŚĂƐW' ?ɲ
itself (Kajimura et al., 2008). Therefore, PRDM16 switches off white fat gene 
expression through docking with CtBP-1/2 and switches on brown fat gene expression 
ďǇƚŚĞĂĐƚŝǀĂƚŝŽŶŽĨW' ?ɲ ?ɴŵĞĚŝĂƚĞĚǀŝĂĚŝƌĞĐƚƉƌŽƚĞŝŶ-protein binding. 
Loss of PRDM16 from brown preadipocytes not only causes nearly total loss of brown 
fat characteristics, but also, surprisingly, promotes skeletal myotube differentiation in 
culture with the features of formation of syncytia and ectopic activation of skeletal 
muscle-specific genes such as Myf5 and Myod. In vivo studies further confirmed this 
as BAT from PRDM16-deficient mice exhibits an abnormal morphology with reduced 
expression of brown fat-selective marker genes and elevated expression level of 
skeletal muscle-specific genes. Conversely, expression of PRDM16 in myogenic 
precursors drives a robust and functional programme of brown adipogenesis (Seale et 
al., 2008). The molecular mechanism of this brown fat/muscle switch was further 
investigated and evidence was provided that PRDM16 forms a transcriptional 
ĐŽŵƉůĞǆ ǁŝƚŚ ƚŚĞ ĂĐƚŝǀĞ ĨŽƌŵ ŽĨ  ?Wɴ  ?ĂůƐŽ ŬŶŽǁŶ ĂƐ >W ) ? ĂĐƚŝŶŐ ĂƐ Ă ĐƌŝƚŝĐĂů
molecular unit that controls the cell fate switch from myoblastic precursors to brown 
ĂĚŝƉŽĐǇƚĞƐ ?ĞƉůĞƚŝŽŶŽĨ ?WɴƐŝŐŶŝĨŝĐĂŶƚůǇďůƵŶƚƐƚŚĞĂďŝůŝƚǇŽĨWZD ? ?ƚŽŝnduce 
ƚŚĞ ďƌŽǁŶ ĂĚŝƉŽŐĞŶĞƐŝƐ ĂŶĚ d ĨƌŽŵ  ?Wɴ-deficient mice displays a similar 
molecular signature to BAT from PRDM16-deficient mice, with reduced expression of 
BAT-selective genes and increased expression of skeletal muscle-specific genes 
(Kajimura et al., 2009). Taken together, these data indicate that a PRDM16- ?Wɴ
complex controls the initiating events of the conversion from myoblastic precursors 
to brown adipocytes (Figure 1.12). Additionally, the combination of these two factors 
is sufficient to induce a fully functional brown fat programme in nonadipogenic cells 
such as embryonic fibroblasts and skin fibroblasts from mouse and man, with 
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extremely high oxygen consumption and high expression of brown fat-selective genes 
ŝŶĐůƵĚŝŶŐhW ?ĂŶĚW' ?ɲ(Kajimura et al., 2009). 
 
 
In conclusion, PRDM16 plays as a brown fat-specific determinant to induce the 
expression of genes associated with mitochondrial biogenesis, oxidative 
phosphorylation and oxidation of lipids, thus determining the thermogenic 
characteristics of brown adipocytes, although might not directly related to 
adipogenesis of BAT. 
Figure 1.12 PRDM16- ?Wɴ ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů ĐŽŵƉůĞǆ ĂĐƚƐ ŝŶ DǇĨ ?-positive 
ŵǇŽďůĂƐƚŝĐƉƌĞĐƵƌƐŽƌƐŽƌƉƌĞĂĚŝƉŽĐǇƚĞƐƚŽŝŶĚƵĐĞƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨWWZɶĂŶĚ
W' ?ɲ ? 
WZD ? ? ĐŽĂĐƚŝǀĂƚĞƐ WWZɶ ĂŶĚ W' ?ɲ ? ǁŚŝĐŚ ƚŚĞŶ ĚƌŝǀĞƐ Ă ďƌŽǁŶ ĨĂƚ
differentiation programme. The cAMP-dependent thermogenic gene programme 
is potentiated by FoxC2 and PRDM16. RIP140, Rb/p107 and TWIST1 antagonize 
ƚŚĞĞǆƉƌĞƐƐŝŽŶŽƌƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŽĨW' ?ɲĂŶĚƌĞƉƌĞƐƐďƌŽǁŶĂĚŝƉŽŐĞŶŝĐ
programme (Kajimura et al., 2010).  
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 ? ? ? ? ?d ?ŶŚĂŶĐĞƌŝŶĚŝŶŐWƌŽƚĞŝŶɴ ? ?Wɴ ? 
C/EBPs encompass a family of transcription factors containing basic leucine zipper 
(bZIP) domains that allow homo- and hetero- dimerization with bZIP transcriptional 
factors as well as DNA-binding elements (Lekstrom-Himes and Xanthopoulos, 1998). 
^ĞǀĞƌĂů ŵĞŵďĞƌƐ ŽĨ  ?W ĨĂŵŝůǇ  ?Ğ ?Ő ?  ?Wɲ ?  ?WɴĂŶĚ  ?Wɷ ) ŚĂǀĞ ƚŝƐƐƵĞ-
restricted expression patterns and have been involved in the regulation of energy 
homeostasis (Cao et al., 1991; Roesler, 2001) ? ?WɴŝƐŵŽƐƚĂďƵŶĚĂŶƚůǇĞǆƉƌĞƐƐĞĚ
in liver, BAT, WAT, reproductive tract and mammary gland (Akira et al., 1990; 
Descombes et al., 1990; Poli et al., 1990) ? dŚĞƌĞ ĂƌĞ ƚǁŽ ŝƐŽĨŽƌŵƐ ŽĨ  ?Wɴ
generated from a single exon mRNA by alternative translation, the full-length active 
form named LAP (liver-ĞŶƌŝĐŚĞĚƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀĂƚŽƌǇƉƌŽƚĞŝŶ ?ƚŚĞĂĐƚŝǀĞ ?Wɴ
isoforms, MW=35kD(LAP) or 38kD (LAP*)) and the truncated protein LIP (liver-
enriched transcriptiŽŶĂůŝŶŚŝďŝƚŽƌǇƉƌŽƚĞŝŶ ?ƚŚĞŝŶŚŝďŝƚŽƌǇ ?WɴŝƐŽĨƌŵ ?DtA? ? ?Ŭ ) ?
which lacks the transactivation domain and acts as a dominant negative regulator of 
LAP (Descombes and Schibler, 1991) (Figure 1.13). 
 
 
&ŝŐƵƌĞ ? ? ? ?^ĐŚĞŵĂƚŝĐƐƚƌƵĐƚƵƌĞĚŝĂŐƌĂŵƐŽĨ ?WɴŝƐŽĨŽƌŵƐ 
dŚĞĂĐƚŝǀĞŝƐŽĨŽƌŵƐŽĨ ?Wɴ>W ?ĂŶĚ>AP, as well as the inhibitory isoform LIP 
are translated from a single exon mRNA by alternative translation. All the three 
isoforms share a regulatory domain (Reg) and the basic leucine zipper tail (bZIP) 
containing a DNA binding domain (DBD) that also serves as primary nuclear 
localization signal (NLS), a dimerization domain (Dimer) and an interaction domain 
that directly interacts with acidic DNA (negative charged). These common 
components constitute the inhibitory isoform LIP and both active isoforms also 
contain transcription activation domain (TAD) which makes them active in 
facilitating the transcription of some certain genes. 
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 ?Wɴ ?ĂƐƌĞǀŝĞǁĞĚĂďŽǀĞ ?ĂĐƚŝǀĂƚĞƐWWZɶďǇŝŶĚƵĐŝŶŐĂƉƌŽŐƌĂŵŵĞůĞĂĚŝŶŐƚŽƚŚĞ
ƐǇŶƚŚĞƐŝƐŽĨWWZɶĐŽ-activators, thus inducing a cascade of adipogenic events. The 
ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶŽĨ ?WɴŝƐĞƐƐĞŶƚŝĂůĨŽƌƚŚĞĞǆƉƌĞƐ ŝŽŶŽĨ ?WɲďǇWWZɶĂŶĚĂ
ƐĞƚŽĨ ?WɲƚĂƌŐĞƚŐĞŶĞƐ(Farmer, 2005). As a crucial regulator of the two essential 
ĂĚŝƉŽŐĞŶŝĐ ƌĞŐƵůĂƚŽƌƐWWZɶĂŶĚ ?Wɲ ? ?WɴŶŽƚ ŽŶůǇƉůĂǇƐ ŝŵƉŽƌƚĂŶƚ ƌŽůĞƐ ŝŶ
ĂĚŝƉŽŐĞŶĞƐŝƐŽĨďŽƚŚtdĂŶĚd ? ŝƚ ĂůƐŽ ? ůŝŬĞ WWZɶ ?ŚĂƐ ƐƉĞĐŝĂůŝǌĞĚ ĨƵŶĐƚŝŽŶƐ ŝŶ
ďƌŽǁŶĂĚŝƉŽĐǇƚĞƐ ? ?WɴŝƐĞŶƌŝĐŚĞĚŝŶďƌŽǁŶƌĞůĂƚŝǀĞƚŽǁŚŝƚĞĂĚŝƉŽĐǇƚĞƐ ? Involved 
ŝŶƚŚĞƌĞŐƵůĂƚŝŽŶŽĨhW ?ƚƌĂŶƐĐƌŝƉƚŝŽŶ ?ƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴŝƐĂůƐŽĞŶŚĂŶĐĞĚŝŶ
BAT after cold exposure (Manchado et al., 1994)  ?ŝŶĚŝĐĂƚŝŶŐƚŚĂƚ ?WɴĞǆƉƌĞƐƐŝŽŶ
ŝŶ d ŝƐ ƌĞŐƵůĂƚĞĚ ďǇ ɴZ ǀŝĂ ƚŚĞ ĐDW-PKA pathway. When placed in cold 
ĞŶǀŝƌŽŶŵĞŶƚ ?  ?Wɴ ŶƵůů ŵŝĐĞ ĐĂŶŶŽƚ ŵĂŝŶƚĂŝŶ ďŽĚǇ ƚĞŵƉĞƌĂƚƵƌĞ ĂůƚŚŽƵŐŚ ƚŚĞ
ĞǆƉƌĞƐƐŝŽŶŽĨhW ?ĂŶĚW' ?ɲŐĞŶĞŝƐŶŽƚƐƵďƐƚĂŶƚŝĂůůǇĂůƚĞƌĞĚĂŶĚƚŚĞ induction of 
gene expression by noradrenaline in BAT is preserved. The UCP1 gene promoter is 
ƌĞƉƌĞƐƐĞĚďǇ>/WĂŶĚƐŝŶĐĞ ?WɴŶƵůůŵŝĐĞůĂĐŬďŽƚŚ ?WɴŝƐŽĨŽƌŵƐ>WĂŶĚ>/W ?
the absence of inhibitory isoform LIP may have a stronger effect than the absence of 
active isoform LAP upon UCP1 gene expression (Carmona et al., 2005). The cAMP-
ŝŶĚƵĐŝďůĞW' ?ɲĂŶĚhW ?ĞǆƉƌĞƐƐŝŽŶŝƐŽŶĞŽĨƚŚĞŵŽƐƚŝŵƉŽƌƚĂŶƚĨĞĂƚƵƌĞƐŽĨďƌŽǁŶ
ďƵƚŶŽƚǁŚŝƚĞĂĚŝƉŽĐǇƚĞƐ ?KǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ ?Wɴ ŝŶ  ?d ?-L1 white preadipocytes 
rescues the cAMP-ŝŶĚƵĐŝďůĞW' ?ɲĂŶĚhW ?ĞǆƉƌĞƐƐŝŽŶďǇĂĐƚŝŶŐŽŶZŝŶW' ?ɲ
ƉƌŽŵŽƚĞƌ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ɴ-adrenergic agonist (Karamanlidis et al., 2007). Most 
ŶŽƚĂďůǇ ?  ?Wɴ ĨŽƌŵƐ Ă ĐŽŵƉůĞǆ ǁŝƚŚ WZD ? ? ƚŽ ŝŶŝƚŝĂƚĞ ŚĞ ďƌŽǁŶ ĂĚŝƉŽŐĞŶŝĐ
programme from myoblastic precursor cells and even to reconstitute a brown fat 
programme in naïve cells when ectopically co-expressed in mouse embryonic 
fibroblasts (MEFs) and primary skin fibroblasts (Kajimura et al., 2009). These data 
ĐŽŶƐŝƐƚĞŶƚůǇ ŝŶĚŝĐĂƚĞ ƚŚĞ ŝŵƉŽƌƚĂŶƚ ƌŽůĞ ŽĨ  ?Wɴ ŝŶ ƌĞŐƵůĂƚŝŶŐ ĂĚĂƉƚŝǀĞ
thermogenesis in BAT as well as the brown fat developmental programme, although 
large part of the regulation mechanism details still remains to be elucidated more 
clearly. 
The interaction of C/EBPɴ with the other (co)activators in regulating UCP1 
transcription was summarized in the following hypothetical model (Figure 1.14), 
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consisting of the critical transcription factor PPARɶ and the primary transcriptional 
regulators PGC1ɲ and PRDM16. 
 
 
 
 
 
Figure 1.14 Model for C/EBPɴ interacting with other (co)activators in regulating 
PGC1ɲ/UCP1 transcription. 
A hypothetical model for higher PGC1ɲ/UCP1 promoter activity through higher 
C/EBPɴ cellular concentration and phosphorylation in response to cAMP-PKA 
signalling pathway is proposed. C/EBPɴ forms a complex with PRDM16 and 
stimulates PGC1ɲ transcription, which in turn increases PGC1ɲ expression itself 
and activates PPARɶ in presence of PPARɶ ligand. The active PPARɶ together with 
PGC1ɲ and PRDM16 act on the PPRE of UCP1 promoter to stimulate the 
transcription. Besides, C/EBPɴ can also act on CRE of PGC1ɲ/UCP1 promoter by 
binding CREB to activate the transcriptional activity. P: phosphate group; L: ligand. 
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1.3.6 Other (co)activators 
Besides the main brown adipogenic and thermogenic regulators reviewed above, 
there are also a number of other (co)activators participating in the complicated and 
delicate regulating network, co-ordinately regulating the function of adaptive 
thermogenesis in BAT.  
Forkhead box C2 (FoxC2) 
FoxC2, a member of the forkhead/ winged helix transcription factor family, promotes 
brown fat phenotype. In particular, increased expression of FoxC2 in adipose tissue 
induces the expression of a set of brown fat-selective genes including UCP1, leading 
to a lean and insulin-sensitive phenotype in white adipose tissue. FoxC2 affects 
ĂĚŝƉŽĐǇƚĞ ŵĞƚĂďŽůŝƐŵ ďǇ ŝŶĐƌĞĂƐŝŶŐ ƚŚĞ ƐĞŶƐŝƚŝǀŝƚǇ ŽĨ ƚŚĞ ɴ-adrenergic-cAMP-PKA 
signalling pathway through alteration of adipocyte PKA holoenzyme composition 
(Cederberg et al., 2001). Despite the function of promoting brown fat development, 
FoxC2 is not preferentially expressed in BAT relative to WAT. In fact, FoxC2 is 
abundantly expressed in adipose tissue, equally in WAT and BAT, at least at the mRNA 
level (Cederberg et al., 2001; Seale et al., 2009). It also remains to be determined 
whether FoxC2 is genetically required in brown adipocyte differentiation and 
thermogenesis by loss of function studies. 
Bone morphogenetic protein 7 (BMP7) 
Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor-ɴ  ?d'&-ɴ ) ƐƵƉĞƌĨĂŵŝůǇ ĂŶĚ ĐŽŶƚƌŽů ŵƵůƚŝƉůĞ ŬĞǇ ƐƚĞƉƐ ŽĨ ĞŵďƌǇŽŶŝĐ
development and differentiation (Chen et al., 2004). Although some members of 
BMPs support white adipocyte differentiation, BMP7 promotes differentiation of the 
mesenchymal cell line C3H10T1/2 to the brown preadipocytes even in the absence of 
the normally required hormonal induction cocktail (Tseng et al., 2008). BMP7 
activates a full programme of brown adipogenesis including induction of early 
ƌĞŐƵůĂƚŽƌƐ ŽĨ ďƌŽǁŶ ĂĚŝƉŽŐĞŶĞƐŝƐ ? WZD ? ? ĂŶĚ W' ?ɲ ? ŝŶĐƌĞĂƐĞĚ ĞǆƉƌĞƐƐŝŽŶ ŽĨ
brown-fat-defining marker UCP1. BMP7 also increases adipogenic transcription 
ĨĂĐƚŽƌƐWWZɶĂŶĚ ?WƐĂŶĚŝŶĚƵĐĞƐŵŝƚŽĐŚŽŶĚƌŝĂůďŝŽŐĞŶĞƐŝƐ ?ǀŝĂƉ ? ?DWŬŝŶĂƐĞ- 
and PGC1-dependent pathways. Moreover, BMP7 knockout embryos show a marked 
paucity of brown fat and an almost complete absence of UCP1. These data reveal a 
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critical role of BMP7 in promoting brown adipocyte differentiation and thermogenesis 
(Tseng et al., 2008).  
A JmjC-containing H3K9 demethylase: Jhdm2a 
JHDM2A specifically demethylates mono- and di- methyl-H3K9 through the Jmjc 
domain and a zinc finger. It has been reported to be important in nuclear hormone 
receptor mediated gene activation and male germ cell development (Yamane et al., 
2006). Disruption of the Jhdm2a gene in mice results in obesity and hyperlipidemia, 
ĚŝƐƌƵƉƚƐɴ-adrenergic-stimulated glycerol release and oxygen consumption in brown 
adipose tissue and decreases fat oxidation and glycerol release in skeletal muscles. 
dŚĞĞǆƉƌĞƐƐŝŽŶŽĨ:ŚĚŵ ?ĂŝƚƐĞůĨŝƐŝŶĚƵĐĞĚďǇɴ-adrenergic stimulation, and it directly 
ƌĞŐƵůĂƚĞƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨhW ?ĂŶĚW' ?ɲďǇďŝŶĚŝŶŐƚŽWWZŽĨƚŚĞƚŚĞƌŵŽŐĞŶŝĐ
ŐĞŶĞƐ ŝŶ ƉƌĞƐĞŶĐĞ ŽĨ ɴ-adrenergic agonist, thus decreasing levels of H3K9Me2 
(dimethylation of lysine 9 of histone H3) at PPRE and facilitating the recruitment of 
WWZɶ ĂŶĚ ZyZɲ ĂƐ ǁĞůů ĂƐ ƚŚĞŝƌ ĐŽ-activators to the PPRE (Tateishi et al., 2009). 
Therefore, Jhdm2a has an essential role in regulating thermogenic gene expression in 
BAT by modifying the pattern of chromatin remodelling on these genes.  
Insulin receptor substrate-1 (IRS-1) 
IRS-1 is one of the insulin receptor substrates, involved in the signalling network of 
insulin promoting adipocyte differentiation. In cultured brown preadipocytes, 
expression of IRS-1 mRNAs and proteins is reduced gradually as the cells differentiate 
into mature adipocytes. IRS-1 knockout mice exhibit severe defects in brown 
adipogenesis and a marked decrease in the expression of the brown adipogenic 
ŵĂƌŬĞƌŐĞŶĞƐŝŶĐůƵĚŝŶŐWWZɶ ? ?WɲĂŶĚƚŚĞƌŵŽŐĞŶŝĐŐĞŶĞW' ?ɲ ?ZĞĐŽŶƐƚŝƚƵƚŝŽŶ
of the IRS-1 knock out cells with the IRS-1 protein rescues the adipogenic capability 
and restores the reduced expression of the brown adipogenic and thermogenic genes 
(Tseng et al., 2004). These data indicate that IRS-1 plays important role in brown 
adipocyte differentiation.  
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Silent mating type information regulation 2, homolog 3 (Sirt 3) and Estrogen-
Related ZĞĐĞƉƚŽƌɲ ?ZZɲ ?
Sirt 3 is a member of the sirtuin family of protein deacetylases with multiple actions 
on metabolism and gene expression and, as a gene localized in mitochondria, its 
expression is associated with energy homeostasis and metabolism in brown adipocyte 
development (Verdin et al., 2010) ?dŚĞĞǆƉƌĞƐƐŝŽŶŽĨ^ŝƌƚ ?ĐĂŶďĞŝŶĚƵĐĞĚďǇW' ?ɲ
in white adipocytes and embryonic fibroblasts as part of its overall induction of a 
brown adipose tissue-ƐƉĞĐŝĨŝĐƉĂƚƚĞƌŶŽĨŐĞŶĞĞǆƉƌĞƐƐŝŽŶ ? /Ŷ^ŝƌƚ  ?ŶƵůůĐĞůůƐ ?W' ?ɲ
fails to induce a complete set of brown fat-specific thermogenic gene expression.  The 
ŽƌƉŚĂŶŶƵĐůĞĂƌƌĞĐĞƉƚŽƌZZɲŝƐƌĞƋƵŝƌĞĚƚŽďŝŶĚƚŚĞƉƌŽǆŝŵĂůƉƌŽŵŽƚĞƌŽĨ^ŝƌƚ ?ĨŽƌ
ĨƵůůǇ ŝŶĚƵĐŝŶŐ ^ŝƌƚ  ? ŐĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ W' ?ɲ ? ƐƵŐŐĞƐƚĞĚ ďǇ ƚŚĞ
ŬŶŽĐŬĚŽǁŶ ĂƐƐĂǇƐ ŽĨ ZZɲ (Giralt et al., 2011) ? /Ŷ ƚŚĞƐĞ ƐƚƵĚŝĞƐ ? ZZɲ ŝƐ ĂĐƚŝŶŐ
positively in stimulating the thermogenic programme in BAT. However, studies from 
>ƵŽĂŶĚĐŽůůĞĂŐƵĞƐƐŚŽǁĞĚƚŚĂƚƚŚĞ ZZɲŶƵůůŵŝĐĞŚĂǀĞƌĞĚƵĐĞĚďŽĚǇǁĞŝŐŚƚĂŶĚ
peripheral fat deposits and are resistant to high-fat diet-induced obesity (Luo et al., 
2003) ?ŝŵƉůǇŝŶŐĂŶĞŐĂƚŝǀĞƌĞŐƵůĂƚŽƌǇƌŽůĞŽĨZZɲŝŶƚŚĞĂĚĂƉƚŝǀĞƚŚĞƌŵŽŐĞŶĞƐŝƐŝŶ
BAT (Collins et al., 2010) ?ƵĞƚŽƚŚĞ ůĂĐŬŽĨĂŶĂƚƵƌĂůZZɲ ůŝŐĂŶĚ ?ĚĞƚĞƌŵŝŶĂƚŝŽŶŽĨ
ƚŚĞƉŚǇƐŝŽůŽŐŝĐĂůĨƵŶĐƚŝŽŶŽĨZZɲŝƐƌĂƚŚĞƌůŝŵŝƚĞĚ ?ƐŽmore research is still required 
ƚŽĐůĞĂƌůǇĞůƵĐŝĚĂƚĞƚŚĞĨƵŶĐƚŝŽŶƐŽĨZZɲĂŶĚƚŚƵƐƚŽĞǆƉůĂŝŶƚŚĞĐŽŶƚƌŽǀĞƌƐǇĂďŽǀĞ ? 
1.3.7 Repressors 
In addition to the much effort to investigate the activating or stimulatory mechanisms 
mentioned above, it is equally important to identify and understand the factors that 
ƌĞƉƌĞƐƐƚŚĞƉƌŽĐĞƐƐŽĨdĂĚĂƉƚŝǀĞƚŚĞƌŵŽŐĞŶĞƐŝƐ ?ĂƐƉŽƚĞŶƚŝĂů “ĂĐƚŝǀĂƚŽƌƐ ?ŵĂǇŶŽƚ
work if there is active repression. Some (co)repressors have already been addressed 
ĂďŽǀĞŝŶƚŚĞƐĞĐƚŝŽŶĂďŽƵƚW' ?ɲ ?Z/W ? ? ?ďǇĚŝƌĞĐƚďŝŶĚ Ő ?^Z ?Ănd pRb), so in the 
ƉĂƌĂŐƌĂƉŚƐďĞůŽǁ ?ƐŽŵĞW' ?ɲ-independent repressing mechanisms and regulators 
will be reviewed to further complete the whole regulating network.  
Receptor-interacting protein 140 (RIP140) 
RIP140 was originally identified by its ability to interact with estrogen receptors and 
to repress their transcriptional activity (Cavailles et al., 1995). Subsequently, RIP140 
was found to bind and repress a number of other nuclear receptors including PPARs, 
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ƚŚǇƌŽŝĚŚŽƌŵŽŶĞƌĞĐĞƉƚŽƌƐ ?dZɲĂŶĚdZɴ )ĂŶĚĞƐƚƌŽŐĞŶ-ƌĞůĂƚĞĚƌĞĐĞƉƚŽƌƐ ?ZZɲĂŶĚ
ZZɴ ) ? ƉĂƌƚŝĐƵůĂƌůǇ ŝŵƉŽƌƚĂŶƚ ŝŶ ƌĞŐƵůĂƚŝŶŐ ŐĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ŝŶ ŵĞƚĂďŽůŝĐ ƚŝƐƐƵĞƐ ?
specifically adipose tissue, muscle and liver (Francis et al., 2003). Knockout of RIP140 
in mice leads to extremely lean phenotype, resistance to obesity, enhanced glucose 
tolerance and insulin sensitivity compared with matched wild-type littermates fed a 
high-fat diet. Depletion of RIP140 in white adipose tissue induces a numbers of brown 
fat-specific features, notably the upregulation of UCP1 (Leonardsson et al., 2004). 
Further studies revealed that RIP140 is essential for both DNA and histone 
methylation of UCP1 gene to maintain the repression. RIP140 expression promotes 
the assembly of DNA and histone methyltransferases (HMTs) on the UCP1 enhancer 
and leads to methylation of specific CpG residues and histones as judged by bisulphite 
genomic sequencing and chromatin immunoprecipitation (ChIP) assays, resulting in 
the inhibition of UCP1 gene transcription (Kiskinis et al., 2007) (Figure 1.14).   
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Figure 1.14 RIP140 acts as a transcriptional corepressor of UCP1 gene. 
RIP140 acts as a transcriptional corepressor of PPARs, blocking UCP1 promoter 
activation through the recruitment of DNA methyltransferase (Dnmt), COOH-
terminal binding protein (CtBP), histone methyltransferase (HMT) and histone 
deacytylase (HDAC) (Fritah et al., 2010). 
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>ŝǀĞƌyZĞĐĞƉƚŽƌɲ ?>yZɲ ? 
LXRs are ligand-activated transcription factors of the nuclear receptor superfamily, 
characterized as key transcriptional regulators of lipid and carbohydrate metabolism 
(Baranowski, 2008). LXR ligand significantly blunts the response of UCP1 gene to 
ŵŝŵŝĐŬĞĚ^E^ƐƚŝŵƵůĂƚŝŽŶƐƵĐŚĂƐƚƌĞĂƚŵĞŶƚǁŝƚŚƚŚĞɴZĂŐŽŶŝƐƚŝƐŽƉƌĞŶĂůŝŶĞŽƌƚŚĞ
adenylyl cyclase activator forskolin, but has no effect on cAMP-ĚĞƉĞŶĚĞŶƚ W' ?ɲ
gene expression (Wang et al., 2008b). There is a direct repeat sequence (DR4), which 
is a potential LXR binding site, in the important enhancer region of UCP1 gene, and 
gel shift and ChIP assay experiments as well as the site mutation in the DR4 region 
ĨŝƌŵůǇƉƌŽǀĞĚƚŚĂƚ>yZɲĚŽĞƐďŝŶĚƚŽƚŚĂƚƌĞŐŝŽŶƚŽƌĞƉƌĞƐƐhW ?ŐĞŶĞƚƌĂŶƐĐƌŝƉƚŝŽŶ ?
This inhibition mechanism involves the differential recruitment of the corepressor 
Z/W ? ? ? ƚŽ ĂŶ >yZɲ ďŝŶĚŝŶŐ ƐŝƚĞ ƚŚĂƚ ŽǀĞƌůĂƉƐ ǁŝƚŚ ƚŚĞ WWZɶ ?W' ?ɲ ƌĞƐƉŽŶƐĞ
element, ƌĞƐƵůƚŝŶŐ ŝŶ ƚŚĞ ĚŝƐŵŝƐƐĂů ŽĨ WWZɶ  ?&ŝŐƵƌĞ  ? ? ? ? )(Wang et al., 2008b). 
WŚŽƐƉŚŽƌǇůĂƚŝŽŶŽĨ>yZɲďǇW<ŚĂƐďĞĞŶƐŚŽǁŶƚŽďĞĂŶĞĐĞƐƐĂƌǇƐƚĞƉŝŶǀŽůǀĞĚ ŝŶ
ƚŚĞ ƌĞƉƌĞƐƐŝŽŶ ŵĞĐŚĂŶŝƐŵ ? ŶŽƚ ƌĞƋƵŝƌĞĚ ĨŽƌ ƚŚĞ ďŝŶĚŝŶŐ ŽĨ >yZɲ ƚŽ DR4 but 
indispensable for recruiting RIP140 to the site (Collins et al., 2010) ?dŚĞĂďŝůŝƚǇŽĨ>yZɲ
to reduce energy expenditure in this way provides another mechanism of maintaining 
the balance between energy storage and utilization. 
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&ŝŐƵƌĞ ? ? ? ?ĂƌƚŽŽŶŵŽĚĞůĨŽƌ>yZɲƌĞŐƵůĂƚŝŽŶŽĨhW ?ŐĞŶĞƚƌĂŶƐĐƌŝƉƚŝŽŶ 
 ?Ă ) ĐƚŝǀĂƚŝŽŶ ŽĨ W< ďǇ ɴZƐ ůĞĂĚƐ ƚŽ Ɖ ? ? DW ŬŝŶĂƐĞ ĂĐƚŝǀŝƚǇ ĂŶĚ
ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ŽĨ ŶƵĐůĞĂƌ ĨĂĐƚŽƌƐ ƐƵĐŚ ĂƐ d& ? ĂŶĚ W' ?ɲ ƚŽ increase 
transcription of the UCP1 gene. Also in response to PKA there is phosphorylation 
ŽĨ>yZɲďǇĂŶƵŶŝĚĞŶƚŝĨŝĞĚŬŝŶĂƐĞ ? ?ď )tŚĞŶĂŶ>yZůŝŐĂŶĚŝƐƉƌĞƐĞŶƚ ?ƚŚĞŶƵĐůĞĂƌ
corepressor RIP140 is recruited to the complex (step 2), and the critical regulator 
PPAR is eliminated from its DR-1 binding site (step 3), the net result of which is 
repression of UCP1 gene transcription (Collins et al., 2010).  
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Cell death-ŝŶĚƵĐŝŶŐEĨƌĂŐŵĞŶƚĂƚŝŽŶĨĂĐƚŽƌɲ-like effector A (CIDEA) 
Cidea is a member of the CIDE family of proteins and shares homology with the N-
terminal region of the apoptotic DNA fragmentation factors Dffb and Dffa, and 
induces caspase-independent cell death when overexpressed (Inohara et al., 1998). 
Cidea is highly expressed in brown adipose tissue, thus is considered as one of the 
brown fat marker genes (Zhou et al., 2003). However, Cidea null mice display a lean 
phenotype, are resistant to diet-induced obesity and diabetes, and have a higher 
metabolic rate, lipolysis in BAT and core body temperature, when subjected to cold 
treatment (Zhou et al., 2003), implying a negative regulatory role of Cidea in 
thermogenic process. Unlike UCP1 that is stimulated by cold exposure, Cidea 
expression is down-regulated by acute cold exposure mediated by sympathetic 
ĂĐƚŝǀĂƚŝŽŶŽĨɴ ?-adrenergic receptor, as evidenced by attenuation of the response by 
ɴ-adrenergic receptor antagonists (Shimizu and Yokotani, 2009). Western blotting 
and immunoprecipitation studies have demonstrated that CIDEA directly binds UCP1 
when the two genes are co-overexpressed in yeast cells, and that this interaction 
between CIDEA and UCP1 inhibits the uncoupling activity of the latter while the 
expression of CIDEA alone does not significantly influence the basal uncoupling 
activity of the cells (Zhou et al., 2003).  
Although Cidea and UCP1 co-localize on the inner membrane of mitochondria and 
expression of both can be up-regulated by the knockdown of some common 
thermogenic repressors (e.g. RIP140, see above), they have opposite response to cold 
exposure, indicating they are regulated differently by the same signalling pathway 
(cAMP-PKA pathway). The inhibitory effect of Cidea on UCP1 expression may reflect a  
mechanism for fine tuning UCP1 activity by increasing the threshold for UCP1 activity 
thus rendering thermogenesis more sensitive to physiological stimuli-controlling 
UCP1 concentration (Zhou et al., 2003).  
Eukaryotic initiation factor 4E binding protein 1 (4E-BP1) 
In mammalian cells, the initiation phase of mRNA translation involves the recognition 
ŽĨƚŚĞŵZE ? ?ĐĂƉƐƚƌƵĐƚƵƌĞďǇƚŚĞĞƵŬĂƌǇŽƚŝĐŝŶŝƚŝĂƚŝŽŶĨĂĐƚŽƌ ?& ?Ě/& ?& )ĐĂƉ-binding 
complex, which consists of three subunits: eIF4A, eIF4E and eIF4G(Poulin and 
Sonenberg, 2003). The activity of eIF4E is regulated by its interaction with a family of 
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three inhibitory proteins, the eIF4E binding proteins (4E-BPs). In its phosphorylated 
form, 4E-BP1 binds to eIF4E and prevents the formation of the eIF4F complex, thus 
inhibiting cap-dependent translation (Gingras et al., 1999; Haghighat et al., 1995). 
Therefore it was reasonable to expect the 4E-BP1 deficient cells to display a global 
increase in tissue protein synthesis, however, surprisingly, the 4E-BP1 knockout mice 
were found to contain an increased number of multilocular adipocytes in the inguinal 
and retro-ƉĞƌŝƚŽŶĞĂůtdĚĞƉŽƚƐĂŶĚĞůĞǀĂƚĞĚW' ?ɲĂŶĚhW ?ĞǆƉƌĞƐƐŝŽŶĂƐǁĞůůĂƐ
increased whole body energy expenditure(Tsukiyama-Kohara et al., 2001). As a 
potential specific repressor of UCP1 expression, 4E-BP1 expression is decreased 
ĚƵƌŝŶŐ ĐŽůĚ ƐƚƌĞƐƐ ĂŶĚ ƚŚŝƐ ŝŶŚŝďŝƚŽƌǇ ĞĨĨĞĐƚ ŝƐ ƌĞǀĞƌƐĞĚ ŝŶ ɴ ?- ? ďƵƚ ŶŽƚ ɴ ? ?ɴ ?-,
adrenoceptor knockout mice. The data indicated that 4E-BP1 is regulated specifically 
ďǇ ɴ ?-adrenergic receptor mediated pathway, in support of its role in adaptive 
thermogenesis (Lehr et al., 2004).  
In summary of the different transcriptional regulators in controlling adaptive 
thermogenesis in brown adipose tissue, the features of different animal models 
(either knockout or transgenic models) targeting brown adipose tissue-related 
proteins were concluded below (Table 1.2) to provide a brief but comprehensive view 
on the functions of the regulators. 
 
Reference  Model 
(KO/TG)  
Changes in BAT  Whole body metabolic 
phenotype  
(Cederberg et 
al., 2001) 
TG FoxC2 
in fat cells  
Higher interscapular BAT 
and increased expression of 
C/EBPɲ, PPARɶ, SREBP1 and 
metabolic rate in TG WAT  
Lower HFD-induced weight gain 
and fat accumulation and 
improved glucose control  
(Picard et al., 
2002) 
SRC1 KO  Higher lipid infiltration and 
lower expression of UCP1 
and PGC1ɲ 
Higher HFD-induced weight gain, 
reduced metabolic rate and 
body temperature at 4°C  
(Picard et al., 
2002) 
TIF2 KO  Lower lipid infiltration and 
higher expression of UCP1 
and PGC1ɲ 
Lower HFD-induced weight gain 
and fat accumulation and 
improved glucose control. 
Higher metabolic rate and body 
Table 1.2 Animal models targeting brown adipose tissue-related proteins 
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temperature at 4°C  
(Coste et al., 
2008) 
SRC3 KO  Lower lipid infiltration and 
increased mitochondrial 
number 
Lower HFD-induced weight gain 
and fat accumulation and 
improved glucose control. 
Higher metabolic rate, body 
temperature and muscle 
mitochondrial content 
(Scime et al., 
2005) 
p107 KO  White fat cells with 
multilocular lipid droplets 
ĂŶĚ ŚŝŐŚ hW ? ĂŶĚ W' ?ɲ
levels 
Lower WAT mass and increased 
metabolic rate 
(Tseng et al., 
2008) 
BMP7 KO  Lower BAT mass at birth Mice are not viable after birth 
(Tseng et al., 
2008) 
BMP7 TG  Increase in brown but not 
white fat mass 
Higher metabolic rate and body 
temperature and lower weight 
gain 
(Leonardsson 
et al., 2004) 
RIP140 KO Higher expression of UCP1 
and CPT1b 
Lower HFD-induced weight gain 
and liver fat accumulation. 
Higher metabolic rate 
(Kang et al., 
2005) 
UCP1-
Wnt10b 
TG  
Lack of functional BAT with 
ůŽǁĞƌ ĞǆƉƌĞƐƐŝŽŶ ŽĨ W' ?ɲ
and UCP1 
Blunted increase in body 
ƚĞŵƉĞƌĂƚƵƌĞ ĂĨƚĞƌ ɴ-agonist 
stimulation 
(Pan et al., 
2009) 
Adipose 
tissue TG 
twist-1  
>ŽǁĞƌ ĞǆƉƌĞƐƐŝŽŶ ŽĨ W' ?ɲ
and UCP1. Lower metabolic 
rate and mitochondrial 
density. Higher lipid 
infiltration.  
Higher HFD-induced weight gain 
and lower body temperature at 
night 
(Pan et al., 
2009) 
Twist-1 
+/-  
Lower lipid infiltration. 
Higher mitochondrial 
number and metabolic rate 
Lower HFD-induced weight gain 
and higher body temperature at 
night 
(Seale et al., 
2010) 
PRDM16 
+/- 
Lower expression of brown 
selective genes including 
hW ? ?ŝĚĞĂĂŶĚW' ?ɲ 
Lowe metabolic rate 
(Seale et al., 
2010; Seale 
et al., 2007) 
PRDM16 
adipose 
tissue TG 
Appearance of multilocular 
adipocytes and higher 
expression of BAT genes, 
including UCP1, Cidea and 
Lower HFD-induced weight gain, 
less fat and more lean mass in 
body composition, higher 
metabolic rate and improved 
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W' ?ɲ ?ŝŶtd glucose control 
(Motyl et al.; 
Staiger et al., 
2009) 
C/EBPɴKO Defective lipid accumulation Reduced peripheral fat mass, 
lower levels of serum insulin and 
leptin 
(Accili et al., 
1999; 
Kulkarni et 
al., 1999; 
Tseng et al., 
2004) 
IRS-1 KO Sever defect in brown 
adipogenesis 
Growth retarded, insulin 
secretory defects and reduced 
insulin expression 
(Tsukiyama-
Kohara et al., 
2001) 
4E-BP1 
KO 
Reduced WAT mass, 
appearance of multilocular 
adipocytes in WAT pad and 
ŝŶĐƌĞĂƐĞĚ hW ? ĂŶĚ W' ?ɲ
expression 
Higher metabolic rate 
(Lin et al., 
2004) 
W' ?ɲ<K Impaired cold-induced UCP1 
expression 
Impaired glucose homeostasis, 
higher O2 consumption rate, 
resistant to HFD-induced obesity 
and insulin resistance, lower 
body temperature at 4°C,  
(Zhou et al., 
2003) 
CIDEA KO Higher metabolic rate and 
lipolysis 
Higher metabolic rate and core 
body temperature at 4°C, lean 
and resistant to HFD-induced 
obesity and diabetes 
Abbreviations: BAT, brown adipose tissue; HFD, high-fat diet; KO, knockout mice; TG, transgenic mice; 
WAT, white adipose tissue. 
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1.4 VIRAL VECTOR-MEDIATED GENE TRANSFER TO ANIMAL CELLS 
The delivery of DNA into animal cells is a fundamental and well-established procedure 
widely used in research, indispensable for gene cloning, the study of gene function 
and regulation. Most of experiments reviewed above involve gene transfer as the 
over-expression (gain-of-function) of a specific target gene has become the most 
commonly used and necessary tool in investigating the function of the gene. 
Additionally, most gene knockout experimental procedures (e.g. RNAi) share the 
identical or similar methods with that of gene transfer. 
Historically, in order to deliver the DNA (or siRNA) of interest into target mammalian 
cells or even animals, investigators have used a number of methods, including 
chemical and physical transfection of naked DNA or plasmid DNA, adenoviral vector-
mediated gene delivery, adeno-associated viral vector-mediated gene delivery, 
retroviral vector-mediated gene delivery and lentiviral vector-mediated gene delivery. 
Some methods only results in temporary transgene expression (transient 
ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ) ƚŚĂƚǁŽŶ ?ƚ ůĂƐƚ ĨŽƌ ůŽŶŐ ƚŝŵĞ Žƌ ƉĂƐƐƚŽ ƚŚĞ ŶĞǆƚŐĞŶĞƌĂƚŝŽŶĚƵƌŝŶŐ
cell division, whereas some other methods can achieve permanent expression of the 
exogenous gene (stable overexpression) which can be used to construct transgenic 
cell lines or transgenic animals. No matter what the mediator is, the gene transfer 
method must obey some basic principles. First of all, the exogenous genetic material 
must be transported across the cell membrane. Secondly, the genetic material must 
be released in the cell and transported to its site of expression or activity. Finally but 
importantly, the exogenous genetic materials must be activated (Twyman, 2005).  
Naked or plasmid DNA is usually delivered into mammalian cells with chemical or 
physical transfection methods. DEAE-dextran (diethylaminoethyl-dextran) was the 
first transfection reagent to be developed (Wall, 1999) and was very widely used to 
deliver plasmid DNA into mammalian cell lines until 1990s. The reagents for this 
method of transfection are inexpensive and the procedure is simple and efficient, 
although the efficiency varies among cell lines. Mostly used for transient 
overexpression of target genes, DEAE-dextran transfection is not particularly efficient 
for the production of stably transformed cell lines. Transfection using calcium 
phosphate is also a widely used transfection method with established cell lines, as it is 
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simple, reliable, applicable to many cell lines, and the reagents are inexpensive. 
However, not all cells are equally amenable to this transfection method, some are 
sensitive to the density of the precipitate, and the transfection efficiency in primary 
cells is very poor (Rorth et al., 1998; Twyman and Jones, 1995). The advent of 
lipofection reagents especially the development of cationic/neutral lipid mixtures 
which spontaneously associate with negatively charged DNA to form complexes, has 
made a breakthrough in chemical mediated-gene delivery, as it greatly increase the 
transfection efficiency compared to the previous methods. Cationic polymers are also 
used as transfection reagent, the first one of which is Polybrene (1, 5-dimethyl-1, 5-
diazaundecamethylene polymethobromide) facilitating the high-efficiency 
transfection of certain cell lines which can be refractory to calcium phosphate 
transfection. Polyethyleneimines (PEIs) are another class of cationic reagents 
developed more recently, which contains numerous amine groups providing a large 
number of positive charges for interaction with DNA. Physical transfection methods 
include electroporation, laser poration, microinjection and transfection by particle 
bombardment or ultrasound, which may give high transfection efficiency in some cell 
lines difficult to transfect by chemicals, but require expensive devices and relatively 
more delicate operating skills (Twyman, 2005).  
Whether chemical or physical, transfections of target DNA carried by plasmid vectors 
may achieve high efficiency in terms of transient over-expression, but as the 
efficiency for the plasmid DNA to integrate into the genome of target cell line is fairly 
low and the integration position in the genome is totally random, it is difficult to 
construct a transgenic cell line that carries the over-expressed gene and has all the 
physiological functions as normal as the wild type cells. As natural viruses have 
evolved to deliver nucleic acids safely into animal cells, mostly into the genomes 
actually, the viral vectors are developed, specifically for extremely high transient 
expression or delivery of the genes of interest into mammalian cells or animals for a 
stable expression. The transfer of exogenous DNA (or RNA) into animal cells as part of 
a recombinant viral particle is known as transduction (Twyman, 2005). The viruses 
that have been commonly used as the gene delivery tools include adenovirus, adeno-
associated virus, retrovirus and lentivirus, which will be addressed in this review 
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about their molecular design, safety, application and limitation in basic research. The 
viral vector-mediated gene delivery (including RNAi) has been of great clinical 
importance as well, as it has provided a promising approach in gene medicine and 
gene therapy, which will also be included in the paragraphs below. 
1.4.1 Adenovirus- and adeno-associated virus- mediated stable 
overexpression 
The adenoviruses are non-enveloped DNA viruses, containing a double-stranded 
linear genome approximately 36 kb in length. The major advantages of adenoviral 
vectors are that they can be purified to extremely high titers (10
12
-10
13
 particles per 
ml), which makes them highly suited for in vivo applications, and the efficiency of 
gene transfer approaches 100% if the target cells bear the appropriate receptors. 
Adenoviral vectors have a broad species and cellular host range including both 
dividing and postmitotic cells, and they are relatively easy to manipulate in vitro. 
Adenoviral vectors can take up to 7.5 kb foreign DNA. Adenoviral vectors show a low 
efficiency of stable transformation, so they are generally suitable for transient 
expression in vitro and in vivo but not useful for the production of stably transformed 
cell lines (Twyman, 2005).  
Adeno-associated virus (AAV) is single-stranded non-enveloped DNA virus. The virus 
has a large host range including most dividing and post-mitotic cells. Stable 
integration using AAV is very efficient. Additionally, the integration of AAV into the 
host cell genome is more efficient in humans than other mammals, and this may 
reflect the specificity of the proviral insertion site. Another strong advantage is that 
AAV is not pathogenic in humans, which could be an advantage in gene therapy as 
well. However, there is one problem with AAV vectors which is the low titer of 
recombinant viral stocks. During the initial development of AAV as a vector, this was 
as low as 10
4
-10
5
 transducing units per ml, although the careful optimization of 
preparation methods has increased titers to 10
9 
(Twyman, 2005).  
1.4.2 Gene delivery with retroviral vectors 
Retroviruses are enveloped RNA viruses, and each viral particle carries two copies of a 
single-stranded, positive-sense RNA genome as well as several proteins required for 
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infection. They are often described as either simple or complex, the former referring 
to the conventional oncoretroviruses such as murine leukaemia virus (MLV) and the 
latter to the lentiviruses (Figure 1.16) such as human immunodeficiency virus (HIV) 
which contain additional genes compared to the basic oncoretrovirus genome. As 
RNA viruses, retroviruses have unique replication strategy. After entering the cell, the 
virus is uncoated and the genomic RNA is transported to the nucleus where it is 
converted into a terminally redundant double-stranded cDNA copy by the virion 
protein reverse transcriptase. Then a second virion protein, integrase, inserts this 
cDNA copy into the host genome as well as subgenomic mRNAs encoding enzymes 
and structural proteins of the viral capsid. Retroviruses are advantageous vectors for 
numerous reasons, including the high viral titers (10
6
-10
8
 particles per ml), the high 
efficiency of stable transduction (both in vitro and in vivo) and the ability to 
pseudotype viral particles and thus engineer the host range of each vector. Moreover, 
the small viral genome is easy to manipulate in the laboratory once it has been 
converted into a cDNA copy, and it carries a useful promoter/ enhancer system, 
which can be used to drive transgene expression (Twyman, 2005).  
The basic strategy to construct retroviral vectors is replacing essential viral genes with 
the transgene of interest and using a packaging line to supply the missing viral 
functions (Twyman, 2005). With high efficiency of virus production and integration, as 
well as relative convenient manipulation, the HIV-1 based Lentiviruses are 
increasingly  used to realize the stable over-expression of target genes in dividing or 
non-dividing cell lines and in vivo, as well as to construct cell lines or animals with 
target gene knocked out. There are several commercially-available lentiviral over-
expression systems, making it a commonly used tool in laboratory and preclinical 
research as well as clinic therapy (Invitrogen, 2010). In the next paragraphs, the 
molecular design and safety of using lentiviral vectors will be discussed to provide an 
overview of this tool, which has been used in the experimental work of this project.  
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Figure 1.16 Gene transfer by a lentiviral vector 
Vectors based on lentiviruses such HIV are able to infect both dividing and non-
dividing cells. After the lentiviral vector has infected, for example, a nondividing 
(resting) hematopoietic stem cell, the vector RNA containing the exogenous gene 
is transcribed into DNA. The DNA forms a preintegration complex with the 
accessory protein Vpr, the enzyme integrase, and the protein matrix. The 
localization sequences of these proteins enable the preintegration complex to 
cross the nuclear membrane (the other viral vectors must wait for the nuclear 
membrane to break down during cell division before they are able to access the 
host DNA). Once inside the nucleus, the DNA is inserted into the host genome by 
integrase (Amado and Chen, 1999).  
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1.4.3 Lentiviral vectors: the evolving molecular design and safety 
HIV-1 based lentiviral vectors were originally derived from cloned proviruses that 
were developed in the 1980s (Adachi et al., 1986; Ratner et al., 1987). They have 
undergone iterative improvement since the first description. The improvements have 
largely focused on the vector and helper design, which are constructed as plasmid 
DNAs that are transfected into HEK 293 or 293T cells to produce viral particles 
(Naldini et al., 1996b; Poznansky et al., 1991). The HIV-1 based lentiviral particles can 
be pseudotyped with heterologous envelope proteins such as vesicular stomatitis 
virus G envelope protein (VSV-G), to confer broad tropism for transduction of a wide 
variety of mammalian cell types (Naldini, 1998; Yee et al., 1994). HIV-1 based 
lentiviral vectors include a transducing vector and separate helper (packaging) 
plasmids, consisting of structural and enzymatic proteins (Gag and Pol) which are 
required for virion formation. From the very beginning, helper constructs have been 
iteratively designed to separate and remove HIV open reading frames to help ensure 
their safety. The accessory genes, known to be important for pathogenesis of the 
wild-type virus were deleted to further improve safety in case of recombination 
(Desrosiers et al., 1998). The native long terminal repeat (LTR) promoter was 
substituted with a heterologous promoter such as the cytomegalovirus (CMV) 
promoter (Vendel and Lumb, 2003).  
To improve the efficiency of gene transfer into target cells, there have also been 
some modifications to match the helper constructs. Early transfer vectors were 
ĐŽŵƉŽƐĞĚŽĨĂ ? ?>dZ ?ŵĂũŽƌƐƉůŝĐĞĚŽŶŽƌƐŝƚĞ ?ƉĂĐŬĂŐŝŶŐƐŝŐŶĂůĞŶĐŽŵƉĂƐƐŝŶŐƚŚĞ ? ?
part of the Gag gene, the reverse-responsive element (RRE), the envelope splice 
acceptor, an internal gene cassette driven by its own proŵŽƚĞƌ ? ĂŶĚ ƚŚĞ  ? ? >dZ
(Dropulic, 2011) ?dŚĞ ? ?>dZǁĂƐŵŽĚŝĨŝĞĚƚŽĚĞůĞƚĞƚŚĞh ?ƌĞŐŝŽŶ ?ǁŚŝĐŚŝƐĞƐƐĞŶƚŝĂů
for replication of the wild-type virus. Removal of enhancers and other 
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůůǇ ĂĐƚŝǀĞ ƐĞƋƵĞŶĐĞƐ ĨƌŽŵ ƚŚĞ ůĞŶƚŝǀŝƌĂů  ? ? >dZ ƌĞƐƵůƚƐ ŝŶ Ă ƐĞůĨ-
inactivating (SIN) LTR (Yu et al., 1986), which is considered safer than native LTR-
containing vectors. The woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE) has been widely used to stabilize transgene mRNA levels and 
therefore increase transgene expression (Dupuy et al., 2005). 
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Basically, the lentiviral expression system in use currently consists of 4 vectors (one 
transgene expression vector and three helper vectors including envelope expression 
vector and two packaging vectors) and a packaging cell line (mostly HEK 293 or 
derived cells) (Figure 1.17) to produce infectious lentivirus to realize stable 
overexpression or knock out in target cell lines or animals.  
 
 
 
Figure 1.17 Schematic of lentiviral vector system for stable expression 
Suitable host cells (such as 293T cells) are transfected with a mixture of plasmids 
consisting of 1) an exogenous gene expression cassette, 2) a packaging cassette 
and (3) a heterologous (VSV-G) viral envelope expression cassette. The generated 
lentivirus is then used to transduce the desired cell type for transgene expression. 
Because only the vector containing the transgene expression cassette (devoid of 
the viral structural genes) integrates into the host cell genome in the transduced 
cells, the gene of interest is continually expressed but infectious virus is not 
produced (Manjunath et al., 2009).  
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Other elements have been successfully incorporated into lentiviral vectors, some for 
specific purposes. Tetracycline (Tet) trans-activators of repressors have been used to 
create inducible lentiviral expression vectors (Pluta et al., 2007) and further 
optimization also solved the problem of high basal activity and increased transgene 
ŝŶĚƵĐŝďŝůŝƚǇǁŚĞŶĐŽŵďŝŶĞĚǁŝƚŚƐŝůĞŶĐŝŶŐĞůĞŵĞŶƚƐƐƵĐŚĂƐ<Z ?<ƌʒƉƉĞů-associated 
box) (Wiznerowicz and Trono, 2005). An alternative method for inducible gene or 
short hairpin RNA (shRNA) expression uses Cre-loxP recombination, but unlike the 
tetracycline system, this mode of transcriptional activation is generally irreversible 
and has particular use in transgenic animals for the study of genes that would 
otherwise generate embryonic lethality (Chang and Zaiss, 2003; Pluck, 1996). More 
recently, it has been discovered that the incorporation of cell type-specific microRNAs 
downstream of a transgene can restrict expression in those particular cell types 
(Brown et al., 2007), so the combination of positively regulating tissue-specific 
promoters with negatively regulating microRNAs can result in highly precise 
transgene expression in specific cells or tissues (Brown and Naldini, 2009). This strictly 
regulated expression increases the vector safety and is particularly useful in 
experimentation in specific cell types, especially in clinical applications.  
Lentiviral vector expression system has been widely and successfully used not only in 
simple over-expression of individual target genes or the knock down of specific genes 
by shRNA, but also in functional genomics with the construct of several lentiviral 
vector cDNA libraries (Chilov et al., 2003; Kurita et al., 2008). It has become a 
powerful and indispensible molecular tool in cell engineering and animal model 
applications.  
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1.5 SUMMARY 
Brown adipose tissue functions primarily to dissipate energy in the form of heat via 
ƵŶĐŽƵƉůŝŶŐƌĞƐƉŝƌĂƚŝŽŶŝŶƌĞƐƉŽŶƐĞƚŽĐŽůĚĞǆƉŽƐƵƌĞŽƌɴ-adrenergic receptor agonists 
(adaptive thermogenesis), therefore BAT, if controlled and regulated properly, can be 
a potential powerful tool to counteract obesity. The crucial gene that mediates the 
uncoupling respiration, also the hallmark gene of BAT, is uncoupling protein 1 (UCP1), 
the expression and activation of which is delicately controlled by a set of transcription 
ĨĂĐƚŽƌƐ  ?WWZɶ ? ZyZɲ ? ĞƚĐ ? ) ? ĐŽ-ĂĐƚŝǀĂƚŽƌƐ  ?W' ?ɲ ? WZD ? ? ?  ?Wɴ ? ĞƚĐ ? ) ĂŶĚ ĐŽ-
repressors (RIP140, CIDEA, etc.) and regulated by multiple signalling pathways (cAMP-
W<ƉĂƚŚǁĂǇĂŶĚWWZɶĂŐŽŶŝƐƚƐŵĞĚŝĂƚĞĚƉĂƚŚway). Preliminary studies suggested 
that the over-ĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴŝŶǁŚŝƚĞƉƌĞĂĚŝƉŽĐǇƚĞ ?d ?-L1 cell line enabled the 
cAMP-inducible expression of UCP1, which is an essential characteristic in brown 
ĂĚŝƉŽĐǇƚĞƐ ďƵƚ ůĂĐŬŝŶŐ ŝŶ ǁŚŝƚĞ ĂĚŝƉŽĐǇƚĞƐ ?  ?Wɴ ŚĂs also been proved to be 
important, by forming the complex with PRDM16, in determination of the brown 
ĂĚŝƉŽŐĞŶŝĐ ůŝŶĞĂŐĞ ĨƌŽŵ ŵǇŽďůĂƐƚƐ ? hŶĚŽƵďƚĞĚůǇ ?  ?Wɴ ŝƐ Ă ĐƌŝƚŝĐĂů ƌĞŐƵůĂƚŽƌ ŝŶ
stimulating brown adipogenic differentiation programme. However, its expression 
during white adipocyte differentiation is greatly reduced after two days of 
differentiation while kept high level throughout brown adipocyte differentiation 
(Karamitri et al., 2009), which inspired the idea that artificially over-expressing 
 ?Wɴ ŝŶ ǁŚŝƚĞ ƉƌĞĂĚŝƉŽĐǇƚĞƐ ƚŚƌŽƵŐŚŽƵƚ ƚŚĞ ǁŚŽůĞĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ƉƌŽĐĞƐƐ ŵŝŐŚƚ
lead to a brown-like phenotype in the cells. Therefore, a series of experiments was 
ĐĂƌƌŝĞĚ ŽƵƚ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ƚŚĞ ƌŽůĞ ŽĨ  ?Wɴ ĂŶĚ ŝƚƐŝŶƚĞƌĂĐƚŝŽŶ ǁŝƚŚ ƚŚĞ ŽƚŚĞƌ ĐŽ-
regulators such as PRDM16 in adipogenic programme in terms of chromatin 
remodelling. To achieve an inducible stable over-expression, the lentiviral expression 
system was used to select for a stable transgenic 3T3-L1 cell line.  
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1.6 EXPERIMENTAL OBJECTIVES 
dŚĞ ŽǀĞƌĂůů ŚǇƉŽƚŚĞƐŝƐ ŽĨ ƚŚŝƐ ƉƌŽũĞĐƚ ŝƐ ƚŽ ƚĞƐƚǁŚĞƚŚĞƌ  ?Wɴ ? ƚŽŐĞƚŚĞƌ ǁŝƚŚ ƚŚĞ
other regulators like PRDM16, increases brown adipogenic differentiation programme 
in white preadipocytes by altering the pattern of chromatin remodelling. 
The objectives of the experimental work described in this manuscript were: 
1. To generate lentiviral vectors to allow tetracycline-inducible stable overexpression 
ŽĨ ?WɴŝŶǁŚŝƚĞƉƌĞĂĚŝƉŽĐǇƚĞ ?d ?-L1. 
 ? ?  dŽ ĞƐƚĂďůŝƐŚ ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ  ?Wɴ ĂŶĚ ƚŚĞ ŽƚŚĞƌ ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů
regulators. 
3. To investigate if the pattern of chromatin remodelling is altered by C/EBPɴ 
overexpression during 3T3-L1 differentiation using chromatin immunoprecipitation 
(ChIP). 
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2 MATERIALS AND METHODS 
2.1 VECTOR CONSTRUCTION 
2.1.1Digest-Ligation Molecular Cloning 
2.1.1.1 Polymerase chain reaction (PCR) 
WZǁĂƐĐĂƌƌŝĞĚŽƵƚŝŶ ? ? ?ʅůƚŚŝŶǁĂůůƚƵďĞƐ  ?^ƚĂƌ>Ăď ? ) on pre-constructed plasmid 
DNA using Phusion® High-Fidelity PCR Master Mix (New England Biolab), according to 
ƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?'ĞŶĞƌĂůůǇ ?ĨŽƌĂ  ? ?ʅůƌĞĂĐƚŝŽŶ ? ? ?ʅůŵĂƐƚĞƌŵŝǆǁĂƐ
ƵƐĞĚ ǁŝƚŚ  ? ? ?ʅD ŽĨ ĞĂĐŚ ƉƌŝŵĞƌ ĂŶĚ  ?-10ng plasmid DNA as template (for PCR 
ƚĂƌŐĞƚŝŶŐ  ?Wɴ ?  ?A? D^K ǁĂƐ ĂĚĚĞĚ ŝŶƚŽ ƚŚĞ ƌĞĂĐƚŝŽŶƚŽ ƉƌĞǀĞŶƚ ĨŽƌŵŝŶŐ
secondary structure of the template). PCR was performed with the following 
temperature profile: an initial denaturation temperature at 98°C for 30sec, 27-30 
cycles of denaturation (5-10sec at 98°C), annealing (10-30sec at optimized 
temperature) and extension (required time at 72°C), followed by a final extension at 
72°C for 5-10min. PCR products were stored at -20°C.   
2.1.1.2 Primer design 
Primers were designed with Primer Express software and synthesized by MWG 
Biotech Ltd. (London, UK). 
The criteria for the primer design are described below: 
 ?>ĞŶŐƚŚŽĨƉƌŝŵĞƌǁĂƐďĞƚǁĞĞŶ ? ?ĂŶĚ ? ? ? 
 ?ŶŶĞĂůŝŶŐƚĞŵƉĞƌĂƚƵƌĞďĞƚǁĞĞŶ ? ? ?ƚŽ ? ? ? ? 
 ?'-C ratio was kept between 45%-55% G-C rich. 
 ?'ƐĂŶĚƐǁĞƌĞƉƌĞĨĞƌƌĞĚĂƚ ? ?ĞŶĚŽĨƚŚĞƉƌŝŵĞƌƐĂŶĚƐĂŶĚdƐǁĞƌĞƉƌĞĨĞƌƌĞĚĂƚ
 ? ?ĞŶĚƚŽĂǀŽŝĚŵŝƐ-priming. 
 ?^ĞůĨ-annealing regions were avoided within each primer. 
 ?/ŶƚƌĂ-primer and inter-primer homology in primer sequence was avoided. 
The primer sequences to amplify the TRE (template: pL3-TRE-LucGFP-2L from 
Addgene Plasmid 11685) or TRE tight (template: pTRE-Tight miR-1 from Addgene 
Plasmid 14896) elements are listed below: 
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TRE_Forward: acgaagttatATCGATgaaccccttcc 
TRE_Reverse: ccaagcttagaACTAGTggatcggtcccggtgtcttc 
TRE tight_Forward: ccccgggATCGATggccctttcgtcttcactcgag 
TRE tight_Reverse: ccccgggACTAGTgcgatctgacggttcactaaac 
EŽƚĞ P ƚŚĞ d'd ŝƐ Ă ƌĞƐƚƌŝĐƚŝŽŶ ƐŝƚĞ ƌĞĐŽŐŶŝǌĞĚ ďǇ ůĂ/  ? ? ? ) ĂŶĚ ƚŚĞ d'd ŝƐ Ă
restriction site recogniǌĞĚďǇ^ƉĞ/ ? ? ? ?ƌĞǀĞƌƐĞĐŽŵƉůĞŵĞŶƚĂƌǇƐĞƋƵĞŶĐĞ ) ? 
The primer sequences to amplify the template for cloning short aP2 promoter 
(template: pBS-aP2 <Plasmid 11424 from Addgene>) 
Short aP2_Forward: cccggGCGGCCGCccaacccaaaccaaacaaagccaaac 
Short aP2_Reverse: cccggGCGGCCGCggttctgactcctggcctgaacttc        
Note: the GCGGCCGC is a restriction site recognized by NotI. 
2.1.1.3 Restriction Endonucleases Digest 
Restriction endonucleases were from either New England Biolab (NEB) or Promega. 
Digestions were performed ĂĐĐŽƌĚŝŶŐƚŽŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ? Specifically, 3µg 
of the pLenti6/V5 backbone vector from Invitrogen was double digested by 2µl of 
BamHI and 2µl of XhoI with 4µl of Buffer B (Promega, 4 CORE® Buffers) in a final 
volume of 40µl made up with sterilized H2O. To generate short aP2 promoter, 1µg of 
the short aP2 PCR product from 2.1.1.2 was digested by 1 µl of NotI with 3 µl of 
Buffer D (Promega) in a final volume of 30µl made up with sterilized H2O. The vector 
with restriction enzymes was incubated at 37°C overnight for a complete digestion. 
2.1.1.4 Gel purification of PCR products or digested DNA fragments 
PCR products or digested DNA fragments were run on 1% agarose gels in 1X TAE 
buffer. Gel purification was performed using GenElutĞ ? 'Ğů ǆƚƌĂĐƚŝŽŶ Kit (Sigma) 
ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ?Specifically, the digested backbone 
vector or target PCR product fragments were excised from agarose gel and weighed 
in separate colourless tubes. 3 gel volumes of the Gel Solubilization Solution was 
added into each gel slice and incubate at 55-60°C for 10 min until the gel slices were 
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completely dissolved. 1 gel volume of 100% isopropanol was added into the mixture 
and mixed until homogenous and then the mixture was loaded into the prepared 
binding columns with vacuum applied. The columns were then washed with 700µl of 
Wash Solution and dried before 50µl of Elution Solution was added into each column 
and incubated for 1 min to elute the bound DNA. The eluted DNAs were checked on 1% 
agarose gel again and quantified with NanoDrop® ND-1000 (NanoDrop Technologies) 
for the future processes or stored at -20°C. 
2.1.1.5 Ligation 
Ligation of insert DNA into plasmid vectors used for cloning (both digested with same 
endonucleases or endonucleases with compatible ends) was performed using T4 DNA 
ůŝŐĂƐĞ  ?WƌŽŵĞŐĂ ) ?&ŽƌĂ  ? ?ʅů ƌĞĂĐƚŝŽŶ for generating pLenti TRE or pLenti TRE tight, 
digested plasmid DNA (100-200ng) was mixed with insert DNA at a molar ratio of 1:5 
ƚŽ  ? P ? ?  ?ʅůŽĨ  ? ?y ůŝŐĂƐĞ ďƵĨĨĞƌĂŶĚ  ? ? ?ƵŶŝƚƐŽĨ d ?NA ligase were added into the 
mixed DNA. For a 10 µl reaction for generating short aP2 promoter vector pBS-sAP2, 
100ng of digested and purified short aP2 PCR product was mixed with  ?ʅů ŽĨ  ? ?y
ligase buffer and 1.5 units of T4 DNA ligase. All the ligation reactions were incubated 
at 15°C overnight. 
2.1.1.6 Transformation 
The ligation products were transformed into E.coli. competent cells either by 
chemical transformation or electroporation method. 
(1) Chemical Transformation 
Ligated plasmid vectors were transformed in Hanahan TOP10 chemical competent 
ĐĞůůƐ ? ŽŵƉĞƚĞŶƚ ĐĞůůƐ ǁĞƌĞ ƚŚĂǁĞĚ ŽŶ ŝĐĞ ĂŶĚ  ? ?ʅů ŽĨ ĐŽŵƉĞƚĞŶƚ ĐĞůůƐ ǁĞƌĞ
transferred into a pre-ĐŚŝůůĞĚ ŵŝĐƌŽĐĞŶƚƌŝĨƵŐĞ ƚƵďĞ ?  ?ʅů ŽĨ ůŝŐĂƚĞĚ ƉƌŽĚƵĐƚƐ ǁĞƌĞ
pipetted into the tube containing competent cells and the DNA/cell mixture was 
swirled gently to mix. Tubes were incubated on ice for 20min and heat-shocked at 
 ? ? ?ĨŽƌ  ? ?ƐĞĐ ?dƵďĞƐǁĞƌĞƌĞƚƵƌŶĞĚƚŽ ŝĐĞĂŶĚĂĨƚĞƌ  ?ŵŝŶ  ? ? ?ʅůŽĨ >ǇƐŽŐĞŶǇďƌŽƚŚ
(LB) medium was added, and the samples were incubated in a shaking incubator 
(200rpm) at 37°C for 1 hour. The transformation mixture (100- ? ? ?ʅů )ǁĂƐƉůĂƚĞĚŽŶ
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LB-ŐĂƌƉůĂƚĞĐŽŶƚĂŝŶŝŶŐƚŚĞĐŽƌƌĞĐƚĂŶƚŝďŝŽƚŝĐƐ ?ĂŵƉŝĐŝůůŝŶĂƚ ? ? ?ʅŐ ?ŵů ?ŬĂŶĂŵǇcin at 
 ? ?ʅŐ/ml) and incubated at 37°C overnight. 
(2) Electroporation 
 ? ?ʅůŽĨ ?ĐŽli. MDS42 electroporation competent cells were taken out from -80°C and 
ƚŚĂǁĞĚŽƵƚŽŶŝĐĞĨŽƌ ?ŵŝŶ ? ?ʅůŽĨůŝŐĂƚĞĚƉůĂƐŵŝĚǀĞĐƚŽƌƐǁĞƌĞƚŚĞŶĂĚĚĞĚŝŶƚŽƚŚĞ
MDS42 competent cells, gently mixed and incubated on ice for 1min before being 
pipetted into a 0.2cm electroporation cuvette (Bio-Rad).  The cuvette was then placed 
in the safety chamber stick of Gene Pulsar (Bio-Rad) apparatus with the settings as 
 ? ?ʅ& ?  ? ? ?Ŭs ?  ? ? ?t ? ĨƚĞƌ ŽŶĞ ƉƵůƐĞ  ?ŶƐƵƌĞ ƚŝŵĞ ĐŽŶƐƚĂŶƚAN ? ĂĨƚĞƌ ƉƵůƐŝŶŐ ? ) ? ƚŚĞ
cuvette was removed from chamber and 1ml LB medium was added in immediately. 
The transformation mixture was pipetted out into a test tube and incubated at 37°C 
for 1 hour before spreading (10- ? ?ʅů ) ŽŶƚŽ >-Agar plates containing the correct 
antibiotics and incubated at 37°C overnight.  
Single colonies were picked from the plate (either chemically or electrically 
transformed) into 3ml LB medium and incubated at 37°C overnight. Plasmid 
minipreps (see below) were performed and the extracted plasmids were digested 
with specific endonucleases to identify if they were the correct clones.  
2.1.1.7 Small scale isolation of plasmid DNA (Miniprep) 
ǇƉƉǇ ?WůĂƐŵŝĚDŝŶŝƉƌĞƉ<ŝƚ ?ǇŵŽZĞƐĞĂƌĐŚ )ǁĂƐƵƐĞĚĨŽƌƐŵĂůůƐĐĂůĞ ? ?- ? ?ʅŐE
per culture) plasmid isolation. After colonies were grown in 3ml of LB medium (12-16 
ŚŽƵƌƐĂƚ ? ? ? ) ?ĂŶĂůŝƋƵŽƚŽĨĐĞůůƐƵƐƉĞŶƐŝŽŶ ? ? ? ?ʅů )ǁĂƐƚĂŬĞŶŽƵƚƚŽŵŝǆǁŝƚŚ ? ? ?ʅů
autoclaved 35% glycerol and kept at -80°C for stock. Plasmid DNA was prepared 
ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?Specifically, an aliquot (~1.3ml) of the 
overnight bacteria culture was taken out into a 1.5ml microcentrifuge tube and 
centrifuged at 8000rpm for 1 min to pellet the bacteria. The bacteria pellet was then 
resuspended with 600 µl of sterilized water. 100 µl of 7× Lysis Buffer was added into 
the tube and the tube was inverted 6-8 times to mix and then incubated at room 
temperature for 2 min to lyse the bacteria cells. To neutralize the lysis mixture, 350 µl 
of 2× Neutralization Buffer was added into the tube and the tube was immediately 
inverted for 10 times to mix thoroughly, indicated by the appearance of yellow 
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precipitates. The tubes were then centrifuged at 13,500rpm for 5 min at room 
temperature to pellet the precipitates. The supernatant was transferred to the 
provided Zymo-Spin ? IIN column and incubated at room temperature for 1 min 
before centrifuged (top speed, room temperature, 15 sec) and discarded the flow 
through. 200 µl of Endo-Wash Buffer was added into each tube to wash away the 
endotoxin and then 400 µl of Wash-Buffer was applied onto the column for a final 
wash. When the column was dried out, 30 µl of Zyppy ? Elution Buffer was added 
directly into the centre of the column, incubated at room temperature for 1 min and 
then centrifuged at 13, 500 rpm for 1 min to elute the plasmid DNA. The eluted DNA 
was then ready for immediate use or stored at -20°C. 
2.1.1.8 Large scale isolation of plasmid DNA (Maxiprep) 
ǇƉƉǇ ?WůĂƐŵŝĚDĂǆŝƉƌĞƉ<ŝƚǁĂƐƵƐĞĚĨŽƌ ůĂƌŐĞƐĐĂůĞ  ? ? ? - ? ? ?ʅŐEƉĞƌ ĐƵůƚƵƌĞ )
plasmid isolation. Colonies were grown in 200ml of LB medium for 12-16 hours at 
 ? ? ? ĂŶĚ ƚŚĞ ƉůĂƐŵŝĚ E ǁĂƐ ƉƌĞƉĂƌĞĚ ĨŽůůŽǁŝŶŐ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ
recommendations. Briefly, 150 ml of fresh bacteria culture was centrifuged at A? 
3,400×g for 10 min to pellet the bacteria, which was then resuspended with 15 ml of 
P1 Buffer. 15 ml of P2 Buffer was then added into the bacteria and the tube was 
inverted 4-6 times then stood at room temperature for 1 min to lyse the cells 
completely. 20 ml of P3 Buffer was then added into the tube to neutralize the mixture 
and the tube was incubated on ice for 5 min when the yellowish precipitate formed. 
The mixture was then added into the Zymo-Maxi Filter ?/ Zymo-Spin ? VI column 
assembly onto a vacuum manifold to let all the liquid flow through both columns. The 
Zymo-Maxi Filter ? ǁĂƐ ƚŚĞŶ ĚŝƐĐĂƌĚĞĚ ĂŶĚ  ? ? ŵů ŽĨ ŶĚŽ-Wash Buffer was added 
into the Zymo-Spin ? VI column to wash away the endotoxin followed by another 
wash with 10 ml of Zyppy ? Wash Buffer. After drying out the residual Wash Buffer in 
the column by keeping the vacuum on for extra 5 min, the Zymo-Spin ? VI column was 
transferred into a clean 50 ml conical tube and 2-3 ml of Zyppy ? Elution Buffer was 
added into the column and incubated at room temperature for 1 min before 
centrifuged at A?3,400×g for 1 min to elute the plasmid DNA. The eluted DNA was then 
ready for immediate use or stored at -20°C.  
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2.1.1.9 Vector sequencing 
The vectors constructed were sent to MWG for sequencing and the sequencing 
reports are attached as Appendix E. 
2.1.2 Gateway® Cloning using the MultiSite Gateway® ProKit (3-fragment 
cloning) 
The MultiSite Gateway® Pro Kits from Invitrogen facilitate rapid and highly efficient 
construction of an expression clone containing the choice of two, three or four 
separate DNA elements. Based on the Gateway® Technology (Hartley et al., 2000; 
Sasaki et al., 2004; Yahata et al., 2005), the MultiSite Gateway® Technology uses site-
specific recombinational cloning to allow simultaneous cloning of multiple DNA 
fragments in a defined order and orientation. The Gateway® Technology is a universal 
cloning method based on the bacteriophage lambda into the E. coli chromosome and 
the switch between the lytic and lysogenic pathways (Landy, 1989). In phage lambda, 
recombination occurs between phage and E. coli DNA via specific recombination 
sequences denoted as att sites. Recombination occurs following two pairs of strand 
exchanges and ligation of the DNAs in a novel form. Recombination is conservative 
and requires no DNA synthesis. The DNA segments flanking the recombination sites 
are switched, such that after recombination, the att sites are hybrid sequences 
comprised of sequences donated by each parental vector. Recombination reactions 
are catalyzed by a mixture of enzymes that bind to the att sites, bring together the 
target sites, cleave them, and covalently attach the DNA. The lysogenic pathway is 
catalyzed by phage lambda integrase (Int) and E. coli Intigration Host Factor (IHF) 
ƉƌŽƚĞŝŶƐ  ?W ůŽŶĂƐĞ ? // ĞŶǌǇŵĞ ŵŝǆ ) ǁŚŝůĞ ƚŚĞ ůǇƚŝĐ ƉĂƚŚǁĂǇ ŝƐ ĐĂƚĂůǇǌĞĚ ďǇ ƚŚĞ
phage lambda Int and Excisionase (Xis) proteins, and the E. coli Integrateion Host 
&ĂĐƚŽƌ ?/,& )ƉƌŽƚĞŝŶ ?>ZůŽŶĂƐĞ ?//WůƵƐĞŶǌǇŵĞŵŝǆ )(Invitrogen, 2006).  
attB, attP, attL and attR are recombination sites that are utilized in the Gateway® 
Technology. attB sites always recombine with attP sites in a reaction mediated by the 
WůŽŶĂƐĞ ?//ĞŶǌǇŵĞŵŝǆ P 
67 
 
 
dŚĞWƌĞĂĐƚŝŽŶŝƐƚŚĞďĂƐŝƐĨŽƌƚŚĞƌĞĂĐƚŝŽŶďĞƚǁĞĞŶƚŚĞĚŽŶŽƌǀĞĐƚŽƌ ?ƉKEZ ? )ĂŶĚ
PCR products or other clones containing attB sites. Recombination between attB and 
attP sites yields attL and attR sites on the resulting plasmids. The entry clone 
containing the PCR product is used in the LR recombination reaction (Invitrogen, 
2006). 
Ăƚƚ>ƐŝƚĞƐĂůǁĂǇƐƌĞĐŽŵďŝŶĞǁŝƚŚĂƚƚZ ŝŶĂƌĞĂĐƚŝŽŶŵĞĚŝĂƚĞĚďǇ>ZůŽŶĂƐĞ ? //WůƵƐ
enzyme mix:  
 
The LR reaction is the basis for the entry clone(s) × destination vector reaction. 
Recombination between attL and attR sites yields attB and attP sites on the resulting 
plasmids. The expression clone containing the PCR product is used in the expression 
system. The by-product plasmid contains the ccdB gene and prevents growth if taken 
up by the competent cells without corresponding resistance after transformation 
(Invitrogen, 2006).  
The MultiSite Gateway® cloning system used in this project was 3-fragment cloning, 
i.e. to recombine the gene of interest, the reverse tetracycline-controlled 
transactivator (rtTA) and the promoter driving rtTA together into a pLenti6 (or 
modified Tet on pLenti) destination vector for conditional transient overexpression or 
lentivirus production. In this process, three PCR products flanked by specific attB or 
attBr sites and three MultiSite Gateway® Pro Donor vectors were used in separate BP 
recombination reactions to generate three entry clones. The three entry clones and a 
destination vector were used together in a MultiSite Gateway® Pro LR recombination 
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reaction to create the expression clone containing three DNA elements. The cloning 
process is illustrated as following (Invitrogen, 2006):  
 
The constructed inducible lentiviral expression vectors would be able to express the 
gene of interest in response to the inducer doxycycline (Dox) and the mechanism of 
the inducible expression is explained by the diagram below: 
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The TRE is located upstream of the minimal CMV promoter (PminiCMV) which is 
silent in the absence of activation. The Tet regulatory protein (rtTA) binds the TRE and 
activates transcription in the presence of Dox. 
For an ambitious plan to realize a fat-specific inducible expression in vivo or in 
embryonic stem cells, a fat-specific promoter aP2 promoter and its artificial truncated 
form short aP2 promoter (sAP2) was to use for driving the expression of rtTA. The 
vector constructed with aP2 promoter would not be available for producing lentivirus 
due to its too big size, but for the purpose of comparing the fat specificity of the 
artificial sAP2 promoter with the original full length aP2 promoter, an entry clone 
containing full length aP2 promoter was also generated and used to generate the 
corresponding pLenti expression vectors in parallel with the sAP2. The plasmid 
pBluescript-aP2 from Addgene was used as the template for amplifying full length aP2 
PCR product.  
2.1.2.1  Construction of Entry Clones for 3-fragment recombination 
1) Generation of the Entry Clone for the gene of interest  ?ŝ ?Ğ ?  ?Wɴ Žƌ
Luciferase/GFP (LucGFP) for control) 
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Appropriate PCR primers were designed ĂŐĂŝŶƐƚ ƚŚĞƐĞƋƵĞŶĐĞ ŽĨ ?Wɴ  ?ƚĞŵƉůĂƚĞ P
pcDNA3.1- ?Wɴ ƉůĂƐŵŝĚ ĨƌŽŵ ĚĚŐĞŶĞ ) Žƌ >ƵĐ'&W  ?ƚĞŵƉůĂƚĞ P Ɖ> ?-TRE-LucGFP-2L 
plasmid from Addgene), and attB1 and attB4 sites were added onƚŽƚŚĞ ? ?ĂŶĚ ? ?ĞŶĚƐ
of the product, respectively.  
C ?Wɴ YĂƚƚ ? Y&orward: GGGG ACA AGT TTG TAC AAA AAA GCA GGC 
Taccatggaagtggccaacttctac 
 ?Wɴ YĂƚƚ ? YZeverse: GGGG AC AAC TTT GTA TAG AAA AGT TGG GTG 
tagcagtggcccgccgaggcc   
Luc/GFP_attB1_Forward: GGGG ACA AGT TTG TAC AAA AAA GCA GGC 
Tccaccatggaagacgccaaaaac 
Glob_Term_attB4_Reverse (for cloning LucGFP): GGGG AC AAC TTT GTA TAG AAA 
AGT TGG Gtgagaagagggacagctatgac 
Note: the italic capital letters stands for the sequence for adding in att sites.  
A BP recombination reaction was performed between the attB1 and attB4-flanked 
PCR product and pDONOR P1-W ?ƚŽŐĞŶĞƌĂƚĞƚŚĞĞŶƚƌǇĐůŽŶĞĨŽƌ ?WɴŽƌ>ƵĐ'&W ?
2) Generation of the Entry Clone for CMV, aP2 or short aP2 (sAP2) promoter 
driving reverse tetracycline-controlled transactivator 
Appropriate PCR primers were designed against the sequence of CMV (template: pTet 
on plasmid from Clontech) aP2 promoter (template: pBS-aP2 from Addgene) or sAP2 
promoter (template: pBS-sAP2 constructed in 2.1.1.5), and attB4r and attB3r sites 
were added onƚŽƚŚĞ ? ?ĂŶĚ ? ?ĞŶĚƐŽĨƚŚĞƉƌŽĚƵĐƚ ?ƌĞƐƉĞĐƚŝǀĞůǇ ? 
CMV_attB4r_Forward: GGGG ACA ACT TTT CTA TAC AAA GTT 
Gtattggctcatgtccaacattaccgcc 
CMV_attB3r_Reverse: GGGG AC AAC TTT ATT ATA CAA AGT 
TGTgagctctgcttatatagacctcc 
aP2_attB4r_Forward: GGGG ACA ACT TTT CTA TAC AAA GTT 
Gatatcgaattcccagcaggaatcaggtagc 
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aP2_attB3r_Reverse: GGGG AC AAC TTT ATT ATA CAA AGT T 
GTctgcagcacaggagggtgctatgagcc 
Note: the italic capital letters stands for the sequence for adding in att sites and aP2 
and sAP2 promoter entry clones share the same forward and reverse cloning primers. 
A BP recombination reaction was performed between the attB4r and attB3r-flanked 
PCR product and pDONOR P4r-P3r to generate the entry clone for CMV, aP2 or sAP2 
promoter.  
3) Generation of the Entry Clone for reverse tetracycline-controlled transactivator 
(rtTA or rtTA advance) 
Appropriate PCR primers were designed against the sequence of rtTA (template: pTet 
on from Clontech) or rtTAadv (PB-CA-rtTA advance from Addgene), and attB3 and 
attB2 sites were added onƚŽƚŚĞ ? ?ĂŶĚ ? ?ĞŶĚƐŽĨƚŚĞƉƌŽĚƵĐƚ ?ƌĞƐƉĞĐƚŝǀĞůǇ ? 
rtTA_attB3_Forward: GGGG ACA ACT TTG TAT AAT AAA GTT Gatccagcctccgcggccccg 
rtTA_polyAattB2_Reverse: GGGG AC CAC TTT GTA CAA GAA AGC TGG 
GTAgcttggtcgagctgatacttcccgtcc 
rtTA adv_attB3_Forward: GGGG ACA ACT TTG TAT AAT AAA GTT 
Ggcaggcttcaccatgtctagactggac 
rtTA adv_glob term_attB2_Reverse: GGGG AC CAC TTT GTA CAA GAA AGC TGG 
GTAggtcgagggatcttcataagagaagaggg 
Note: the italic capital letters stands for the sequence for adding in att sites. 
A BP recombination reaction was performed between the attB3 and attB2-flanked 
PCR product and pDONOR P3-P2 to generate the entry clone for rtTA or rtTA adv.  
All the primers above were designed using the computer programme AmpliX Version 
1.5.4. The forward primers must contain following structure: 
 ? ?&ŽƵƌŐƵĂŶŝŶĞ ?' )ƌĞƐŝĚƵĞƐĂƚƚŚĞ ? ?ĞŶĚĨŽůůŽǁĞĚďǇ 
2. the 22 or 25 bp attB or attBr site followed by 
3. at least 18-25 bp of template- or gene-specific sequences 
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The reverse primer MUST contain the following structure: 
1. Four guanine (G) residues at the 5 ?end followed by 
2. the 22 or 25 bp attB or attBr site followed by 
3. 18-25 bp of template- or gene-specific sequences 
The attB-flanked PCR products were purified using GenElutĞ ? 'Ğů ǆƚƌĂĐƚŝŽŶ <ŝƚ
 ?^ŝŐŵĂ )ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐ ? 
To perform the BP recombination reaction, the attB-flanked PCR product and the 
corresponding pDONOR vector were mixed as following 
components Sample 
attB PCR products (15-150 ng) 1-7 µl 
pDONR噡 vector (150 ng/ µl ) 1 µl 
1× TE Buffer (pH 8.0) To 8 µl 
2 µl of BP Clonase噡 II enzyme mix was added into each of the above sample and 
mixed well by vortexing briefly twice and then incubated at 25°C overnight. 1µl of 
Proteinase K solution was added to each reaction and Incubated at 37°C for 10min 
and then proceeded to transform One Shot® Mach1噡 T1R Competent Cells with the 
method mentioned in 2.1.1.6. The correct entry clones were verified by sequencing 
and restriction digest as described in 2.1.1.6. 
2.1.2.2  Creation of expression vectors by performing LR recombination reactions. 
The 3 entry clones above and the destination vector pLenti6.2/V5 (or pLentiTRE, 
pLenti TRE tight) were mixed as following 
components Sample 
Entry clones (10 fmoles each) 1-7 µl 
Destination vector (20 fmoles) 1 µl 
1× TE Buffer (pH 8.0) To 8 µl 
2 µl of LR Clonase噡 Plus enzyme mix was added into each sample above and mixed 
well by vortexing briefly twice. The reaction was then incubated at 25°C for 16 hours. 
1 µl of the Proteinase K solution was added to each reaction and incubated for 10 
minutes at 37°C and then proceeded to transform One Shot® Mach1噡 T1R Competent 
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Cells with the method described in 2.1.1.6.  The correct expression vectors were 
verified by restriction digest as described in 2.1.1.6. 
 
2.1.3 Luciferase reporter and expression gene plasmid constructs 
The luciferase reporter constructs including pGL3-264bp or - ? ? ? ?ďƉW' ?ɲƉƌŽŵŽƚĞƌ, 
pGL3-CRE constructs were generated using pGL3-basic vector (Promega) by Dr. G. 
Karamanlidis ĨŽůůŽǁŝŶŐƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐƉƌŽƚŽĐŽů ?The pGL3-3.1kb UCP1 promoter 
was from Dr. Kozak LP. The pGL3- ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌƉůĂƐŵŝĚ (Plasmid 8887) and 
pGL3-PPRE-TK plasmid (Plasmid 1015) were from Addgene. The mutated pGL3-2.6kb 
PGC1ɲ promoter constructs pGL3-2.6kb PGC1ɲ (ȴCRE) and pGL3-2.6kb PGC1ɲ (ȴPPRE) 
were kindly gifts from Dr. Villarroya F.  
The expression gene plasmids pcDNA3.1- ?Wɴ (Plasmid 12557), pcDNA-PRDM16 
(Plasmid 15503), pcDNA-WWZɶ (Plasmid 8895) and pcDNA-flag-W' ?ɲ(Plasmid 1026) 
all came from Addgene. 
 
 
2.2 CELL CULTURE (INCLUDING PASSAGING, FREEZING AND 
DIFFERENTIATING CELLS) 
 
Handling of media and cells was carried out in an airflow cabinet (ŝƌ^ƚƌĞĂŵ ?). Prior 
and after use, the bench surfaces of the flow cabinet were wiped with tissue and 70% 
ethanol. The brown preadipocyte cell line, HIB-1B, which was isolated from brown fat 
tumour of a transgenic mouse (Klaus et al., 1994), was kindly provided by Prof. Bruce 
Spiegelman (Dana Farber Cancer Institute). The white preadipocyte 3T3-L1 cell line, 
which was derived from disaggregated Swiss 3T3 mouse embryos (Green and Kehinde, 
1975), was bought from American Type Culture Collection (ATCC). Cell lines were 
obtained as frozen cultures in 90% (v/v) FBS and 10% (v/v) dimethyl sulfoxide (DMSO) 
and kept in liquid nitrogen until use. In order to resuscitate the cell lines, cryovials 
containing the cells were taken out from liquid nitrogen and transferred immediately 
to a water bath at 37°C. After approximately 2-3 minutes (min) cells were pipetted 
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out in to a 25cm
2
flask and 5ml of pre-warmed growth medium containing DƵůďĞĐĐŽ ?Ɛ
ŵŽĚŝĨŝĞĚ ĂŐůĞ ?Ɛ DĞĚŝĂ  ?DD ? A?  ? ? ?0mg/l Glucose, + L-Glutamine, - Pyruvate) 
supplemented with 10% (v/v) FBS, 1% (v/v) penicillin and streptomycin, and 1% 
sodium pyruvate and mixed by swirling. The growth media for 293FT cells contained 
ƵůďĞĐĐŽ ?Ɛ ŵŽĚŝĨŝĞĚ ĂŐůĞ ?Ɛ DĞĚŝĂ  ?DD ? A?  ? ? ?0mg/l Glucose, + L-Glutamine, - 
Pyruvate) supplemented with 10% (v/v) non heat-inactivated FBS, 1% sodium 
pyruvate, 0.1mM MEM Non-Essential Amino Acid (NEAA), another 2mM L-glutamine 
ĂŶĚ  ? ? ?ʅŐ ?ŵů'ĞŶĞƚŝĐŝŶ ? The flask was then incubated in a humidified environment 
containing 5% CO2 at 37°C. 
 
2.2.1 Passaging and seeding HIB-1B, 3T3-L1, Cos7, 293FT, LentiX 293T and 
HT1080 cells. 
Sub-confluent cells were routinely passaged 1:10 to 1:20 depending on original and 
required cell density in T75 flasks (ŽƌŶŝŶŐ ?). Growth medium (described before) was 
removed; the cells were washed with pre-warmed 1x Phosphate Buffered Saline (PBS) 
and 2ml of trypsin/EDTA added. The cells were incubated at 37°C for about 3 min, 
then 8ml of pre-warmed growth medium was added and the trypsinised cells were 
transferred with the medium into a 25ml Universal tube and centrifuged for 5 min at 
1000 rpm at room temperature (RT). The old medium was discarded and the cells re-
suspended in fresh medium. As the cells start to differentiate at confluence, they 
were passaged at 70% confluence. 
For seeding cells for experiments, cells were counted using haemocytometer, diluted 
according to the required cell numbers and seeded into the appropriate cell culture 
dishes or plates.  
 
2.2.2 Long term storage of cells 
Cells from a 70% confluent flask were detached and pelleted as above. The pellet was 
re-suspended in 1ml of cell freezing medium (10% DMSO and 90% FBS) and pipetted 
in to cryovials (usually 1ml/cryovial). They were then transferred to -80°C freezer 
overnight and finally to liquid nitrogen for long term storage. 
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2.2.3 3T3-L1 differentiation 
To stimulate 3T3-L1 cells to differentiate, they were grown to confluence in growth 
medium in 6-well plates. Two days lateƌ ? ? ? ?ʅD ?-isobutyl-1-methylxanthine (IBMX), 
250nM dexmethasone (Dex) and 167nM insulin in 2ml/well growth medium was 
added. Forty eight hours later, cells were fed with fresh growth medium 
supplemented with 167nM insulin. This medium was replaced every other day. Lipid 
droplets were observed 5-6 days after the cells were induced to differentiate. 
 
2.2.4 Oil Red O and haematoxylin counter staining 
Oil red O was used to stain lipids and haematoxylin stained the nucleus.  Lab coat, 
gloves and eye protections were required during the work. Solutions were made up in 
fume hood.  
The 0.5% w/v stock solution of Oil Red O was made up by adding 5g Oil Red O into 1L 
isopropanol and heated for 2 hours at 60°C with continuous stirring then stored at 
room temperature in the dark. Oil Red O stock was diluted 1:1.5 in 1% dextrin (able to 
decrease precipitation and to intensify the stain) to make up the working solution, 
which was then filtered with filter paper (Whatman ?) after standing at room 
temperature for 1 hour.  
To stain the cells, growth medium was removed from the cells and they were fixed 
with 3.7% formaldehyde for 20min and then rinsed quickly (15 sec) with 60% 
isopropanol diluted in ddH2O. Oil Red O was added into the cells and left for 20min at 
room temperature. Cells were then briefly washed in 60% isopropanol for 15 sec and 
rinsed in tap water. Haematoxylin (working solution from Sigma) was added onto the 
cells for 3min for counter staining and cells were then rinsed in tap water followed by 
ďƌŝĞĨǁĂƐŚĞƐ ? ? ‘ĚŝƉƐ ? )ǁŝƚŚ^ĐŽƚƚ ?ƐƚĂƉǁĂƚĞƌ ? ?>Ě,2O+ 20g sodium bicarbonate+ 3.5g 
magnesium sulphate). The counter-stained cells were air dried for a few minutes and 
covered by a layer of 50% glycerol. 
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2.3 TRANSIENT TRANSFECTION IN MAMMALIAN CELL LINES AND 
REPORTER ASSAY  
 
2.3.1 Transient transfection in HIB-1B cells 
For reporter gene assays, HIB-1B cells were seeded into 96-well plate at the density of 
7000 cells/well in antibiotic free growth medium so that they could get 60-70% 
confluence the next day for transfection. On the day of transfection, 100ng/well 
reporter gene plasmid together with expression plasmids (20ng/well each) were 
diluted in DMEM and FugeneHD® (Roche) was added into the same mixture at a 
charge ratio of 3:1 to DNA. After 20 min incubation at room temperature, the 
transfection mixture was applied to the cells. 24 hours after transfection, the 
transfection medium was removed and replaced with fresh antibiotic growth medium 
containing appropriate treatment for the cells. For RNA extraction, cells were plated 
in 6-well plates and when they reached 60-70% confluence they were transiently 
ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ĞǆƉƌĞƐƐŝŽŶ ƉůĂƐŵŝĚƐ  ? ?ʅŐ E ?ǁĞůů ) ƵƐŝŶŐ &ƵŐĞŶĞ,® as stated 
above. 
 
2.3.2 Transient transfection in 3T3-L1 cells 
Transfection protocol with Lipofectamine2000 (Invitrogen) 
For reporter gene assays, 3T3-L1 cells were seeded into 24-well plates at a density of 
2×10
4
 cells/well in antibiotic free medium so that they could reach 90-95% confluence 
in two days, for transfection. On the day of transfection, the medium was removed 
from the cells and fresh antibiotic free media was added onto the cells about 2 hours 
before doing transfection. Transfection mixture was prepared in two separate tubes. 
One with the DNA mixture containing 400ng/well reporter gene plasmid and 
 ? ?ŶŐ ?ǁĞůůŽĨĞĂĐŚĞǆƉƌĞƐƐŝŽŶƉůĂƐŵŝĚĚŝůƵƚĞĚŝŶ  ? ?ʅů ?ǁĞůůKƉƚŝŵĞŵ® and  the other 
ǁĂƐ>ŝƉŽĨĞĐƚĂŵŝŶĞ ? ? ? ?ŵŝǆƚƵƌĞǁŚĞƌĞ>ŝƉŽĨĞĐƚĂŵŝŶĞ ? ? ? ?ǁĂƐĂĚĚĞĚŝŶƚŽ ? ?ʅů ?ǁĞůů
Optimem® at the charge ratio of 2:1 to DNA and incubated at room temperature for 5 
min. Then the two mixtures were mixed together and incubated at room temperature 
for another 15-20 min before applying to the cells.  Transfection medium was taken 
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out and fresh antibiotic medium was added onto the cells 6-8 hours post transfection. 
24 hours after transfection, the transfection medium was removed and replaced with 
fresh antibiotic growth medium containing appropriate treatment for the cells. For 
RNA extraction, cells were plated in 6-well plates and when they reached 90-95% 
confůƵĞŶĐĞƚŚĞǇǁĞƌĞƚƌĂŶƐŝĞŶƚůǇƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚĞǆƉƌĞƐƐŝŽŶƉůĂƐŵŝĚƐ ? ?ʅŐE ?ǁĞůů )
using Lipofectamine2000 as stated above. 
Transfection protocol with FugeneHD® (Roche) 
For reporter gene assays, 3T3-L1 cells were seeded in 24-well plates at a density of 
3×10
4
 cells/well in antibiotic free growth medium so that they could reach 70-80% 
confluence the next day for transfection. On the day of transfection, 400ng/well 
reporter gene plasmid together with expression plasmids (50ng/well each) were 
diluted in DMEM and FugeneHD® (Roche) was added into the same mixture at a 
charge ratio of 3:1 to DNA. After 20 min incubation at room temperature, the 
transfection mixture was applied to the cells. 24 hours after transfection, the 
transfection medium was removed and replaced with fresh antibiotic free growth 
medium containing appropriate treatment for the cells. For RNA extraction, cells 
were plated in 6-well plates and when they reached 70-80% confluence they were 
ƚƌĂŶƐŝĞŶƚůǇƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚĞǆƉƌĞƐƐŝŽŶƉůĂƐŵŝĚƐ ? ?ʅŐE ?ǁĞll) using FugeneHD® as 
stated above. 
As the tranfection of 3T3-L1 with FugeneHD® saved one day of time and cells were in 
better status because the medium was changed for fewer times compared with using 
Lipofectamine2000, the FugeneHD® transfection protocol was finally used for 3T3-L1 
transient transfection. 
2.3.3 Luciferase reporter gene assay 
For measuring the firefly luciferase activity (pGL3), the multiwell plates (96 well or 24 
well plates) containing the transfected cells were wasŚĞĚŽŶĐĞǁŝƚŚW^ ?dŚĞŶ ? ? ?ʅů
of phenol red-ĨƌĞĞŵĞĚŝĂ ?DD ?/ŶǀŝƚƌŽŐĞŶ )ĂŶĚ ? ?ʅůŽĨƵĂů-Glo Luciferase Buffer 
and substrate mix were added in each well. Plates were gently rocked on an orbital 
shaker (Stuart Scientific) for 10 min at room temperature (RT) and then transferred 
into a 96-well white plate compatible with the luminometer (Turner) and the firefly 
ůƵŵŝŶĞƐĐĞŶĐĞǁĂƐŵĞĂƐƵƌĞĚ ?dŽŵĞĂƐƵƌĞƚŚĞƌĞŶŝůůĂůƵĐŝĨĞƌĂƐĞĂĐƚŝǀŝƚǇ ?ƉZ> ) ? ? ?ʅůŽĨ
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Dual-'ůŽ  “^ƚŽƉ  ?'ůŽ ?ďƵĨĨĞƌŵŝǆĞĚǁŝƚŚ  ? ? ?ʅůŽĨ  “^ƚŽƉ  ?'ůŽ ?ƐƵbstrate were added 
into the same wells in which firefly luciferase activity had been measured.  The plates 
were then rocked gently at RT for another 10min before the renilla luminescence was 
measured. Values were expressed as ratios of the luminescence from the firefly 
(experimental vector: pGL3) to renilla (control vector: pRL-SV40) luciferase activity. 
 
2.4 PRODUCING LENTIVIRUS IN 293T CELLS 
2.4.1 Transfection of 293FT cells to produce lentivirus 
Protocol 1  ?ĨƌŽŵ/ŶǀŝƚƌŽŐĞŶ “ǀŝƌĂƉŽǁĞƌůĞŶƚŝǀŝƌĂůƐǇƐƚĞŵŵĂŶƵĂů ? )
5×10
6
 293FT cells in 10ml antibiotic free growth medium (described before) were 
seeded into a 10cm dish to reach 90-95% confluence the next day for transfection. On 
the day of transfection, medium was removed from the cells and replaced with 5ml of 
ŐƌŽǁƚŚ ŵĞĚŝƵŵ ǁŝƚŚŽƵƚ ĂŶǇ ĂŶƚŝďŝŽƚŝĐƐ ? /Ŷ Ă ƐƚĞƌŝůĞ ƚƵďĞ  ?ʅŐ ŽĨ ƚŚĞ sŝƌĂWŽǁĞƌ ?
WĂĐŬĂŐŝŶŐDŝǆƉůĂƐŵŝĚĂŶĚ ?ʅŐŽĨŽŶĞŽĨƚŚĞƉůĞŶƚŝ ?ĞǆƉƌĞƐƐŝŽŶǀĞĐƚŽƌƐǁĞƌĞĚŝůƵƚĞĚ
in 1.5ml Opti-MEM® I Medium without serum and mixed gently. In a separate tube, 
 ? ?ʅůŽĨ>ŝƉofectamine2000 was diluted in 1.5ml Opti-MEM® I Medium without serum, 
gently mixed and incubated at RT for 5min. The two tubes were then combined 
together and incubated at RT for another 20min and then added into each plate of 
293FT cells. The medium containing DNA-Lipofectamine2000 complexes was replaced 
with 10ml growth media without antibiotics the next day and the lentivirus could be 
harvested 48-72 hours posttransfection. 
Protocol 2 (from Roslin Institute) 
2.5×10
6
 LentiX293T (293T) cells in 5ml antibiotic free growth medium (described 
before) were seeded into a T25 flask to reach 70-80% confluence the next day for 
ƚƌĂŶƐĨĞĐƚŝŽŶ ?KŶƚŚĞĚĂǇŽĨƚƌĂŶƐĨĞĐƚŝŽŶ ?ƚƌĂŶƐĨĞĐƚŝŽŶŵŝǆǁĂƐƉƌĞƉĂƌĞĚďǇĂĚĚŝŶŐ ?ʅŐ
ŽĨ ƉƐWy ? ƉĂĐŬĂŐŝŶŐ ƉůĂƐŵŝĚ ?  ?ʅŐ ŽĨ ƉƐs^s-G plasmid, 1. ?ʅŐ ŽĨ ŽŶĞ ŽĨ ƚŚĞ ƉůĞŶƚŝ ?
ĞǆƉƌĞƐƐŝŽŶƉůĂƐŵŝĚƐĂŶĚ ? ?ʅů&ƵŐĞŶĞ,® ŝŶƚŽ ? ? ?ʅůKƉƚŝ-MEM® serum free medium. 
After 20min incubation at RT, the transfection mix was applied onto the cells. 
Medium on the cells was changed into fresh antibiotic free growth medium or serum 
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free medium the next morning and the lentivirus could be harvested 48 hours 
posttransfection. 
 
2.4.2 Harvest and concentrate the lentivirus 
Supernatant was collected from the dish or flask of transfection and centrifuged at 
2000g for 5min at 4°C to pellet debris, and then filtered through a Millex-,s ? ? ? ?ʅŵ
PVDF filter. Virus were then concentrated by ultracentrifuge at 52,000g for 2 hours at 
4°C and resuspended in TSSM buffer (20mM Trizma base, 0.1M NaCl, 10g/L sucrose 
and 10g/L mannitol, pH7.4). The pellet needed to be loosened on ice on flatbed 
rocker for 1 hour before pippeting gently to resuspend. A spin of 2000rpm for 2min 
was applied to the resuspended virus to get rid of any residual debris. The 
concentrated virus was then aliquoted and stored at -80°C. 
2.4.3 Titering the lentivirus in HT1080 cells 
HT1080 cells in antibiotic free growth medium (described above) were seeded into 6-
well plates at 2×10
6
cells/well so they could reach 30-50% confluence the next day for 
transduction. On the day of transduction, each of the un-concentrated lentiviral 
stocks was serially diluted by the factors of 10
2
, 10
3
, 10
4
, 10
5
 and 10
6
 in 1ml antibiotic 
ĨƌĞĞŵĞĚŝƵŵĂŶĚƚŚĞŶĂƉƉůŝĞĚƚŽƚŚĞ,d ? ? ? ?ĐĞůůƐǁŝƚŚ ?ʅŐ ?ŵůƉŽůǇďƌĞŶĞ ?dŚĞǀŝƌƵƐ-
containing medium was replaced by fresh antibiotic free medium the next day and 
 ?ʅŐ ?ŵů ďůĂƐƚŝĐŝĚŝŶ ǁĂƐ ĂĚĚĞĚ ŝŶƚŽ ƚŚĞ ŵĞĚŝƵŵ ĨŽƌ ƐĞůĞĐƚŝŽŶ ŽŶĞ ĚĂǇ ůĂƚĞƌ ? dŚĞ
selection process lasted 10-12 days with medium changed every 3-4 days.  
 
2.5 TRANSDUCTION OF STABLE CELL LINES OVEREXPRESSING C/EBP 
Ȳd ?KZ>h'&W^ONTROL) WITH LENTIVIRUS 
2.5.1 Infect the 3T3-> ?ƉƌĞĂĚŝƉŽĐǇƚĞƐǁŝƚŚĐŽŶƐƚŝƚƵƚŝǀĞĂŶĚŝŶĚƵĐŝďůĞ ?Wɴ
and LucGFP control lentivirus and select with blasticidin. 
3T3-L1 preadipocytes were plated in complete growth medium in 96-well plates at 
the density of 1.5×10
3
 cells/well so the cells were 30-50% confluence the next day for 
transduction. On the day of transduction, the lentiviral particles containing the genes 
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of interest were diluted into 100µl of the growth medium so that the Multiplicity of 
Infection (MOI) was about 30. The diluted virus was applied to the 3T3-L1 cells with 
 ?ʅŐ ?ŵů ƉŽůǇďƌĞŶĞ ? dŚĞ ǀŝƌƵƐ-containing medium was replaced by fresh growth 
ŵĞĚŝƵŵƚŚĞŶĞǆƚĚĂǇĂŶĚ ?ʅŐ ?ŵůďůĂƐƚŝĐŝĚŝŶǁĂƐĂĚĚĞĚŝŶƚŽƚŚĞŵĞĚŝƵŵĨŽƌƐĞůĞĐƚŝŽŶ 
one day later. The transduced cells were transferred into larger wells after growing 
confluent. The medium was changed every 3-4 days and the selection process lasted 
for 10-12 days so that the surviving cells reached high confluence in the wells.  
2.5.2 Testing the expression of transgenes in the survived cell polyclones 
The surviving 3T3-L1 cells transduced by LucGFP lentiviral particles were checked with 
fluorescence microscopy (Leica DFC 420C) for GFP expression according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛinstructions. Photos were taken with 150× magnification. The LucGFP 
lentivirus transduced cells were also checked for the luciferase activity with luciferase 
assay as described in 2.3.3. The surviving ĐĞůůƐ ƚƌĂŶƐĚƵĐĞĚ ďǇ  ?Wɴ ůĞŶƚŝǀŝƌĂů
particles were chĞĐŬĞĚ ĨŽƌ ?Wɴ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶďǇŵĞĂƐƵƌŝŶŐ ƚŚĞ ƌĞůĂƚŝǀĞ ŵZE
ůĞǀĞůŽĨ ?WɴĐŽŵƉĂƌĂƚŝǀĞůǇ ŝŶŵŽĐŬĂŶĚƚƌĂŶƐĚƵĐĞĚĐĞůůƐƵƐŝŶŐƚŚĞŵĞƚŚŽĚƐƚŚĂƚ
will be addressed in 2.6. 
2.5.3 Select monoclones expressing the genes of interest 
As the integration of viral DNAs into the cell genome is random, it is not guaranteed 
that every cell survives from blasticidin selection can also express the genes of 
interest efficiently. Therefore it is necessary to pick up single colonies of cells and to 
test the expression level of transgene in each colony. Two methods were used to 
select for the monoclone cells expressing the genes of interest.  
The first one was to trypsinize the blasticidin resistant cells, count them and dilute 
into 5 or 2 cells/100µl growth medium into one well of 96-well plates. The growth of 
the cells were then monitored by microscopy day by day and the cells in the wells 
containing only one cell colony were picked out and transferred into bigger culture 
dish for further growth.  
The second method was used before the selection process finished, i.e. when the 
cells were still at low confluence and the cell colonies could be clearly distinguished. 
Cloning rings (small plastic rings cut from the 200µl tips) were used to surround each 
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single cell colony and the cells were trypsinised within the ring and transferred into 
bigger culture dish.  
With either method, the transferred single colonies of cells were grown until high 
confluence and the expression of transgenes were checked with the methods 
described in 2.5.2. 2-3 colonies with high level of transgene expression were stored in 
liquid nitrogen or kept growing for future experiments.  
 
2.6 TEST OF GENE EXPRESSION  
2.6.1 RNA Isolation (RNA extraction from cell lines, Quantification of RNA) 
Total RNA from 3T3-L1 and HIB-1B cells was isolated using Trizol® reagent (Invitrogen). 
ĞůůƐǁĞƌĞǁĂƐŚĞĚŽŶĐĞǁŝƚŚĐŽůĚW^ĂŶĚ  ? ? ?ʅůŽĨdƌŝǌŽů® reagent was added into 
each well and pipetted in and out to break nucleoprotein complex. Reactions were 
incubated at room temperature for 10-15 min and then transferred to 1.5ml micro 
centrifuge tubes and were kept at -80°C until processing further.  
To process cell lysate for RNA extraction, samples were thawed at room temperature 
ĨŽƌ  ? ?ŵŝŶ ĂŶĚ  ? ? ?ʅů ŽĨ ĐŚůŽƌŽĨŽƌŵ ǁĂƐ ĂĚĚĞĚ ŝŶƚŽ ĞĂĐŚsample. After 15sec 
vortexing, samples were incubated at room temperature for 15min and then 
centrifuged at 12,000g for 15min at 4°C. Supernatants were transferred to fresh 
 ? ? ?ŵůŵŝĐƌŽĐĞŶƚƌŝĨƵŐĞƚƵďĞƐĂŶĚ ? ? ?ʅůŽĨ  ? ? ?A? ŝƐŽƉƌŽƉĂŶŽůǁĞƌĞƉŝƉĞƚƚĞŝŶƚŽĞĂĐŚ
sample to precipitate the RNA. Tube contents were mixed gently and incubated at 
room temperature for 10-20min (or -20°C overnight if necessary), followed by 
another centrifuge of 12,000g for 15min at 4°C. Pellet was then air-dried for 10min 
and resuspended in 50- ? ? ?ʅůŽĨŶƵĐůĞĂƐĞ-free water. RNA samples were quantified 
ƵƐŝŶŐEĂŶŽĚƌŽƉĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐĂŶĚƚŚĞn kept at -80°C 
until processed further. 
2.6.2 DNase treatment and cDNA synthesis 
RNA used for quantitative real time PCR (qRT-PCR) was initially treated with 
deoxyribonuclease (DNase) to remove residual contaminating genomic DNA. 200ng of 
ZEǁĞƌĞŵŝǆĞĚǁŝƚŚ ?ʅůŽĨ ? ?× EĂƐĞďƵĨĨĞƌĂŶĚ ?ʅůŽĨZEĂƐĞ-free DNase (Promega) 
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ŝŶĂƚŽƚĂůǀŽůƵŵĞŽĨ  ? ?ʅů ?ŵĂĚĞ ƵƉǁŝƚŚŶƵĐůĞĂƐĞ-free water and then incubated at 
 ? ? ? ĨŽƌ  ? ?ŵŝŶ ? ZĞĂĐƚŝŽŶƐ ǁĞƌĞ ƐƚŽƉƉĞĚ ďǇ ĂĚĚŝŶŐ ŝŶ  ?ʅů ŽĨ EĂƐĞ ^ƚŽƉ ^ŽůƵƚŝŽŶ
 ?WƌŽŵĞŐĂ )ƚŽŐĞƚŚĞƌǁŝƚŚ ? ? ?ʅŐŽĨZĂŶĚŽŵWƌŝŵĞƌƐ ?WƌŽŵĞŐĂ ) ?^ĂŵƉůĞƐǁĞƌĞŚĞĂƚĞĚ
at 65°C for 10min to inactivate the DNase and to denature the RNA. The addition of 
primers before heating also allowed them to anneal better on the RNA.  
For complementary DNA (cDNA) synthesis, the Omniscript® Reverse Transcriptase Kit 
(Qiagen) was used. The DNase treated RNA samples containing random primers were 
ŵŝǆĞĚǁŝƚŚ ?ʅůŽĨ ? ?-ĚĞŽǆǇŶƵĐůĞŽƐŝĚĞ ? ?-triphosphate (dNTP) mix (5mM each dNTP), 
 ?ʅů ŽĨ  ? ?× ZĞǀĞƌƐĞ dƌĂŶƐĐƌŝƉĂƐĞ ƵĨĨĞƌ ?  ?ʅů ŽĨ KŵŶŝĐƌŝƉƚ ZĞǀĞƌƐĞ dƌĂŶƐĐƌŝƉƚĂƐĞ  ? ?
units) and 0.2 ?ʅů ŽĨ ZŶĂƐŝŶ ? (RNase inhibitors from Promega) to a final volume of 
 ? ?ʅů ? ŵĂĚĞ ƵƉ ǁŝƚŚ ŶƵĐůĞĂƐe-free water. One control reaction was also set up 
ĐŽŶƚĂŝŶŝŶŐ ŶŽ KŵŶŝƐĐƌŝƉƚ ďƵƚ ǁĂƚĞƌ ĂƐ ƚŚĞ ƌĞƉůĂĐĞŵĞŶƚ  ? “ŶŽ Zd ? ĐŽŶƚƌŽů ) ƚŽ ƚĞƐƚ
whether there was DNA contamination. Samples were centrifuged briefly and 
incubated at 37°C for 2 hours. cDNAs were stored at -20°C. 
2.6.3 Real time PCR 
The LightCycler® 480 DNA SYBR Green I Master Mix (Roche) was used in the Real 
Time PCR analysis. SYBR Green I binds to all double-stranded DNA molecules and on 
binding fluorescence at 522nm increases. All cDNA samples were diluted (1:7.5 
dilution) to ensure a smaller pipetting error between reactions set up in 384-well 
ƉůĂƚĞƐ ?/ŶĞĂĐŚƌĞĂĐƚŝŽŶ ? ? ? ?ʅůŽĨ^zZ'ƌĞĞŶ/DĂƐƚĞƌDŝǆ ? ?y )ǁĂƐŵŝǆĞĚǁŝƚŚ ? ? ?ʅů
of diluted cDNĂŶĚ ? ? ? ?ʅůŽĨĞĂĐŚƉƌŝŵĞƌ ? ? ?ʅD ) ?>ŝŐŚƚǇĐůĞƌ ? ? ? ?/ŶƐƚƌƵŵĞŶƚ was 
used to perform the PCR reactions with the following temperature profile: an initial 
denaturation temperature at 95°C for 15min, 35-40 cycles of denaturation (20 sec at 
95°C), annealing (20 sec at optimized annealing temperature) and extension (20 sec 
at 72°C). The data acquisition was performed during the extension period and a 
melting curve was acquired between 72°C and 95°C to check for primer dimers or 
other non-specific amplicons. The specificity of PCR products were also checked by 
agarose gel electrophoresis. 
 
The primer sequences used for measuring gene expression were provided in the 
following table. The primers were designed using the software Primer Express.  
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Name &ŽƌǁĂƌĚWƌŝŵĞƌ ? ? ?ƚŽ ? ? ) ZĞǀĞƌƐĞWƌŝŵĞƌ ? ? ?ƚŽ ? ? )
PGC- ?ɲ GTGCTTCGAAAAAGAAGTCCCATA GTTGTTGGTTTGGCTTGAGCAT 
UCP1 GCCATCTGCATGGGATCAA GGTCGTCCCTTTCCAAAGTG 
WWZɶ GTGCCAGTTTCGATCCGTAGA GGCCAGCATCGTGTAGATGA 
 ?Wɴ AGCGGCTGCAGAAGAAGGT GGCAGCTGCTTGAACAAGTTC 
Resistin CTGTCCAGTCTATCCTTGCACAC CAGAAGGCACAGCAGTCTTGA 
PRDM16 TCTTACTTCTCCGAGATCCGAAA GATCTCAGGCCGTTTGTCCAT 
RIP140 CGACTTCCAGACCCACAACA GGCGCTCTTGGCATCGT 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
36B4 TCCAGGCTTTGGGCATCA TTATCAGCTGCACATCACTCAGAAT 
 
 
2.8 STATISTICAL ANALYSIS 
Data in figures is presented as average ± SEM from 2 or 3 independent replicate 
experiments with duplicate or triplicate wells in each experiment. Effects of 
treatments were determined by performing ^ƚƵĚĞŶƚ ?Ɛt-test or Analysis of Variance 
(ANOVA) as indicated in individual figure legend. Significance was accepted if P<0.05. 
All statistical analyses were performed on SPSS statistical package version 16 (SPSS 
Inc. Chicago, IL, USA).  
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3 CONSTRUCTION OF LENTIVIRAL 
VECTORS ALLOWING TETRACYCLINE-
INDUCIBLE STABLE OVEREXPRESSION 
OF C/EBP BETA IN 3T3-L1 
3.1 INTRODUCTION  
 ?Wɴ ƉůĂǇƐ ĂŶ ŝŵƉŽƌƚĂŶƚ ƌŽůĞ ŝŶ ĂĚŝƉŽŐĞŶĞƐŝƐ ? dŚŝƐ ŚĂƐ ďĞĞŶ ĚĞŵŽŶƐƚƌĂƚĞĚ ďǇ
promotion of 3T3-L1 differentiation and conversion of multipotent NIH3T3 fibroblasts 
ŝŶƚŽĐŽŵŵŝƚƚĞĚĂĚŝƉŽďůĂƐƚƐ ?ďǇŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴŝŶƚŚĞĂďƐĞŶĐĞŽĨŚŽƌŵŽŶĞ
inducers (Yeh et al., 1995). Furthermore, the use of a dominant negative C/EBP 
(lacking functional DNA-binding and transactivation domain) that forms stable 
ŚĞƚĞƌŽĚŝŵĞƌƐ ǁŝƚŚ  ?Wɴ ? ƌĞƐƵůƚƐ ŝŶ ŝŶŚŝďŝƚŝŽŶ ŽĨĂĚŝƉŽŐĞŶĞƐŝƐ ĂŶĚ ŵŝƚŽƚŝĐ ĐůŽŶĂů
expansion in 3T3-L1 preadipocytes (Zhang et al., 2004c) ? DŽƌĞŽǀĞƌ ?  ?Wɴ ŝƐ ĂůƐŽ
indispensible in thermogenesis for adipocytes. Its overexpression rescues the cAMP-
ŝŶĚƵĐŝďůĞĞǆƉƌĞƐƐŝŽŶŽĨW' ?ɲĂŶĚhW ?ŝŶǁŚŝƚĞƉƌĞĂĚŝƉŽĐǇƚĞƐ (Karamanlidis et al., 
2007) ?  ?Wɴ ? ƚŽŐĞƚŚĞƌ ǁŝƚŚ WZD ? ? ? ĂůƐŽ ĨĂĐŝůŝƚĂƚĞƐ ƚŚĞ ƐǁŝƚĐŚ ĨƌŽŵ ŵǇŽďůĂƐƚ
progenitors to brown fat cells, morphologically and functionally (Kajimura et al., 
2009). However, during hormone induced differentiation of white preadipocyte 3T3-
> ? ĐĞůůƐ ? ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?Wɴ ĚŝŵŝŶŝƐŚĞƐ ĂƌŽƵŶĚ ĂǇ  ? ? ǁŚĞƌĞĂƐ ŝŶ ďƌŽǁŶ
ĂĚŝƉŽĐǇƚĞĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ? ?WɴĞǆƉƌĞƐƐŝŽŶis maintained at a high level throughout 
the whole process (Karamitri et al., 2009; Lane et al., 1999). The different expression 
ƉĂƚƚĞƌŶƐ ŽĨ  ?Wɴ ŝŶƐƉŝƌĞĚ ƚŚĞ ŝĚĞĂ ƚŚĂƚ ƚŚĞ ƐƚĂďůĞ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?Wɴ ŝŶ
white preadipocytes 3T3-L1s throughout the differentiation process may cause more 
brown-like terminal differentiated adipocytes.  
To construct a stable transgenic 3T3-> ?ĐĞůů ůŝŶĞŽǀĞƌĞǆƉƌĞƐƐŝŶŐ ?Wɴ ?ƚŚĞůĞŶƚŝǀŝƌĂů
vector expression system was chosen, as the system is known for its high viral titer 
and high efficiency in delivering exogenous gene into the genome of both dividing 
and non-dividing mammalian cells and animals (Twyman, 2005). Moreover, to easily 
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control when and how much to overexpress the gene, a tetracycline controlled (Tet 
on) expression system was also introduced to the viral vector (Pluta et al., 2007), thus 
ƚŚĞĞǆŽŐĞŶŽƵƐ ?Wɴ ŝƐŽǀĞƌĞǆƉƌĞƐƐĞĚ ŝŶƚŚĞ ƉƌĞƐĞŶĐĞŽĨƚŚĞ ŝŶĚƵĐĞƌĚŽǆǇĐǇĐůŝŶĞ ?
The expression is also induced in a dose-dependent manner, so the expression level 
can be controlled by the concentration of doxycycline added into cells (Clontech). The 
Tet on expression system has two essential components, the tetracycline responsive 
element (TRE) and the reverse tetracycline-controlled transactivator (rtTA), both of 
which have evolving design and sequences. The original TRE-based promoter was 
developed by Gossen and colleagues (Gossen and Bujard, 1992); it can realize the 
inducible expression in the presence of doxycycline but has a relatively high 
background noise (so-ĐĂůůĞĚ  “ůĞĂŬŝŶĞƐƐ ? ) ? dŚĞ ŝŵƉƌŽǀĞĚ dZ ƉƌŽŵŽƚĞƌ ? dZ ƚŝŐŚƚ
(developed by Clontech) demonstrates greater inducibility coupled with extremely 
low basal activity by closer design of the 7 tetO sequences that make up the TRE and 
the removal of the potential binding sites of endogenous transcription factors 
(Clontech). The Tet on transactivator rtTA also has been improved (rtTA advanced) by 
utilizing human codon preferences and removing cryptic splice sites from the mRNA 
sequences to improve the expression in mammalian cells. It also contains some 
specific mutations that both increase its sensitivity to doxycycline and significantly 
diminish residual binding to TREs in the absence of doxycycline (Urlinger et al., 2000). 
Therefore there are two versions of TREs and two versions of rtTA, thus four different 
combinations, to test and select for a best backbone of doxycycline inducible 
expression. 
The aim of the experimental work described in this chapter was to construct and 
select for the best inducible lentiviral backbone vector using a luciferase GFP (LucGFP) 
reporter gene with the multi-gateway recombination cloning method, and to use this 
ďĂĐŬďŽŶĞƚŽŽǀĞƌĞǆƉƌĞƐƐ ?WɴŝŶ ?d ?-L1 cells inducibly. More ambitiously, the fat-
specific inducible lentiviral vectors were also to be constructed with either a full 
length or truncated fat-specific promoter (aP2 promoter) for the potential use of this 
vector into embryonic stem cells or pronuclear injection. Unfortunately, the full 
length aP2 promoter is about 5.6kb in size, which has already exceeded the maximal 
insert size (4-5kb in total) of pLenti6 destination vector (Invitrogen), so a 1.2kb 
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truncated aP2 promoter, short aP2, containing only the fat-specific enhancer and the 
proximal promoter of the original aP2 promoter (Graves et al., 1992), was used to 
generate the vectors for lentivirus production. However, to compare the fat 
specificity of the two versions of aP2 promoter, both were used in plasmid vector 
construct and the consequential test for fat specificity in a transient transfection 
system.   
The specific objectives of the experimental work described in this chapter include 
1. To integrate TRE or TRE tight into the original pLenti6/V5 destination vector to 
make the tetracycline inducible lentiviral backbone vectors.  
2. To clone the LucGFP reporter gene with either rtTA or rtTA advance transactivator 
into the TRE or TRE tight modified lentiviral destination vector to make the four 
inducible lentiviral vectors expressing LucGFP. 
3. To test the four inducible lentiviral vectors in 3T3-L1 and HIB-1B preadipocyte cell 
lines using transient transfection method and to use the best one to overexpress 
 ?Wɴ ? 
4. To put the fat-specific promoter into the best inducible lentiviral backbone(s) to 
make the fat-specific inducible lentiviral vectors expressing LucGFP. 
5. To investigate the adipogenic conditions in the transient system to test the fat 
specificity of the fat-specific inducible lentiviral vectors in preadipocyte cell lines and 
ƚŽƐĞůĞĐƚĨŽƌƚŚĞďĞƐƚŽŶĞƚŽŽǀĞƌĞǆƉƌĞƐƐ ?Wɴ ?
3.2 EXPERIMENTAL DESIGN 
3.2.1 Construction of tetracycline inducible lentiviral vector backbone with 
ligation-mediated cloning  
The tetracycline response element (TRE) was amplified from a plasmid named pL3-
TRE-LucGFP-2L (Addgene) by PCR, and ClaI and SpeI restriction sites were added onto 
ƚŚĞ ? ?ĂŶĚ ? ?ĞŶĚƐŽĨƚŚĞWZƉƌŽĚƵĐƚƌĞƐƉĞĐƚŝǀĞůǇ. An improved version of TRE, TRE 
tight was amplified from the plasmid pTRE-Tight miR-1 (Addgene) by PCR and the 
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ƐĂŵĞ ƌĞƐƚƌŝĐƚŝŽŶ ƐŝƚĞƐ ůĂ/ ĂŶĚ ^ƉĞ/ ǁĞƌĞ ĂĚĚĞĚ ŽŶƚŽ ƚŚĞ  ? ? ĂŶĚ  ? ? ĞŶĚƐ ŽĨ WZ
product as well. Each PCR product was then cloned into the original pLenti6/V5 
destination vector as described in 2.1.1. The modified destination vectors, named 
pLenti TRE and pLenti TRE tight, were then identified by restriction digest and DNA 
sequencing.  
3.2.2 Construction of entry clones of CMV promoter, aP2 promoter, short aP2 
ƉƌŽŵŽƚĞƌ ? ?Wɴ ?>ƵĐiferase/GFP (LucGFP), and rtTA or rtTA advance with 
BP reaction (Gateway cloning) and the generation of constitutive and 
inducible (non-tissue specific) lentiviral expression vectors of LucGFP with LR 
reaction (Gateway cloning) 
The lentiviral expression vectors were designed to integrate three components into 
ƚŚĞďĂĐŬďŽŶĞ ?ƚŚĞŐĞŶĞŽĨ ŝŶƚĞƌĞƐƚ  ?>ƵĐ'&WŽƌ ?Wɴ ) ?ƚŚĞƉƌŽŵŽƚĞƌ(CMV, aP2 or 
short aP2) driving the expression of the transactivator, and the transactivator (rtTA or 
rtTA advance). Therefore all the genes of interest, promoters and transactivators 
were cloned into corresponsive entry clone backbones as described in 2.1.2.1. The 
entry clones were checked by restriction digest and DNA sequencing. The constitutive 
lentiviral expression vector of LucGFP was generated from the recombination of the 
entry clones of LucGFP, CMV and rtTA integrated into pLenti6/V5 destination vector 
by LR recombination reaction as described in 2.1.2.2. The non-tissue specific inducible 
lentiviral expression vectors of LucGFP were generated in the same way but with an 
inducible lentiviral destination backbone vector, thus contained four combinations 
between two different inducible backbones (TRE and TRE tight) and two different 
transactivators (rtTA and rtTA advance). All the lentiviral expression vectors 
generated above were checked by restriction digest.  
3.2.3 Selection for the best inducible backbone and to use the backbone for 
 ?WɴŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ?
The four non-tissue specific inducible lentiviral expression vectors of LucGFP were 
introduced into 3T3-L1 and HIB-1B preadipocytes by plasmid DNA transfection 
method to transiently overexpress the luciferase and GFP genes in the presence of 
doxycycline (Dox). Cells were seeded in 24-well plates and transfected with the 
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inducible expression vectors by FugeneHD® as described in 2.3.2 and Dox was added 
to the cells 24 hours post transfection. Luciferase activity was measured 24 hours 
after adding Dox as described in 2.3.3. The vector(s) displaying low basal expression 
ůĞǀĞů ?ůŽǁ “ůĞĂŬŝŶĞƐƐ ? )ĂŶĚŐŽŽĚŝŶĚƵĐŝďŝůŝƚǇǁĞƌĞƵƐĞĚƚŽŐĞŶĞƌĂƚĞ ?WɴĞǆƉƌĞƐƐŝŽŶ
vector(s) by LR reaction.  
3.2.4 Generation of fat-specific inducible expression vectors of LucGFP with 
the aP2 and short aP2 entry clones and the best inducible backbone. 
The best non-tissue specific inducible lentiviral expression backbone(s) selected 
above were used to generate the fat-specific inducible lentiviral expression vectors of 
LucGFP together with entry clones of LucGFP and aP2 or short aP2 by LR 
recombination reaction. The generated vectors were checked by restriction digest. 
3.2.5 Investigation on transient adipogenic conditions to test the fat-specific 
lentiviral expression vectors in a transient overexpression system.  
Two methods were used to stimulate the adipogenic programme transiently in HIB-
1B and 3T3-L1 preadipocytes. The first was to treat the confluent HIB-1B and 3T3-L1 
preadipocytes in 6-well plates with 10µM rosiglitazone for 24 hours and in the latter 3 
hours 10µM forskolin was added in before extracting RNA from the cells as described 
in 2.6.1. The second was to transiently transfect the preadipocytes with 
ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ƉůĂƐŵŝĚƐ ŽĨ  ?Wɴ ĂŶĚ WWZɶ ĂŶĚ ƚŽ ƚƌĞĂƚ ƚŚĞ ĐĞůůƐ ǁŝƚŚ  ? ?A?D
rosiglitazone 24 hours post-transfection and RNA was extracted from the cells 24 
hours after adding rosiglitazone. The extracted RNAs were used to synthesize 
complimentary DNA (cDNA) as described in 2.6.2 and to perform real time PCR 
(described in 2.6.3) to detect if the expression of adipogenic marker gene aP2 was 
elevated compared with control groups. The effective adipogenic condition(s) were 
used to check the fat specificity of the fat-specific inducible lentiviral expression 
vectors of LucGFP. These vectors were introduced into HIB-1B and 3T3-L1 
preadipocytes by plasmid transfection method (see 2.3.1 and 2.3.2) and treated with 
the transient adipogenic conditions as described above. Dox was given to the cells 24 
hours before the luciferase activity was measured to check the fat-specificity and 
inducibility of each vector.  
90 
 
3.3 RESULTS 
3.3.1 Identification of tetracycline inducible backbone pLenti-TRE and pLenti-
TRE tight  
The inducible lentiviral backbone vectors pLentiTRE and pLentiTRE tight derived from 
the original lentiviral vector pLenti6/V5 were digested with BamHI and XhoI 
ƐĞƉĂƌĂƚĞůǇĂƚ ? ?ȗĨŽƌ ?ŚŽƵƌƐďĞĨŽƌĞƌƵŶŶŝŶŐĂ ?A?ĂŐĂƌŽƐĞŐĞů to check the sizes of 
digested fragments (Figure 3.1). The putative sizes of the fragments in each digest 
were obtained from the Vector NTI software from Invitrogen, and indicated in the 
text below the figure. Seen from the gel image, all the three vectors, pLenti6/V5, 
pLentiTRE and pLentiTRE tight, gave correct fragments in both BamHI and XhoI 
digests, indicating the proper identity of the modified inducible lentiviral destination 
vectors.  
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Figure3.1 Restriction digest of pLenti6/V5, pLenti TRE and pLenti TRE tight 
destination vectors 
pLenti6/V5 (Lane 1 &4), pLenti TRE (Lane 2&5) and pLenti TRE tight (Lane 3&6) 
were digested by either BamHI or XhoI as indicated. 1kb ladder was loaded in Lane 
7 and the size of each band has been labeled on the right. The putative sizes of 
digested fragments (in bp) were Lane1 (7749+ 703+ 236), Lane 2 (7874+ 703), Lane 
3 (7733+ 703), Lane 4 (8688), Lane 5 (6329+ 2198) and Lane 6 (6344+ 2092).  
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3.3.2 Restriction digests of entry clones of CMV promoter, aP2 promoter, 
short aP2 promoter, LucGFP, rtTA and rtTA advance 
Entry clones of CMV promoter, aP2 and short aP2 promoter, LucGFP, rtTA and rtTA 
advance derived from BP reactions were examined by double digests (Figure 3.2) with 
the restriction enzymes indicated in the text below the figure. The putative sizes of 
the fragments were obtained from Vector NTI (Invitrogen) and indicated below the 
figure as well. All the digested entry clones demonstrated correct sizes of the 
fragments in the agrose gel electrophoresis, indicating the correct identity of the 
entry clones.  
 
 
Figure 3.2  Restriction digest of entry clones 
Entry clones of LucGFP, CMV promoter, aP2 promoter, short aP2 promoter, rtTA 
and rtTA advance were digested with specific restriction enzymes. 1kb ladder was 
loaded in Lane 1 and the size of each band has been labelled on the left. The 
putative sizes of digested fragments were Lane 2 (BamHI+ HindIII, 5081+ 754), 
Lane 3 (SpeI +PstI, 2247+ 733), Lane 4 (SpeI+ PvuI, 6054+ 1863), Lane 5 (EcoRI+ 
PstI, 2206+ 1179+ 164), Lane 6 (EcoRI+ PstI, 2159+ 1598) and Lane 7 (XbaI+ XmaI, 
2304+ 735).  
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3.3.3 Restriction digests of the 4 inducible expression vectors of LucGFP (TRE 
rtTA, TRE tight rtTA, TRE rtTA adv and TRE tight rtTA advance) 
The constitutive lentiviral expression vector of LucGFP pLenti6/v5-LucGFP and the 
four non-tissue specific inducible lentiviral expression vectors of LucGFP, pLentiTRE 
LucGFP rtTA, pLentiTRE tight LucGFP rtTA, pLentiTRE LucGFP rtTA advance and 
pLentiTRE tight rtTA advance were checked by double digests (Figure 3. 3) with the 
enzymes indicated in the text below the figure. The putative sizes of digested 
fragments were obtained from the analysis of Vector NTI (Invitrogen) and also 
indicated below the figure. The agarose gel image demonstrated that all the 
expression vectors examined gave correct fragment sizes in the digest, indicating the 
correct identity.  
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Figure 3.3 Restriction digest of non-tissue sepcific lentiviral expression vectors 
of LucGFP  
Constitutive and the four inducible (non-tissue specific) lentiviral expression 
vectors of LucGFP were digested with specific restriction enzymes. The putative 
sizes of digested fragments were Lane 1 (PstI+ XhoI, 6951+ 5838), Lane 2 (PstI+ 
BamHI, 7300+ 3638+ 1690), Lane 3 (PstI+ BamHI, 7209+ 3638+ 1690), Lane 4 
(PstI+ SacII, 6771+5139), Lane 5 (PstI+ SacII, 6680+5113). 1kb ladder was loaded 
in Lane 6 and the size of each band has been labelled on the right.  
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3.3.4 Comparison of the 4 inducible LucGFP lentivral expression vectors in 
3T3-L1 and HIB-1B preadipocytes 
The four non-tissue specific inducible lentiviral expression vectors of LucGFP were 
introduced separately into 3T3-L1 and HIB-1B preadipocytes by transient transfection. 
1µM doxycycline (Dox) was given to the cells 24 post-transfection and treated for 24 
hours before luciferase assay (Figure 3.4). Results demonstrated that the pLentiTRE 
LucGFP rtTA advance and pLentiTRE tight LucGFP rtTA advance had low basal activity 
in the absence of Dox and the induced activity (5.5 and 6 fold induced, respectively, 
P<0.05) of both were comparable with the constitutive vector in 3T3-L1 cells (Figure 
3.4A). In HIB-1B cells (Figure 3.4B), the pLentiTRE LucGFP rtTA advance had even 
lower basal activity and a better induciblity (7.7 fold induced, P<0.05) although the 
absolute value of induced luciferase activity was only half of the constitutive value. 
Similar to the result in 3T3-L1, pLentiTRE tight LucGFP rtTA advance in HIB-1B cells 
also had relative low leakiness and good inducibility (6.2 fold induced, P<0.05), and 
the induced luciferase activity was comparable to that of the constitutive value.  
 
 
Figure 3.4 Comparison of different Tet on LucGFP vectors (CMV driven) by 
luciferase assay in 3T3-L1 (A) and HIB-1B (B) preadipocytes. 
HIB-1B and 3T3-L1 preadipocytes were transiently transfected with different Tet 
on LucGFP vectors (CMV driven), the empty vector pLenti TRE (negative control) or 
the constitutive vector pLenti 6 CMV LucGFP (positive control). Cells were given 
1µg/ml doxycycline (Dox) 24 hours post-transfection and treated for 24 hours. 
Luciferase activity was relative to the value from the cells transfected with TRE 
tight LucGFP CMV rtTA adv vector without doxycycline induction. Results 
represent mean ± S.E.M from 2 independent replicate experiments performed in 
triplicate wells. ^ƚƵĚĞŶƚ ?Ɛt-test was used to analyse the data. *P<0.05 caused by 
gene overexpressions ǁŝƚŚƌĞƐƉĞĐƚƚŽ “dZƌƚd ?-Žǆ ) ?ŐƌŽƵƉ ? ?P<0.05 caused by 
Dox with respect to the group overexpressing the same vector without Dox 
treatment. 
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The results demonstrated clearly that the improved version of transactivator rtTA 
advance could significantly decrease the basal expression of the vectors in the 
absence of Dox, compared with the original transactivator rtTA. In terms of the 
absolute expression level in presence of Dox, the combination of TRE with rtTA 
advance performed slightly higher than the combination of TRE tight with rtTA 
advance in 3T3-L1 cells, but in HIB-1B cells, the results were quite opposite that the 
expression level of TRE+ rtTA advance was much lower than that of TRE tight+ rtTA 
advance, which might reflect the various sensitivity of different cell lines to the 
elements. It was also known that the expression of the Tet on vectors could be 
induced by Dox in a dose-dependent manner (Tang et al., 2009), so the dose response 
experiment of both vectors (TRE rtTA advance and TRE tight rtTA advance) were 
performed in 3T3-L1 cell line (Figure 3. 5). The results demonstrated that the TRE 
LucGFP rtTA advance vector (blue line) was more sensitive to doxycycline than TRE 
tight LucGFP rtTA advance vector (red line), as the luciferase activity of the former 
was upregulated 8 fold by low concentration (0.5µg/ml) of Dox while the fold change 
of the latter was 4 at the same concentration of Dox. The fold change at 1µg/ml Dox, 
the concentration used in the previous induction experiments, was 12 and 5 for the 
two vectors respectively, which were different from the previous experiment in 
Figure 3.4A (5.5 and 6 fold respectively), might reflect the normal variety between 
experiments because of the slight different situations of the cells. The activity of TRE 
LucGFP rtTA advance vector increased when doxycycline concentration increased 
from 0.5 µg/ml to 1 µg/ml (from 8 fold to 12 fold relative to the basal activity) but did 
not significantly vary from 1 µg/ml to 3 µg/ml doxycycline treatments (12, 10, 11, 13 
fold at 1, 1.5, 2 and 3 µg/ml). The activity achieved the peak at 5 µg/ml to 17.8 fold 
relative to basal activity and started to decrease to 13 fold at 8 µg/ml. The activity of 
TRE tight LucGFP rtTA advance vector did not significantly vary from 0.5 µg/ml to 1.5 
µg/ml (all about 4 fold relative to basal activity) but increased to 7 and 7.6 fold at 2 
µg/ml and 3 µg/ml respectively, decreased to 6 fold at 5 µg/ml and further reduced to 
3 fold at 8 µg/ml. The different properties of the dose responding curves might imply 
some intrinsic differences derived from the structures of these two vectors or the 
different interactions between the vectors and the host cells. Although the TRE 
LucGFP rtTA advance vector displayed higher sensitivity and inducibility than TRE 
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tight LucGFP rtTA advance vector, the inducibility of both vectors were acceptable. 
Therefore either of the two backbones could be chosen to produce the corresponding 
non-tissue sƉĞĐŝĨŝĐ ŝŶĚƵĐŝďůĞ ůĞŶƚŝǀŝƌĂůĞǆƉƌĞƐƐŝŽŶǀĞĐƚŽƌƐŽĨ ?WɴĂŶĚƚŽŐĞŶĞƌĂƚĞ
the fat-specific inducible vectors of LucGFP. 
 
 
 
 
Figure 3.5 The Tet on LucGFP vectors responded to doxycycline in a dose-dependent 
manner 
3T3-L1 preadipocytes were transfected with either TRE LucGFP rtTA advance or TRE 
tight LucGFP rtTA advance vector. Doxycycline was added into the cells 24 hours post 
transfection at the concentration indicated in the graph. Firefly luciferase activity was 
measured 24 hours after the addition of doxycycline. The error bars represent S.E.M 
from 2 independent replicate experiments performed in triplicate wells.  
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 ? ? ? ? ?dŚĞŝŶĚƵĐŝďůĞŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴǁŝƚŚƚŚĞƐĞůĞĐƚĞĚTet on 
pLentiviral vector backbone in 3T3-L1  
Since both pLenti TRE tight rtTA advance and pLenti TRE rtTA advance backbones 
were showed to be equally efficient for inducible expression of LucGFP in 3T3-L1 cells, 
and the former was even more efficient than the latter in terms of expression level in 
HIB-1B cells, the pLenti TRE tight rtTA advance backbone was chosen to express the 
C/EBPɴ gene. The C/EBPɴ entry clone was constructed as described in 2.1.2.1 and 
checked by restriction digest (Figure 3.6A) and DNA sequencing. The constitutive and 
non-tissue specific Tet on lentiviral vectors for expressing C/EBPɴ ? Ɖ>ĞŶƚŝ ?- ?Wɴ
and pLenti TRE tight- ?WɴDsƌƚdĂĚǀĂŶĐĞ ?were constructed by LR reactions as 
described in 2.1.2.2 and checked by restriction digest (Figure 3.6A). To check the 
expression level and inducibility of the vectors, the empty pLenti-TRE vector, pLenti6-
C/EBPɴĂŶĚƉLenti TRE tight- ?WɴDsƌƚdĂĚǀĂŶĐĞ vectors were transfected into 
3T3-L1 preadipocytes by Fugene HD mediated transient transfection and 1µg/ml 
doxycycline (Dox) or vehicle was added to cells transfected with the Tet on C/EBPɴ 
vector for 24-hour treatment before the cells were lysed for RNA extraction. Gene 
expression level of C/EBPɴ was analysed by quantitative real-time PCR and 
normalised to 18S expression (Figure 3.6B) and results showed that doxycycline 
induced (P<0.001) the expression of C/EBPɴ  4 fold in the cells transfected with the 
Tet on C/EBPɴ vector, but the induced expression level was still significantly lower 
(P<0.001) than that in the cells transfected with constitutive pLenti6-C/EBPɴ vector. It 
seemed that although with the same plentiviral vector backbone pLenti TRE tight 
CMV rtTA advance, the inducibility of the Tet on C/EBPɴ vector was not as good as 
that of the Tet on LucGFP vector (6 fold induced in Figure 3.4A), implying the 
inducible expression cassette might have different sensitivity to doxycycline 
depending on specific target genes. Although not as high as the constitutive 
expression, the doxycycline induced C/EBPɴĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůǁĂƐƐƚŝůů  ? ? ĨŽůĚŚŝŐŚĞƌ
(P<0.05) than the eŶĚŽŐĞŶŽƵƐ  ?Wɴ ĞǆƉƌĞƐƐŝŽŶ ŵĞĂƐƵƌĞĚ ĨƌŽŵ ƚŚĞ ĐĞůůƐ
transfected with empty vector pLenti TRE; given that even in HIB-1B brown 
ƉƌĞĂĚŝƉŽĐǇƚĞƐǁŚĞƌĞ ?Wɴ ŝƐƐĞŶƐŝƚŝǀĞƚŽĐDWƐƚŝŵƵůĂƚŝŽŶ ŝŶĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ?ƚŚĞ
ĐDWƐƚŝŵƵůƵƐĨŽƌƐŬŽůŝŶŽŶůǇŝŶĚƵĐĞƐ ?WɴĞǆpression by, at most, 6 fold during the 
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differentiation process (Karamitri et al., 2009) ? ƚŚĞ  ? ? ĨŽůĚ ŚŝŐŚĞƌ  ?Wɴ
overexpression induced by doxycycline in 3T3-L1 cells should be sufficient.  
  
 
 
 
 
 
 
Figure 3.6 Constitutive and inducible overexpression of C/EBPɴ ŝŶ  ?d ?-L1 
preadipocytes by plentiviral expression vectors 
 ? ) ŶƚƌǇ ĐůŽŶĞ ŽĨ  ?Wɴ  ?>ĂŶĞ  ? ) ? ĐŽŶƐƚŝƚƵƚŝǀĞ ĞǆƉƌ ƐƐŝŽŶ ǀĞĐƚŽƌ Ɖ>ĞŶƚŝ- ?Wɴ
(Lane 2) and Tet on expression vector pLenti TRE tight- ?Wɴ ƌƚdĂĚǀ  ?>ĂŶĞ  ? )
were digested with specific restriction enzymes. The putative sizes of digested 
fragments were: Lane 1 (EcoR I, 2815+1514), Lane 2 (XhoI, 8958) and Lane 3 (XhoI, 
6344+3989). 1kb ladder was loaded in Lane 6 and the size of each band has been 
labelled on the right. (B) 3T3-L1 preadipocytes were grown to 70% confluence in 6-
well plates and then transiently transfected with the empty pLenti TRE vector, the 
constitutive pLenti6- ?Wɴ Žƌ ƚŚĞ ŝŶĚƵĐŝďůĞ Ɖ>ĞŶƚŝ dZ ƚŝŐŚƚ- ?Wɴ Ds ƌƚd
advance vectors by Fugene HD. 1µg/ml doxycycline (Dox) or vehicle was added to 
the cells transfected with the inducible C/EWɴ ǀĞĐƚŽƌ ĂŶĚ ƚƌĞĂƚĞĚ ĨŽƌ  ? ? ŚŽƵƌƐ ?
RNAs were extracted from the cells 48 hours post transfection and the mRNA level 
ŽĨ ?WɴǁĂƐƋƵĂŶƚŝĨŝĞĚďǇƌĞĂů-time PCR and normalised against 18S expression. 
Results represent mean ±S.E.M from two independent replicate experiments 
ƉĞƌĨŽƌŵĞĚ ŝŶ ĚƵƉůŝĐĂƚĞ ǁĞůůƐ ? ^ƚƵĚĞŶƚ ?Ɛ ƚ-test was used to analyse the data. 
*P<0.05 caused by overexpressions with respect to control; #P<0.05 caused by Dox 
with respect to the group overexpressing the same vector without Dox treatment. 
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3.3.6 Restriction digests of the 4 fat-specific inducible expression vectors of 
LucGFP 
Entry clones of LucGFP, rtTA advance and aP2 or short aP2 were integrated into 
either pLentiTRE or pLentiTRE tight destination vector by LR recombination reactions 
to generate the fat-specific inducible lentiviral expression vectors of LucGFP. The 
constructed vectors were identified by restriction digest (Figure 3.7) with the 
enzymes indicated in the text below the figure. The putative sizes of digested 
fragments were calculated by VectorNTI (Invitrogen) and indicated in the figure 
legend. All the digested vectors demonstrated correct sizes of the fragments in the 
agarose gel electrophoresis.  
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Figure 3.7 Restriction digest of fat-specific inducible sepcific lentiviral expression 
vectors of LucGFP  
Fat-specific inducible lentiviral expression vectors of LucGFP with either full length 
aP2 or truncated aP2 (short aP2) promoter were digested by specific restriction 
enzymes. 1kb ladder was loaded in Lane 1 and the size of each band has been 
labelled on the left. The putative sizes of digested fragments were Lane 2 (XhoI, 
10518+ 6329), Lane 3 (PstI, 7650+4829), Lane 4 (XhoI, 10412+ 6344) and Lane 5 
(PstI, 7559+ 4829).  
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3.3.7 Investigation of adipogenic conditions for transient transfection in 3T3-
L1 and HIB-1B 
The transiently overexpressed luciferase or GFP signals were only detectable 48-60 
hours post transfection, and then the signals diminished as the expression was not 
stable. In order to test the fat-specificity and inducibility of the four fat-specific 
inducible lentiviral expression vectors of LucGFP (TRE LucGFP aP2 rtTA advance, TRE 
tight LucGFP aP2 rtTA advance, TRE LucGFP short aP2 rtTA advance and TRE tight 
short aP2 rtTA advance), an adipocyte culture differentiation induction system in 
which aP2 was expressed within 24h of induction had to be found to test the 
constructs in a transient overexpression system. Rosiglitazone has been described to 
stimulate adipocyte differentiation by activating the master regulator of adipogenesis 
WWZɶ (Lehrke and Lazar, 2005) ? &ŽƌƐŬŽůŝŶ ? ĂƐ ĂŶ ĂŐŽŶŝƐƚ ŽĨ ɴ-adrenergic receptor, 
also favours adipogenesis through activating the cAMP-PKA pathway (Yarwood et al., 
1995). Therefore the first adipogenic recipe chosen was to treat confluent 
preadipocytes with both 10µM rosiglitazone and 10µM forskolin acutely, and then to 
measure the mRNA level of aP2 (Figure 3.8). aP2 expression in treated HIB-1B cells 
was increased by over a hundred fold (P<0.001) compared with the control HIB1B 
cells (Figure 3.8B), which implied a good adipogenic effect of this recipe in this cell 
line. However, aP2 expression level was only increased by around 4 fold (P<0.05) in 
the 3T3-L1 cells (Figure 3.8A), indicating this induction system was not good enough 
for 3T3-L1 to stimulate quick adipogenesis, probably because rosiglitazone and 
forskolin both favour brown adipogenesis more than white and the activation of 
ƐŽŵĞ  “ďƌŽǁŶ ? ŐĞŶĞƐ ŵŝŐŚƚ ŚĂǀĞa somewhat suppressive ĞĨĨĞĐƚ ŽŶ  “ǁŚŝƚĞ ? ŐĞŶĞ
expression or white adipogenesis.  
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Figure 3.8 Stimulation of adipogenesis by acute treatment of rosiglitazone and 
forskolin in 3T3-L1 and HIB-1B cells 
10 µM rosiglitazone (Rosi) were added into confluence 3T3-L1 and HIB-1B cells and 
10µM forskolin (Fsk) was added into the culture 12 hours later. RNAs were 
extracted from the cells 12 hours after adding forskolin and the mRNA level of aP2 
gene in treated 3T3-L1 (A) and HIB-1B (B) cells was determined by quantitative real 
time PCR and normalised against 36B4 housekeeping gene expression. Each bar 
represents the mean ± S.E.M from 2 independent replicate experiments performed 
in duplicate wells. *P<0.05 ďǇ^ƚƵĚĞŶƚ ?Ɛt-test with respect to controls. 
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ĂƐĞĚŽŶƚŚĞŬŶŽǁůĞĚŐĞƚŚĂƚ ?WɴĂŶĚWWZɶĞǆƉƌĞƐƐŝŽŶďŽƚŚƉůĂǇĐƌŝƚŝĐĂůƌŽůĞƐŝŶ
the early adipogenic programme, the second approach was to mimic their increase in 
ĞǆƉƌĞƐƐŝŽŶ ĂĨƚĞƌ ĂĚŝƉŽŐĞŶŝĐ ŝŶĚƵĐƚŝŽŶ ďǇ ƚƌĂŶƐŝĞŶƚůǇ ŽǀĞƌĞǆƉƌĞƐƐŝŶŐ  ?Wɴ ĂŶĚ
WWZɶŝŶƚŽ ?d ?-> ?ĐĞůůƐĂŶĚƚŚĞŶĂĐƚŝǀĂƚŝŶŐWWZɶďǇadding 10µM rosiglitazone. aP2 
gene expression was then measured to check if the adipogenesis was stimulated by 
the treatment. To determine the best treatment time for rosiglitazone (Rosi) to 
ĂĐƚŝǀĂƚĞ WWZɶ ? ƚŚƌĞĞĚŝĨĨĞƌĞŶƚ ƚŝŵĞƉŽŝŶƚƐ ?  ? ? ŚŽƵƌƐ ?  ? ŚŽƵƌƐĂŶĚ  ? ?ŚŽƵƌƐǁĞƌĞ
used (Figure 3.9A). The results showed that 24 hours treatment with rosiglitazone 
ŐĂǀĞƚŚĞ ďĞƐƚĂĐƚŝǀĂƚŝŶŐĞĨĨĞĐƚŽŶWWZɶ ƚŽ ƐƚŝŵƵůĂƚĞ ĂĚŝƉŽŐĞŶĞƐŝƐ ?ďƵƚ ƚŚĞ ŚŝŐŚĞƐƚ
aP2 expression stimulated by co-ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?Wɴ ĂŶĚ WWZɶ ĂĐƚŝǀĂƚĞĚ ďǇ
rosiglitazone was still only increased (P<0.05) 3-4 fold compared with the control cells 
transfected with pcDNA, which was similar to the level stimulated by rosiglitazone 
and forskolin co-treatment without overexpression of the transcription factors, as 
described above (Figure 3.8A). Moreover, when taking into account the expression 
level of aP2 in mature differentiated 3T3-L1 adipocytes, which was more than a 
hundred fold compared with the 24 hour control cells transfected with pcDNA (Figure 
3.9B), the 3-4 fold increase by the co-overexpression and rosiglitazone treatment 
indicated that the treated cells were still at a very early stage of differentiation. 
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Although the two systems induced aP2 expression levels well below those observed 
in fully differentiated cells, there was induction of early adipogenesis so the two 
protocols were thought to be sufficient to test the fat-specific expression vectors. 
3.3.8 Comparison of 4 fat-specific inducible lentiviral LucGFP expression 
vectors in 3T3-L1 and HIB-1B 
The four fat-specific inducible lentiviral LucGFP expression vectors were first 
transiently overexpressed in 3T3-L1 preadipocytes, co-ŽǀĞƌĞǆƉƌĞƐƐĞĚ ǁŝƚŚ  ?Wɴ
ĂŶĚWWZɶĂŶĚƚƌĞĂƚĞĚǁŝƚŚƌŽƐŝŐůŝƚĂǌŽŶĞĨŽƌ ? ?ŚŽƵƌƐďĞĨŽƌĞĚĞƚĞĐƚŝŶŐƚŚĞůƵĐŝĨĞƌĂƐĞ
activity from the cells (Figure 3.10). Data was analysed by two-way ANOVA with each 
adipogenesis inducible lentiviral vector. Results showed that the vector with full 
length aP2 promoter and TRE-rtTA advance combination demonstrated relatively 
good doxycycline and adipogenic inducibility, i.e. the co-ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ  ?Wɴ
ĂŶĚWWZɶĂŶĚƌŽƐŝŐůŝƚĂǌŽŶĞƚƌĞĂƚŵĞŶƚŝŶĚƵĐĞĚĂŚŝŐŚĞƌ(P<0.001) luciferase activity 
(~ 2 fold) compared to the control group, and the addition of doxycycline further 
stimulated (P<0.001) the luciferase expression to about 9 fold compared to the 
control value (Figure 3.10A, left). However, the vector with aP2 promoter and TRE 
Figure 3.9 ^ƚŝŵƵůĂƚŝŽŶŽĨĂĚŝƉŽŐĞŶĞƐŝƐďǇŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴĂŶĚWWZɶŝŶ
3T3-L1 cells 
(A) 3T3-L1 preadipocytes were transfected with  ?WɴĂŶĚWWZɶďǇ&ƵŐĞŶĞHD. 
10 µM rosiglitazone (Rosi) were added into the cells 24 hours post-transfection 
and RNA was extracted from the cells 24 hours after adding rosiglitazone. (B) The 
differentiated 3T3-L1 cells (dif 3T3-L1) were derived from a standard differentiated 
protocol. The mRNA level of aP2 gene in treated cells was determined by 
quantitative real time PCR and normalised against 18s housekeeping gene 
expression, relative to the value from the 14 hours pcDNA transfected cells. Each 
bar represents the mean ± S.E.M from 2 independent replicate experiments 
performed in duplicate wells. ^ƚƵĚĞŶƚ ?Ɛt-test was used to analyse the data. 
*P<0.05 caused by time of Rosi treatment or differentiation with respect to the 
control at 14h; #P<0.05 caused by overexpression with respect to the control at 
the same time point. 
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tight-ƌƚdĂĚǀĂŶĐĞĐŽŵďŝŶĂƚŝŽŶĚŝĚŶ ?ƚƐŚŽǁĂŶǇĂĚŝƉŽŐĞŶŝĐŝŶĚƵĐŝďŝůŝƚǇĂƐƚŚĞƌĞǁĂƐ
no significant difference between the groups with or without the co-overexpression 
and rosiglitazone treatment, either in absence or presence of doxycycline, although 
Dox significantly induced the promoter activity (P<0.001) (Figure 3.10A, right).  
In the vectors constructed with short aP2 promoter (sAP2), neither with TRE-rtTA 
advance nor TRE tight-rtTA advance combination was able to demonstrate good 
adipogenic or doxycycline inducibility (Figure 3.10B). As neither of the TRE tight-rtTA 
advance vectors could give adipogenic inducibility in the above test, only the two 
vectors with TRE-rtTA advance were used in the further investigations. 
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Figure 3.10 Test of fat specific inducible lentiviral expression vectors of LucGFP in 
3T3-L1. 
The inducible LucGFP lentiviral vectors with full length aP2 promoter (Tet on aP2 
vectors, A) or with truncated aP2 promoter (Tet on short aP2 vectors, B) were co-
ŽǀĞƌĞǆƉƌĞƐƐĞĚ ǁŝƚŚ  ?Wɴ ĂŶĚ WWZɶ ŝŶƚŽ  ?d ?-L1 preadipocytes. 10µM 
rosiglitazone (Rosi) and 1µM doxycycline (Dox) were added to the cells 24 hours 
post-transfection as indicated and treated for 24 hours before luciferase assay. 
Firefly luciferase activity was interpreted relative to the control value (no co-
overexpression, no drug treatments) of each group. Each bar represents the mean 
± S.E.M from 2 independent replicate experiments performed in triplicate wells. 
Data was analysed by two-way ANOVA with each lentiviral vector. (A) TRE aP2 
(left): Dox (P<0.001) and adipogenic condition (P<0.001) both significantly 
increased aP2 promoter activity and there was no interaction (P=0.18) between 
the two treatments; TRE tight aP2 (right): Dox (P<0.001) significantly increased aP2 
promoter activity while adipogenic condition not (P=0.31) and there was no 
interaction (P=0.091). (B) Neither Dox nor adipogenic condition treatment had 
significant effect on short aP2 promoter activity (P>0.05).  
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The selected two fat-specific vectors, pLenti TRE LucGFP aP2 rtTA advance and pLenti 
TRE LucGFP short aP2 advance were then tested in the other transient adipogenic 
condition, i.e. treatment of rosiglitazone and forskolin, in both 3T3-L1 and HIB-1B 
preadipocytes (Figure3.11). Data was analysed by two-way ANOVA. In 3T3-L1 cells, 
the vector with full length aP2 promoter (Figure 3.11A, left) had a higher (P<0.001) 
luciferase activity when treated with rosiglitazone and forskolin compared to the 
untreated cells (~1.7 fold), and the addition of doxycycline induced (P<0.001) further 
expression to about 4 fold  over the basal value of untreated cells, but the stimulatory 
ĞĨĨĞĐƚǁĂƐŶŽƚƐŽƐŝŐŶŝĨŝĐĂŶƚĂƐƚŚĂƚ ŝŶƚŚĞŽƚŚĞƌĐŽŶĚŝƚŝŽŶŽĨ ?WɴĂŶĚWWZɶĐŽ-
overexpression (3 and 9 fold before and after Dox induction, respectively; Figure 
3.10A, left). The vector with short aP2 promoter (Figure 3.11A, right) also showed 
adipogenic inducibility (P=0.008) in 3T3-L1 cells, but the magnitude increased (25%) 
was not as high as with full length aP2 promoter vector (56%). In HIB-1B cells, Dox 
(P<0.001) and Fsk+Rosi (P<0.001) treatments independently increased the luciferase 
activity  of both full length and short aP2 promoter driven vectors and the fold 
increased by Fsk+Rosi treatment was higher than that in 3T3-L1 cells with or without 
Dox. 
The results from HIB-1B experiments indicated that the adipogenic inducible 
expression vectors with either full length or truncated aP2 promoter were able to 
express the reporter genes in fat cells with good inducibility in response to doxycyline. 
However, experiments in 3T3-> ? ĐĞůůƐ ĚŝĚŶ ?ƚ ƐŚŽǁ ĐŽŶƐŝƐƚĞŶƚ ƌĞƐƵůƚƐ(as shown in 
Figure 3.8 and 3.9) since neither of the transient adipogenic conditions was ideal for 
3T3-L1 preadipocytes in terms of the expression level of adipogenic marker gene aP2, 
explaining why the fat specific vectors showed very low or even no adipogenic 
inducibilityin this cell line as they were not stimulated properly. 
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Figure 3.11 Test of fat specific inducible lentiviral expression vectors of LucGFP in 
3T3-L1 and HIB-1B preadipocytes. 
The two fat specific expression vectors, pLenti TRE LucGFP aP2 rtTA advance and 
pLenti TRE LucGFP short aP2 rtTA advance were transiently expressed into 3T3-L1 (A) 
or HIB-1B (B) preadipocytes. 10µM Rosiglitazone (Rosi) and 10µM forskolin (Fsk), as 
indicated, were added to the cells 24 and 36 hours post-transfection respectively. 
1µM doxycycline (Dox) was added to the cells 24 hours post-transfection to induce 
the expression of the Tet on vectors. Luciferase assay was carried out 48 hours after 
transfection and firefly luciferase activity was interpreted relative to the control 
value (no Rosi, no Fsk, and no Dox) of each group. Each bar represents the mean ± 
S.E.M from 2 independent replicate experiments performed in triplicate wells. Data 
was analysed by two-way ANOVA with each lentiviral vector. (A) left: no interaction 
between Dox and Fsk+Rosi treatments (P=0.111) but Dox (P<0.001) and Fsk+Rosi 
(P<0.001) both independently increased aP2 promoter activity; right: no interaction 
between Dox and Fsk+Rosi treatments (P=0.459) while Dox (P<0.001) and Fsk+Rosi 
(P=0.008) both independently increased short aP2 promoter activity. (B) No 
interaction between Dox and Fsk+Rosi treatments (P>0.05) and Dox and fsk+Rosi 
independently increased both full length and short aP2 promoter activity (P<0.001). 
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3.4 DISCUSSION 
The tetracycline inducible expression vectors constructed in the above experimental 
work showed different levels of basal activity and inducibility as a result of different 
combinations of tetracycline response elements (TRE or TRE tight) with reverse 
tetracycline-controlled transactivators (rtTA or rtTA advance). The first combination 
used in the project was pLentiTRE LucGFP rtTA, but the basal activity of the vector 
was high and it nearly had no sensitivity to doxycycline (Figure 3.4). The inducibility 
was slightly improved (~2 fold, P<0.05) when the vector was linearized (data not 
shown) but still not good enough for the requirement of inducible expression. There 
were two potential reasons responsible for the leakiness, 1) the residual binding of 
rtTA to tetO sequence of TRE in the absence of inducer ligand doxycline (Baron and 
Bujard, 2000) and 2) the basal transcriptional activity of the tetracycline responsive 
promoter even without binding to rtTA.  Replacing the TRE with TRE tight (the latter 
was supposed to be a more tightly controlled tetracycline response element), did not 
improve the inducibility but the basal activity was slightly reduced (Figure 3.4), 
indicating that the residual binding of rtTA to tetO sequence should be the primary 
reason contributing to the leakiness and poor inducibility of the vectors. 
Replacing the original rtTA with rtTA advance, which contains specific mutations that 
both increase its sensitivity to doxycycline and significantly diminish residual bindings 
to tetO sequence in the absence of inducer ligand (Urlinger et al., 2000), greatly 
improved the inducibility of the Tet on vectors with lower basal activity (50% 
decreased) and much higher induced expression (7-8 fold)(Figure 3.4). However, even 
the low basal activity could cause problems if the target cell lines or animals were 
very sensitive to the overexpressed gene, as even the basal expression of the gene 
was enough to stimulate some certain physiological changes in such ultra-sensitive 
cells and the tetracycline-dependent regulation of the gene expression might make 
no sense or even cause harm to the cells. Fortunately, the endogenous expression 
ůĞǀĞůŽĨƚŚĞŐĞŶĞŽĨŝŶƚĞƌĞƐƚŝŶƚŚŝƐƉƌŽũĞĐƚ ? ?Wɴ ?ǁĂƐŶŽƚƚŚĂƚůŽǁ ?&ŝŐƵƌĞ 5.1C) in 
3T3-L1 (pre)adipocytes, so the cell line should probably be able to tolerate the 
ŝŶĨůƵĞŶĐĞŽĨƚŚĞďĂƐĂůĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴĨƌŽŵƚŚĞŝŶĚƵĐŝďůĞŽǀĞƌĞǆƉƌĞƐƐŝŽŶsystem. 
ĚĚŝƚŝŽŶĂůůǇ ?ĂƐƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨ ?Wɴ ŝƐŝŶĐƌĞĂƐĞĚďǇ ?-3 fold in BAT during cold 
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exposure (Karamitri et al., 2009) ?ŽƵƌĂŝŵƚŽŝŶĚƵĐĞ ?WɴĞǆƉƌĞƐƐŝŽŶďǇĂƌŽƵŶĚ ? ?
fold was at physiological level.  
The inducible vectors with either TRE or TRE tight and rtTA advance displayed similar 
inducibility and expression levels in 3T3-L1 cells (Figure 3.4A), but in HIB-1B cells, the 
TRE rtTA advance vector showed low expression level of LucGFP although the 
inducibility was even better than the vector with TRE tight rtTA advance (Figure 3.4B). 
The difference might reflect the natural variance of different cell lines in response to 
different regulatory sequences. So if the vector backbones were used to overexpress 
other genes in HIB-1B cells, the TRE rtTA advance vector would be suitable for the 
genes that HIB-1Bs were ultra-sensitive to because of its very low basal activity and 
the TRE tight rtTA advance vector would be suitable for the genes which had high 
endogenous expression in the cells.  
When the fat specific promoters were introduced into the inducible expression 
vectors, the difference between the two inducible backbones was even more obvious. 
In 3T3-L1 cells, the full length aP2 promoter driving TRE rtTA advance vector, in the 
presence of doxycycline the adipogenic induction, displayed stimulated luciferase 
activity of about 3 fold over the unstimulated value, whereas the luciferase activity of 
aP2 promoter driving TRE tight rtTA advance vector was not increased at all by the 
adipogenic conditions (Figure 3.10A). The difference seemed to show that some 
specific regulatory sequences in the TRE tight element might influence the fat 
specificity of the aP2 promoter, but this could not be confirmed as the same 
experiments were not done in any other cell line.  
The adipogenic induction conditions used for 3T3-L1 increased aP2 expression by 3 
fold, not comparable to the aP2 expression levels in the routinely differentiated 3T3-
L1 cells (Figure 3.8A and Figure 3.9), whereas the rosiglitazone and forskolin 
treatment was able to successfully induce adipogenesis in HIB-1B cells within 48 
hours, in terms of aP2 expression (Figure 3.8B). It is well known that differentiation of 
3T3-L1 cells requires a critical early phase of mitotic clonal expansion (MCE), when 
the confluent growth arrested cells re-enter cell cycle and prepare for the 
differentiation for 48 hours (Tang et al., 2003b). It has been demonstrated that the 
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MCE is a prerequisite for differentiation of 3T3-L1 preadipocytes to adipocytes, but 
the differentiation of HIB-1B preadipocytes does not require this phase.  This 
difference could possibly explain why the same adipogenic induction conditions 
worked well in HIB-1B but had poor effect in 3T3-L1 preadipocytes since the MCE was 
omitted as it would not have allowed measurement of the reporter expression from 
the transiently transfected vectors.  
Even without perfect adipogenic conditions, the full length aP2 promoter driving TRE 
rtTA advance vector still showed the adipogenic inducibility in 3T3-L1 cells, whereas 
the vector with the same backbone but short aP2 promoter did not display clear 
adipogenic inducibility under the same conditions (Figure 3.11A). This observation 
suggested that other regions of aP2 promoter, besides the enhancer and proximal 
promoter, might contribute to aP2 expression in response to adipogenic signals. This 
was shown not to be the case as the short aP2 promoter driving vector showed 
adipogenic inducibility in HIB-1B cells, and it is therefore reasonable to conclude that 
when the short aP2 driving vector is integrated into the genome of 3T3-L1 
preadipocytes and experiences MCE and the routine differentiation induction 
protocol, the gene of interest should be able to express in a fat specific manner in the 
presence of doxycycline. 
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4 PRODUCTION OF LENTIVIRUS 
PARTICLES AND TRANSGENIC CELL 
LINES OVEREXPRESSING C/EBP BETA 
4.1 INTRODUCTION 
dŚĞ sŝƌĂWŽǁĞƌ ? >ĞŶƚŝǀŝƌĂů ǆƉƌĞƐƐŝŽŶ ^ǇƐƚĞŵ  ?/ŶǀŝƚƌŽŐĞŶ ) ǁĂƐ ƵƐĞĚ ƚŽ ƉƌŽĚƵĐĞ
lentiviral particles containing constitutively active vectors expressing the target 
 ?Wɴ Žƌ ƚŚĞ ĐŽŶƚƌŽů >ƵĐ'&W ŐĞŶĞ ? dŚŝƐ ƐǇƐƚĞŵ ĂůůŽǁƐ ĐƌĞĂƚŝŽŶ ŽĨ ƌĞƉůŝĐĂƚŝŽŶ-
incompetent, HIV-1-based lentiviral particles that are used to deliver and express the 
gene of interest in either dividing or non-dividing mammalian cells. The major 
components of the system include 1) an expression plasmid containing the gene of 
ŝŶƚĞƌĞƐƚ  ? ?Wɴ Žƌ >ƵĐGFP as control in this project) under the control of chosen 
promoters (TRE-CMV in this work), and elements that allow packaging of the 
construct into virions (contained in the pLenti6/V5 destination vector backbone); 2) 
an optimized mix of the three packaging plasmids (pLP1 (gag/pol), pLP2 (rev), and 
envelope plasmid pLP/VSVG, Appendix F) that supply the structural and replication 
proteins in trans that are required to produce the lentivirus; and 3) the 293FT cell line, 
which allows production of lentivirus following cotransfection of the expression 
plasmid and the plasmids in the packaging mix (Invitrogen, 2010). This system has 
been reported to have several advantages as following: 1) the HIV-1-based lentivirus 
generated from the system effectively transduces both dividing and non-dividing 
mammalian cells, thus broadening the potential application beyond those of 
traditional Moloney Leukaemia Virus (MoMLV)-based retroviral system (Naldini, 
1998); 2) it efficiently delivers the gene of interest to mammalian cells in culture or in 
vivo (Dull et al., 1998); 3) it provides stable, long-term expression of a target gene 
beyond that offered by traditional adenoviral-based systems (Dull et al., 1998; Naldini 
et al., 1996a); 4) it produces a pseudotyped virus with a broadened host range (Yee et 
al., 1994); and 5) it includes multiple features designed to enhance the biosafety of 
the system.  
119 
 
Besides producing lentivirus with the pLP 3-plasmid packaging system, a second 
generation of packaging plasmid for producing virus, psPAX2, together with the 
envelope plasmid pCMV-VSVG, was also used in experiments to try to increase the 
production efficiency. psPAX2 contains a robust CAG promoter for efficient 
expression of packaging proteins: gag, pol and rev (Appendix F). The second 
generation system has been reported to produce a higher titer lentivirus, compared 
with the lentivirus packaged by the first generation packaging plasmids (Addgene). 
The second generation packaging system has a higher transfection efficiency when 
transfected into 293FT cell line, as only 2 plasmids are transfected compared to 3 
plasmids which decreases the virus production efficiency (see Discussion for details).  
The aim of this part of the work was to produce lentiviral particles that could 
generate stable inducible expression of C/EWɴ ?Žƌ>ƵĐ'&W )ŝŶƚŚĞƚĂƌŐĞƚĐĞůůůŝŶĞ ?d ?-
> ? ƉƌĞĂĚŝƉŽĐǇƚĞƐ ? dŚĞ ůĞŶƚŝǀŝƌĂů ǀĞĐƚŽƌƐ Ɖ>ĞŶƚŝ dZƚŝŐŚƚ  ?Wɴ  ?Žƌ >ƵĐ'&W ) ƌƚd
advance were used for virus production. However, as the virus production system 
needed to be optimized first, a constitutively-expressed control pLenti6-LucGFP 
vector was used for optimizing the virus production system. Another positive control 
vector pLenti6-LucRFP (kind gift from Dr. Phil Hill, see schematic diagram of structure 
in Figure 4.5 A) was also used for comparison with the lentiviral vectors generated in 
our system, to establish virus production and transduction efficiency. 
The specific objectives of the experimental work described in this chapter were  
1. To produce lentiviral particles containing constitutive LucGFP in 293FT packaging 
cell line.  
2. To optimize the viral titer to at least 10
5
 TU/ml.  
3. To optimize the transduction conditions in 3T3-L1 preadipocytes and to select 
monoclones from the transduced cells. 
4. To apply the optimized conditions with thĞ ŝŶĚƵĐŝďůĞ Ɖ>ĞŶƚŝdZƚŝŐŚƚ ?Wɴ  ?Žƌ
LucGFP) rtTA advance vectors to produce transgenic cell lines that stably overexpress 
the target gene.   
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4.2 EXPERIMENTAL DESIGN 
4.2.1 Transfection of packaging cell line 293FT with the constitutive lentiviral 
expression vector of LucGFP to produce lentiviruses 
Two different protocols were used to produce lentivirus in 293FT cell line, as 
ĚĞƐĐƌŝďĞĚŝŶ ? ? ? ? ? ?ƚŚĞĨŝƌƐƚĨƌŽŵƚŚĞsŝƌĂWŽǁĞƌ ?>ĞŶƚŝǀŝƌĂůǆƉƌĞƐƐŝŽŶ^ǇƐƚĞŵDĂŶƵĂů
(Invitrogen) and the other kindly provided by Mr Simon Lillico, Roslin Institute. The 
basic principles of the two protocols were the same, i.e. to transiently transfect 293FT 
cell line with the lentiviral expression vector and packaging plasmid mix for packaging 
the lentiviral particles containing the gene of interest and to harvest the lentivirus by 
collecting the culture supernatant after the packaged viral particles have been 
released from the 293FT cells. Besides the different packaging plasmids, the two 
protocol also employed different transfection reagents when transfecting 293FT cells: 
lipofectamine 2000® (Invitrogen) with the ViraPowĞƌ  ? ƐǇƐƚĞŵ ĂŶĚ &ƵŐĞŶĞ ,® 
(Roche) with the Roslin protocol. Lentivirus production was performed with these two 
protocols in parallel to determine which one gave higher viral titer. The need for high 
viral titer in this project was due to the difficulty in transducing 3T3-L1 cells, as it 
requires a multiplicity of infection (MOI) to be 30 compared to the easily transduced 
HT1080 cell line which only needs MOI to be 1 (Invitrogen). 
4.2.2 Ultracentrifugation of the produced lentivirus to increase the titer 
To further increase the lentiviral titer, the viral particles harvested from the 
supernatant of transfected 293FT cells were concentrated by ultracentrifugation as 
described in 2.4.2. The lentiviruses before and after ultracentrifugation were titered 
in HT1080 cell line as described in 2.4.3 to determine the viral titer and the effect of 
ultracentrifugation. 
4.2.3 Transduction of the target 3T3-L1 cell line with the LucGFP lentivirus 
vector to determine transduction efficiency and to select for a monoclonal 
cell line overexpressing the LucGFP gene 
3T3-L1 preadipocytes were transduced with the concentrated and purified lentiviral 
particles containing the constitutively expressing LucGFP vector as described in 2.5.1. 
The transduced 3T3-L1 cells were screened for GFP expression using fluorescence 
microscopy and selected for single cell colonies that overexpress LucGFP efficiently as 
121 
 
described in 2.5.1. As the lentivirus integrates into the cell genome randomly, it is 
necessary to pick several single colonies and to quantitatively measure the expression 
level of the transgene by luciferase assay. This step was also necessary to estimate 
how many colonies to pick from the blasticidin resistant cell colonies to guarantee 
there was at least one colony that could efficiently overexpress the gene of interest. 
dŚŝƐƚŚĞŶƉƌŽǀŝĚĞĚŐƵŝĚĂŶĐĞǁŚĞŶƐĞůĞĐƚŝŶŐĐĞůůĐŽůŽŶŝĞƐŽǀĞƌĞǆƉƌĞƐƐŝŶŐ ?WɴŐĞŶĞ ? 
 ? ? ? ? ?WƌŽĚƵĐƚŝŽŶŽĨŝŶĚƵĐŝďůĞ>ƵĐ'&WĂŶĚ ?WɴůĞŶƚŝǀŝƌƵƐ ?ƚƌĂŶƐĚƵĐƚŝŽŶŽĨ
3T3-L1 cells and selection for the corresponding monoclonal transgenic cell 
lines 
dŚĞ Ɖ>ĞŶƚŝ dZ ƚŝŐŚƚ  ?Wɴ  ?Žƌ >ƵĐ'&W ) ƌƚd ĂĚǀĂŶĐĞ ůĞŶƚŝǀŝƌĂů ǀĞĐƚŽƌ ǁĂƐ
transfected into 293FT cell line with optimized packaging protocol to produce the 
ůĞŶƚŝǀŝƌĂů ƉĂƌƚŝĐůĞƐ ĐŽŶƚĂŝŶŝŶŐ ƚŚĞ ŝŶĚƵĐŝďůĞ  ?Wɴ ?Žƌ >ƵĐ'&W ) ? dŚe viral particles 
were then used to transduce 3T3-L1 preadipocytes and select for the stable cell lines 
ŽǀĞƌĞǆƉƌĞƐƐŝŶŐ ?Wɴ ?Žƌ>ƵĐ'&W )ŝŶƚŚĞƉƌĞƐĞŶĐĞŽĨ ĚŽǆǇĐǇĐůŝŶĞ ?ƵƐŝŶŐƚŚĞƉƌŽƚŽĐŽů
optimized with constitutive LucGFP virus. The selected cell lines were then tested for 
ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞů ŽĨ  ?Wɴ  ?Žƌ >ƵĐ'&W ) ŵZE  ?ĂƐ ĚĞƐĐƌŝďĞĚ ŝŶ  ? ? ? ? ? ) ǁŝƚŚ
different doxycycline concentrations to establish a dose response relationship.  
 
4.3 RESULTS 
4.3.1 Comparison of Lipofectamine 2000® or Fugene HD® transfection 
reagents ǁŝƚŚsŝƌĂWŽǁĞƌ ?ƉĂĐŬĂŐŝŶŐƉůĂƐŵŝĚŵŝǆfor transfecting 
constitutively active LucGFP lentiviral vector in 293FT cells. 
dŚĞ sŝƌĂWŽǁĞƌ ? >ĞŶƚŝǀŝƌĂů ǆƉƌĞƐƐŝŽŶ ^ǇƐƚĞŵ DĂŶƵĂů  ?/ŶǀŝƚƌŽŐĞŶ ) ƐƵŐŐĞƐƚƐ ƚŚĂƚ
293FT cells should be transfected by the lipofectamine 2000® transfection reagent for 
packaging lentiviral particles. However, transfection efficiency using lipofectamine 
was lower compared with Fugene HD® in routine transient transfection in our 
laboratory, using both 3T3-L1 and HIB-1B cells (data not shown). Given that 
transfection efficiency was especially important for the multi-plasmid transfection 
system, it was necessary to compare the transfection efficiency of these two reagents 
in 293FT cells when mediating the 4-plasmid transfection (3-plasmid packaging mix 
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and one expression vector). As described in 2.4.1, 5×10
6
 293FT cells in 10ml medium 
ǁĞƌĞƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚ ?A?ŐŽĨƚŚĞsŝƌĂWŽǁĞƌ ?WĂĐŬĂŐŝŶŐDŝǆƉůĂƐŵŝĚĂŶĚ ?A?ŐŽĨƚŚĞ
constitutive LucGFP lentiviral expression vector  (pLenti6-LucGFP) by either 36µl of 
lipofactamine 2000® or 36µl of Fugene HD®. 60 hours post transfection, photos of the 
transfected cells were taken using the fluorescence microscope (Figure 4.1). Results 
showed clearly that more cells were transfected by Fugene HD® when fluorescence 
was compared with that of the lipofectamine 2000® transfected cells, and that the 
fluorescence in the former was more intense than the latter. These data indicated 
that Fugene HD® was much more efficient in mediating a 4-plasmid transfection in 
293FT cells than lipofectamine 2000®; therefore the Fugene HD® was used in all of 
the following transfections in 293FT cells. 
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Figure 4.1 Fugene HD® transfection reagent increased transfection efficiency in 
293FT cell line compared to lipofectamine 2000®. 
293FT cells were grown to 90%, (for Lipofectamine 2000® transfection) or 80% (for 
Fugene HD® transfection) confluence, and were then tranfected with pLenti6-
>ƵĐ'&WĂŶĚsŝƌĂWŽǁĞƌ ?ƉĂĐŬĂŐŝŶŐƉůĂƐŵŝĚƐƵƐŝŶŐ>ŝƉŽĨĞĐƚĂŵŝŶĞ ? ? ? ?® and Fugene 
HD®, respectively. Photos were taken under fluorescence microscope 60 hours post 
transfection (magnification=100). The exposure time for both fluorescent photos 
was 2.0 seconds at the magnification of 100.  
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 ? ? ? ? ?ŽŵƉĂƌŝƐŽŶŽĨƚŚĞƚŝƚĞƌƐŽĨůĞŶƚŝǀŝƌƵƐƉƌŽĚƵĐĞĚĨƌŽŵsŝƌĂWŽǁĞƌ ?
packaging system and psPAX2 packaging protocols 
The improved protocol of VirĂWŽǁĞƌ ? ƉĂĐŬĂŐŝŶŐ ƐǇƐƚĞŵ ǁŝƚŚ &ƵŐĞŶĞ ,® 
transfection reagent was used in parallel with the psPAX2 packaging protocol to 
produce lentiviral particles containing the constitutive LucGFP gene, for comparing 
the virus producing efficiency of these two packaging systems. As described in 2.4.1, 
the pLenti6-LuGFP expression vector was co-transfected with either packaging 
plasmid mix into 293FT cells using the corresponding protocol. Photos of the 
transfected cells were taken 60 hours post transfection (Figure 4.2), and show that 
both methods gave similar percentage (50-60%) of fluorescent cells out of total cell 
numbers. However, the morphology of the 293FT cells transfected with different 
ƉĂĐŬĂŐŝŶŐ ŵŝǆ ǁĂƐ ŵĂƌŬĞĚůǇ ĚŝĨĨĞƌĞŶƚ ? dŚĞ sŝƌĂWŽǁĞƌ ? ƉĂĐŬĂŐŝŶŐ ŵŝǆ ƚƌĂŶƐĨĞĐted 
cells looked much healthier than the cells transfected with psPAX2 packaging mix. As 
expression of VSV-G glycoprotein causes 293FT cells to fuse, resulting in the 
appearance of syncytia (large, multinucleated cells) (Invitrogen, 2010), it was logical 
to infer that the psPAX2 packaging mix was able to express more VSV-G glycoprotein 
ƚŚƵƐƉƌŽďĂďůǇƚŽƉĂĐŬĂŐĞŵŽƌĞůĞŶƚŝǀŝƌĂůƉĂƌƚŝĐůĞƐƚŚĂŶƚŚĞsŝƌĂWŽǁĞƌ ?ƉĂĐŬĂŐŝŶŐŵŝǆ.  
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Figure 4.2 psPAX2 packaging plasmid mix caused more syncytia formation in the 
ĐĞůůƐƚŚĂŶsŝƌĂWŽǁĞƌ ?ƉĂĐŬĂŐŝŶŐƉůĂƐŵŝĚƐǁŚĞŶƚƌĂŶƐĨĞĐƚĞĚŝŶƚŽ ? ? ?&dĐĞůůůŝŶĞ ? 
 ? ? ?&d ĐĞůůƐ ǁĞƌĞ ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ĞŝƚŚĞƌ sŝƌĂWŽǁĞƌ ?(upper panel) or psPAX2 
(lower panel) packaging mix together with pLenti6-LucGFP expression vector 
using Fugene HD®. Photos were taken under fluorescence microscope 60 hours 
post transfection (x100 magnification). The exposure time for both fluorescent 
photos were 2.0 seconds. 
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The lentiviral particles produced from the two protocols were diluted by 10
-6
, 10
-5
,10
-4
, 
10
-3
 and 10
-2 
and applied to the HT1080 cells for titering (Figure 4.3). Calculated from 
the figure, ƚŚĞǀŝƌĂůƚŝƚĞƌƐŽĨsŝƌĂWŽǁĞƌ ?ĂŶĚƉƐWy ?ƉĂĐŬĂŐĞĚůĞŶƚŝǀŝƌƵƐǁĞƌĞ ?A? ? ?2 
TU/ml and (20×10
2
+2×10
3
)/2= 2×10
3
 TU/ml respectively before ultracentrifugation. 
The psPAX2 packaged lentiviral particles were concentrated by ultracentrifugation as 
described in 2.4.2 and then diluted by 10
-5
, 10
-4
, 10
-3
 and 10
-2 
before performing the 
titering experiment. The viral titer of the psPAX2 packaged particles was 
(15×10
4
+2×10
5
)/2= 1.75×10
5
 TU/ml after ultracentrifugation, nearly 90 fold higher 
than the titer before concentration. The results suggested that psPAX2 packaging mix 
could produce the lentivirus with about 7 fold higher titer than that of the virus 
ƉƌŽĚƵĐĞĚďǇ ƚŚĞ sŝƌĂWŽǁĞƌ ?ƉĂĐŬĂŐŝŶŐŵŝǆĂŶĚƵůƚƌĂĐĞŶƚƌŝĨƵŐĂƚŝŽŶĐŽƵůĚŵĂƌŬĞĚůǇ
increase viral titer by about 10
3
 fold. But even with ultracentrifugation, the protocols 
just barely achieved the required threshold of viral titer 10
5
 TU/ml with the pLenti6-
LucGFP expression vector, indicating that the virus production process was not that 
efficient.  
 
 
 
 
Figure 4.3 TitĞƌƐ ŽĨ ƚŚĞ ůĞŶƚŝǀŝƌĂů ƉĂƌƚŝĐůĞƐ ĨƌŽŵ sŝƌĂWŽǁĞƌ ? ĂŶĚ ƉƐWy ?
packaging system.  
Lentiviral particles produced with pLenti6->ƵĐ'&WǀĞĐƚŽƌ ĨƌŽŵĞŝƚŚĞƌsŝƌĂWŽǁĞƌ ?
(top) of psPAX2 (middle) packaging system were diluted by 10
-6
, 10
-5
, 10
-4
, 10
-3
 and 
10
-2
 then applied to HT1080 cells for titering. 6 µg/ml of polybrene was used to 
facilitate transduction. The titers of the lentivirus were 3×10
2
 TU/ml (top) and 
2×10
3
 TU/ml (middle) respectively. The lentivirus produced from psPAX2 system 
(middle) were concentrated by ultracentrifugation (52,000g, 2 hours, 4°C) and 
diluted by 10
-2
, 10
-3
, 10
-4
 and 10
-5
 then titered in HT1080 cells (bottom). The label 
 “WƌĞ  ? ?-1 ? ŝŶĚŝĐĂƚĞƐƚŚĞ ĐĞůůƐǁĞƌĞƚƌĂŶƐĚƵĐĞĚďǇƚŚĞƉƌĞ-concentrated lentivirus 
diluted by 10
-1
. The titer of the concentrated virus was 1.75×10
5
 TU/ml.  
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4.3.3 Infection of 3T3-L1 preadipocytes with concentrated constitutive 
LucGFP lentivirus 
Although the concentrated lentiviral particles containing constitutive LucGFP did not 
achieve a titer higher than 10
5
 TU/ml suggested as being necessary for efficient 
transduction (ViraPower ? Manual, Invitrogen),  an attempt was made to transduce 
3T3-L1 preadipocytes with the lentivirus by reducing the cell numbers to increase the 
multiplicity of infection (MOI). The transduction was performed in 96-well format 
with 1500 cells seeded in each well and 100µl of the concentrated constitutive 
LucGFP lentivirus (titer= 1.75×10
5
 TU/ml) was diluted 1: 2 and applied to the cells at 
MOI=30, as described in 2.5.1. Photos were taken of the transduced 3T3-L1 cells 24 
hours post infection (Figure 4.4), showing some fluorescent particles which seemed 
to be located outside the cells instead of glowing from inside the cell itself. During the 
following blasticidin selection process, the green fluorescence diminished gradually, 
and the luciferase assay performed on these blasticidin resistant 3T3-L1 cells, failed to 
give any luciferase activity above the background value (data not shown). These data 
indicated a failure in transducing 3T3-L1 cells with the constitutive LucGFP lentivirus. 
Possible reasons for this are that the lentivirus was not so efficiently infectious (low 
titer or poor purity) that some parts of the pLenti6-LucGFP expression vector did 
harm to the virus packaging process, or that the 3T3-L1 preadipocytes were even 
more difficult to transduce than expected.  
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Figure 4.4 Transduction of 3T3-L1 cells with the concentrated LucGFP lentivirus  
3T3-L1 preadipocytes were seeded in 96-well plate and transduced the next day 
with lentivirus produced from pLenti6-LucGFP at MOI=30. 6 µg/ml of polybrene 
was used to facilitate transduction. Photos were taken under Leica DFC 420C 
fluorescence microscope 24 hours post transduction with the magnification=100 
and 2.0 seconds of exposure time (fluorescent image).  
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To further investigate the cause of the unsuccessful transduction, a positive control 
vector pLenti6-LucRFP which had successfully been employed in transduction 
experiments (kind gift from Dr. Phil Hill) was used to produce lentivirus and then to 
infect 3T3-L1 cells in parallel with the pLenti6-LucGFP vector. The positive control 
pLenti6-LucRFP vector shared the same backbone of pLenti6/V5 with pLenti6-LucGFP, 
but the luciferase gene in this vector was fused with a red fluorescent protein (RFP) 
instead of GFP, and ĚŝĚŶ ?ƚ ĐŽŶƚĂŝŶ ƚŚĞ Ds-rtTA element which, although not 
performing any role in the constitutive pLenti6-LucGFP vector expression, was 
included in the construct for the convenience of cloning.  
4.3.4 Comparison of lentiviral production from pLenti6-LucGFP and pLenti6-
LucRFP  
To compare the pLenti6-LucGFP and pLenti6-LucRFP vectors directly in producing 
lentivirus, parallel experiments were performed to prepare lentiviral particles using 
either of the two expression vectors with the psPAX2 packaging plasmid mix, in 293FT 
cell line (Figure 4.5B). The harvested lentiviral particles without ultracentrifugation 
were applied to HT1080 cells for titering (Figure 4.6). Figure 4.5 showed transfection 
of a lower percentage of green fluorescent cells (~50%) compared to that of red 
fluorescent cells (70-80%) out of total cell numbers, demonstrating that different 
lentiviral expression vector did have different packaging efficiencies, at least in 293FT 
cells. The viral titers of LucGFP and LucRFP lentiviruses calculated from Figure 4.6 
were 2×10
3
 and 3.6×10
5
 respectively, indicating that the pLenti6-LucRFP vector was 
more efficient than pLenti6-LucGFP vector in producing infectious lentivirus.  
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Figure 4.5 Transfection of 293FT cells to produce LucGFP or LucRFP lentivirus  
(A) Schematic diagram of the structures of pLenti6-LucGFP (upper) and pLenti6-
LucRFP (lower) vectors. pLenti6-LucGFP contained the Tet on regulatory element 
rtTA and the CMV promoter to drive rtTA while pLenti6-LucRFP did not have these 
ĐŽŵƉŽŶĞŶƚƐ ? dŚĞ ŐĞŶĞ >ƵĐ'&W ĐŽŶƚĂŝŶĞĚ ƌĂďďŝƚ ɴŐůŽďŝŶŝŶƚƌŽŶ ĂŶĚ ƉŽůǇ
terminator to facilitate the expression in mammalian cells, while the pLenti6-
LucRFP gene only possessed a polyA terminator but no intron. (B) 293FT cells 
were transfected with psPAX2 packaging plasmid mix together with either 
pLenti6-LucGFP (left) or the control pLenti6-LucRFP (right) vector by Fugene HD. 
Photos were taken under fluorescence microscope 60 hours post transduction 
before harvesting the lentiviruses. The magnification was 100 fold and exposure 
time for fluorescent images was 2.0 seconds.  
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Figure 4.6 Titers of the lentiviral particles produced from either pLenti6-LucGFP 
or pLenti6-LucRFP vector  
Unconcentrated Lentiviral particles produced with either pLenti6-LucGFP (upper) 
or pLenti6-LucRFP (lower) vector from psPAX2 packaging system were diluted by 
10
-6
, 10
-5
, 10
-4
, 10
-3
 and 10
-2
 then applied to HT1080 cells for titering. 6 µg/ml of 
polybrene was used to facilitate transduction and 8µg/ml of blasticidin was added 
into the culture 48 hours post transduction for 12-day selection. The titer of the 
LucGFP lentivirus was 2×10
3
 TU/ml (upper) while the LucRFP lentivirus had the 
titer of 3.6×10
5
 TU/ml (lower).  
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To check the importance of target cell type,  LucGFP and LucRFP lentiviral particles  
were concentrated by ultracentrifugation as described in 2.4.2 and then the  easily-
transducible cell line HT1080 was infected with each concentrated virus as described 
in 2.5.1 at MOI=1. Fluorescence from the transduced cells was checked by Leica 
Fluorescence microscope 3 days post-transduction (Figure 4.7). The transduced cells 
were at full confluence 3 days after transduction, but very few LucGFP transduced 
cells had green fluorescence and the fluorescence was quite weak as shown in the 
photo (Figure 4.7, left), whereas 70-80% of the LucRFP transduced cells showed clear 
red fluorescence (Figure 4.7, right). These data confirmed that the LucRFP lentiviral 
particles were more infectious than LucGFP virus, consistent with the result from the 
titering experiment (Figure 4.6).  
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Figure 4.7 Transduction of HT1080 cells with lentiviral particles produced from 
either pLent6-LucGFP or pLenti6-LucRFP vector 
HT1080 cells were seeded in 96-well plate and transduced the next day with 
concentrated lentiviruses produced from pLenti6-LucGFP (left) or pLenti6-LucRFP 
(right) at MOI=1. 6 µg/ml of polybrene was used to facilitate transduction and 
8µg/ml of blasticidin was added into the culture 48 hours post transduction for 
selection. Photos were taken under a fluorescence microscope 3 days post 
transduction with the x100 magnification. The exposure time of the green 
fluorescent image (left) was 4.0 seconds while the red fluorescent image used 1.5 
seconds for exposure. 
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4.3.5 Transduction efficiency varies in different cell lines  
To address the question whether the unsuccessful transduction in 3T3-L1 cells with 
LucGFP lentivirus (Figure 4.4) was also partly due to the specific difficulty to transduce 
3T3-L1 cell line, the positive control LucRFP lentiviruses were used to infect HT1080, 
293FT and 3T3-L1 cell lines in parallel as described in 2.5.1 at MOI=1, 5 and 30 
respectively. The red fluorescence from the three cell lines was checked by 
microscopy 4 days post transduction (Figure 4.8). Results showed that 70-80% of the 
transduced HT1080 cells were glowing bright red fluorescence (Figure 4.8, top), 30-40% 
of the transduced 293FT cells were glowing red although the fluorescence was not as 
bright as seen in HT1080s (Figure 4.8, middle), while less than 10% of the transduced 
3T3-L1 cells were glowing red and the fluorescence was quite weak (Figure 4.8, 
bottom). The data indicated clearly that 3T3-L1 cell line was more difficult to 
transduce compared with the other two, which also could be a reason for the 
unsuccessful transduction shown in Figure 4.4, besides that the LucGFP lentivirus was 
not efficiently infectious.  
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Figure 4.8 3T3-L1 cells were more difficult to transduce compared with HT1080 or 
293FT cells 
HT1080 (top), 293FT (middle) and 3T3-L1 (bottom) cells were seeded in 96-well 
plate and transduced by the lentivirus produced from pLenti6-LucRFP vector at the 
MOI=1, 5 and 30 respectively. 6 µg/ml of polybrene was used to facilitate 
transduction and 8µg/ml of blasticidin was added into the culture 48 hours post 
transduction for selection. Photos were taken under a fluorescence microscope 4 
days post transduction with the magnification=100. The exposure time of the 
fluorescent images were 1.5 seconds. 
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4.3.6 Monoclonal selection of transduced 3T3-L1 cells overexpressing LucRFP 
control gene  
Although the 3T3-L1 cell line proved difficult to transduce, even with the LucRFP 
lentivirus, monoclonal selection could be used to achieve the stable integration of a 
vector, despite poor transduction efficiency. Therefore following the LucRFP 
transduction experiments in 3T3-L1 cells, described in 4.3.4, cells were grown in a 96-
well plate until 80% confluence then divided into two groups, 1) to be trypsinised, 
counted then seeded at 2 or 5 cells per well into a 96-well plate and selected for wells 
containing single cell colony under microscope; 2) all the cells to be transferred into 
6-well plates for a larger growing space so that single colonies could be obtained by 
ƚŚĞ “ĐůŽŶŝŶŐƌŝŶŐ ?ŵĞƚŚŽĚ ?ĂƐĚĞƐĐƌŝďĞĚŝŶ ? ? ? ? ? ?dǁĞůǀĞ ƐŝŶŐůĞĐŽůŽŶŝĞƐŽĨĐĞůůƐǁĞƌĞ
picked from both methods and seeded into 24-well plates and allowed to reach 
confluence at which point a luciferase assay was performed as described in 2.3.3, to 
determine which colonies expressed the LucRFP transgene efficiently (Figure 4.9). The 
data demonstrated that 4 (Clone 2, 8, 9 and 10) out of 12 single colonies had higher 
(P<0.001) luciferase activity compared with the polyclone cells (blasticidin resistant 
cells without monoclonal selection), and the highest expression (Clone 8) achieved 
5.5 fold over the level of polyclone cells. The 1 in 3 rate (4 out of 12 colonies) 
indicated that to get one monoclone with high expression of transgene, about three 
single colonies should be picked and grown from the transduced and blasticidin-
selected cells. It was also clear in the graph that 7 single colonies (Clone 1, 3, 4, 5, 6, 7 
and 12) had nearly no expression of luciferase and the luciferase activity in the other 
colony (Clone 11) was also much lower (P<0.01) than that in the polyclone cells, firmly 
demonstrating that the transgene expression in transduced cells varied very much 
depending on where it integrated into the cell genome.  
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At the same time, the LucGFP lentivirus transduced 3T3-L1 cells were also selected for 
monoclones, using identical methods with the LucRFP lentivirus transduced cells. 
There were some cells surviving from the chronic blasticidin selection, but displayed 
no green fluorescence under the microscope and no luciferase activity (data not 
shown).  
 
 
Figure 4.9 Different expression levels of luciferase activity in monoclones of 3T3-L1 
stably expressing LucRFP 
3T3-L1 preadipocytes transduced by LucRFP lentivirus were selected using 8µg/ml 
blasticidin and monoclones separated as described in 2.5.3. The separated single 
colonies were re-seeded into 24-well plates and grown to full confluence. Luciferase 
assay was then performed on these colonies. Polyclone 1 and 2 stands for two multi-
colonies of the transduced and selected 3T3-L1 cells which did not undergo the 
monoclone separation process. Results are means ± S.E.M from a single experiment 
performed in triplicate wells. ^ƚƵĚĞŶƚ ?Ɛt-test was used to analyse the data. *: 
significant increases (P<0.05) with respect to Polyclone 1; #: significant decreases 
(P<0.05) with respect to Polyclone 1. 
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4.4 DISCUSSION 
When optimizing the protocol for lentivirus production, the transfection efficiency in 
293FT packaging cell line was considered as a primary factor. Figure 4.1 showed that 
the efficiency of Fugene HD® mediated transfection was about 50-60% while the 
lipofectamine 2000® mediated transfection had an efficiency of less than 10%, judged 
from the ratio of green fluorescent stained cells to total cell numbers in the field. In 
the lentivirus packaging system, only the cells which have been transfected with the 
lentiviral expression vector and all the packaging vectors would be able to package 
viral particles successfully. Assuming the 293FT cells did not discriminate different 
plasmids of similar sizes in terms of transfection efficiency, then the efficiency of 
transfection of the lentiviral expression vector, estimated from the number of green 
fluorescent cells, should be similar to that of any other plasmid and every transfection 
event should be random and independent of each other. Therefore in the 
sŝƌĂWŽǁĞƌ ? ƉĂĐŬĂŐŝŶŐ ƐǇƐƚĞŵ ĐŽŶƚĂŝŶŝŶŐ  ? ƉĂĐŬĂŐŝŶŐ ƉůĂƐŵŝĚƐ ĂŶĚ ƚŚĞ ůĞŶƚŝǀŝƌĂů
expression vector, if the transfection efficiency was 60%, the chance for a single cell 
to be able to produce viral particles would be (60%)
4
= 13%. But if the transfection 
efficiency dropped to 10%, the chance would decrease to (10%)
4
= 0.01%, which was 
nearly impossible to produce viral particles. In 4.3.2, the capability of two different 
lentivirus packaging systems was compared. Although there was no significant 
difference in transfection efficiency (50-60%, Figure 4.2), the 2-plasmid packaging 
system psPAX2 had an advantage as a 60% transfection efficiency here could result in 
the chance of (60%)
3
=21.6% to successfully package viral particles, which was 1.7 fold 
ŽĨƚŚĂƚǁŝƚŚsŝƌĂWŽǁĞƌ ?ƉĂĐŬĂŐŝŶŐƐǇƐƚĞŵ ?&ƵƌƚŚĞƌŵŽƌĞ ?ƚŚĞ ? ? ?&dĐĞůůƐƚƌĂŶƐĨĞĐƚĞĚ
with the psPAX2 packaging plasmids looked unhealthier, corresponding to syncytia 
formation, resulting in areas devoid of cells (Figure 4.2). Given that the expression of 
the VSV-G, glycoprotein of vesicular stomatitis virus, which is responsible for enabling 
viral entry, has the function of fusing cells and forming  syncytia (Norkin, 2010), it 
would be predicted that the high expression of VSV-G would cause morphological 
changes to the cells and expect the formation of syncytia to indicate  increased 
expression levels of the packaging plasmids. Therefore it could be inferred from 
Figure 4.2 that the psPAX2 packaging mix had a higher packaging efficiency than the 
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sŝƌĂWŽǁĞƌ ?ƉĂĐŬĂŐŝŶŐƐǇƐƚĞŵ ?ǁŚŝĐŚǁĂƐlater confirmed in the titering experiments 
(Figure 4.3).  
It was planned to produce lentiviral particles mediating the inducible expression of 
C/EBPɴ (or LucGFP) in the target cell line and to select for monoclones with stable 
expression of the transgene from transduced 3T3-L1 cells. However, the pilot 
experiments with the constitutive LucGFP lentiviral expression vector, pLenti6-LucGFP, 
did not succeed, which indicated some essential problems with the virus production 
and transduction system or the structure of the designed lentiviral expression vectors. 
Therefore the work with the inducible LucGFP and C/EBPɴ lentiviral expression 
vectors could not be carried out without first optimising the transduction system. 
Using a positive control pLenti6-LucRFP vector, it was demonstrated that the 
protocols were capable of producing efficiently infectious lentiviral particles (Figure 
4.6) and mediating high level stable expression of the insert gene in the target cell 
line 3T3-L1 (Figure  ? ? ?ĂŶĚ ? ? ? ) ?,ŽǁĞǀĞƌ ?ƚŚĞŝĚĞŶƚŝĐĂůƉƌŽĐĞƐƐĚŝĚŶ ?ƚǁŽƌŬǁĞůůǁŝƚŚ
pLenti6-LucGFP vector that was constructed in 3.3.3, implying that the problem must 
be due to the structural difference between the positive control pLenti6-LucRFP and 
the LucGFP vectors. As mentioned in 4.3.3, the pLenti6-LucGFP vector differed from 
the pLenti6-LucRFP vector in two ways. Firstly the pLenti6-LucGFP vector contained 
an additional Tet on regulatory antigen element (rtTA) coupled to a CMV promoter 
used to drive rtTA expression. And secondly, the LucGFP construct contained a Rabbit 
ɴGlobin Intron between the coding region of the gene and the polyA terminator 
whereas the LucRFP construct contained no introns before or after the polyA 
terminator. All the extra elements made the pLenti6-LucGFP vector ~1.8kb bigger in 
size than the pLenti6-LucRFP vector resulting in the total insert size of the former 
being around 5kb which was nearly the maximum allowed by the lentiviral vector 
expression system (Invitrogen, 2010). It is indicated in the protocol that the virus titer 
drops approximately 2-fold for each kb over 4kb of insert size and that the insert 
should not exceed 5.6kb. The larger size of the vector could therefore be the 
explanation for the low titer of the LucGFP lentivirus. Ultracentrifugation was 
therefore employed to concentrate and obtain a suitable virus titer (Invitrogen, 2010), 
resulting in an increased titer for the LucGFP virus by 10
2
 fold (Figure 4.3). However, 
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when the concentrated lentivirus were applied to the 3T3-L1 cells, the cells were still 
not transduced efficiently as there were lots of green fluorescent particles outside the 
cells but no fluorescence were observed inside the cells (Figure 4.4).  A possibility that 
was considered was that the ultracentrifuged LucGFP viral particles were not 
resuspended properly thus formed clumps which prevented the viral particles from 
efficiently infecting the cells. To avoid this, the ultracentrifuged lentivirus was briefly 
sonicated (Danovaro et al., 2001; Yen et al., 2009) to resuspend more efficiently and 
then used to transduce the 3T3-L1 cells but no improvements were observed (data 
not shown), indicating it was not the improper resuspension that had caused the 
problem. However, when the concentrated LucGFP lentivirus was titered in HT1080 
cells, no obvious cell clumping was observed. Given that the growth medium for 
HT1080 cells contained the non-heat inactivated FBS while 3T3-L1 medium consisted 
of heat inactivated FBS, it could be some remaining active components in the former 
medium that helped preventing the clumping in HT1080 cells. As the growth of 3T3-
L1 cells was interfered by the non-heat inactivated FBS (data not shown), the 
hypothesis could be tested, though not done yet, by using the heat inactivated FBS 
for maintaining HT1080 after transduction with concentrated LucGFP lentivirus. If the 
transduced HT1080 cells were still not clumped with the heat inactivated FBS, it 
would be more probable that the clumping was a feature of some poorly transduced 
cells such as 3T3-L1 when the virus could not enter the cells; however, no such 
phenomena has been reported in literature.  
As for the optimal MOI of infecting 3T3-L1, although it was 30 as recommended from 
Invitrogen User Manual, there were different suggestions from different research 
groups. The Life Science Group from Bio-Rad company successfully transduced 3T3-L1 
preadipoctes using virus-containing supernatant at a concentration of 40-120ng p24 
per 10
5
 cells which is equivalent to MOI of 1-3 (Schmidt and Al-Hasani, 2007), while  
another group used 200-400ng p24 per 10
5
 cells which equivalent to MOI of 5-10 to 
realize an effective transduction in 3T3-L1 (Carlotti et al., 2004). Although the insert 
of our LucGFP virus was challenging the size limit of the system, the higher MOI used 
(around 30) to transduce the 3T3-L1 cells should be able to overcome the 
disadvantage from the size; yet the transductions were still not successful. 
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Since concentrating the virus and using a higher MOI failed to sort out the problem of 
the low infectious LucGFP lentivirus, it is possible that the size of the pLenti6-LucGFP 
vector needed modifying to generate vectors with the same functions but more 
suitable for lentivirus production. As the final target was to realize inducible 
expression of target genes, the Tet on regulatory element rtTA and its CMV promoter 
cannot be removed. It has been  suggested by Twyman that the intron in the insert 
gene of the lentiviral vector might have a negative effect on virus production, i.e. to 
decrease the viral titers (Twyman, 2005). Therefore, one practical solution would be 
to remove the Rabbit ɴGlobin Intron, which will reduce the insert size by about 0.6kb. 
This decrease in size might still be insufficient to produce virus efficiently according to 
sŝƌĂWŽǁĞƌ ? ƉƌŽƚŽĐŽů ? ^ƚƵŬĞ ĂŶĚ ĐŽůůĞĂŐƵĞƐ ŽŶĐĞ ŐŽƚ ƚĞƚƌĂĐǇĐůŝŶĞ-regulated highly 
inducible expression of human prion protein in murine 3T3 cells by transfecting the 
TRE-CMV driving prion vector into the 3T3-L1 cell line which had already been stably 
integrated with the Tet-off vector (Stuke and Strom, 2005). Pan et al also described 
the work to co-transduce murine macrophage cells derived from a mouse strain 
expressing rtTA with two lentiviruses: one was to constitutively express a selectable 
ƐƵƌĨĂĐĞ ŵĂƌŬĞƌ ĂŶĚ ƚŚĞ ŽƚŚĞƌ ƚŽ ĞǆƉƌĞƐƐ  “ƚŚĞ ŐĞŶĞ ŽĨ ŝŶƚĞƌĞƐƚ ? ĚƌŝǀĞŶ ďǇ Ă
doxycycline-inducible promoter (Pan et al., 2008). These data implied another 
approach which might be able to sort out the size problem of our lentiviral vectors: to 
divide a single Tet on lentiviral vector into two vectors, one containing the TRE 
modified promoter that drives the expression of the C/EBPɴ (or LucGFP), the other 
containing the rtTA and its promoter. In this way, both vectors can be smaller in size 
but the target cell line has to be double transduced to have both C/EBPɴ (or LucGFP) 
and rtTA gene expression cassettes integrated into a single genome. 
To summarize, the experimental work in this chapter compared the first and second 
generation of lentivirus production system ViraPower ? and psPAX2 packaging 
plasmid mix, and the latter 2-plasmid system had higher efficiency than the former 3-
plasmid system in packaging lentiviral particles in 293FT cell line. However, the first 
try of producing constitutive LucGFP lentiviral particles failed to achieve high titer and 
to effectively transduce the target cell line, 3T3-L1, even after the viral titer was 
increased to 10
5
 TU/ml by ultracentrifugation and the MOI was as high as 30. 
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Meanwhile the positive LucRFP lentivirus was 3×10
2
 fold higher in viral titer than the 
LucGFP virus and successfully transduced 3T3-L1, although at a higher MOI (30) 
compared with the MOI used in HT1080 (MOI=1) and 293FT (MOI=5) cells. 
Monoclonal 3T3-L1 cells stably expressing LucRFP were successfully separated 
through the processes described in 2.5.3, but the processes failed to result in LucGFP 
transduced monoclonal 3T3-L1 cells although blasticidin-resistant cell colonies were 
obtained.  
In conclusion, the whole procedure of producing lentiviral particles with second 
generation packaging plasmid mix psPAX2, transducing target cell line 3T3-L1 and 
selecting for monoclonal transduced cells was successful, demonstrated by the data 
with positive LucRFP vector. The data also showed that the 3T3-L1 cell line was more 
difficult to transduce compared to HT1080 and 293FT cell lines. However, the 
lentivirus produced from constructed constitutive LucGFP vector was low infectious 
even after being concentrated to higher titer (10
5
 TU/ml), probably due to the size of 
the designed vector challenging the limit of the lentivirus production system (5kb) 
and the problem could only be solved by re-designing the vectors. 
Therefore in the absence of a successful lentiviral vector for overexpressing genes, in 
the following parts of the project transient overexpression was used to investigate 
ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ  ?Wɴ ĂŶĚ ŽƚŚĞƌ ĨĂĐƚŽƌƐ ŝŶ ƌĞŐƵůĂƚŝŶŐ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ
UCP1 gene in 3T3-L1 cell line.  
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5 INTERACTION dtE ?WȲd ?
W' ?Ȱ>W, ?WZD ? ?ND PPAR 
GAMMA IN REGULATING UCP1 
EXPRESSION DURING 3T3-L1 
DIFFERENTIATION 
5.1 INTRODUCTION 
The transcription factor C/EBPɴ has been found to play a critical role in adipogenesis 
and thermogenesis, specifically stimulating the expression of the adipogenic master 
regulator PPARɶ and the hallmark gene of brown adipose tissue UCP1 respectively 
(see 1.3.5). The cAMP-PKA signalling pathway modulates both C/EBPɴ and PPARɶ 
expression, interacting with the PPAR ligand mediated signalling pathway and the 
activation of co-activators PGC1ɲ and PRDM16, etc. Stimulation of the cAMP-PKA and 
PPAR signalling pathways with forskolin and rosiglitazone, respectively, has been 
shown to increase the thermogenic activity of brown fat (Cao et al., 2004; Robidoux 
et al., 2005; Teruel et al., 2005) but the exact mechanisms responsible for the 
interplay between the two pathways has not been elucidated. A hypothetical model 
of the mechanism by which C/EBPɴstimulates UCP1 expression was proposed in the 
Introduction (Figure 1.14) involving interaction with the (co)activators PGC1ɲ and 
PRDM16 and the (co)repressors  RIP140 and CIDEA, in response to the specific 
signalling pathways.  
WƌĞǀŝŽƵƐǁŽƌŬŝŶŽƵƌůĂďĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚ ?WɴďŝŶĚƐƚŽcAMP Response Element 
(CRE) ŽŶƚŚĞ ƉƌŽǆŝŵĂůƉƌŽŵŽƚĞƌŽĨW' ?ɲƚŽĂĐƚŝǀĂƚĞƚƌĂŶƐĐƌŝƉƚŝŽŶ (Karamanlidis et 
al., 2007). It was proposed that  ?Wɴ was able to stimulate UCP1 expression in the 
3T3-L1 white preadipocytes cell line, by increasing W' ?ɲ expression (Karamanlidis et 
al., 2007).  It has been illustrated in Figure 1.9 that the UCP1 promoter also contains 
CREs and a PPAR response element (PPRE) which facilitates its transcription in 
response to cAMP-PKA or PPAR ligand mediated signalling pathways respectively. The 
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aim of this chapter was to investigate the mechanism by which  ?WɴĂĐƚƐŽŶƚŚĞ 
UCP1 promoter. Two luciferase reporter vectors with artificial promoters were used, 
one with 3 repeated DR1 of PPRE as an enhancer in a TK promoter driving luciferase 
expression (pGL3-PPRE-TK) and the other with 6 repeated CREs as the promoter 
(pGL3-CRE).  
Ideally, the role of C/EBPɴ in 3T3-L1 differentiation should be tested using a stable 
overexpression system (as described in Chapter 3), in which C/EBPɴ is stably 
overexpressed and switched on/off by the presence or absence of doxycycline 
throughout the whole differentiation process of 3T3-L1. However, as the previous 
work failed to produce highly infectious lentivirus to realize the stable overexpression 
of C/EBPɴ in 3T3-L1, the transient transfection method (as described in 1.4) was used 
to test the model described in Figure 1.14, and investigate the interaction between 
C/EBPɴ and WWZɶ ?W' ?ɲĂŶĚWZD ? ?, in the regulation of UCP1 expression in 3T3-
L1 cells. The main limitation of the transient transfection method is that the 
overexpression vector can only be transfected at high efficiency, before the cells are 
fully confluent so the effect of the overexpression must be tested, at latest, one day 
post confluence, to avoid loss of vector overexpression. Therefore, the experiments 
performed in this way can only demonstrate the effect oĨ ?WɴŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽŶ
UCP1 expression in 3T3-L1 at confluence. The data gained from these experiments 
only reveals mechanisms directing the development of the brown adipogenic 
programme during the very early stages of differentiation.  The transient transfection 
system is also very useful for the investigation of the interaction between regulatory 
molecules in modulating the acute regulation of the transcriptional activity of the 
UCP1 promoter and UCP1 mRNA expression, triggered by the cAMP-PKA signalling 
pathway. 
The specific objectives of the experimental work described in this chapter were: 
 ? ?dŽŝŶǀĞƐƚŝŐĂƚĞŚŽǁƚŚĞŐĞŶĞĞǆƉƌĞƐƐŝŽŶƉĂƚƚĞƌŶŽĨ ?Wɴ ?W' ?ɲ ?WWZɶ ?WZD ? ?
and UCP1 changes in response to chronic rosiglitazone or acute forskolin treatment 
during 3T3-L1 differentiation. 
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 ? ?dŽŝŶǀĞƐƚŝŐĂƚĞƚŚĞĞĨĨĞĐƚŽĨ ?Wɴ ?ĐŽ-ŽǀĞƌĞǆƉƌĞƐƐĞĚǁŝƚŚWZD ? ?ŽƌWWZɶ ?ŽŶ
UCP1 transcription in confluent 3T3-L1 preadipocytes. 
 ? ?dŽůŽĐĂƚĞǁŚĞƌĞ ?WɴĂĐƚs on the promoter of UCW ? ?ŝ ?Ğ ?ǁŚĞƚŚĞƌ ?WɴďŝŶĚƐ
to PPRE or CRE on UCP1 promoter. 
5.2 EXPERIMENTAL DESIGN 
5.2.1 Analysis of gene expression profiles in 3T3-L1 differentiation and the 
effects of rosiglitazone/forskolin on gene expression 
3T3-L1 cells were grown to confluence on 6-well plates in 2ml/well growth medium 
and two days later (DAY 1), the induction medium containing 10% FBS, 500µM IBMX, 
250nM dexamethasone and 167nM insulin was applied to the cells and treated for 48 
hours. The medium was then changed to maintenance medium containing 10% FBS 
and 167µM insulin for another 6 days (DAY 8) as described in 2.2.3. 1µM rosiglitazone 
was added to the differentiation medium from DAY 1. On DAY 8 of differentiation, 
10µM forskolin was added to the cells and treated for 3 hours before cells were lysed 
for RNA extraction as described in 2.6.1. cDNAs were synthesised (as described in 
2.6.2) from the extracted RNA and quantitative real time PCR (described in 2.6.3) was 
used to measure the expression of UCP1, C/EBPɴ, PPARɶ ?PGC1ɲĂŶĚWZD ? ? ?
To investigate the time course of rosiglitazone effect on gene expression pattern in 
3T3-L1 cells during differentiation, 1µM rosiglitazone was added to the differentiation 
medium of 3T3-L1 cells from DAY1 of differentiation. Cells were lysed for RNA 
ĞǆƚƌĂĐƚŝŽŶŽŶz  ? ?  ? ?  ? ?  ? ?  ? ?  ? ?  ? ?  ? ?  ? ?  ? ?ĂŶĚŐĞŶĞĞǆƉƌĞƐƐŝŽŶŽĨhW ? ? ?Wɴ ?
WWZɶ and aP2 was measured by quantitative real time PCR as described in 2.6.3. 
 ? ? ? ? ?ĨĨĞĐƚƐŽĨ ?WɴĂŶĚWZD ?6 co-overexpression on transcriptional 
ĂĐƚŝǀŝƚǇŽĨhW ?ĂŶĚW' ?ɲƉƌŽŵŽƚĞƌs. 
To investigate whether C/EBPɴ could increase transcription from the UCP1 promoter, 
and the interaction with PRDM16, 3T3-L1 preadiocytes were seeded into 24-well 
plates. At  80% confluence, a  3.1kb UCP1 promoter luciferase reporter vector 
(3.1UCP1 pGL3-Luc) or 2.6kb PGC1ɲ promoter reporter vector  ? ? ? ?W' ?ɲƉ'> ?-Luc) 
were separately co-transfected with C/EBPɴ and/or PRDM16 expression vectors into 
3T3-L1 cells as described in 2.3.2. 36 hours later, 10µM forskolin was added to the 
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transfected cells and 12 hours later, firefly luciferase activity was measured as 
described in 2.3.3 to quantify the transcriptional activity of either promoter with the 
overexpression of C/EBPɴ and/or PRDM16. 
To further confirm the results from the reporter assay experiments described above, 
mRNA level of UCP1 was also measured in 3T3-L1 transfected with C/EBPɴ and/or 
PRDM16. Cells were seeded in 6-well plates and transfected with 1µg of C/EBPɴ 
and/or 1µg of PRDM16 vector as described in 2.3.2. 10µM forskolin was added into 
the culture about 40 hours post transfection and treated for 3 hours before the cells 
were lysed for RNA extraction as described in 2.6.1. The mRNA level of C/EBPɴ, 
PRDM16, UCP1 and PGC1ɲ ǁĂƐ ƋƵĂŶƚŝĨŝĞĚ ďǇ ƌĞĂů ƚŝŵĞ WZ ƚŽ ĐŚĞĐŬ ŝĨ ƚŚĞ
overexpression was successful and the effect of the overexpression on the 
endogenous ĞǆƉƌĞƐƐŝŽŶŽĨhW ?ĂŶĚW' ?ɲ ? 
5.2.3 Effects of  ?WɴĂŶĚWWZɶĐŽ-overexpression on transcriptional 
ĂĐƚŝǀŝƚǇŽĨhW ?ĂŶĚW' ?ɲƉƌŽŵŽƚĞƌ ? 
To investigate whether C/EBPɴ could increase the transcriptional activity of UCP1 
promoter when co-overexpressed with PPARɶ, 3T3-L1 preadiocytes were separately 
transfected with either the 3.1 UCP1 pGL3-Luc vector or 2.6 PGC1ɲ pGL3-Luc vector, 
together with C/EBPɴ and/or PPARɶ expression vectors as described in 2.3.2. 10µM 
PPARɶ ligand rosiglitazone was added to the cultures 24 hours post transfection with 
10µM forskolin added to the transfected cells 12 hours after rosiglitazone. Firefly 
luciferase activity was measured 48 hours post transfection as described in 2.3.3 to 
quantify the transcriptional activity of either promoter with the overexpression of 
C/EBPɴ and/or PPARɶ. 
To further confirm the results from the reporter assay experiments described above, 
the mRNA level of UCP1 was also measured in 3T3-L1 transfected with C/EBPɴ and/or 
PPARɶ. Cells were seeded in 6-well plates and transfected with 1µg of C/EBPɴ and/or 
1µg of PPARɶ vector as described in 2.3.2. 10µM rosiglitazone was added to the cells 
24 hours after transfection and treated for 24 hours. 10µM forskolin was added to 
the culture about 40 hours post transfection and treated for 3 hours before the cells 
were lysed for RNA extraction as described in 2.6.1. The mRNA level of C/EBPɴ, PPARɶ, 
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UCP1 and PGC1ɲǁĂƐƋƵĂŶƚŝĨŝĞĚďǇƌĞĂůƚŝŵĞWZƚŽĐŚĞĐŬŝĨƚŚĞŽǀĞƌĞǆƉƌĞƐƐŝŽŶǁĂƐ
successful and the effect of the overexpression on the expression of UCP1 anĚW' ?ɲ ? 
 ? ? ? ? ?ĨĨĞĐƚƐŽĨ ?WɴŽŶWWZĂŶĚZŝŶ ?d ?-L1. 
To locate where C/EBPɴ acts on the UCP1 and PGC1ɲ promoters, the artificial 
reporter vectors containing either PPRE or CRE driven luciferase reporter plasmids 
(pGL3-PPRE-TK or pGL3-CRE) were co-transfected with C/EBPɴ into the 3T3-L1 
preadipocytes in 24-well plates as described in 2.3.2. 24 hours post transfection, 
10µM rosiglitazone was added to the cells transfected with pGL3-PPRE-TK and 
treated for 24 hours, while 10µM forskolin was added to the cells transfected with 
pGL3-CRE 36 hours post transfection and treated for 12 hours. Luciferase assay was 
performed 48 hours after transfection to check if the overexpression of C/EBPɴ 
increased the luciferase expression activated by PPRE or CRE.  
Data in figures is presented as average ± SEM from 2 or 3 independent replicate 
experiments with duplicate or triplicate wells in each experiment. Effects of 
treatments were determined by performing ^ƚƵĚĞŶƚ ?Ɛt-test or Analysis of Variance 
(ANOVA) as indicated in individual figure legend. Significance was accepted if P<0.05.  
5.3 RESULTS 
5.3.1 The effect of rosiglitazone (chronic) and forskolin (acute) on the 
ĞǆƉƌĞƐƐŝŽŶŽĨ ?Wɴ ?WWZɶ ?W' ?ɲ ?WZD ? ?ĂŶĚhW ?ŝŶ ?d ?-L1 before 
and after differentiation. 
The synthetic PPARɶ agonist triglitazone has been reported to stimulate brown 
adipogenesis in 3T3-L1 preadipocytes or fibroblasts over-expressing PPARɶ 
(Vernochet et al., 2009). Acute treatment of norepinepharine is also said to favour 
brown fat differentiation (Petrovic et al., 2009). These findings have confirmed the 
important role of both signalling pathways in brown adipogenesis and inspired the 
idea to test the effect of another PPARɶ agonist rosiglitazone and the cAMP inducer 
forskolin, on differentiation of the white preadipocyte 3T3-L1 cell line. We tested the 
hypothesis that chronic treatment with rosiglitazone and acute treatment with 
forskolin could stimulate brown adipogenic gene expression phenotypes during the 
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3T3-L1 differentiation process. The 3T3-L1 preadipocytes were differentiated as 
described in 2.3.3.  
 
 
 
 
 
 
 
 
Figure 5.1 Forskolin and Rosiglitazone effects on gene expressions in 
differentiated 3T3-L1. 
3T3-L1 preadipocytes were grown to 100% confluence in DMEM containing 10% 
FBS. 2 days post confluence, cells were induced to differentiate by DMEM 
containing 10% FBS, 0.5mM IBMX, 167nM Insulin and 250nM dexamethasone 
with or without rosiglitazone (Rosi, 1µM) for 2 days. After induction, cells were 
maintained in DMEM containing 10% FBS and 167nM Insulin with or without Rosi 
for another 6 days before RNA extraction. Forskolin (Forsk) was added to the cells 
3 hours before RNA extraction as indicated. Gene expression levels of UCP1 (A), 
PGC1ɲ  ? ) ?  ?Wɴ  ? ) ? WWZɶ2 (D), RIP140 (E) and Resistin (F) was analyzed by 
quantitative real-time PCR and normalized against 18S expression. 3T3-L1 pre 
stands for the data from 3T3-L1 preadipocytes (Day 0); DIF 3T3-L1 stands for the 
data from differentiated 3T3-L1 adipocytes (Day 8). Results represent mean ± 
S.E.M from 2 independent replicate experiments performed in triplicate wells. 
*P<0.05 by Student ?Ɛt-test due to differentiation with respect to 3T3-L1 pre 
samples; data of differentiated cells was analysed by two-way ANOVA.   
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As shown in Figure 5.1A, the expression of UCP1 was increased (P<0.01) 7 fold by 
differentiation and in differentiated 3T3-L1 adipocytes, UCP1 expression was 
significantly increased (P<0.01)  4.5 fold by the treatment of forskolin or 13.4 fold by 
rosiglitazone, but there was no additive effect when treating cells with both drugs. 
The expression of PGC1ɲ was increased (P<0.01) 8 fold in differentiated cells 
compared to preadipocytes (Figure 5.1B), but forskolin treatment did not further 
increase the expression and rosiglitazone treatment slightly reduced PGC1ɲ 
expression (P=0.048). C/EBPɴ expression was increased (P<0.01) 4 fold by 
differentiation and in mature 3T3-L1 adipocytes, the acute treatment of forskolin 
increased (P<0.05)  ?Wɴ expression 2 fold but rosiglitazone treatment had no 
ƐŝŐŶŝĨŝĐĂŶƚ ĞĨĨĞĐƚ ŽŶ  ?Wɴexpression in fully differentiated 3T3-L1 cells (Figure 
5.1C). RIP140 has been reported as a co-repressor of UCP1 transcription and 
thermogenesis in brown adipose tissue (Kiskinis et al., 2007); its expression was 
significantly stimulated (P<0.01) by the 3T3-L1 differentiation process but this 
stimulation was reduced (P<0.01) by about 50% by the treatment with either 
forskolin or rosiglitazone, but there was no significant interaction between the two 
drug treatments (Figure 5.1E). The pattern of RIP140 expression responses to 
treatments during differentiation was opposite to the pattern for UCP1 expression 
(Figure 5.1A). As the marker gene of adipogenesis, PPARɶ2 expression was markedly 
increased (P<0.001) 14 fold  after differentiation compared to the expression level in 
preadipocytes, but forskolin treatment had no significant effect on PPARɶ2 
expression in mature adipocytes (Figure 5.1D). Surprisingly, treatment with PPARɶ 
ligand rosiglitazone significantly reduced (P<0.01) the expression of PPARɶ2 by 72% in 
differentiated 3T3-L1 cells. As one of the genes induced during adipogenesis (Kershaw 
and Flier, 2004), resistin displayed the identical expression pattern with that of PPARɶ, 
greatly increased (P<0.001) by differentiation process (1200 fold) but significantly 
decreased (P<0.01) by 86% by the treatment of rosiglitazone (Figure 5.1F), consistent 
with data in literature (Steppan et al., 2001). The down-regulation of PPARɶ and 
resistin by rosiglitazone treatment indicated an impaired white adipogenesis, at least 
in terms of lipid accumulation. To further validate this conclusion, another set of 3T3-
L1 cells were differentiated with or without 1µM rosiglitazone for 12 days, and then 
counter-stained by haematoxylin and Oil Red O as described in 2.2.4 to check the lipid 
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accumulation as a reference of white adipogenesis. It was clear in Figure 5.2 that 
there were lots of big lipid droplets (stained red) in the adipocytes without 
rosiglitazone treatment (Figure 5.2, upper) while the adipocytes differentiated with 
rosiglitazone had much fewer and smaller lipid droplets (Figure 5.2, lower), 
confirming that rosiglitazone did impaired lipid accumulation in white adipogenesis.  
 
 
Figure 5.2 Haematoxylin-Oil Red O counter staining of 3T3-L1 adipocytes 
differentiated with or without rosiglitazone treatment.  
3T3-L1 preadipocytes were differentiated as described in 2.3.3, with or without 
1µM rosiglitazone in the induction and maintenance medium from DAY 0 of 
differentiation. At DAY 12, medium was removed from the cells and the 
differentiated cells were then stained by Oil Red O and Haematoxylin as described 
in 2.2.4. Photos were taken using Leica DFC 420C microscope (bright field) with 
the magnification of 100.   
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5.3.2 Time course of lipid droplet accumulation and the expression of 
 ?Wɴ ?WWZɶ ?aP2 and UCP1 in 3T3-L1 differentiation in response to chronic 
treatment of rosiglitazone.  
An experiment was first conducted to examine the effect of rosiglitazone treatment 
on the time course of lipid droplet accumulation during 8 days of differentiating 3T3-
L1 cells.  It was observed that the 3T3-L1 cells treated with rosiglitazone seemed to 
differentiate at a faster pace compared with the ones without rosiglitazone treatment, 
especially on DAY 3 when the cells treated with rosiglitazone started to accumulate 
lipid droplets while there were no lipid droplets appearing in the cells without 
rosiglitazone (Figure 5.3A). On DAY 5, there were more lipid droplets accumulating in 
the rosiglitazone treated cells than the untreated ones, but the difference gradually 
disappeared and the two sets of cells looked similar in terms of lipid droplet 
accumulation on DAY 6 (Figure 5.3A). By DAY 7 and DAY 8, there seemed to be more 
lipid droplets in the cells without rosiglitazone treatment than in the treated cells, 
although the difference was slight (Figure 5.3B). Given that there were more lipid 
droplets accumulated in the fully differentiated 3T3-L1 adipocytes without 
rosiglitazone treatment than the treated cells (Figure 5.2), it was reasonable to infer 
that in the late stage of differentiation (DAY 8 to DAY 12), rosiglitazone inhibited the 
formation of lipid droplets.  
 
 
 
 
Figure 5.3 Daily progress of 3T3-L1 differentiation with or without rosiglitazone.  
3T3-L1 preadipocytes were grown to 100% confluence and differentiated as 
described in 2.3.3, with or without 1µM rosiglitazone (Rosi) in the induction and 
maintenance medium from DAY 0 of differentiation. Photos in bright field were 
taken daily from DAY 0 to DAY 8 using Leica DFC 420C microscope.  (A) Photos 
from DAY 0 to DAY 3 were taken at the magnification of 100. (B) Photos from DAY 
4 to DAY 8 were taken at the magnification of 400.  
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To investigate how the expression pattern of critical adipogenic and thermogenic 
genes was influenced by rosiglitazone treatment during different stages of 3T3-L1 
differentiation, a time course experiment was performed in differentiating 3T3-L1 
cells using the same protocol and  over the same period as described  in 5.3.1. 3T3-L1 
preadipocytes were grown to confluence and, 2 days later as described in 2.3.3, 
induced to differentiate with or without 1µM rosiglitazone. Cells were lysed for RNA 
extraction on DAY 0, 1, 2, 3, 4, 5, 6, 7, 9, 11 as described in 2.6.1 and quantitative real-
time PCR was used to measure the expression level of C/EBPɴ and the adipogenic 
marker gene PPARɶ as well as aP2 and UCP1 genes (Figure 5.4). 
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Figure 5.4 Time course of PPARɶ, C/EBPɴ ?ĂW ?ĂŶĚhW ? expression during 3T3-
L1 differentiation progress. 
3T3-L1 preadipocytes were differentiated as described in 2.3.3, with or without 
1µM rosiglitazone (Rosi) from DAY 0. Cells were lysed for RNA extraction on DAY 0, 
1, 2, 3, 4, 5, 7, 9 and 11 as described in 2.6.1 and gene expression of C/EBPɴ (A), 
PPARɶ (B), aP2 (C) and UCP1 (D) was analysed by quantitative real-time PCR and 
normalized against 18S expression. Results represent mean ± S.E.M from 2 
independent replicate experiments performed in duplicate wells. Data was 
analysed by two-way ANOVA and P<0.001 for time×Rosi for all the four genes. 
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Two-way ANOVA analysis indicated that the effect of rosiglitazone significantly 
differed  (P<0.001) depending on differentaition time for all the four genes tested. 
Expression of C/EBPɴ (Figure 5.4A) increased 4 fold in the first 2 days of 
differentiation and rosiglitazone up-regulated its expression to 6.7 fold. However, the 
expression level decreased afterwards and there was no response to rosiglitazone. 
Expression of PPARɶ (Figure 5.4B) reached the peak, which was about 14 fold higher 
compared with the preadipocytes, on DAY 4-5, but decreased afterwards. 
Rosiglitazone down-regulated the peak expression of PPARɶ by 40-50% but had no 
significant effect before or after it. The expression of aP2 increased after DAY 3 and 
peaked between DAY 4-6, returning to just above basal by DAY 7 of differentiation. 
Rosiglitazone treatment up-regulated the early response in aP2 expression, producing 
a pronounced 15 fold higher rise at DAY2 which was sustained until DAY 6 and then 
fell by DAY 7, but still remaining higher than the control cells (Figure 5.4C). UCP1 
expression was significantly up-regulated 2 fold between 2-4 days of differentiation, 
falling back to baseline afterwards. Rosiglitazone treatment suppressed UCP1 
expression only at DAY 2 but stimulated expression from DAY 9 (Figure 5.4D).  
 ? ? ? ? ?ŝĨĨĞƌĞŶƚƌĞƐƉŽŶƐĞƐŽĨhW ?ĂŶĚW' ?ɲƉƌŽŵŽƚĞƌƚŽĐŽ-overexpression 
ŽĨ ?WɴĂŶĚWZD ? ?ŝŶ ?d ?-L1 cells. 
It has been reported that C/EBPɴ is able to form a complex with PRDM16 to initiate a 
brown adipogenic lineage from Myf5 positive progenitors by increasing expression of 
PGC1ɲ (Kajimura et al., 2009). To investigate whether the combination of C/EBPɴ and 
PRDM16 could stimulate the expression of the brown adipogenic genes such as UCP1 
and PGC1ɲ ŝŶǁŚŝƚĞ  ?d ?-L1 preadipocytes, C/EBPɴ and PRDM16 expression vectors 
were co-transfected with either 3.1UCP1 pGL3-Luc or 2.6PGC1ɲ pGL3-Luc reporter 
vectors, into 3T3-L1 cell line as described in 2.3.2. 10µM forskolin was added into the 
cell culture 36 hours post transfection and 12 hours later the cells were assayed for 
luciferase luminescence as described in 2.3.3, to measure the transcriptional activity 
of both promoters (Figure 5.5). Data was analysed by three-way ANOVA. Figure 5.5A 
showed that C/EBPɴ and PRDM16 had a significant interaction (P=0.026), indicating a 
synergistic effect on increasing transcriptional activity of 3.1kb UCP1 promoter in 3T3-
L1.  Forskolin addition to increase cAMP further induced (P<0.001) the C/EBPɴ and/or 
PRDM16 stimulated transcriptional activity of the UCP1 promoter. In contrast, 
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overexpression of C/EBPɴ or PRDM16 alone failed to activate the 2.6kb PGC1ɲ 
promoter (Figure 5.5B). But there was significant interaction (P=0.006) between 
 ?Wɴ ĂŶĚ WZD ? ? ǁŚĞŶ ĐŽ-overexpressed. Forskolin treatment had marginal 
significant effect (P=0.051).  
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Co-overexpression of C/EBPɴ and PRDM16 activated the transcription 
of UCP1 but not PGC1ɲ in 3T3-L1. 
3T3-L1 preadipocytes were grown to 70-80% confluence and then transfected 
with pGL3-3.1kb UCP1 promoter (A) or pGL3-2.6kb PGC1ɲ promoter (B) in the 
ƉƌĞƐĞŶĐĞ ŽĨ ?WɴĂŶĚ ?ŽƌWZD ? ?ŽǀĞƌĞǆƉƌĞƐƐŝŽŶĂƐ ŝŶĚŝĐĂƚĞĚ ŝŶ ƚŚĞ ŐƌĂƉŚƐ ?
&ŽƌƐŬŽůŝŶ ? ? ?ʅD )ǁĂƐĂĚĚĞĚƚŽƚŚĞĐĞůůƐ ? ?ŚŽƵƌƐƉŽƐƚƚƌĂŶƐĨĞĐƚŝŽŶ ?ĂŶĚůƵĐŝĨĞƌĂƐĞ
assay was carried out 48 hours post transfection.  Firefly luciferase activity was 
relative to the values from the cells transfected only with the promoter vector 
and treated with DMSO. Results are mean ± S.E.M from 3 independent replicate 
experiments performed in triplicate wells. The data was analysed by three-way 
ANOVA. As neitŚĞƌ ?WɴŶŽƌWZD ? ?ŚĂĚƐŝŐŶŝĨŝĐĂŶƚŝŶƚĞƌĂĐƚŝŽŶ ?WAN ? ? ?  )ǁŝƚŚ
forskolin, the P values of the vector-drug interactions are not indicated in the 
figures.  
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To further confirm the results from reporter assays above, 3T3-L1 preadipocytes were 
transfected with C/EBPɴ or/and PRDM16 overexpression vectors as described in 2.3.2, 
and 36 hours post transfection, cells treated with 10µM forskolin for 3 hours before 
the cells were lysed for RNA extraction. The mRNA level of UCP1 and PGC1ɲ was 
determined by quantitative real-time PCR (Figure 5.6). Data was analysed by three-
way ANOVA. Despite successful overexpression of C/EBPɴ and PRDM16, as 
demonstrated by increased mRNA levels (Figure 5.6A&B), the expression of UCP1 or 
PGC1ɲ was not significantly altered, even after forskolin treatment (Figure 5.6C&D, 
P>0.05). When checking the PCR products of the UCP1 and PGC1ɲ RT-PCR on 2% 
agarose gel, the bands at expected size (75bp) for UCP1 or PGC1ɲ looked faint for the 
control samples (Lane 1&2) (Figure 5.6E), probably because the expression of both 
genes were too low in the template to pick up by PCR and the PCR signals were 
possibly primer dimers or other non-specific amplification. Interestingly, there was a 
significant C/EBPɴA?PRDM16×forskolin interaction (P=0.004) in Figure 5.6A: the mRNA 
level of C/EBPɴ was higher in the cells co-transfected with C/EBPɴ and PRDM16 than 
those only transfected with C/EBPɴ although the C/EBPɴ mRNA in the cells 
transfected with only PRDM16 remained at the same level with that in the mock 
transfected cells; moreover, the co-overexpression of PRDM16 abolished the 
forskolin-induced increase of C/EBPɴ in the cells overexpressing C/EBPɴ only. This 
suggested a synergistic positive feedback effect of C/EBPɴ-PRDM16 co-
overexpression on expression of C/EBPɴ from the overexpression plasmid. But the 
same effect was not shown on PRDM16 expression, as the expression did not 
significantly differ in the cells transfected with only PRDM16 and the ones co-
transfected with both vectors (Figure 5.6B). However, as both the overexpression 
vectors were driven by constitutive promoter CMV, it was less likely that one of the 
overexpressed genes could be regulated by the other, so the observation above 
might just result from different levels of mRNA turnover, and this also suggested that 
Western Blotting should be a more reliable method to detect gene expression as it 
directly reflects the difference at protein level. Alternatively, as the exogenous 
C/EBPɴ and PRDM16 were both driven by the CMV promoter in the overexpression 
vectors, there might be some competition for transcription factors when 
overexpressing the two genes in the transfected 3T3-L1 cells.  
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Figure 5.6 The expression level of UCP1 and PGC1ɲ was not changed by 
overexpression of C/EBPɴ or/and PRDM16 in 3T3-L1 preadipocytes.  
3T3-L1 preadipocytes were grown to 70-80% confluence in 6-well plates and then 
transfected with over expression vectors for C/EBPɴ or/and PRDM16 (or just 
pcDNA as mock) by Fugene HD as described in 2.3.2. 36 hours post transfection, 
10µM forskolin was added to the cell culture and treated for 3 hours before the 
cells were lysed for RNA extraction. The mRNA level of C/EBPɴ ? ) ?PRDM16 (B), 
UCP1 (C) and PGC1ɲ  ? ) was determined by quantitative real-time PCR and 
normalised against 18S expression. Results represent mean ± SD from one of the 
duplicate experiments performed in triplicate wells. Data was analysed by three-
way ANOVA: (A) P=0.004 for C/EBPɴA?PRDM16×forskolin; (B) P<0.001 for PRDM16; 
(C) P>0.05; (D) P>0.05. (E) The PCR products of UCP1 (upper) and PGC1ɲ (lower) 
were checked by electrophoresis on a 2% agarose gel. Template list: Lane 1- 
pcDNA transfected cells, Lane 2- pcDNA transfected cells treated with forskolin, 
Lane 3- C/EBPɴ transfected cells, Lane 4- C/EBPɴ transfected cells treated with 
forskolin, Lane 5- PRDM16 transfected cells, Lane 6- PRDM16 transfected cells 
treated with forskolin, Lane 7- C/EBPɴ and PRDM16 cotransfected cells, Lane 8- 
C/EBPɴ and PRDM16 cotransfected cells treated with forskolin.  
1 2 3 4 5 6 7 8 
1 2 3 4 5 6 7 8 
E 
UCP1 
PGC1ɲ 
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 ? ? ? ? ?ĨĨĞĐƚŽĨ ?WɴĂŶĚWWZɶĐŽ-ŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽŶW' ?ɲƉƌŽŵŽƚĞƌand 
UCP1 promoter in 3T3-L1. 
/ƚŝƐǁŝĚĞůǇĂĐĐĞƉƚĞĚƚŚĂƚW' ?ɲŝƐĞƐƐĞŶƚŝĂůĨŽƌďƌŽǁŶĂĚŝƉŽĐǇƚĞĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶĂŶĚ
induction of the UCP1 gene, as the ectopic expression of PGC1ɲ in white adipocytes 
induces expression of a number of mitochondrial and thermogenic genes including 
UCP1 (Puigserver et al., 1998; Tiraby et al., 2003). However, the above data suggests 
that C/EBPɴ increased UCP1 promoter activity independent of activating PGC1ɲ 
transcription (Figure 5.6) despite the results of previous literature (Kajimura et al., 
2009; Karamanlidis et al., 2007). A possible model for explaining these inconsistent 
results is that C/EBPɴ indirectly regulates PGC1ɲ expression to increase UCP1 
expression, through interaction with other regulators that were not optimised. Since 
PPARɶ is a critical transcription factor necessary to activate both the PGC1ɲ and UCP1 
promoters (Hondares et al., 2006), it was the first candidate to examine the effect of 
co-overexpression with C/EBPɴ, on the transcriptional activity of 3.1kb UCP1 
promoter and 2.6kb PGC1ɲ promoter. Although the overexpression of C/EBPɴ on its 
own increased (P<0.001) transcription activity of 3.1kb UCP1 promoter in the absence 
and presence of forskolin (Figure 5.6A), the addition of rosiglitazone did not further 
stimulate the transcription activity (Figure 5.7A). In contrast, PPARɶ overexpression 
alone failed to activate the 3.1kb UCP1 promoter even with forskolin and 
rosiglitazone. When C/EBPɴ and PPARɶ were co-transfected together, there was a 
significant (P<0.05) stimulation of the 3.1kb UCP1 promoter activity in the presence 
of both forskolin and rosiglitazone (Figure 5.7A), even though there was no further 
response, compared with C/EBPɴ overexpression alone, in the absence or presence of 
forskolin only. When the transcriptional activity of the 2.6kb PGC1ɲ promoter in 
response to the same treatments was assessed, there was no effect of 
overexpression of either C/EBPɴ or PPARɶ alone, or with rosiglitazone treatment but 
co-overexpression of the two genes significantly stimulated (P<0.05) the 2.6kb PGC1ɲ 
promoter activity and the treatment of rosiglitazone further enhanced (P<0.01) this 
stimulating effect (Figure 5.7B). dŚĞƌĞ ǁĂƐ ƐŝŐŶŝĨŝĐĂŶƚ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ  ?Wɴ
ĂŶĚWWZɶ ?WA? ? ? ?01). 
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Figure 5.7 Effect of overexpression of C/EBPɴ and PPARɶ on 3.1kb UCP1 promoter 
and 2.6kb PGC1ɲ promoter activity in 3T3-L1 
3T3-L1 preadipocytes were grown to 70-80% confluence and then transfected with 
3.1UCP1 pGL3-Luc (A) or 2.6PGC1ɲ pGL3-Luc  ? )ŝŶƚŚĞƉƌĞƐĞŶĐĞŽĨ ?WɴĂŶĚ ?Žƌ
PPARɶ overexpression as indicated in the graphs. 10µM rosiglitazone (Rosi) was 
ŐŝǀĞŶƚŽƚŚĞĐĞůůƐ ? ?ŚŽƵƌƐƉŽƐƚƚƌĂŶƐĨĞĐƚŝŽŶǁŚŝůĞ ? ?ʅD&ŽƌƐŬŽůŝŶ ?&ƐŬ )ǁĂƐĂĚĚĞĚ
into the cells 36 hours post transfection as indicated. Luciferase assay was carried 
out 48 hours post transfection.  Firefly luciferase activity was normalised to renilla 
luciferase activity. Results are mean ± S.E.M. of 2 or 3 independent replicate 
experiments performed in triplicate wells. Data was analysed by three-way ANOVA. 
P values of vector-drug interactions are not indicated if not significant. (A) *P<0.05 
by Student ?Ɛt-test compared to the cells overexpressing the same vector(s) but 
treated with Fsk only.  
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To confirm the results from reporter assay above, 3T3-L1 preadipocytes were 
transfected with C/EBPɴ or/and PPARɶ expression vector as described in 2.3.2, and 
the mRNA level of UCP1 and PGC1ɲ  was determined by quantitative real-time PCR 
(Figure 5.8). Data was analysed by three-way ANOVA. The overexpression of C/EBPɴ
and PPARɶ was successful, demonstrated by increased mRNA levels (Figure 5.7A&B). 
Interestingly, significant C/EBPɴA?PPARɶA?FskRosi interaction was observed when 
checking either C/EBPɴ  ?WA? ? ? ? ? ? ) Žƌ WWZɶ  ?WA? ? ? ? ? ? ) ĞǆƉƌĞƐƐŝŽŶ ?However, the 
expression of UCP1 or PGC1ɲ was not significantly increased, even after Fsk+Rosi 
treatment (Figure 5.7C&D), although significant C/EBPɴA?PPARɶ interaction (P<0.001) 
was observed when checking PGC1ɲ expression. The PCR products of UCP1 and 
W' ?ɲwere run on a 2% agarose gel, there were no clear bands at the expected size, 
similar to Figure 5.6E  ?ĚĂƚĂŶŽƚƐŚŽǁŶ ) ?ŝŶĚŝĐĂƚŝŶŐƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨhW ?ĂŶĚW' ?ɲ
was still too low to pick up, so the real time PCR data in Figure 5.8 C&D was not 
reliable.  
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 ? ? ? ? ?ŝĨĨĞƌĞŶƚƌĞƐƉŽŶƐĞƐŽĨ ?WɴĂŶĚWWZɶĐŽ-ŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽŶW' ?ɲ
promoter in different cell lines (3T3-L1, HIB-1B, Cos7). 
The present study (Figures 5.5B and 5.7B) failed to confirm a previous study which 
demonstrated that C/EBPɴ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŝŶ  ?d ?-L1 preadipocytes increases the 
ƚƌĂŶƐĐƌŝƉƚŝŽŶ ĂĐƚŝǀŝƚǇ ŽĨ ƚŚĞ ƉƌŽǆŝŵĂů ƉƌŽŵŽƚĞƌ ŽĨ W' ?ɲ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ĐDW
(Karamanlidis et al., 2007). However, the previous study used a proximal 264bp 
W' ?ɲ reporter construct, compared to the full length 2.6kb PGC1ɲ promoter 
employed in the present study. A previous study (Kajimura et al., 2009) suggested 
that C/EBPɴ and PRDM16 could form an activating complex to stimulate PGC1ɲ 
transcription in brown preadipocytes  but co-overexpression with C/EBPɴ and 
PRDM16 also failed stimulate PGC1ɲ transcription in 3T3-L1 cells in present work 
(Figure 5.5B). Surprisingly, the co-overexpression of C/EBPɴ and PPARɶ in 3T3-L1 cells 
significantly increased the transcriptional activity of 2.6kb PGC1ɲ promoter in the 
absence or presence of rosiglitazone (Figure 5.7B). These results suggest that 3T3-L1 
may lack PPARɶ, or contain repressive factors which ŝŶŚŝďŝƚ  ?Wɴ ĨƌŽŵ ĂĐƚŝǀĂƚŝŶŐ
W' ?ɲ ƚƌĂŶƐĐƌŝƉƚŝŽŶ, which is removed by co-overexpression with WWZɶ. To test 
these hypotheseƐ ?  ?Wɴ ǁĂƐ ŽǀĞƌĞǆƉƌĞƐƐĞĚ ǁŝƚŚ Žƌ ǁŝƚŚŽƵƚ WWZɶ ŝŶƚŽ ƚǁŽ
Figure 5.8 The expression level of UCP1 and PGC1ɲ was not changed by 
overexpression of C/EBPɴ or/and PPARɶ in 3T3-L1 preadipocytes.  
3T3-L1 preadipocytes were grown to 70-80% confluence in 6-well plates and then 
transfected with expression vector of C/EBPɴ or/and PRDM16 (or just pcDNA as 
mock) by Fugene HD as described in 2.3.2. 24 hours post transfection, 10µM 
rosiglitazone (Rosi) was added into the cells and treated for 24 hours and 10µM 
forskolin (Fsk) was also added into the cell culture as indicated and 3 hours before 
the cells were lysed for RNA extraction. The mRNA level of C/EBPɴ  ? ) ?PPARɶ (B), 
UCP1 (C) and PGC1ɲ  ? ) was determined by quantitative real-time PCR and 
normalised against 36B4 house-keeping gene expression. Results represent mean ± 
SD from one of the duplicate experiments performed in triplicate wells. Data was 
analysed by three-way ANOVA: (A) P=0.026 for C/EBPɴA?PPARɶA?FskRosi; (B) P=0.002 
for C/EBPɴA?PPARɶA?FskRosi; (C) P>0.05 for all variables and interactions; (D) P<0.001 
for C/EBPɴA?PPARɶ ? 
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different cell lines, HIB-1B and Cos7. The transfected cells were also treated with 
10µM rosiglitazone for 24 hours before they were used for luciferase assay and the 
luciferase activity data was compared with that obtained from 3T3-L1 cells (Figure 
5.9). Four-way ANOVA on the data suggested that all the three cell types responded 
to rosiglitazone (P<0.001), especially when C/EBPɴ was overexpressed. There is a cell 
ƚǇƉĞA?  ?WɴA? WWZɶ ŝŶƚĞƌĂĐƚŝŽŶ  ?WA? ? ? ? ? ? ) ? ďƵƚ Ăůů ƚŚƌĞĞ ĐĞůů ƚǇƉĞƐ ƐŚŽǁĞĚ ƐŝŵŝůĂƌ
ƌĞƐƉŽŶƐĞƐ ƚŽ  ?Wɴ ĂŶĚ ? Žƌ WWZɶ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ĂŶĚ ƌŽƐŝŐůŝƚĂǌŽŶĞ ƚƌĞĂƚŵĞŶƚ ?
ĂůƚŚŽƵŐŚ ƚŚĞ ŵĂŐŶŝƚƵĚĞ ǀĂƌŝĞĚ ? ,ĞŶĐĞ  ?Wɴ ĂŶĚ WWZɶ ǁĞƌ  ƐǇŶĞƌŐŝƐƚŝĐ ŝŶ
ŝŶĐƌĞĂƐŝŶŐ  ? ? ?Ŭď W' ?ɲ ƉƌŽŵŽƚĞƌ ĂĐƚŝǀŝƚǇ ŝŶ Ăůů ƚŚĞƚŚƌĞĞ ĐĞůů ƚǇƉĞƐ ĂŶĚ ƚŚŝƐ
stimulatory effect was enhanced by the addition of rosiglitazone. However, the 
ǀĂƌŝŽƵƐ ŵĂŐŶŝƚƵĚĞ ŽĨ ƚŚĞ ƐƚŝŵƵůĂƚŽƌǇ ĞĨĨĞĐƚ ŽĨ  ?WɴŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ĂůŽŶĞ ŵŝŐŚƚ
ƌĞĨůĞĐƚĚŝĨĨĞƌĞŶƚWWZɶĞǆƉƌĞƐƐŝŽŶďĂĐŬŐƌŽƵŶĚƐŝŶĚŝĨĨĞƌĞŶƚĐĞůůƚǇƉĞƐ ? 
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 ? ? ? ? ?ĨĨĞĐƚƐŽĨ ?WɴĐŽ-ŽǀĞƌĞǆƉƌĞƐƐĞĚǁŝƚŚWZD ? ?ŽƌWWZɶŽŶƉ'> ?-
PPRE-TK and pGL3-CRE reporter vectors in 3T3-L1 in response to rosiglitazone 
and forskolin, respectively. 
It is well described that full length UCP1 aŶĚW' ?ɲƉƌŽŵŽƚĞƌďŽƚŚĐŽŶtain PPRE and 
several CRE response elements, which allow them to bind different transcription 
ĨĂĐƚŽƌƐƐƵĐŚĂƐWWZɶĂŶĚ ?Wɴ(Cannon and Nedergaard, 2004; Karamanlidis et al., 
2007) ?dŚĞƌĞƐƵůƚƐĚĞƐĐƌŝďĞĚĂďŽǀĞĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚ ?WɴŝŶĐƌĞĂƐĞĚƚƌĂŶƐĐƌŝƉƚŝŽŶ
activity of 3.1kb UCP1 promoter with or without co-overexpression of PRDM16 in 
ƌĞƐƉŽŶƐĞ ƚŽ ĨŽƌƐŬŽůŝŶĂŶĚ ƚŚĂƚ ?Wɴ ƵƉ-ƌĞŐƵůĂƚĞĚ  ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌĂĐƚŝǀŝƚǇ
when co-ŽǀĞƌĞǆƉƌĞƐƐĞĚǁŝƚŚWWZɶ ?dŽŝŶǀĞƐƚŝŐĂƚĞǁŚĞƚŚĞƌƚŚĞƐƚŝŵƵůĂƚŝŶŐĞĨĨĞĐƚƐŽĨ
 ?Wɴ ǁĞƌĞ ĚƵĞ ƚŽ ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶƐ ďĞƚǁĞĞŶ  ?Wɴ ĂŶĚ ƚŚĞ ĐŽƌƌĞƐƉŽŶĚŝŶŐ cis 
ĞůĞŵĞŶƚƐ  ?WWZ Žƌ Z ) ŽŶ ƚŚĞ hW ? ĂŶĚ W' ?ɲ ƉƌŽŵŽƚĞƌƐ ? ĂƌƚŝĨŝĐŝĂů ůƵĐŝĨĞƌĂƐĞ
reporter vectors driven either by repeated CRE (pGL3-CRE) or PPRE-TK (pGL3-PPRE-TK) 
was co-ƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚ ?Wɴ ?WZD ? ?Žƌ ?ĂŶĚWWZɶŝŶƚŽ ?d ?-L1 cells and treated 
with 10µM forskolin or/and 10µM Rosiglitazone. Data was analysed by three-way 
ANOVA. Results from the luciferase assays (Figure 5.10) demonstrate that the pGL3-
CRE reporter vector was highly induced by forskolin (P<0.001), but that 
overexpression with  ?Wɴ ?WZD ? ? ?WWZɶŽƌƚŚĞĐŽŵďŝŶĞĚŽǀĞƌĞǆƉƌĞƐƐŝŽŶǁere 
Figure 5.9 Effect of C/EBPɴ and PPARɶ overexpression on 2.6kb PGC1ɲ 
promoter. 
3T3-L1 preadipocytes, Cos7 kidney fibroblasts and HIB-1B preadipocytes were 
grown to 70-80% confluence and then transfected with 2.6PGC1ɲ pGL3-Luc vector 
ŝŶ ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ  ?Wɴ ĂŶĚ ?Žƌ WWZɶ overexpression as indicated in the 
graphs. 10µM rosiglitazone (Rosi) was given to the cells 24 hours post transfection 
and treated for 24 hours before luciferase assay was carried out.  Firefly luciferase 
activity was normalised to renilla luciferase activity and relative to the values from 
control cells without rosiglitazone treatment. Results are average values of 2 or 3 
independent replicate experiments performed in triplicate wells. Data was 
analysed by 4-way ANOVA. The interactions that are not listed in figure were 
insignificant (P>0.05).  
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unable to further alter the cAMP sensitivity of pGL3-CRE reporter vector.  
Rosiglitazone also elicited no further stimulating effect on CRE when combined with 
forskolin (Figure 5.10A). Three-way ANOVA indicated that there were significant 
interactions  ?WA? ? ? ? ? ? )between overexpression (vector) and drug treatments (Rosi or 
Fsk+Rosi) in stimulating pGL3-PPRE-TK reporter vector (Figure 5.10B). This reporter 
vector had no response to addition of rosiglitazone but combined addition of 
rosiglitazone and forskolin stimulated transcription. Overexpression with  ?Wɴ Žƌ
WWZɶ, but not PRDM16, also increased transcription from the pGL3-PPRE-TK 
reporter, with these effects being increased by addition of rosiglitazone and further 
increased by combined addition of rosiglitazone and forskolin. The greatest response 
of the pGL3-PPRE-TK vector was observed in response to the combined 
overexpression with  ?Wɴand WWZɶin the presence of rosiglitazone and forskolin 
(Figure 5.10B).  These results were consistent with the findings from cells transfected 
ǁŝƚŚ ? ? ?W' ?ɲ pGL3-Luc vector ĂŶĚ ?WɴŽƌ ?ĂŶĚWWZɶ ?&ŝŐƵƌĞ ? ? ? )except that in 
ƚŚĞƉƌĞƐĞŶĐĞŽĨƌŽƐŝŐůŝƚĂǌŽŶĞ ? ?WɴĂŶĚWWZɶŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽŶ their own were 
able to up-regulate the pGL3-PPRE-TK activity and an additive effect was observed 
when both genes co-overexpressed (Figure 5.10B).  
The results from the pGL3-PPRE-TK luciferase reporter experiments suggest that the 
stimulatory ĞĨĨĞĐƚ ŽĨ  ?Wɴ ĂŶĚ WWZɶ overexpression on transcription from the 
 ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌŵŝŐŚƚďĞĚƵĞƚŽƚŚĞŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚthe PPRE located in the 
promoter. However, the results in Figure 5.10A seemed not to support the hypothesis 
ƚŚĂƚ ?WɴĂŶĚWZD ? ?ƐƚŝŵƵůĂƚĞĚhW ?ƉƌŽŵŽƚĞƌĂĐƚŝǀŝƚǇ ŚƌŽƵŐŚŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚ
CRE, since pGL3-ZŚĂĚŶŽƌĞƐƉŽŶƐĞƚŽ ?WɴŽƌ ?ĂŶĚWZD ? ?ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ? 
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dŽ ĨƵƌƚŚĞƌ ŝŶǀĞƐƚŝŐĂƚĞ ǁŚĞƚŚĞƌ ƚŚĞ ƐƚŝŵƵůĂƚŽƌǇ ĞĨĨĞĐƚ ŽĨ  ?Wɴ-WWZɶ ĐŽ-
ŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽŶ ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌǁĂƐƚŚƌŽƵŐŚƚĞZŽƌWWZcis elements 
ŽŶƚŚĞƉƌŽŵŽƚĞƌ ?ƚŚĞŵƵƚĂƚĞĚ ? ? ?W' ?ɲpGL3-Luc ƌĞƉŽƌƚĞƌǀĞĐƚŽƌƐ ?ȴZŽƌȴWWZ, 
Figure 5.11A) were transfected into 3T3-L1 preadipocytes with co-overexpression of 
 ?WɴĂŶĚWWZɶĂƐĚĞƐĐƌŝďĞĚ ŝŶ  ? ? ? ? ? ?  ? ?A?DƌŽƐŝŐůŝƚĂǌŶĞǁ ƐĂĚĚĞĚ to the cells 
and treated for 24 hours respectively before the cells were collected for luciferase 
assay (Figure 5.11B). Three-way ANOVA indicated that the synergistic stimulatory 
ĞĨĨĞĐƚŽĨWWZɶco-overexpression and Rosi treatment ŽŶƚŚĞ ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌ
was significantly affected (P=0.040) when the CRE or PPRE was mutated in the 
promoter. Consistent with the data shown in Figure 5.7B, co-overexpression of 
 ?Wɴ ĂŶĚ WWZɶ ƐŝŐŶŝĨŝĐĂŶƚůǇ ŝŶĐƌĞĂƐĞd ƚŚĞ  ? ? ?Ŭď W' ?ɲ ƉƌŽŵŽƚĞƌ  ?ďůƵĞ ďĂƌƐ )
activity in 3T3-> ?ĐĞůůƐĐŽŵƉĂƌĞĚǁŝƚŚƚŚĂƚ ŝŶƚŚĞĐĞůůƐŽǀĞƌĞǆƉƌĞƐƐŝŶŐ ?WɴĂůŽŶĞ
and rosiglitazone treatment further increased this stimulating effect. The mutation in 
Figure 5.10 The effect of C/EBPɴ overexpression on CRE and PPRE elements in 
3T3-L1 preadipocytes. 
(A) 3T3-L1 preaidpocytes were grown to 70-80% confluence when transfected with 
pGL3-CRE vector in the presence of overexpression of C/EBPɴ, PRDM16 or/and 
PPARɶ. Cells were treated with 10µM forskolin (Fsk) for 12 hours or the 
combination of 10µM rosiglitazone (Rosi) and 10µM Fsk as indicated before 
luciferase assay was carried out 48 hours post transfection. (B) 3T3-L1 
preadipocytes were transfected with pGL3-PPRE-TK reporter vector together with 
the overexpression of C/EBPɴ, PRDM16 or/and PPARɶ. Cells were treated with 
10µM Rosi or the combination of 10µM Rosi and 10µM Fsk before measuring the 
luciferase activity 48 hours post transfection. Firefly luciferase activity was 
normalised to the renilla luciferase activity and relative to the values from cells 
transfected with only reporter vector and treated with DMSO. Results represent 
mean ± S.E.M. of independent duplicate experiments performed in triplicate wells. 
Data was analysed by three-way ANOVA: (A) P>0.05 for vector×Fsk and 
vector×FskRosi, P= 0.062 for vector, P<0.001 for Fsk and FskRosi; (B) PA?0.001 for 
vector×Rosi and vector×FskRosi.  
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CRE (red bars) markedly attenuated ƚŚĞ ƐƚŝŵƵůĂƚŝŶŐ ĞĨĨĞĐƚ ŽĨ  ?Wɴ-WWZɶ ĐŽ-
ŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽŶƚŚĞ ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌĂŶĚƌŽƐŝŐůŝƚĂǌŽŶĞƚƌĞĂƚŵĞŶƚĐŽƵůĚŶŽƚ
rescue the attenuation. The mutation in PPRE (green bars) also reduced the 
stimulating effect of the co-overexpression even further and completely blocked the 
response to rosiglitazone, resulting in a remarkable decrease in luciferase activity 
ĐŽŵƉĂƌĞĚ ƚŽ ƚŚĂƚ ŝŶ ƚŚĞ ĐĞůůƐ ŽǀĞƌĞǆƉƌĞƐƐŝŶŐ ďŽƚŚ  ?Wɴ ĂŶĚ WWZɶ ĂŶĚ ƚƌĞĂƚĞĚ
with rosiglitazone. These data suggested that both CRE and PPRE were indispensable 
ĨŽƌ  ?Wɴ ĂŶĚ WWZɶ ĐŽ-overexpression to maximally ƐƚŝŵƵůĂƚĞ  ? ? ?Ŭď W' ?ɲ
promoter activity in response to rosiglitazone in 3T3-L1 preadipocytes. 
 
 
  
178 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 C/EBPɴ and PPARɶ co-overexpression increased 2.6kb PGC1ɲ 
promoter activity via CRE and PPRE elements on the promoter. 
(A) Sequences of PPRE and CRE in the original and mutated (A?CRE or A?PPRE) 
2.6PGC1ɲ pGL3-Luc vectors. The underlined sequences are the two close PPREs in 
(-2033/-2061) region and the mutations are in red. The bold italic sequence is the 
CRE in (-129/-146) region and this whole region was deleted in A?CRE vector. (B) 
3T3-L1 preadipocytes were grown to 70-80% confluence and then transfected with 
the original or the CRE or PPRE mutated 2.6PGC1ɲ pGL3-Luc vector in the presence 
ŽĨ  ?Wɴ ĂŶĚ ?Žƌ WWZɶ overexpression as indicated in the graphs. 10µM 
rosiglitazone (Rosi) was given to the cells 24 hours post transfection and treated for 
24 hours before luciferase assay was carried out.  Firefly luciferase activity was 
normalised to renilla luciferase activity and relative to the values from cells 
overexpressing C/EBPɴ alone without rosiglitazone treatment. Results are mean ± 
S.E.M. of 2 or 3 independent replicate experiments performed in triplicate wells. 
Data was analysed by three-way ANOVA: P=0.040 for Rosi×PPARɶA?promoter.  
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5.4 DISCUSSION  
According to Kajimura et al, C/EBPɴ and PRDM16 form a complex which switches 
myoblastic progenitors towards the brown adipogenic lineage by stimulating the 
transcription of a series of brown adipogenic genes. They also demonstrated that the 
co-overexpression of C/EBPɴ and PRDM16 increases PGC1ɲ promoter activity in 
murine immortalized brown preadipocyte cell line (Kajimura et al., 2009). However, in 
the present study, when C/EBPɴ and PRDM16 were co-overexpressed in 3T3-L1 
preadipocytes, they were not able to significantly stimulate the full length PGC1ɲ 
promoter (Figure 5.5B) although the co-overexpression successfully activated 
transcription from the 3.1kb UCP1 promoter (Figure 5.5A). The different result on 
PGC1ɲ ƉƌŽŵŽƚĞƌĨƌŽŵ<ĂũŝŵƵƌĂ ?ƐǁŽƌk might have reflected the intrinsic difference 
between the brown and white preadipocytes, indicating there might be some 
repressive factors in the 3T3-L1 white preadipocytes inhibiting the formation of 
C/EBPɴ-PRDM16 complex or the interaction between the complex and the PGC1ɲ 
promoter. In fact, some (co)repressors, such as RIP140 and pRb, are more abundant 
in white than in brown preadipocytes, and could potentially inhibit the activation of 
PGC1ɲ transcription or its activity in co-activating PPARɶ (Cavailles et al., 1995; 
Hallberg et al., 2008; Leonardsson et al., 2004; Scime et al., 2005). The promoters of 
brown fat-selective genes might also be more repressively modified by chromatin 
remodelling in white compared with brown (pre)adipocytes. Studies by Shore and 
colleagues demonstrated that one of the essential CREs in the enhancer of the UCP1 
promoter contains a CpG dinucleotide which has a higher methylation state in 
differentiated 3T3-L1 cells compared to HIB-1B cells.  This study also revealed that a 
cold environment increases the association of silencing DiMethH3K9 histone 
modification on the UCP1 enhancer in white adipose tissue, and the appearance of 
the active TriMethH3K4 histone mark at the UCP1 promoter in brown adipose tissue 
(Shore et al., 2010). Since the pGL3-CRE reporter vector is induced to the same extent 
by forskolin administration in 3T3-L1 and HIB-1B cells (Karamanlidis et al., 2007), the 
CREs themselves do not discriminate between the different cell types in cAMP 
sensitivity. It is more probable that the lower sensitivity to noradrenaline in 3T3-L1 
cells results from the more repressive pattern of chromatin remodelling on the 
promoters of specific thermogenic genes.  
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Despite the lack of activation in PGC1ɲ transcription, co-overexpression of C/EBPɴ 
and PRDM16 still increased the transcriptional activity of UCP1 promoter (Figure 
5.5A), implying a PGC1ɲ-independent pathway of activating UCP1 transcription, 
which has not been reported in literature to date. C/EBPɴ overexpression alone 
stimulated the 3.1kb UCP1 promoter activity in response to forskolin (Figure 5.5A), 
but when rosiglitazone was added to the system, there was no further activation in 
UCP1 transcription (Figure 5.7A), indicating UCP1 expression was regulated by C/EBPɴ 
through a cAMP-PKA pathway and not a PPARɶ mediated pathway. The results were 
predictable as C/EBPɴ has been reported to bind to the CRE on the proximal PGC1ɲ 
promoter to facilitate PGC1ɲ transcription in 3T3-L1 cells (Karamanlidis et al., 2007) 
and the UCP1 promoter has four characterised CREs (Cannon and Nedergaard, 2004) 
which could  possibly bind C/EBPɴ and activate UCP1 transcription through a similar 
mechanism. However, C/EBPɴ ŽǀĞrexpression with or without PRDM16 failed to 
increase the activity of the artificial promoter vector pGL3-CRE in the presence or 
absence of forskolin (Figure 5.10A), which contradicts this speculation. It is possible 
that the pGL3-CRE was so sensitive to cAMP that forskolin treatment alone was able 
to maximally stimulate transcription from the pGL3-CRE so that no other factors 
could increase it any further. It would be more helpful if the 3.1kb UCP1 promoter 
with mutated CRE luciferase reporter vector were constructed so that it could be 
ĐŽŶĨŝƌŵĞĚŝĨZǁĂƐŝŶĚŝƐƉĞŶƐŝďůĞĨŽƌ ?WɴďŝŶĚŝŶŐƚŽĂĐƚŝǀĂƚĞƚŚĞhW ?ƉƌŽŵŽƚĞƌ
ĂĐƚŝǀŝƚǇ ?KŶƚŚĞŽƚŚĞƌŚĂŶĚ ?ŐŝǀĞŶƚŚĂƚ ?WɴŽǀĞƌĞǆƉƌĞƐƐŝŽŶĂůŽŶĞŝŶĐƌĞĂƐĞĚƉ'> ?-
PPRE-TK activity (Figure 5.10B), it was tempting to speculate that the stimulating 
ĞĨĨĞĐƚŽĨ ?WɴŽŶhW ?ƉƌŽŵŽƚĞƌǁĂƐƚŚƌŽƵŐŚƚŚĞWWZĞůĞŵĞŶƚ ?ďƵƚƚŚŝƐĐĂŶŶŽƚ
ĞǆƉůĂŝŶƚŚĞƐǇŶĞƌŐŝƐƚŝĐĞĨĨĞĐƚŽĨ ?WɴĂŶĚWZD ? ? ŝŶƐƚŝŵƵůĂƚŝŶŐhW ?ƉƌŽŵŽƚĞƌ ?
as the co-overexpression failed to synergistically increase pGL3-PPRE-TK activity in 
3T3-L1 cells. The UCP1 promoter also contains a CCAAT box which can be 
transactivated by  ?Wɴ(Cannon and Nedergaard, 2004; Yoshitomi et al., 1999) so it 
is  ƉŽƐƐŝďůĞ ƚŚĂƚ ƚŚĞƌĞ ĂƌĞ ŽƚŚĞƌ ƐŝƚĞƐ ŽŶ hW ? ƉƌŽŵŽƚĞƌǁŚĞƌĞ  ?Wɴ Žƌ ?ĂŶĚ
PRDM16 bind and activate the transcription of UCP1, but more investigation such as 
chromatin immunoprecipitation (ChIP) assays need to be performed on the UCP1 
promoter in 3T3-L1 cells to test the possibility.  
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The work on pGL3-PPRE-TK vector also demonstrated clearly that the PPRE element 
responds not only to the PPARɶ ligand rosiglitazone but also to cAMP induced by 
forskolin treatment (Figure 5.10B), implying cross-talk between the cAMP-PKA and 
PPARɶ ligand mediated signalling pathways in regulating UCP1 and PGC1ɲ 
transcription. Although ŶŽƌĂĚƌĞŶĂůŝŶĞ ŚĂƐ ďĞĞŶ ƌĞƉŽƌƚĞĚ ƚŽ ĚĞĐƌĞĂƐĞ WWZɶ ?
expression in brown adipocytes (Lindgren et al., 2004), the basal adrenergic tone has 
been found necessary for maximal stimulation of rat BAT UCP1 expression by chronic 
WWZɶ ĂĐƚŝǀĂƚŝŽŶ (Festuccia et al., 2010). These findings were supported by the 
observation that UCP1 mRNA level was up-regulated by both acute forskolin and 
chronic rosiglitazone treatments in differentiated 3T3-L1 adipocytes (Figure 5.1A). 
Surprisingly, C/EBPɴ overexpression alone in 3T3-L1 preadipocytes did not increase 
PGC1ɲ ƚƌĂŶƐĐƌŝƉƚŝŽŶĞǀĞŶǁŝƚŚ ĨŽƌƐŬŽůŝŶ ƚreatment, either by reporter assay (Figure 
5.7B) or mRNA measurement (Figure 5.8D), contradicting the work of Karamanlidis et 
al who demonstrated that  ?WɴŽǀĞƌĞǆƉƌĞƐƐŝŽŶŝŶĐƌĞĂƐĞs proximal (264bp) W' ?ɲ
promoter activity as well as its sensitivity to cAMP, and up-ƌĞŐƵůĂƚĞƐW' ?ɲŵZE
level in response to forskolin in confluent 3T3-L1 preadipocytes (Karamanlidis et al., 
2007) ? tŽƌŬ ĨƌŽŵ tĂŶŐ ĂŶĚ ĐŽůůĞĂŐƵĞƐ ĂůƐŽ ŝĚĞŶƚŝĨŝĞĚ  ?Wɴ ĂƐ Ă ĚŝƌĞĐƚ
transcriptional ĂĐƚŝǀĂƚŽƌŽĨW' ?ɲ ŝŶ ůŝǀĞƌ ďǇďŝŶĚŝŶŐ ƚŽ ?WĂŶĚZ ƐŝƚĞƐ ŝŶ ƚŚĞ
W' ?ɲƉƌŽŵŽƚĞƌ(Wang et al., 2008a). It is difficult to explain the completely different 
results, as all the methods involved in this experimental work, such as transfection, 
luciferase assay, RNA extraction and real time PCR were identical with those used in 
the literature and the materials such as cells, plasmids and drugs were also the same 
as ƚŚĞ ŽŶĞƐ ƵƐĞĚ ŝŶ <ĂƌĂŵĂŶůŝĚŝ ?Ɛ ǁŽƌŬ ? ,ŽǁĞǀĞƌ ? ŝƚ ǁĂƐ ĂůŽ ƉŽƐƐŝďůĞ ƚŚĂƚ ƚŚĞƌĞ
might be some unnoticed minor operating details that have led to the final difference.  
WŚĞŶ  ?Wɴ ǁĂƐ ŽǀĞƌĞǆƉƌessed in HIB-1B or Cos7 cells, it increased the 
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŽĨ ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌ ?ĞŝƚŚ ƌǁŝƚŚŽƌǁŝƚŚŽƵƚƌŽƐŝŐůŝƚĂǌŽŶĞ
(Figure 5.9). The different results from that in 3T3-L1 cells might indicate that there 
were some specific repressive factors in 3T3-> ? ĐĞůůƐ ƚŚĂƚ ƉƌĞǀĞŶƚĞĚ  ?Wɴ ĨƌŽŵ
ĂĐƚŝǀĂƚŝŶŐ ƚŚĞ W' ?ɲ ƉƌŽŵŽƚĞƌ ? Žƌ ƚŚĂƚ ƚŚĞƌĞ ǁĞƌĞ ƐŽŵĞ ĞǆƚƌĂ ĂĐƚŝǀĂƚŝŶŐ ĨĂĐƚŽƌƐ 
 ?ƐƵĐŚĂƐŵŽƌĞWWZɶĞǆƉƌĞƐƐŝŽŶ ) in HIB- ?ĂŶĚŽƐ ?ĐĞůůƐƚŚĂƚĨĂĐŝůŝƚĂƚĞĚ ?WɴƚŽ
stimulate the transcriptional activity of PG ?ɲ ?ƐŽƐ ? ŝƐĂŶĨƌŝĐĂŶ'ƌĞĞŶDŽŶŬĞǇ
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kidney fibroblast-like cell line which highly resembles fibroblasts in humans (Gluzman, 
1981), it has no  potential of adipocyte lineage and is often considered having simple 
cellular context which facilitates investigation of the regulation of gene expression 
(Kajimura et al., 2008; Shipley and Waxman, 2004; Steffensen et al., 2002). Therefore 
it is less likely that Cos 7 cells contain factors favouring the expression of the brown 
ĂĚŝƉŽŐĞŶŝĐŐĞŶĞW' ?ɲ, as might be expected in HIB-1B preadipocytes. The failure of 
 ?WɴŽǀĞƌĞǆƉƌĞƐƐŝŽŶĂůŽŶĞ ŝŶĂĐƚŝǀĂƚŝŶŐW' ?ɲƉƌŽŵŽƚĞƌ ŝŶ  ?d ?-L1 preadipoyctes 
was possibly because of some specific repressors or repressive chromatin 
modifications in 3T3-> ? ƚŚĂƚ ŝŶŚŝďŝƚĞĚ ƚŚĞ ƉƌŽƉŽƐĞĚĂĐƚŝǀĂƚŝŽŶŽĨ ?WɴŽŶW' ?ɲ
promoter. 
The transcriptional activity of the W' ?ɲƉƌŽŵŽƚĞƌǁĂƐƐŝŐŶŝĨŝĐĂŶƚůǇŝŶĐƌĞĂƐĞĚŝŶ ?d ?-
L1 cells ǁŚĞŶ WWZɶ ǁĂƐ ĐŽ-ŽǀĞƌĞǆƉƌĞƐƐĞĚ ǁŝƚŚ  ?Wɴ ?suggesting that a lack of 
WWZɶ may limit the response to  ?Wɴor that WWZɶ ǁĂƐ ĂďůĞ ƚŽ ƌĞŵŽǀĞ Žƌ
overcome the repression caused by unknown factor(s) (Figure 5.7B, Figure 5.9). The 
first proposal is supported by the observation that the ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůŽĨWWZɶ ŝƐ
higher in HIB-1B than in 3T3-L1 (pre)adipocytes (Petrovic et al., 2009).  Interestingly, 
the pGL3-PPRE-TK vector was not sensitive to rosiglitazone treatment (Figure 5.10B) 
in 3T3-L1 preadipocytes but rosiglitazone treatment stimulated transcription of this 
vector in HIB-1B cells (unpublished data from H.Y. Chen in our lab). Overexpression of 
 ?Wɴor WWZɶ ĐůĞĂƌůǇ ŝŶĐƌĞĂƐĞĚ transcription from the pGL3-PPRE-TK vector in 
3T3-L1 cells in response to rosiglitazone (Figure 5.10B), which emphasized again the 
ŝŵƉŽƌƚĂŶĐĞŽĨWWZɶŝŶƌĞůĞĂƐŝŶŐƚŚĞƌĞƉƌĞƐƐŝǀĞƐƚĂƚĞŽĨƚŚĞƌŵŽŐĞŶŝĐŐĞŶĞƉƌŽŵŽƚĞƌƐ
in 3T3-L1 preadipocytes. The largest transcriptional activity from the pGL3-PPRE-TK 
vector in 3T3-L1 cells was when  ?Wɴ and WWZɶ were co-overexpressed, in the 
presence of both rosiglitazone and forskolin, emphasising the importance of 
transactivation of the PPRE by combined activation of the PPAR-ligand and cAMP-PKA 
signalling pathways. /ŶƚĞƌĞƐƚŝŶŐůǇ ? ŝŶ Ăůů ƚŚĞ ƚŚƌĞĞ ĐĞůů ƚǇƉĞƐ ? WWZɶ ŽǀĞƌ ǆƉƌĞƐƐŝŽŶ
alone was not able to up-ƌĞŐƵůĂƚĞƚŚĞW' ?ɲƉƌŽŵŽƚĞƌĂĐƚŝǀŝƚǇ ?ĞǀĞŶŝŶƚŚĞƉƌĞƐĞŶĐĞ
ŽĨ ƌŽƐŝŐůŝƚĂǌŽŶĞ ? ŝŶĚŝĐĂƚŝŶŐ ƚŚĂƚ  ?Wɴ ǁĂƐ ŝŶĚŝƐƉĞŶƐŝďůĞ ŝŶ ĂĐƚŝǀĂƚŝŶŐ W' ?ɲand 
UCP1 promoters.  
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'ŝǀĞŶ ƚŚĂƚ ƚŚĞŵƵƚĂƚŝŽŶ ŽĨĞŝƚŚĞƌZŽƌWWZ ĞůĞŵĞŶƚƐ ŝŶ  ? ? ?ŬďW' ?ɲƉƌŽŵŽƚĞƌ
significĂŶƚůǇĚĂŵƉĞŶĞĚƚŚĞƐƚŝŵƵůĂƚŝŶŐĞĨĨĞĐƚŽĨ ?Wɴ-WWZɶĐŽ-overexpression in 
response to rosiglitazone (Figure 5.11), both CRE and PPRE were indispensable in the 
stimulating mechanism. It is understandable that PPRE is important as it is the site 
ƚŚĂƚ WWZɶ directly binds to (Hondares et al., 2006), and it is consistent with the 
results from pGL3-PPRE-TK ƌĞƉŽƌƚĞƌĂƐƐĂǇ ƚŚĂƚ ?WɴĂŶĚWWZɶŚĂĚĂ ƐǇŶĞƌŐistic 
effect in up-regulating the luciferase activity in response to rosiglitazone (Figure 
5.10B). However, according to the results from pGL3-CRE reporter assay (Figure 
 ? ? ? ? ) ?  ?Wɴ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ? ĞŝƚŚĞƌ ĂůŽŶĞ Žƌ ǁŝƚŚ WWZɶ ? ĨĂŝůĞĚ ƚŽ ŝŶĐƌĞĂƐĞ
luciferase activity in the presence of forskolin and rosiglitazone, suggesting that 
 ?WɴŽƌWWZɶĚŽŶŽƚƌĞƋƵŝƌĞƚŚĞZƚŽĂĐƚŝǀĂƚĞƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶ ?ĐŽŶƚƌĂĚŝĐƚŝŶŐ
the conclusions from Karamanlidis and colleagues (Karamanlidis et al., 2007). It is 
possible that the full length (2.6kb) promoter might act differently to the proximal 
(264bp) ƉƌŽŵŽƚĞƌ ŽĨ W' ?ɲwhich ǁĂƐ ŝŶǀĞƐƚŝŐĂƚĞĚ ŝŶ <ĂƌĂŵĂŶůŝĚŝ ?Ɛ ǁŽƌŬ ?Further 
studies using ChIP and Electrophoretic Mobility Shift Assay (EMSA) are needed to 
ŝŶǀĞƐƚŝŐĂƚĞ ǁŚĞƌĞ ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ ƚŚĞ ĨƵůů ůĞŶŐƚŚ W' ?ɲ ƉƌŽŵŽƚĞƌ ĂŶĚ
C/EBPɴ ?WWZɶis localized. 
The level of  ?WɴŵZEŝŶĚŝĨĨĞƌĞŶƚŝĂƚĞĚ ?d ?-L1 adipocytes was significantly higher 
than in the preadipocytes at confluence, was further increased by forskolin treatment, 
but had no response to rosiglitazone (Figure 5.1C). This suggests that although in 
undifferentiated 3T3-> ? ƉƌĞĂĚŝƉŽĐǇƚĞƐ  ?Wɴ ĞǆƉƌĞƐƐŝŽŶ ǁĂƐ ŶŽƚ ƐĞŶƐŝƚŝǀĞ ƚŽ
forskolin (Figure 5.6A), in differentiated cells,  ?Wɴ ƚƌĂŶƐĐƌŝƉƚŝŽŶis regulated 
through cAMP-PKA pathway. The influence of adipogenic induction  and forskolin 
ƚƌĞĂƚŵĞŶƚŽŶ ?WɴŵZEŝŶ ?d ?-L1 cells has been previously measured (Lane et al., 
1999), ĂŶĚƚŚĞƌĞƐƵůƚƐĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚ ?WɴĞǆƉƌĞƐƐŝŽŶŝƐŝŶƐĞŶƐŝƚŝǀĞƚŽĐDWŝŶ
preadipocytes (Karamanlidis et al., 2007) but sensitively up-regulated by the 
differentiation inducers, of which IBMX has been shown ƚŽŝŶĚƵĐĞ ?WɴĞǆƉƌĞƐƐŝŽŶ
through cAMP activation (Tae et al., 1995). This high level expressioŶ ŽĨ  ?Wɴ
gradually disappeared afterwards when the inducers are removed from the medium 
(Lane et al., 1999). The experimental data in this chapter also agreed with the above 
literature (Figure 5.4A). In vivo ĞǆƉĞƌŝŵĞŶƚƐĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚ ?WɴŝƐŝŶĚƵĐŝďůĞďǇ
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ĐŽůĚ ƐƚƌĞƐƐ Žƌ ɴ-adrenergic administration in mouse interscapular white adipose 
tissue (iWAT) (Karamitri et al., 2009). Although  ?WɴĐould not be stimulated by the 
cAMP stimulus, forskolin, in confluent 3T3-L1 white preadipocytes in both this thesis 
(Figure 5.6A and 5.8A) and previous literature (Karamanlidis et al., 2007), the 
forskolin treatment in fully differentiated 3T3-L1 adipocytes significantly increased 
 ?Wɴ ĞǆƉƌĞƐƐŝŽŶ  ?&ŝŐƵƌĞ  ? ? ? ) ? ĐŽŶƐŝƐƚĞŶƚ ǁŝƚŚ ƚŚĞ in vivo results from Karamitri 
(Karamitri et al., 2009) ? dŽ ŝŶǀĞƐƚŝŐĂƚĞ ǁŚĞŶ ĂŶĚ ŚŽǁ ƚŚĞ  ?Wɴ ŐĞŶĞ ďĞĐŽŵĞƐ
ĐDW ƐĞŶƐŝƚŝǀĞ ? ƚŚĞ ƚŝŵĞ ĐŽƵƌƐĞ ŽĨ  ?Wɴ ĞǆƉƌĞƐƐŝŽŶ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ĨŽƌƐŬŽůŝŶ
treatment during 3T3-L1 differentiation process will be necessary for the future work.  
The transcriptional activity of the 3.1kb UCP1 promoter was significantly increased by 
co-overexpression of C/EBPɴ and PRDM16 in response to forskolin in 3T3-L1 
preadipocytes (Figure 5.5A), so theoretically the same co-overexpression should be 
able to increase UCP1 transcripts in 3T3-L1s treated with forskolin. However, when 
the mRNA level of UCP1 was measured in 3T3-L1 cells where C/EBPɴ and PRDM16 
were co-overexpressed in the presence of forskolin, it did not show any significant 
increase compared with that in the mock transfected cells (Figure 5.6C) and the PCR 
products gave very faint bands in agarose gel electrophoresis (Figure 5.6E), indicating 
that the template abundance of UCP1 gene was too low to amplify in 3T3-L1 
preadipocytes. Given that the co-overexpression was successful (Figure 5.6 A&B), it 
was confusing that UCP1 transcription was not up-regulated, which contradicted the 
previous work in our lab demonstrating that C/EBPɴ overexpression alone increased 
mRNA level of UCP1 in 3T3-L1 preadipocytes in response to forskolin (Karamanlidis et 
al., 2007). When checking the melting curves of UCP1 amplifying in Figure 5.6C, there 
was a single peak in each melting curve but most of the curves indicated there was 
extremely low amplification in the well (data not shown). As the primer sequences 
and cycling parameters were exactly the same as previous work carried out by 
Karamanlidis and colleagues, the very low level of amplification was probably due to 
primer dimers from the templates. Interestingly, the melting curves of UCP1 
amplifying from 3T3-L1 (pre)adipocytes without transfection (Figure 5.1A) had single 
peak corresponding to the expected target and the curves showed an acceptable 
level of amplification (data not shown), which demonstrated that the methods of RNA 
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extraction and cDNA synthesis used in the experimental work were not the reason for 
low amplification observed in the above experiments. The main difference between 
the experiments in Figure 5.1 and Figure 5.6 was that in the latter experiments, cells 
were transiently transfected, while in the former experiment cells were not 
transfected at all. It seems that the transfection process may have interfered with the 
template quality or the endogenous gene expression in the 3T3-L1 preadipocytes, 
which led to the low amplification during qRT-PCR for UCP1 gene. IŶ <ĂƌĂŵĂŶůŝĚŝƐ ?
work UCP1 was also measured in transfected 3T3-L1 cells, so in this case the different 
results might be due to different sensitivity of various light cyclers used in the 
experiments. However, more experiments are needed to confirm either of the above 
speculations.  
RIP140 transcription was dramatically up-regulated during differentiation of 3T3-L1 
adipocytes and both acute forskolin and chronic rosiglitazone treatments 
synergistically reduced its transcription (Figure 5.1E). Interestingly, the response 
pattern of RIP140 to forskolin and rosiglitazone treatments was opposite to that of 
UCP1 which was up-regulated by both drugs (Figure 5.1A). Given that RIP140 
represses UCP1 transcription in adipocytes (Kiskinis et al., 2007), the opposite 
responding patterns might suggest RIP140 has multiple inhibitory roles in different 
signalling pathways regulating UCP1 expression. RIP140 plays essential roles in both 
DNA and histone methylation to maintain UCP1 gene repression (Kiskinis et al., 2007). 
RIP140 has also been reported to inhibit the ɴ-adrenergic receptor mediated, cAMP 
dependent UCP1 gene expression, by recruiting the inhibitory transcription factor 
LXRɲ to an LXRɲ binding site that overlaps with the PPARɶ/PGC1ɲ response element 
(PPRE) on the UCP1 promoter, resulting in the dismissal of PPARɶ and suppression of 
UCP1 transcription (Wang et al., 2008b). Interestingly, in differentiated HIB-1B cells, 
forskolin treatment significantly increases the binding affinity of RIP140 to UCP1 
enhancer, which enhances the repressive effect (Wang et al., 2008b), but actual UCP1 
transcription is still up-regulated in this circumstance (Karamitri et al., 2009). The 
seemingly conflicting results might reflect a likely regulatory mechanism that works 
through balancing the competing repressive and activating factors by reinforcing both 
binding affinity to the target promoter but differentially regulating the expression 
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abundance of different regulators, as shown in Figure 5.1E where RIP140 
transcription was reduced by forskolin treatment. The speculated mechanism might 
ƉůĂǇĂƐĂ “ďƌĂŬĞ ?ŝŶƌĞŐƵůĂƚŝŶŐƚŚĞƌŽďƵƐƚĞǆƉƌĞƐƐŝŽŶŽĨhW ?ŝŶĚŝĨĨĞƌĞŶƚŝĂƚĞĚ,/-1B 
cells to restrain the expression within a reasonable range, but this speculation will 
need testing by more studies. RIP140 is an essential co-repressor in regulating UCP1 
ĞǆƉƌĞƐƐŝŽŶ ? ďƵƚ ŝƚ ŚĂƐ ŶŽƚ ƐŚŽǁŶ ĂŶǇ ŝŶƚĞƌĂĐƚŝŽŶ ǁŝƚŚ  ?Wɴ ĞŝƚŚĞƌ ŝŶ ƚŚĞ
experimental work presented here or any previous literature.  
ZŽƐŝŐůŝƚĂǌŽŶĞ ďĞůŽŶŐƐ ƚŽ ƚŚĞ ƚŚŝĂǌŽůŝĚŝŶĞĚŝŽŶĞ  ?d ) ĐůĂƐƐ ŽĨ WWZɶ ĂŐŽŶŝƐƚƐ ĂŶĚ ŝƚ
ďŝŶĚƐ ƚŽ WWZɶ ǁŝƚŚ ŚŝŐŚ ĂĨĨŝŶŝƚǇ ƚŽ ĂĐƚŝǀĂƚĞ ƚŚĞ transcriptional function of the 
protein (Kameda et al., 2000). In the work presented in this chapter, treatment with 
ƌŽƐŝŐůŝƚĂǌŽŶĞ ƐŝŐŶŝĨŝĐĂŶƚůǇ ĚĞĐƌĞĂƐĞĚ WWZɶ ŵZE ůĞǀĞů ŝŶ ĚŝĨĨĞƌĞŶƚŝĂƚĞĚ  ?d ?-L1 
adipocytes (Figure 5.1D). As early as 1998, this rosiglitazone dependent down-
regulation of PPARɶ ŝŶ  ?d ?-L1 adipocytes was observed and reported but no clear 
mechanism was suggested to explain the unexpected decrease (Rosenbaum and 
Greenberg, 1998). In 1999, retinoic acid isomers and PPAR agonists, specific for either 
PPARɲ or PPARɶ, were found to oppositely regulate each PPAR subtype. For example,  
PPARɶ agonists up-regulated PPARɲ but down-regulate PPARɶ expression in brown 
adipocytes which was argued to represent a regulatory mechanism responsible for 
the specific physiological roles for PPARɲ and PPARɶ in controlling brown fat 
differentiation and thermogenic activity (Valmaseda et al., 1999). This down-
regulation was then confirmed by Hauser and colleagues who reported that PPARɶ 
protein levels are significantly reduced in adipocytes and fibroblasts in response to 
TZD ligands and further demonstrated that the degradation of PPARɶ protein 
correlates well with the ability of ligands to activate this receptor. Although ligand 
binding and activation increase the transcriptional function of PPARɶ, these same 
processes also induce ubiquitination and subsequent degradation of this receptor by 
the proteasome (Hauser et al., 2000). A number of later studies on adipocytes also 
confirmed the discovery (Petrovic et al., 2008; Petrovic et al., 2009). The rosiglitazone 
induced decrease in PPARɶ ĞǆƉƌĞƐƐŝŽŶ ǁĂƐ ŶŽƚ ŽŶůǇ observed in adipocytes and 
fibroblasts, but also in microglia where rosiglitazone reverses 1-methyl-4-phenyl-
1,2,3,6-ƚĞƚƌĂŚǇĚƌŽƉǇƌŝĚŝŶĞƉƌŽďĞŶĞĐŝĚ ?DWdWƉ )ŝŶĚƵĐĞĚWWZɶŽǀĞƌĞǆƉƌĞƐƐŝŽŶ(Carta 
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et al., 2011). The rosiglitazone dependent down-ƌĞŐƵůĂƚŝŽŶŽĨWWZɶŵZEƉƌĞƐĞŶƚĞĚ
in this chapter is highly consistent with the literature listed above. However, Su and 
colleagues reported that in murine mesenchymal stem cell line C3H10T1/2, PPARɶ 
expression is increased by the administration of rosiglitazone, demonstrated by 
Western blotting using a specific PPARɶ monoclonal antibody (Su et al., 1999). It is 
probable that different cell lines have different responses to rosiglitazone, but this 
possibility needs proving by more studies across varieties of cell lines.  
Chronic rosiglitazone treatment has been reported to accelerate and augment 
differentiation of brown adipocytes in primary culture as assessed by both cell 
morphology and gene expression (Petrovic et al., 2008). In this chapter, 1µM 
rosiglitazone treatment also seemed to accelerate the early stage of differentiation in 
3T3-L1 cell, as by DAY 5 lipid droplet accumulation in rosiglitazone treated cells was 
greater than the control cells. However, the difference was not apparent after DAY 7 
of differentiation and in the fully differentiated control cells there was more lipid 
accumulation than the rosiglitazone treated cells (Figure 5.3). These observations are 
consistent with previous literature reporting that rosiglitazone treatment in white 
adipocytes triggers a brown-like phenotype and decreases lipid accumulation 
(Petrovic et al., 2009). Although the fat-specific staining (Oil-Red-O staining) was not 
performed on the cells during early differentiation, time course of C/EBPɴ mRNA 
measurement (Figure 5.4A) reflected clearly the difference of control and 
rosiglitazone treated differentiation processes from the perspective of gene 
expression. As an early gene regulating the induction of adipogenesis, C/EBPɴ
expression in 3T3-L1 cells increased when the preadipocytes were induced to 
differentiate and achieved the highest level on DAY 2 of differentiation as expected 
(Karamanlidis et al., 2007). Rosiglitazone treatment significantly increased  ?Wɴ
expression above control level from DAY 1, implying that the early differentiation 
ƉƌŽĐĞƐƐǁĂƐĂĐĐĞůĞƌĂƚĞĚ ?dŚĞĚŝĨĨĞƌĞŶĐĞ ŝŶ ?WɴĞǆƉƌĞƐƐŝŽŶĂĐŚŝĞǀĞĚ a maximum 
on DAY 2 but disappeared after DAY3. C/EBPɴ is known to respond to cAMP signalling 
pathway (Karamanlidis et al., 2007; Staiger et al., 2009; Zhang et al., 2004b), so the 
early increase in expression may represent a response to IBMX which was increased 
by rosiglitazone. 
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The period when rosiglitazone significantly increased aP2 expression (DAY 2-6) 
roughly coincided with the period when rosiglitazone treated cells had larger 
amounts of lipid accumulation than the untreated cells (Figure 5.3), possibly 
reflecting that the addition of rosiglitazone increased the rate of differentiation in 
terms of lipid accumulation, but the cells rapidly regulate themselves back to normal 
status within two days. Surprisingly, PPARɶ expression during the period of increased 
lipid droplet accumulation and aP2 expression was reduced by rosiglitazone, even 
though aP2 has been reported to be a target for PPARɶ (Tontonoz et al., 1994b; 
Tontonoz et al., 1994c). These results could be explained by changes in PPARɶ protein 
levels, translocation to the nucleus, and post-translational activation by 
phosphorylation and transactivation activity, all of which were not measured in the 
present study. 
^ŝŵŝůĂƌƚŽƚŚĞĞǆƉƌĞƐƐŝŽŶƉĂƚƚĞƌŶŽĨ ?Wɴ ?ƚŚĞsignificantly higher expression of the 
adipogenic marker gene, WWZɶ during DAY3 to DAY 5, in the rosiglitazone treated 
cells, had disappeared after DAY 6. Also consistent with pattern of WWZɶĞǆƉƌĞƐƐŝŽŶ, 
the expression of aP2 was also significantly changed in the early stage of 
differentiation, i.e. remarkably up-regulated by rosiglitazone to its maximal 
expression level, by DAY 2, which was 2 days earlier than the control group. 
/ŶƚĞƌĞƐƚŝŶŐůǇ ? ƚŚĞ ƌŽƐŝŐůŝƚĂǌŽŶĞ ƐƚŝŵƵůĂƚĞĚ ĂW ? ĞǆƉƌĞƐƐŝŽŶ  “ƉĞĂŬ ? ĂůƐŽ ƐƚĂƌƚĞĚ ƚŽ
decrease from DAY 6, identical with the result from control cells. While the 
ĂĚŝƉŽŐĞŶŝĐ ŐĞŶĞƐ WWZɶ ĂŶĚ ĂW ? ĚĞŵŽŶƐƚƌĂƚĞĚ Ɛŝŵŝlar response to rosiglitazone 
treatment in terms of time course, the thermogenic gene UCP1 displayed a different 
pattern, which showed nearly no response to rosiglitazone in the early and middle 
stage of rosiglitazone and only began to be up-regulated by the treatment from DAY 9, 
which was relatively late in the differentiation process, indicating the thermogenic 
programme started up late in the rosiglitazone induced 3T3-L1 differentiation.  
These data were consistent with Vernochet and co-worŬĞƌƐ ?ǁŽƌŬ ?ŝŶǁŚŝĐŚ “ǀŝƐĐĞƌĂů
ǁŚŝƚĞ ? ŐĞŶĞƐ ĂƌĞ ĚŽǁŶ-ƌĞŐƵůĂƚĞĚ ǁŚŝůĞ  “ďƌŽǁŶ ? ŐĞŶĞƐ ĂƌĞ ŝŶĐƌĞĂƐĞĚ ŝŶ 3T3-L1 
ĂĚŝƉŽĐǇƚĞƐ ƚƌĞĂƚĞĚ ǁŝƚŚ ƚƌŽŐůŝƚĂǌŽŶĞ ? ĂŶŽƚŚĞƌ d WWZɶ ůŝŐĂŶĚ (Vernochet et al., 
2009). All the data indicated that chronic rosiglitazone treatment of 3T3-L1 
preadipocytes had multiple effects 1) to accelerate the early period of differentiation 
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(before DAY 5) but failed to have long-lasting effect on differentiation progress 
afterwards, 2) to reduce lipid accumulation in fully differentiated mature 3T3-L1 
adipocytes and 3) to stimulate the thermogenic gene expression programme in 
differentiated 3T3-L1 adipocytes.  
dŽƐƵŵŵĂƌŝǌĞ ?ƚŚĞĞǆƉĞƌŝŵĞŶƚĂůǁŽƌŬŝŶƚŚŝƐĐŚĂƉƚĞƌĨŽĐƵƐĞĚŽŶƚŚĞƌŽůĞŽĨ ?WɴŝŶ
regulating UCP1 transcription. Co-overexpression of C/EBWɴĂŶĚWZD ? ?ƐŝŐŶŝĨŝĐĂŶƚůǇ
increased the transcription activity from the full length UCP1 promoter in response to 
ĨŽƌƐŬŽůŝŶ ǁŝƚŚŽƵƚ ĂĐƚŝǀĂƚŝŶŐ ƚŚĞ ĨƵůů ůĞŶŐƚŚ W' ?ɲ ƉƌŽŵŽƚĞƌ ĂĐƚŝǀŝƚǇ ŝŶ  ?d ?-L1 cells. 
 ?Wɴ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ĂůŽŶĞ ǁĂƐ ĂďůĞ ƚŽ ƵƉ-regulate transcriptional activity of full 
ůĞŶŐƚŚW' ?ɲƉƌŽŵŽƚĞƌŝŶ,/-1B and Cos7 but not 3T3-> ?ĐĞůůƐ ?ďƵƚW' ?ɲƉƌŽŵŽƚĞƌ
activity in 3T3-> ? ĐĞůůƐ ǁĂƐ ŵĂƌŬĞĚůǇ ƐƚŝŵƵůĂƚĞĚ ǁŚĞŶ  ?Wɴ ĂŶĚ WWZɶ ǁĞƌĞ ĐŽ-
overexpressed with or without rosiglitazone. However, this stimulating effect 
ĚŝƐĂƉƉĞĂƌĞĚǁŚĞŶ ƚŚĞ Z ŽƌWWZĞůĞŵĞŶƚǁĂƐŵƵƚĂƚĞĚ ŝŶ ƚŚĞ ĨƵůů ůĞŶŐƚŚW' ?ɲ
ƉƌŽŵŽƚĞƌ ?ŵZEŵĞĂƐƵƌĞŵĞŶƚŽĨhW ?ĂŶĚW' ?ɲĨĂŝůĞĚƚŽĐŽŶĨŝƌŵƚŚĞĂďŽǀĞĚĂƚĂ
ĨƌŽŵ ƌĞƉŽƌƚĞƌĂƐƐĂǇĞǆƉĞƌŝŵĞŶƚƐĂƐ ƚŚĞ hW ?ĂŶĚW' ?ɲ ƚƌĂŶƐĐƌŝƉƚƐ ŝŶ transfected 
3T3-L1 preadipocytes were too low to pick up by the current qPCR protocol. The 
artificial promoter reporter pGL3-CRE was highly sensitive to forskolin in 3T3-L1 cells, 
but the luciferase activity from this reporter vector could not be increased by 
overexpression ŽĨ  ?Wɴ ? WZD ? ? ? WWZɶ Žƌ ĂŶǇ ĐŽŵďŝŶĂƚŝŽŶ ŽĨ ƚŚĞƐĞ ŐĞŶĞƐ ? KŶ
the contrary, the luciferase activity of the artificial promoter reporter pGL3-PPRE-TK 
could be synergistically up-ƌĞŐƵůĂƚĞĚďǇƚŚĞŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨ ?WɴĂŶĚWWZɶ ŝŶ
3T3-L1 cells and it showed sensitivity to both forskolin and rosiglitazone. Chronic 
rosiglitazone treatment in the differentiating 3T3-L1 cells increased the mRNA level of 
 ?Wɴ ďĞĨŽƌĞ z  ? ŽĨ ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ? ŝŶĐƌĞĂƐĞĚ ĂW ? ďƵƚ ĚĞĐƌĞĂƐĞĚ WWZɶ ŵZE
from DAY 2 to DAY 6, but all of the above gene expression changes in response to 
rosiglitazone returned to control levels (without rosiglitazone treatment) after DAY 6. 
In contrast, mRNA of UCP1 was not changed until DAY 9 of differentiation when it 
was increased by rosiglitazone treatment. Oil Red O-staining of fully differentiated 
3T3-L1 adipocytes on DAY 12 demonstrated that chronic rosiglitazone treatment 
severely reduced the lipid in the mature white adipocytes. 
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In conclusion, the reporter assay experiments demonstrated ƚŚĂƚ  ?Wɴ ĂŶĚ
PRDM16 co-ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŝŶĐƌĞĂƐĞĚ hW ? ƉƌŽŵŽƚĞƌ ƚƌĂŶƐĂĐƚŝǀŝƚǇ ŝŶ Ă W' ?ɲ
independent manner. Some unknown repressive factors (either genes or chromatin 
modifications) Žƌ ƚŚĞ ůĂĐŬ ŽĨ WWZɶ ĞǆƉƌĞƐƐŝŽŶ in 3T3-L1 preadipocytes prevented 
 ?Wɴ ĨƌŽŵĂĐƚŝǀĂƚŝŶŐW' ?ɲƉƌŽŵŽƚĞƌďƵƚƚŚĞƌĞƉƌĞƐƐŝŽŶĐŽƵůĚďĞƌĞŵŽǀĞĚďǇƚŚĞ
co-ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ WWZɶ ? ŽƚŚ Z ĂŶĚ WWZ ĞůĞŵĞŶƚƐ ǁĞƌĞ ŝŶĚŝƐƉĞŶƐĂďůĞ ĨŽƌ
 ?Wɴ-WWZɶĐŽ-overexpression to activate W' ?ɲƉƌŽŵŽƚĞƌŝŶ ?d ?-L1 although no 
direct evidence was foƵŶĚ ƚŚĂƚ  ?Wɴ Žƌ WWZɶ ďŽƵŶĚ ƚŽ Z ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ
forskolin or rosiglitazone. Rosiglitazone accelerated the early period of 3T3-L1 
differentiation reflected by the up-ƌĞŐƵůĂƚŝŽŶŽĨ ?WɴĂŶĚĂW ?ŵZEďĞĨŽƌĞz ?
of differentiation. The decrease in PPAZɶ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŝŶ response to rosiglitazone 
during this same period might be because ƚŚĞ ůŝŐĂŶĚ ƌŽƐŝŐůŝƚĂǌŽŶĞ ŝŶĐƌĞĂƐĞĚWWZɶ
ĂĐƚŝǀŝƚǇƐŽůĞƐƐĂŵŽƵŶƚŽĨWWZɶǁĂƐŶĞĞĚĞĚďǇƚŚĞĐĞůůƐƚĞŵƉŽƌĂƌŝůǇ, reflecting the 
negative feedback. Rosiglitazone up-regulated UCP1 mRNA in the late stage of 3T3-L1 
differentiation (from DAY 9) and finally significantly decreased the lipid accumulation 
in the mature 3T3-L1 adipocytes, suggesting the white preadipocytes differentiated to 
 “ďƌŽǁŶĞƌ ?ĂĚŝƉŽĐǇƚĞƐ ? 
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6 GENERAL DISCUSSION 
The factors controlling the transdifferentiation from white preadipocytes to brown 
adipocytes are one of the major focuses of current bioscience and medical research, 
since by understanding and controlling the signals and genes responsible for the 
transdifferentiation we could aid prevention and treatment of metabolic diseases 
such as obesity, diabetes and cardiovascular diseases. The general aim of the studies 
reported in this thesis was to further the understanding of the molecular mechanisms 
that are responsible for producing brown adipocyte phenotype during the white 
preadipocyte differentiation.  
The specific objective of this thesis was to investigate the roles of C/EBPɴ ?ƚŽŐĞƚŚĞƌ 
with other regulators like PRDM16, in stimulating brown adipocyte phenotypes 
including up-regulation of UCP1 in 3T3-L1 white preadipocytes. The original plan of 
investigation was to construct a stable transgenic 3T3-L1 cell line overexpressing 
doxycycline inducible C/EBPɴ and to investigate the effects of the exogenous C/EBPɴ
on chromatin remodelling pattern of UCP1 promoter during the 3T3-L1 
differentiation. Unfortunately, the lentiviral expression vectors constructed in this 
work failed to produce lentiviral particles with high titre because the designed insert 
was challenging the size limit of the lentiviral expression system we used (pLenti6/V5). 
The low titre lentiviral particles also failed to transduce 3T3-L1 cells as this cell line is 
especially difficult to transduce. Therefore in the absence of a successful lentiviral 
vector for overexpressing genes, transient overexpression was used to investigate the 
ŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶ ?WɴĂŶĚŽƚŚĞƌ ĨĂĐƚŽƌƐ ŝŶ ƌĞŐƵůĂƚŝŶŐ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶŽĨhW ?
gene in the 3T3-L1 cell line. The experiments suggested that C/EBPɴ ? ĐŽ-
overexpressed with PRDM16, stimulated UCP1 promoter transcription activity in the 
ƉƌĞƐĞŶĐĞ ŽĨ ĨŽƌƐŬŽůŝŶ ǁŝƚŚŽƵƚ ĂĐƚŝǀĂƚŝŶŐ ƚŚĞ ĨƵůů ůĞŶŐƚŚ W' ?ɲ ƉƌŽŵŽƚĞƌ ŝŶ  ?d ?-L1 
preadipocytes. It would be simplistic though to suggest ƚŚĂƚ  ?Wɴ ĐŽƵůĚ ŽŶůǇ
ĂĐƚŝǀĂƚĞhW ?ƚƌĂŶƐĐƌŝƉƚŝŽŶŝŶĂW' ?ɲŝŶĚĞƉĞŶĚĞŶƚŵĂŶŶĞƌ ?ƐŝŶĐĞƉƌĞǀŝŽƵƐůŝƚĞƌĂƚƵƌĞ
ĚĞŵŽŶƐƚƌĂƚĞĚ  ?Wɴ ďŝŶĚƐ ĂŶĚ ĂĐƚŝǀĂƚĞƐ ƚŚĞ ƉƌŽǆŝŵĂů ƉƌŽŵŽƚĞƌ ŽĨ W' ?ɲ ŝŶ
response to forskolin in 3T3-L1 (Karamanlidis et al., 2007). So other genes were co-
ŽǀĞƌĞǆƉƌĞƐƐĞĚ ǁŝƚŚ  ?Wɴ ƚŽ ĂĐƚŝǀĂƚĞ ƚŚĞ ĨƵůů ůĞŶŐƚŚ W' ?ɲ ƉƌŽŵŽƚĞƌ ĂŶĚ WWZɶ
was found to ĨĂĐŝůŝƚĂƚĞ ?WɴŝŶƵƉ-regulating the transcription activity of full length 
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W' ?ɲƉƌŽŵŽƚĞƌ ŝŶƚŚĞƉƌĞƐĞŶĐĞ ŽĨ ƌŽƐŝŐůŝƚĂǌŽŶĞ.  UCP1 promoter activity was also 
increased by the co-overexpression of PWZɶ and  ?Wɴ ŝŶƌĞƐƉŽŶƐĞƚŽ treatment 
with ƌŽƐŝůŐůŝƚĂǌŽŶĞĂŶĚĨŽƌƐŬŽůŝŶ ?dŚĞĚĂƚĂƐƵŐŐĞƐƚĞĚƚŚĂƚ ?WɴƉůĂǇĞĚĂŬĞǇƌŽůĞŝŶ
activating the UCP1 promoter in 3T3-> ?ƉƌĞĂĚŝƉŽĐǇƚĞƐŝŶďŽƚŚW' ?ɲĚĞƉĞŶĚĞŶƚĂŶĚ
independent manner. Rosiglitazone treatment appeared to be more important in the 
W' ?ɲĚĞƉĞŶĚĞŶƚŵĂŶŶĞƌ ?ƐŽŵŽƌĞĞǆƉĞƌŝŵĞŶƚƐĂďŽƵƚƚŚĞƌŽůĞŽĨƌŽƐŝŐůŝƚĂǌŽŶĞǁĞƌĞ
undertaken and the results revealed that rosiglitazone accelerated the early stage of 
3T3-L1 differentiation and promoted brown adipogenic phenotypes in fully 
differentiated 3T3-L1 adipocytes both in cell morphology and gene expression pattern.  
As the cloning work to construct the transgenic cell line was time consuming and no 
successful transgenic cell lines were produced, the time for the transient 
overexpression based experiments was limited and not many analytical methods 
were used. The results from reporter assays and quantitative RT-PCR still provided 
clues as to ŚŽǁ  ?Wɴ ? ƚŽŐĞƚŚĞƌ ǁŝƚŚ WZD ? ? ĂŶĚ WWZɶ ? ƌĞŐƵlated UCP1 
transcription in the presence of forskolin or/and rosiglitazone in the 3T3-L1 cell line 
and furthered the understanding of the relevant molecular mechanisms. The results 
ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ  ?Wɴ ƵƉ-regulated UCP1 expression in 3T3-L1 preadipocytes in 
W' ?ɲ ŝŶĚĞƉĞŶĚĞŶƚĂŶĚĚĞƉĞŶĚĞŶƚŵĂŶŶĞƌƐǁŚĞŶĐŽ-overexpressed with PRDM16 
ŽƌWWZɶ ?ƌĞƐƉĞĐƚŝǀĞůǇ ? 
6.1 SUMMARY OF PRINCIPAL CONCLUSIONS 
The main findings reported in this thesis are summarised below: 
1) The combination of reverse tetracycline-controlled transactivator element rtTA 
advance with either tetracycline response element TRE or TRE tight was selected as 
the ideal Tet on lentiviral expression vector backbone. The target C/EBPɴ and the 
control LucGFP gene were cloned into the backbones and transient transfection in 
3T3-L1 preadipocytes demonstrated that the basal expression level without induction 
was low and the expression was sensitively induced by doxycycline in a dose-
dependent manner. 
2) The combination of rtTA advance and TRE was selected for the ideal fat-specific 
lentiviral expression vector backbone. The truncated fat specific promoter short aP2 
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was used in the vector due to the size limit of lentiviral expression vectors. Transient 
transfection in 3T3-L1 cells with the fat-specific vector did not show good fat 
specificity, probably because the transient adipogenic conditions (co-overexpression 
of PPARɶ and C/EBPɴ, or treatment with rosiglitazone and forskolin) used in the 
experiments were not ideal for 3T3-L1 cells. The short aP2 driving Tet on lentiviral 
LucGFP expression vector was highly adipogenic and doxycycline inducible when 
transiently transfected into HIB-1B cells and treated with rosiglitazone and forskolin.  
3) The whole procedure of producing lentiviral particles with second generation 
packaging plasmid mix psPAX2, transducing target cell line 3T3-L1 and selecting for 
monoclonal transduced cells was successful, demonstrated by the data with positive 
LucRFP vector. However, the lentivirus produced from constructed constitutive 
LucGFP vector was poorly infectious even after being concentrated to high titer (10
5
 
TU/ml), probably due to the size of the designed vector challenging the limit of the 
lentivirus production system (5kb). 
4) The 3T3-L1 cell line is more difficult to transduce compared with HT1080 or 293FT 
cells, as evidenced by the observation that the LucRFP lentivirus infected 3T3-L1 cells 
less efficiently although at a higher Multiplicity of Infect (MOI), indicating that highly 
infectious lentiviral particles are especially critical for successfully transducing 3T3-L1 
cells. 
5) Co-overexpression of C/EBPɴ and PRDM16 increased transcriptional activity of the 
UCP1 promoter in 3T3-L1 preadipocytes in response to forskolin without activating 
PGC1ɲ transcription.  
6) C/EBPɴ overexpression alone activated the PGC1ɲ promoter in HIB-1B and Cos7 
cells but not in 3T3-L1 preadipocytes, indicating some 3T3-L1 specific repressive 
mechanisms.  Co-overexpression of PPARɶ with C/EBPɴ released the repressive effect 
in the presence of rosiglitazone and both CRE and PPRE elements were indispensible 
for PGC1ɲ promoter to be activated by the co-overexpression in 3T3-L1 cells.  
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7) C/EBPɴ and PPARɶ overexpression synergistically stimulated the artificial luciferase 
reporter vector pGL3-PPRE-TK in 3T3-L1 preadipocytes in response to rosiglitazone, 
and forskolin treatment.   
8) The artificial luciferase reporter vector pGL3-CRE was highly sensitive to forskolin 
but there was no further response to rosiglitazone in 3T3-L1. Overexpression of 
C/EBPɴ, PRDM16, PPARɶ individually or in any combinations failed to significantly 
increased the luciferase activity of pGL3-CRE in 3T3-L1 cells.  
9) Rosiglitazone accelerated the early period of 3T3-L1 differentiation assessed by the 
up-ƌĞŐƵůĂƚŝŽŶŽĨ ?WɴĂŶĚĂW ?ŵZEďĞĨŽƌĞz ?ŽĨĚŝĨĨĞƌ ŶƚŝĂƚŝŽŶ. The decrease 
in PPAZɶmRNA may not be important as rosiglitazone increases WWZɶĂĐƚŝǀŝƚǇƐŽless 
WWZɶ would be needed to stimulate differentiation.  
10) Rosiglitazone up-regulated UCP1 mRNA in the late stage of 3T3-L1 differentiation 
(from DAY 9) and significantly dampened lipid accumulation in the mature 3T3-L1 
ĂĚŝƉŽĐǇƚĞƐ ?ůĞĂĚŝŶŐƚŚĞǁŚŝƚĞƉƌĞĂĚŝƉŽĐǇƚĞƐĚŝĨĨĞƌĞŶƚŝĂƚŝŶŐƚŽ “ďƌŽǁŶĞƌ ?ĂĚŝƉŽĐǇƚĞƐ ? 
6.2 USE OF 3T3-L1 CELL LINE AS A MODEL FOR STUDYING GENE 
REGULATION IN WHITE ADIPOCYTE DIFFERENTIATION 
Although primary cells are often preferred to cultured cell lines for investigations, 
because they more closely allow investigators to reproduce in vivo functions in vitro, 
they are of limited use due to their short lifespan and variability and due to the 
influence of the genotype and phenotype of the donor. Immortal cell lines possess 
major advantages over primary cells: 
1) They are not contaminated with any other cell types which are present in the 
stromal vascular fraction of adipose tissue.  
2) They have high proliferative capacity. 
3) Cell lines are much easier to transfect with plasmid DNA or siRNA. 
4) Experiments could be repeated under the same conditions and using the same 
source of cells. 
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Despite the usefulness of immortal cell lines in studying the molecular events leading 
to differentiation of certain tissues, they are aneuploid and therefore, diploid primary 
cells can reflect better the in vivo context (Gregoire et al., 1998). The details of the 
origin and selection of each individual cell line is important for assessing how each 
ĐĞůů ?Ɛ ƉŚĞŶŽƚǇƉŝĐ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ŵĂǇ Žƌ ŵĂǇ ŶŽƚ ƌĞƉƌĞƐĞŶƚ ƚŚĞ ŶĂƚŝǀĞ Đells. For 
instance, many cell lines are derived from long-term cultures that spontaneously 
transformed. This spontaneous transformation generally follows a time period in 
culture termed crisis, during which cells cease dividing, some of them die or they 
exhibit features of senescence. The cells that break out of this crisis represent a small 
subpopulation of cells and usually contain abnormal number of chromosomes, which 
is a likely cause of their transformation (Sell, 2004). In addition other cell lines are 
derived from cancerous lesions, wherein transformation has occurred in vivo, instead 
of in vitro, and they may also lose bits of chromosomes or carry a number of 
chromosomal abnormalities that may not represent the native cells (Sell, 2004). 
Furthermore, recent cell lines have been formed by introducing genes into cells that 
can impact immortality, such as the SV40 large T-antigen and hence divide 
indefinitely. The criticism of this method is that although the mechanism of 
immortalization is known, the transforming gene is always expressed, which is non-
physiologic and may have unknown effect on the physiology of the host cell (Sell, 
2004).  
3T3-L1 and 3T3-F442A (both subclones of the spontaneously immortalized Swiss 3T3 
cells), have been widely used to study white adipogenesis (Green and Kehinde, 1975). 
3T3-L1 cell differentiation is a well-described system for WAT differentiation and 
believed to be a faithful model of preadipocyte differentiation as demonstrated by in 
vivo implantation studies: when 3T3-L1 cells were injected into nude mice, the cells 
developed into mature fat pads that were indistinguishable from normal adipose 
tissue, suggesting that adipose cell conversion occurs by similar mechanisms in vivo 
(Gregoire et al., 1998; Lane et al., 1999; MacDougald et al., 1994; MacDougald and 
Lane, 1995; Tang and Lane, 1999; Wu et al., 1996). One disadvantage of 3T3-L1 cells is 
that they exhibit low efficiency with which foreign DNA can be introduced by 
transfection, and the experiments in this thesis also demonstrated that 3T3-L1 cells 
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are more difficult to transduce by lentiviral particles. The Ob17 cell line derived from 
epididymal WAT of adult ob/ob mice has been also largely employed in WAT studies 
(Negrel et al., 1978). In this thesis, 3T3-L1 cell line was selected for studying the role 
of C/EBPɴŝŶ UCP1 gene regulation for the following reasons: 
1) 3T3-L1 cell line was successfully differentiated into white adipocytes using the 
classical hormonal cocktail and the protocols for plasmid DNA transfection, RNAi, RNA 
extraction and Western Blot have been optimized previously in this lab. 
2) The key brown adipogenic genes UCP1 and PGC1ɲ are ɴ-adrenergic inducible in 
brown adipocytes but not in 3T3-L1 (pre)adipocytes. 
3) C/EBPɴ expression is increased by forskolin in 3T3-L1 cells during the first 48 hours 
post confluence, similar to the response observed in brown adipocytes.  
4) The previous work in our lab demonstrated that C/EBPɴ overexpression could 
rescue the insensitivity of PGC1ɲ gene to cAMP stimulation in 3T3-L1 cells 
(Karamanlidis et al., 2007), although the effect of C/EBPɴ on UCP1 expression still 
remains to be determined. 
These data suggested that 3T3-L1was an appropriate model for studying the role of 
C/EBPɴ in regulating UCP1 gene expression during white adipogenesis. In addition, to 
avoid the spontaneous transformation from the long term culture, the high passage 
(Passage> 32) 3T3-L1 cells were not used in any experiments. 
6.3 PGC1 ȰLPHA -DEPENDENT AND -INDEPENDENT PATHWAYS IN UCP1 
GENE REGULATION 
Many of the pathways regulating UCP1 gene expression in adipose tissue have been 
proposed to act indirectly by changing PGC1ɲ gene expression or activity. One of the 
examples for a PGC1ɲ dependent activating mechanism is that PRDM16 forms a 
complex with C/EBPɴ and up-regulates the transcription activity of PGC1ɲ promoter 
to induce the brown adipogenic programme, including stimulation of UCP1 gene 
expression (Kajimura et al., 2009).  
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In the experimental work presented in this thesis, C/EBPɴ was also shown to be 
involved in both PGC1ɲ dependent and independent mechanisms in regulating UCP1 
transcription in 3T3-L1 cells. When co-overexpressed with PRDM16, C/EBPɴ 
significantly increased the transcription activity of UCP1 promoter with or without 
forskolin treatment (Figure 5.5A), but the same co-overexpression did not have any 
significant effects on the full length PGC1ɲ promoter activity (Figure 5.5B), indicating 
that C/EBPɴ, under these circumstances, regulated UCP1 transcription in a PGC1ɲ 
independent manner. On the other hand, when C/EBPɴ was co-overexpressed with 
PPARɶ ? ŝƚ ŵĂƌŬĞĚůǇ ŝŶĐƌĞĂƐĞĚ W' ?ɲ ƉƌŽŵŽƚĞƌ ĂĐƚŝǀŝƚǇ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ƌŽƐŝŐůŝƚĂǌŽŶĞ
 ?&ŝŐƵƌĞ ? ? ? )ĂŶĚ ?WɴĂŶĚWWZɶĂůƐŽŚĂĚĂŶĂĚĚŝƚŝǀĞĞĨĨĞĐƚŝŶƵƉ-regulating UCP1 
promoter activity in the presence of forskolin and rosiglitazone (Figure 5.7A), which 
ĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚ ?WɴĐŽƵůĚĂůƐŽďĞŝŶǀŽůǀĞĚŝŶĂW' ?ɲĚĞƉĞŶĚĞŶƚŵĞĐŚĂŶŝƐŵ
to stimulate UCP1 transcription. However, as the real time PCR was not sensitive 
enough to pick up the low amount of ƚĞŵƉůĂƚĞhW ?ĂŶĚW' ?ɲĨƌŽŵƚŚĞƚƌĂŶƐĨĞĐƚĞĚ
confluent 3T3-L1 cells, there was no direct evidence for the mRNA changes of UCP1 
ĂŶĚW' ?ɲ ?dŚĞƌĞĨŽƌĞĂŶ ŝŵƉƌŽǀĞĚƌĞĂů ƚŝŵĞWZƉƌŽƚŽĐŽů ŝƐ needed and the other 
methods for detecting gene expression such as Western Blot and immunostaining 
could be used to ǀĂůŝĚĂƚĞƚŚĞĚŝƐĐŽǀĞƌǇƚŚĂƚ ?WɴĐŽƵůĚ ŝŶĐƌĞĂƐĞhW ?ĞǆƉƌĞƐƐŝŽŶ
ŝŶ ďŽƚŚ W' ?ɲ ĚĞƉĞŶĚĞŶƚ ĂŶĚ ŝŶĚĞƉĞŶĚĞŶƚ ŵĂŶŶĞƌƐ ? dŚĞƉŽƚĞŶƚŝĂů ƐĐŚĞŵĂƚŝĐ
ĚŝĂŐƌĂŵ ŽĨ  ?Wɴ ƌĞŐƵůĂƚŝŶŐ hW ? ĞǆƉƌĞƐƐŝŽŶ ĐŽƵůĚ ďĞŝůůƵƐƚƌĂƚĞĚ ĂƐ ĨŽůůŽǁŝŶŐ
(Figure 6.1) 
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Figure 6.1 Model for C/EBPɴ interacting with other (co)activators in regulating 
UCP1 transcription in 3T3-L1 preadipocytes at confluence. 
A possible model for higher UCP1 promoter activity through higher C/EBPɴ 
cellular concentration and phosphorylation in response to cAMP-PKA signalling 
pathway or/and ligand (rosiglitazone)-activated PPARɶ/ PGC1ɲ is proposed. The 
PGC1ɲ independent manner is illustrated on the right side of the dotted line: 
higher concentration of C/EBPɴ forms a complex with PRDM16 and stimulates 
UCP1 transcription in response to forskolin treatment through an unknown site on 
the UCP1 promoter. On the left side of the dotted line, there is the PGC1ɲ 
dependent manner: higher concentration of C/EBPɴ ŝŶƚĞƌĂĐƚƐ ǁŝƚŚ ƚŚĞ
ŽǀĞƌĞǆƉƌĞƐƐĞĚ WWZɶ ĂĐƚŝǀĂƚĞĚ ďǇ PGC1ɲ in presence of PPARɶ ligand 
rosiglitazone and the complex stimulates the transcription activity of UCP1 
promoter through the PPRE (or maybe CRE as well) on the promoter. P: phosphate 
group; L: ligand. 
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LXRɲ regulates UCP1 expression without influencing PGC1ɲ expression and activity 
(Wang et al., 2008b) and plays a direct role as a transcriptional inhibitor of cAMP-
dependent UCP1 gene expression through its binding to the critical enhancer region 
of the UCP1 promoter. However, LXRɲ might not be totally PGC1ɲ independent, as it 
involves the differential recruitment of the corepressor RIP140 to an LXRɲ binding 
site that overlaps with the PPARɶ/PGC1ɲ response element (PPRE), resulting in the 
dismissal of PPARɶ which PGC1ɲ can no longer co-activate to stimulate UCP1 gene 
expression (Wang et al., 2008b). Another example of the PGC1ɲ dependent but 
repressive mechanism is that RIP140 interacts directly with PGC1ɲ and suppresses its 
activity in inducing the promoter activity of CIDEA (Hallberg et al., 2008), which is 
highly expressed in BAT but directly interacts with and inhibits the uncoupling activity 
of UCP1 (Zhou et al., 2003).  Interestingly, RIP140 also directs histone and DNA 
methylation to maintain repressive state of UCP1 gene transcription in white 
adipocytes (Kiskinis et al., 2007), which is a PGC1ɲ independent regulatory pathway. 
RIP140 expression promotes the assembly of DNA and histone methyltransferases 
(HMTs) on the UCP1 enhancer and leads to methylation of specific CpG residues and 
histones, so RIP140 serves as a scaffold for both DNA and HMT activities to inhibit 
UCP1 transcription by two key epigenetic repression systems (Kiskinis et al., 2007). 
Therefore PGC1ɲ may not be indispensible to the regulation of UCP1 gene expression. 
Furthermore, the listed two regulatory mechanisms involving RIP140 indicate that a 
single regulator may be able to influence the target gene expression or activity 
through different mechanisms, in this case, in PGC1ɲ dependent or independent 
pathways, to regulate UCP1 gene.  
The fact that one target gene can be regulated either dependent or independent of 
some specific regulators (usually the key regulators) has the advantage that in case of 
the malfunction of any regulator, the other pathways independent of this regulator 
could compensate for the lost regulating function to minimize the influence of the 
specific malfunction on the overall expression and activity of the target gene. 
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6.4 UNCOUPLING PROTEINS AND METABOLIC SYNDROME 
The metabolic syndrome (MS) is a clinical entity that describes the clustering of 
factors including dyslipidaemia, glucose intolerance and hypertension with central 
adiposity as risk factors for coronary heart disease. The syndrome is increasing 
worldwide as a consequence of increasing obesity prevalence. The urgency for 
understanding the specific mechanisms that lead to development of MS and 
consequently discovery of new treatments to combat obesity is summarized below: 
 ? )ƋƵĂƌƚĞƌŽĨƚŚĞǁŽƌůĚ ?ƐĂĚƵůƚƐŚĂǀĞŵĞƚĂďŽůŝĐƐǇŶĚƌŽŵĞ(Dunstan et al., 2002) 
2) People with metabolic syndrome are twice as likely to die from, and three times as 
likely to have a heart attack or stroke compared with people without the syndrome 
(Isomaa et al., 2001) 
3) People with metabolic syndrome have a five-fold greater risk of developing type II 
diabetes (Stern et al., 2004) 
4) Up to 80% of the 200 million people with diabetes globally will die of 
cardiovascular disease (www.idf.org) 
5) The above statistical data puts metabolic syndrome and diabetes far ahead of 
HIV/AIDS in morbidity and mortality terms yet the problem is not as well recognized 
(www.idf.org) 
Obesity has now reached pandemic proportions leading to a collection of morbidities 
referred to as metabolic syndrome. The expansion of adipose tissue is a direct cause 
of these comorbidities due to excessive accumulation of triglycerides within 
adipocytes, causing disruption of normal adipose function (Vernochet et al., 2010). 
Brown adipose tissue has been well recognized for its potential and demonstrated 
anti-ŽďĞƐŝƚǇ ƉƌŽƉĞƌƚŝĞƐĚƵĞ ƚŽ ŝƚƐ ĨƵŶĐƚŝŽŶŽĨ  “ďƵƌŶŝŶŐ ? ĨĂƚ ďǇ ƚŚĞ high capacity for 
energy expenditure in the form of uncoupled respiration, mediated by the brown fat 
marker gene UCP1. Therefore, UCP1 could potentially play a key role in combating 
obesity to decrease the prevalence and morbidity of metabolic syndrome. Genetic 
ablation of UCP1 induces obesity and significantly decreases the metabolic rate in 
mice fed with either control or high-fat diet (Feldmann et al., 2009). 
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Recent studies have confirmed the thermogenic function of UCP1. Overexpression of 
UCP1 in pancreatic INS-1 cells enables the cells to show signs of uncoupling evidenced 
by the increased oxygen consumption and decreased mitochondrial membrane 
potential in response to the addition of fatty acids (Galetti et al., 2009). In contrast,  
overexpression of an uncoupling protein homologue UCP2 in the same cell line 
cannot stimulate the uncoupling process, indicating the  distinct functional difference 
between UCP1 and UCP2 although they have 59% identity with each other in 
sequence (Fisler and Warden, 2006; Galetti et al., 2009). Similarly, another 
homologue UCP3, sharing 57% identity with UCP1, also has markedly different 
physiological roles from UCP1. Gene expression of UCP2 and UCP3 increases during 
fasting (Cadenas et al., 1999), the opposite of what would be expected for 
thermogenic function and neither UCP2 nor UCP3 knockout mice are obese 
(Arsenijevic et al., 2000; Gong et al., 2000). However, transgenic mice overexpressing 
a UCP2 or UCP3 construct are leaner than wild type (Fuller et al., 2000; Horvath et al., 
2003). These data provide evidence against these proteins contributing to whole 
body thermogenesis in the same way as the homologue UCP1. In population studies, 
a polymorphism of the uncoupling proteins was investigated to evaluate the influence 
of a single nucleic acid difference in the promoter sequence on the gene function in 
association with metabolic syndrome. Studies demonstrated that polymorphism -
3826 A/G of the UCP1 gene is associated with a greater BMI, greater percentage of 
body fat and higher arterial tension (AT) in obese individuals (Forga et al., 2003). A 
common polymorphism in the UCP2 promoter, -866 G/A, is associated with a reduced 
risk of obesity in Caucasian Europeans (Esterbauer et al., 2001; Krempler et al., 2002). 
Interestingly, the same UCP2 -866 G/A polymorphism and a -55 C/T polymorphism in 
UCP3 are both associated with significantly reduced prevalence of diabetic 
neuropathy in type I diabetics (Rudofsky et al., 2006).  
In conclusion, among the three uncoupling protein homologues, only UCP1 positively 
contributes to whole body thermogenesis thus has the anti-obesity function. 
Increased UCP2 expression results in ɴ-cell dysfunction, impaired insulin sensitivity 
and earlier, more severe diabetes, but may protect from diabetic neuropathy. 
Increased UCP3 may reduce muscle insulin resistance (Fisler and Warden, 2006).  
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6.5 THE FEASIBILITY TO ALLEVIATE OBESITY AND RELEVANT METABOLIC 
SYNDROME IN HUMANS BY CONTROLLING THE EXPRESSION OF C/EBP 
Ȳd  
Since the work in this thesis demonstrated the potential of C/EBPɴ to up-regulate 
UCP1 expression in white 3T3-L1 preadipocytes, it provides the possibility to reduce 
the chance of obesity by transdifferentiating white adipocytes into brown like cells by 
overexpressing C/EBPɴ in white adipose tissue. A direct way of doing this is gene 
therapy, i.e. to deliver the C/EBPɴ gene directly into the tissues of patients by 
recombinant adenoviral-associated vector (rAAV) (Liau et al., 2001). However, as 
gene therapy is a newly developed technique, there is much concern about its safety 
and it has only been suggested for the treatment of extremely serious diseases such 
as cancers and some genetic deficiency. Although there are positive clinical trial 
results using this technique in therapeutics on several severe diseases including pro-
angiogenesis (Liau et al., 2001), the long term safety issue and the efficacy of this 
novel therapeutic method still await the result of on-going clinical trials. Besides, as 
the first case of gene therapy in humans was in 1990 (Oldfield et al., 1993), there has 
not been enough time to evaluate the long-term side effects including any negative 
influence on life-span. Therefore, gene therapy seems to be less valid to treat obesity 
ďǇŝŶĐƌĞĂƐŝŶŐ ?WɴĞǆƉƌĞƐƐŝŽŶůĞǀĞů ? 
Another way is to identify ĚƌƵŐƐƚŚĂƚĐĂŶ ŝŶĐƌĞĂƐĞ ?WɴĞǆƉƌĞƐƐŝŽŶŽƌĂĐƚŝǀŝƚǇ ?Ɛ
demonstrated in this thesis, treating the differentiating 3T3-L1 cells with forskolin 
ƐŝŐŶŝĨŝĐĂŶƚůǇ ŝŶĐƌĞĂƐĞĚ  ?Wɴ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŝŶ ŵĂƚƵƌĞ ĂĚŝƉŽĐǇƚĞƐ  ?&ŝŐƵƌĞ  ? ? ? ) ĂŶĚ
the treatment with rosiglitazone during the induction period of differentiation 
ŵĂƌŬĞĚůǇ ƐƚŝŵƵůĂƚĞĚ  ?Wɴ ĞǆƉƌĞƐƐŝŽŶ ŝŶ  ?d ?-L1 cells (Figure 5.4A).  Therefore a 
combination of ɴ-adrenergic stimulus and the anti-diabetic drug, rosiglitazone, could 
be possible candidatĞĚƌƵŐƐƚŽƐƚŝŵƵůĂƚĞ ?WɴĞǆƉƌĞƐƐŝŽŶŝŶǁŚŝƚĞĂĚŝƉŽƐĞƚŝƐƐƵĞin 
vivo. However, the drugs would not only affect adipose tissue, but have systemic 
actions as they would be transported by blood circulation all around body and may 
cause changes in metabolism and internal homeostasis to an unexpected extent. 
'ŝǀĞŶƚŚĂƚ ?WɴƉůĂǇƐĂŶŝmportant role in cell cycle regulation of many cell types 
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such as MEFs (Gagliardi et al., 2003; Sebastian et al., 2005), leukemic cells (Duprez et 
al., 2003; Guerzoni et al., 2006), hepatic cells (Buck et al., 1999; Greenbaum et al., 
1998) and adipocytes (Tang et al., 2003a) ?ƚŚĞƐŝŵƉůĞ ŝŶĐƌĞĂƐĞŽĨ ?WɴĞǆƉƌĞƐƐŝŽŶ
by drugs could result in more extensive influence or side effects in tissues and organs 
all over the body.  
Besides expression levels, the trans-ĂĐƚŝǀĂƚŝŽŶ ƉŽƚĞŶƚŝĂů ŽĨ  ?Wɴ ĐĂŶ ĂůƐŽ ďĞ
influenced by its phosphorylation state (Tang et al., 2005), so drugs targeting the 
ŬŝŶĂƐĞƐ ǁŚŝĐŚ ƌĞŐƵůĂƚĞ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ƐƚĂƚĞ ŽĨ  ?WɴƐŚŽƵůĚ ĂůƐŽ ƚŚĞŽƌĞƚŝĐĂůůǇ
activate  ?Wɴwithout changing its expression level. When growth-arrested 3T3-L1 
preadipocytes are induced to differentiate, C/EBPɴ is rapidly expressed but still lacks 
DNA-binding activity. After a 14-hour lag, glycogen synthase kinase 3ɴ (GSK- ?ɴ) 
enters the nucleus, which correlates with hyperphosphorylation of C/EBPɴ and 
acquisition of DNA-binding activity; concurrently, 3T3-L1 preadipocytes 
synchronously enter S phase and undergo mitotic clonal expansion (MCE), a 
prerequisite for terminal differentiation (Tang et al., 2005). During this MCE period, 
the histone H4, is transcriptionally activated by phophorylated C/EBPɴ ? and H4 
expression is correlated with DNA content change during the cell cycle, (Zhang et al., 
2011). Since it has been demonstrated ƚŚĂƚ ?Wɴis sequentially phosphorylated by 
mitogen-activating protein kinase (MAPK) and GSK- ?ɴ(Tang et al., 2005) in 3T3-L1 
ĂĚŝƉŽŐĞŶĞƐŝƐ ĂŶĚ ƚŚĂƚ  ?Wɴ ŝƐ ƌĞgulated in a cAMP-PKA mediated signalling 
pathway in thermogenesis in brown adipocytes (Karamanlidis et al., 2007), the drugs 
targeting the above kinases, GSK- ?ɴ ? DW< ĂŶĚ W< ?are candidate molecules for 
drug screening. These kinases play important phosphorylating roles all around the 
body, so there is still the problem of how to restrict the drug effects ŽŶůǇŽŶ ?Wɴ
in adipose tissue.  
Despite the challenges in developing treatments to alleviate obesity and the related 
metabolic syndrome, ďǇĚŝƌĞĐƚůǇŝŶĐƌĞĂƐŝŶŐ ?WɴĞǆƉƌĞƐƐŝŽŶŽƌĂĐƚŝǀŝƚǇŝŶŚƵŵĂŶs, 
it is still necessary to clarify the roles ŽĨ ?WɴŝŶƚŚĞƌĞŐƵůĂƚŽƌǇŶĞƚǁŽƌŬcontrolling 
UCP1 expression in white adipose tissue.  &ƵƌƚŚĞƌŵŽƌĞ ƚŚĞ ƌŽůĞ ŽĨ  ?Wɴin 
regulating the cell cycle could be useful to establish an effective drug or therapeutic 
method for the treatment of ŽďĞƐŝƚǇďǇŵĂŶŝƉƵůĂƚŝŶŐ ?WɴĞǆƉƌĞƐƐŝŽŶŽƌĂĐƚŝǀŝƚǇ ? 
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6.6 FUTURE WORK 
The results in this thesis demonstrated the technical problems in constructing a stable 
transgenic 3T3-L1 preadipocyte line overexpressing C/EBPɴ. Therefore it is important 
to improve the lentivirus production protocol, maybe by using a different lentiviral 
vector backbone which has the capacity to take bigger size insert or use two-vector 
ƐǇƐƚĞŵƚŽĐůŽŶĞ ?WɴĂŶĚƌƚdƐĞƉĂƌĂƚĞůǇƚŽƌĞĚƵĐĞƚŚĞŝŶƐĞƌƚƐŝǌĞĨŽƌĞĂĐŚǀĞĐƚŽƌ
(refer to the discussion in Chapter 4). Alternatively, the adenoviral expression system 
could be used to stably ŽǀĞƌĞǆƉƌĞƐƐ ?Wɴ ŝŶ  ?d ?-L1 preadipocytes. This approach 
suffers from the disadvantage that the transgene would not be permanently 
integrated into the genome of the adenovirus infected cells, and would not create a 
genetically modified cell line. Once the transgenic 3T3-L1 cell line is constructed, it 
would be differentiated using the typical hormonal induction protocol and the gene 
expression level of UCP1 measured by qRT-PCR and Western Blot in response to 
ŽǀĞƌĞǆƉƌĞƐƐĞĚ  ?Wɴ ŝŶĚƵĐĞĚ ďǇ ĚŝĨĨĞƌĞŶt doses of doxycycline. Further studies 
could examine the chromatin remodelling pattern on the UCP1 promoter by ChIP 
assays targeting the activate markers (AcH3, AcH4 and H3K4Me2) and the repressive 
markers (H3K9Me2, H3K9Me3, H3K27Me2 and H3K27Me3) of the histones. 
The work on the 3T3-> ? ĐĞůůƐ ƚƌĂŶƐŝĞŶƚůǇ ŽǀĞƌĞǆƉƌĞƐƐŝŶŐ  ?Wɴ Žƌ ?ĂŶĚ ƚŚĞ ŽƚŚĞƌ
 ?ĐŽ )ĂĐƚŝǀĂƚŽƌƐ ?WZD ? ?ĂŶĚWWZɶ )ƌĞǀĞĂůed  ƚŚĂƚ ?WɴŵŝŐŚƚďĞŝŶǀŽůǀĞĚŝŶďŽƚŚ
W' ?ɲ ĚĞƉĞŶĚĞŶƚ ĂŶĚ ŝŶĚĞƉĞŶĚĞŶƚ ŵĞĐŚĂŶŝƐŵƐ ƚŽ ƌĞŐƵůĂƚĞ UCP1 expression and 
that there might be a 3T3-> ? ƐƉĞĐŝĨŝĐ ƌĞƉƌĞƐƐŝǀĞ ŵĞĐŚĂŶŝƐŵ ƚŚĂƚ ƉƌĞǀĞŶƚƐ  ?Wɴ
from activating UCP1 transcription. Further studies are needed to improve the qRT-
WZƉƌŽƚŽĐŽů ĨŽƌĂŵƉůŝĨǇŝŶŐhW ?ĂŶĚW' ?ɲ ĨƌŽŵ  ?d ?-L1 cDNA, probably by using 
another lightcycler which is more sensitive to pick up the low concentration 
templates. Furthermore, Western Blot can be applied to detect how UCP1 expression 
is changed by the overexpression ŽĨ ?WɴŽƌ ?ĂŶĚWZD ? ?ŽƌWWZɶat the protein 
level to further verify the data from reporter assays and mRNA measurement. The 
cells with the transient overexpression ŽĨ ?WɴŽƌ ?ĂŶĚWZD ? ?ŽƌWWZɶ can also 
be used to perform ChIP assays to explore whether the overexpression(s) interact 
directly to the UCP1 promoter and to investigate whether they changed the 
chromatin remodelling pattern of the promoter by using antibodies against the 
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typical active and repressive markers of histone. The ChIP assays also provide 
possibilities to identify other geneƐƚŚĂŶWWZɶƚŚĂƚŚĂǀĞƚŚĞƉŽƚĞŶƚŝĂůƚŽƌĞůĞĂƐĞƚŚĞ
3T3-> ? ƐƉĞĐŝĨŝĐ ƌĞƉƌĞƐƐŝŽŶ ŽŶ  ?Wɴ ƐƚŝŵƵůĂƚŝŽŶ ŽĨ hW ? ĞǆƉƌĞƐƐŝŽŶ ? &ŝŶĂůůǇ ? ĂƐ
phosphorylation probably influences the trans-activation potential of  ?Wɴ and the 
studies in the 3T3-L1 transiently tranƐĨĞĐƚĞĚ ǁŝƚŚ  ?Wɴ ŚĂǀĞ ƚŽ ĨŽĐƵƐ ŽŶ  ? ?-48 
ŚŽƵƌƐ ƉŽƐƚ ĐŽŶĨůƵĞŶĐĞ ŽĨ ƚŚĞ ĐĞůůƐ ? ŝŶ ǁŚŝĐŚ ƉĞƌŝŽĚ  ?Wɴ ƐƚĂƌƚƐ ƚŽ ŐĂŝŶ ŝƚƐ E-
binding activity through phosphorylation (Tang et al., 2005), the phosphorylation 
ƐƚĂƚĞŽĨ ?WɴƉƌŽďĂďůǇĂĨĨĞĐƚƚŚĞĂďŝůŝƚǇŽĨ ?WɴƚŽƌĞŐƵůĂƚĞhW ?ĞǆƉƌĞƐƐŝŽŶ ? It 
ǁŝůů ďĞ ŚĞůƉĨƵů ƚŽ ĐŽƌƌĞůĂƚĞ ƚŚĞ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ůĞǀĞů ŽĨ  ?Wɴ ǁŝƚŚ ƚŚĞ hW ?
exprĞƐƐŝŽŶĂŶĚĂĐƚŝǀŝƚǇŝŶƚŚĞĐĞůůƐŽǀĞƌĞǆƉƌĞƐƐŝŶŐ ?WɴŽƌǁŝƚŚŽƚŚĞƌ ?ĐŽ )ĂĐƚŝǀĂƚŽƌƐ ? 
ŵďŝƚŝŽƵƐůǇ ? Ă ƚƌĂŶƐŐĞŶŝĐ ŵŽƵƐĞ ŽǀĞƌĞǆƉƌĞƐƐŝŶŐ  ?Wɴ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ĚŽǆǇĐǇĐůŝŶĞ
induction specifically in adipose tissue could be constructed, either by pronuclear 
injection of the fat-ƐƉĞĐŝĨŝĐ ŝŶĚƵĐŝďůĞ  ?Wɴ ǀĞĐƚŽƌ Žƌ ďǇ ĐŽŶƐƚƌƵĐƚŝŶŐ Ă ŵŽƵƐĞ
embryonic stem cell line bearing such characteristics and then developing the target 
transgenic mouse [reviewed in (Luo et al., 2011)]. 
In conclusion, the experiments and model proposed above warrant further research 
to define the role of C/EBPɴ in the regulation of UCP1 gene expression in white 
(pre)adipocytes. 
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APPENDIX A - SOLUTIONS AND REAGENTS 
 
Ampicillin 100mg/ml 
Stock solution of ampicillin (Sigma) was prepared by adding 100mg per ml in 
autoclaved distilled water, filtered with 0.2µm filter (Millipore), dispensed in 200µl 
aliquots and stored at -20°C. It was used at 100µg/ml final concentration in liquid and 
solid medium.  
Kanamycin 50mg/ml 
Stock solution of kananycin (Sigma) was prepared by adding 50mg per ml in 
autoclaved distilled water, filtered with 0.2µm filter (Millipore), dispensed in 200µl 
aliquots and stored at -20°C. It was used at 50µg/ml final concentration in liquid and 
solid medium.  
Blasticidin 8mg/ml 
Stock solution of blasticidin (Invitrogen) was prepared by adding 200mg powder into 
dH2O with the final volume adjusted to 25ml, dispensed in 500µl aliquots and stored 
at -20°C. 
Doxycycline 10mg/ml 
10mg/ml stock solution of doxycycline (Sigma) was prepared by dissolving 50mg of 
doxycycline powder with dH2O into a final volume of 5ml, yielding a clear, yellow-
green solution. Aliquots were made in 50µl/vial and stored at -20°C. 
EDTA 0.5M (1000ml) 
186.1g of disodium ethylenediamine tetraacetate acid dihydrate (EDTA; Sigma) was 
dissolved in 1000ml of distilled water (dH2O). The pH was adjusted at 8.0 with 10M 
NaOH and the solution was autoclaved at 121°C for 15 min.  
NaCl 5M (100ml) 
29.2g of NaCl (Sigma) were dissolved in dH2O to a final volume of 00ml and 
autoclaved at 121°C fo 15 min.  
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Phosphate Buffer Saline (PBS; 200ml) 
PBS solution was prepared by dissolving one PBS tablet (Sigma) into 200ml dH2O and 
autoclaved at 121°C for 15 min.  
TAE buffer (50× stock; 1000ml) 
50× TAE stock solution was prepared by adding 242g of Tris base (Sigma), 57.1ml 
Glacial Acetic Acid (Sigma) and 18.6g of EDTA (Sigma) into 900ml dH2O and the final 
volume was adjusted to 1L with additional dH2O. 
Tris-HCl 1M (1000ml) 
121g of Tris base were dissolved in 1000ml dH2O. The pH was adjusted at 8.0 and the 
solution was autoclaved 121°C for 15 min.  
TSSM buffer (100ml) 
0.24g of Tris base, 0.585g of NaCl, 1g of sucrose and 1g of mannitol were dissolved in 
90ml dH2O. The pH was adjusted to 7.4 and final volume was adjusted to 100ml with 
dH2O. The solution was autoclaved at 121°C for 15 min.  
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APPENDIX B - BACTERIOLOGICAL MEDIA USED 
 
LB medium (1000ml) 
10g tryptone (Sigma), 5g yeast extract (Sigma) and 10g NaCl were dissolved in 1000ml 
dH2O and autoclaved at 121°C for 15 min.  
LB-Agar (400ml) 
4g tryptone, 2g yeast extract, 4g NaCl and 6g agar (Sigma) were dissolved in 400ml 
dH2O and autoclaved at 121°C for 15 min. For plating, medium was allowed to cool to 
55°C then appropriate antibiotics was added at designed concentration and 25-30ml 
of medium was poured into 10cm petri dishes. Once the agar was solid, plates were 
stored at 4°C until used for up to a month.  
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APPENDIX C - COMPOSITION OF DMEM AND GROWTH MEDIUM 
 
Growth medium for 3T3-L1 and HIB-1B cells was composed of 88% DMEM, 10% FBS 
(heat inactivated; Invitrogen), 1% Sodium Pyruvate (Invitrogen) and 1% of Penicillin/ 
Spectromycin (Invitrogen). Growth medium for HT1080 and 293FT cells was 
composed of 88% DMEM, 10% FBS (non-heat inactivated; Invitrogen) and 1% Sodium 
Pyruvate (Invitrogen). 
COMPONENTS OF DMEM M. W. mg/L mM 
Amino Acids 
Glycine 75 30 0.4 
L-Arginine hydrochloride 211 84 0.398 
L-Cystine 2HCl 313 63 0.201 
L-Glutamine 146 580 3.97 
L-Histidine hydrochloride-H2O 210 42 0.2 
L-Isoleucine 131 105 0.802 
L-Leucine 131 105 0.802 
L-Lysine hydrochloride 183 146 0.798 
L-Methionine 149 30 0.201 
L-Phenylalanine 165 66 0.4 
L-Serine 105 42 0.4 
L-Threonine 119 95 0.798 
L-Tryptophan 204 16 0.0784 
L-Tyrosine 181 72 0.398 
L-Valine 117 94 0.803 
Vitamins 
Choline chloride 140 4 0.0286 
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D-Calcium pantothenate 477 4 0.00839 
Folic Acid 441 4 0.00907 
i-Inositol 180 7.2 0.04 
Niacinamide 122 4 0.0328 
Pyridoxine hydrochloride 204 4 0.0196 
Riboflavin 376 0.4 0.00106 
Thiamine hydrochloride 337 4 0.0119 
Inorganic Salts 
Calcium Chloride (CaCl2-2H2O) 147 264 1.8 
Ferric Nitrate (Fe(NO3)3"9H2O) 404 0.1 0.000248 
Magnesium Sulfate (MgSO4-7H2O) 246 200 0.813 
Potassium Chloride (KCl) 75 400 5.33 
Sodium Bicarbonate (NaHCO3) 84 3700 44.05 
Sodium Chloride (NaCl) 58 6400 110.34 
Sodium Phosphate monobasic (NaH2PO4-2H2O) 154 141 0.916 
Other Components 
D-Glucose (Dextrose) 180 4500 25 
Phenol Red 376.4 15 0.0399 
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APPENDIX D - MAPS OF CONSTRUCTS  
 
LENTIVIRAL DESTINATION VECTORS 
 
(1) pLenti6/V5 
 
 
 
 
 
 
 
 
pLenti6/V5-DEST
8688 bp
Amp(R)
Bsd(R)
ccdB
Cm(R)
V5 epitope
3 stops
deltaU3/3' LTR
deltaU3
HIV-1 5' LTR
HIV-1 3' LTR
HIV-1 psi packaging signal
SV40 pA
CMV forw ard primer
V5 reverse primer
CMV promoter
RSV promoter
RSV/5' LTR hybrid promoter
SV40 early promoter
bla promoter
EM7 promoter
HIV-1 Rev response elemen
f1 origin
pUC origin
splice donor
splice acceptor
splice acceptor
TATA box
attR1
attR2
ClaI (1796)
SpeI (2407)
Xho I (4170)
BamHI (2401)
BamHI (2637)
BamHI (3340)
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(2) pLenti-TRE 
 
 
 
 
 
 
 
 
 
 
 
pLenti6-TRE
8527 bp
3 stops
V5 epitope
Cm(R)
ccdB
Bsd(R)
Amp(R)
HIV-1 3' LTR
HIV-1 5' LTR
deltaU3
deltaU3/3' LTR
HIV-1 psi packaging signal LNCX primer
pCEP fw d primer
TRE
SV40 pA
V5 reverse primer
SV40 early promoter
RSV/5' LTR hybrid promoter
RSV promoter
EM7 promoterbla promoter
HIV-1 Rev response element
pUC origin
f1 origin
splice acceptor
splice acceptor
splice donor
attR2
attR1
ClaI (1)
SpeI (451)
Xho I (16)
Xho I (2214)
BamHI (681)
BamHI (1384)
215 
 
 
(3) pLenti-TRE tight 
 
 
 
 
 
 
 
 
pLenti6-TRE Tight
8436 bp
Amp(R)
Bsd(R)
ccdB
Cm(R)
V5 epitope
3 stops
deltaU3/3' LTR
deltaU3
HIV-1 5' LTR
HIV-1 3' LTR
HIV-1 psi packaging signal
TRE Tight
miniCMV
SV40 pA
V5 reverse primer
RSV promoter
RSV/5' LTR hybrid promoter
SV40 early promoter
bla promoter
EM7 promoter
HIV-1 Rev response elemen
f1 origin
pUC origin
splice donor
splice acceptor
splice acceptor
attR1
attR2
ClaI (1805)
SpeI (2143)
BamHI (2385)
BamHI (3088)
Xho I (1826)
Xho I (3918)
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ENTRY CLONES 
 
(1) C/EBPɴ 
 
(2) LucGFP 
 
Entry Clone/pDONR-P1P4-C/EBPbeta-intron-polyA
4329 bp
Kan(R)
C/EBPbeta
bGlob intron
attL1
attL4
pDONR201 forw ard primer
pDONR201 reverse primer
rrnB T1 transcription terminato
rb Glob polyA terminator
ApaLI (1495)
Hin dIII (3143)
EcoRI (2289)
EcoRI (3803)
AvaI (2137)AvaI (2256)
AvaI (3095)
Nco I (2301)
Nco I (2691)
Nco I (3298)
PstI (103)
PstI (2288)
PstI (3033)
Entry Clone/pDONR-P1P4/LucGFP attB1B4
5843 bp
Kan(R)
EGFP
Orf frame 2
attL1
attL4
bGlob int
EGFP C primer
EGFP N primer
firefly Luciferase
LucNrev primer
pDONR201 forward primer
pDONR201 reverse primer
rrnB T1 transcription terminato
rb glob PA terminator
BamHI (3903)
HindIII (4657)
217 
 
(3) CMV promoter 
 
 
 
(4) aP2 promoter 
 
 
 
 
Entry Clone/pDONR-P4rP3r/CMV from Tet-ON
2980 bp
Kan(R)
attR3
attR4
pDONR201 reverse primer
pDONR201 forward primer
CMV tetON
rrnB T2 transcription terminator
rrnB T1 transcription terminator
PstI (155)
SpeI (2402)
Entry Clone/pDONR-P4rP3r/ap2 pcr product
7917 bp
Kan(R)
aP2 enhancer
attR3
attR4
pDONR201 reverse primer
pDONR201 forward primer
aP2 promoter
rrnB T2 transcription terminator
rrnB T1 transcription terminator
Pvu I (690)
SpeI (2553)
218 
 
(5) short aP2 promoter 
 
 
 
(6) rtTA 
 
 
Entry Clone/pDONR-P4rP3r/short aP2
3549 bp
Kan(R)
attR3
attR4
sAP2
pDONR201 reverse prime
pDONR201 forward primer
rrnB T2 transcription terminator
rrnB T1 transcription terminator
EcoRI (2361)
PstI (155)PstI (3540)
Entry Clone/pDONR-P3P2/rTTA pcr product
3757 bp
Kan(R)
rTta
attL2
attL3
pDONR201 reverse prime
pDONR201 forward primer
rrnB T2 transcription terminator
rrnB T1 transcription terminator
EcoRI (2262)
PstI (103)
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(7) rtTA advance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entry Clone/pDONR-P3P2/rtTA adv PCR product
3039 bp
Kan(R)
attL2
attL3
rtTA advance
pDONR201 reverse prime
pDONR201 forward primer
rrnB T2 transcription terminator
rrnB T1 transcription terminator
Xma I (3019)
Xba I (2284)
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EXPRESSION VECTORS (NON-FAT SPECIFIC) 
 
(1) Constitutive expression vector for LucGFP (pLenti-LucGFP) 
 
 
 
 
 
 
 
 
 
 
 
pLenti6/V5 LucGFP
12789 bp
3 stops
V5 epitope
Bsd(R)
Amp(R)
Orf frame 2
EGFP
rTta
HIV-1 3' LTR
HIV-1 5' LTR
deltaU3
deltaU3/3' LTR
HIV-1 psi packaging signal
attB1
attB2
attB3
attB4
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int SV40 pA
V5 reverse primer
CMV forw ard primer
SV40 early promoter
RSV/5' LTR hybrid promoter
RSV promoter
CMV promoter
CMV tetON
EM7 promoter
bla promoter
HIV-1 Rev response element
pUC origin
f1 origin
splice acceptor
splice acceptor
splice donor
TATA box
rb glob PA terminator
PstI (6991)
Xho I (40)
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(2) Constitutive expression vector for C/EBPɴ (pLenti-C/EBPɴ) 
 
 
 
 
pLenti6/V5-CEBPbeta
8958 bp
Amp(R)
Bsd(R)
V5 epitope
3 stops
C/EBPbeta
bGlob intron
deltaU3/3' LTR
deltaU3
HIV-1 5' LTR
HIV-1 3' LTR
HIV-1 psi packaging signal
SV40 pA
CMV forw ard primer
V5 reverse primer
CMV promoter
RSV promoter
RSV/5' LTR hybrid promoter
SV40 early promoter
bla promoter
EM7 promoter
HIV-1 Rev response elemen
f1 origin
pUC origin
splice donor
splice acceptor
splice acceptor
TATA box
rb glob polyA terminator
SpeI (2407)
Xho I (4440)
BamHI (2401)
ClaI (1796)
EcoRI (3923)
Nhe I (3246)
Not I (921)
Xma I (4887)
ApaI (3833)
ApaI (4456)
StuI (4865)
StuI (6079)
Xba I (2395)
Xba I (3281)
Xba I (4446)
SacII (2580)
SacII (2748)
SacII (2781)
SacII (4459)
HindIII (308)
HindIII (864)
HindIII (1448)
HindIII (1801)
HindIII (3263)
HindIII (5610)
HindIII (8954)
222 
 
(3) Inducible expression vector for LucGFP ķ pLenti TRE-LucGFP-CMV-rtTA 
 
 
 
 
 
 
 
 
 
 
 
Expression Clone/pLenti6-TRE/LucGFP/CMV/rtTA
12628 bp
Amp(R)
Bsd(R)
V5 epitope
3 stops
Orf frame 2
EGFP
rTta
deltaU3/3' LTR
deltaU3
HIV-1 5' LTR
HIV-1 3' LTR
HIV-1 psi packaging signal
attB1
attB2
attB3
attB4
TRE
pCEP fwd primer
LNCX primer
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int
SV40 pA
V5 reverse primer
RSV promoter
RSV/5' LTR hybrid promoter
SV40 early promoter
CMV tetON
bla promoter
EM7 promoter
HIV-1 Rev response element
f1 origin
pUC origin
splice donor
splice acceptor
splice acceptor
rb glob PA terminator
Pst I (6830)
BamHI (8520)
BamHI (12158)
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(4) Inducible expression vector for LucGFP ĸ pLenti TRE-LucGFP-CMV-rtTA advance 
 
 
 
 
 
 
 
 
 
 
 
Expression Clone/pLenti6-TRE/Luc-GFP/CMV/rtTA advance
11910 bp
Amp(R)
Bsd(R)
V5 epitope
3 stops
Orf frame 2
EGFP
deltaU3/3' LTR
deltaU3
HIV-1 5' LTR
HIV-1 3' LTR
HIV-1 psi packaging signalTRE
pCEP fwd primer
LNCX primer
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int
rtTA advance
SV40 pA
V5 reverse primer
RSV promoter
RSV/5' LTR hybrid promoter
SV40 early promoter
CMV tetON
bla promoter
EM7 promoter
HIV-1 Rev response element
f1 origin
pUC origin
splice donor
splice acceptor
splice acceptor
rb glob PA terminator
PstI (6830)
SacII (59)
224 
 
(5) Inducible expression vector for LucGFP Ĺ pLenti-TRE tight LucGFP CMV rtTA 
 
 
 
 
 
 
 
 
 
 
 
Expression Clone/pLenti6-TRE Tight LucGFP CMV rtTA
12537 bp
3 stops
V5 epitope
Bsd(R)
Amp(R)
Orf frame 2
EGFP
rTta
HIV-1 3' LTR
HIV-1 5' LTR
deltaU3
deltaU3/3' LTR
HIV-1 psi packaging signal
attB1
attB2
attB3
attB4
miniCMV
TRE Tight
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int SV40 pA
V5 reverse primer
SV40 early promoter
RSV/5' LTR hybrid promoter
RSV promoter
CMV tetON
EM7 promoter
bla promoter
HIV-1 Rev response element
pUC origin
f1 origin
splice acceptor
splice acceptor
splice donor
rb glob PA terminator
Pst I (6739)
BamHI (8429)
BamHI (12067)
225 
 
(6) Inducible expression vector for LucGFP ĺ pLenti-TRE tight LucGFP CMV rtTA 
advance 
 
 
 
 
 
 
 
 
 
 
 
Expression Clone/pLenti6-TRE tight/LucGFP/CMV/rtTA adv
11793 bp
3 stops
V5 epitope
Bsd(R)
Amp(R)
Orf frame 2
EGFP
HIV-1 3' LTR
HIV-1 5' LTR
deltaU3
deltaU3/3' LTR
HIV-1 psi packaging signal
attB1
attB2
attB3
attB4
miniCMV
TRE Tight
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int
SV40 pA
V5 reverse primer
SV40 early promoter
RSV/5' LTR hybrid promoter
RSV promoter
CMV tetON
EM7 promoter
bla promoter
HIV-1 Rev response element
pUC origin
f1 origin
splice acceptor
splice acceptor
splice donor
rb glob PA terminator
Pst I (6739)
Sac II (59)
226 
 
 
(7) Inducible expression vector for C/EBPɴ: pLenti TRE tight C/EBPɴ CMV rtTA 
advance 
 
 
 
 
 
 
 
 
Expression Clone/pLenti6-TRE Tight/ CEBPbeta-intron polyA/CMV /rtTA a
10373 bp
3 stops
V5 epitope
Bsd(R)
Amp(R)
C/EBPbeta
bGlob intron
HIV-1 3' LTR
HIV-1 5' LTR
deltaU3
deltaU3/3' LTR
HIV-1 psi packaging signal
miniCMV
TRE Tight
rtTA advance
SV40 pA
V5 reverse primer
SV40 early promoter
RSV/5' LTR hybrid promoter
RSV promoter
CMV tetON
EM7 promoter
bla promoter
HIV-1 Rev response element
pUC origin
f1 origin
splice acceptor
splice acceptor
splice donor
Cebpb
Cebpb
Cebpb
Rb Glob polyA terminator
ClaI (6363)
EcoRI (6730)
EcoRI (8226)
SpeI (6701)
SpeI (8984)
Xba I (46)
Xba I (9618)
Xho I (40)
Xho I (6384)
227 
 
 
EXPRESSION VECTORS (FAT SPECIFIC) 
 
(1) TRE LucGFP aP2 rtTA advance 
 
 
 
 
Expression Clone/pLenti6-TRE/LucGFP/aP2/rtTA adv
16847 bp
Amp(R)
Bsd(R)
V5 epitope
3 stops
Orf frame 2
EGFP
aP2 enhancer
deltaU3/3' LTR
deltaU3
HIV-1 5' LTR
HIV-1 3' LTR
HIV-1 psi packaging signal
attB1
attB2
attB3
attB4
TRE
pCEP fw d primer
LNCX primer
LucNrev  primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int
rtTA adv ance
SV40 pA
V5 rev erse primer
RSV promoter
RSV/5' LTR hybrid promoter
SV40 early promoter
aP2 promoter
bla promoter
EM7 promoter
HIV-1 Rev  response element
f1 origin
pUC origin
splice donor
splice acceptor
splice acceptor
rb glob PA terminator
Xho I (40)
Xho I (6369)
228 
 
 
(2) TRE LucGFP short aP2 rtTA advance 
 
 
 
 
 
 
 
 
 
 
 
Expression Clone/pLenti6-TRE/Luc-GFP/sAP2/rtTA advance
12479 bp
Amp(R)
Bsd(R)
V5 epitope
3 stops
Orf frame 2
EGFP
deltaU3/3' LTR
deltaU3
HIV-1 5' LTR
HIV-1 3' LTR
HIV-1 psi packaging signal
TRE
pCEP fw d primer
LNCX primer
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int
sAP2
rtTA advance
SV40 pA
V5 reverse primer
RSV promoter
RSV/5' LTR hybrid promoter
SV40 early promoter
bla promoter
EM7 promoter
HIV-1 Rev response element
f1 origin
pUC origin
splice donor
splice acceptorsplice acceptor
rb glob PA terminator
PstI (6830)
PstI (11659)
229 
 
 
(3) TRE tight-LucGFP aP2 rtTA advance 
 
 
 
 
 
Expression Clone/pLenti6-TRE Tight/LucGFP/aP2/rtTA adv
16756 bp
3 stops
V5 epitope
Bsd(R)
Amp(R)
Orf frame 2
EGFP
aP2 enhancer
HIV-1 3' LTR
HIV-1 5' LTR
deltaU3
deltaU3/3' LTR
HIV-1 psi packaging signal
attB1
attB2
attB3
attB4
miniCMV
TRE Tight
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int
rtTA advance
SV40 pA
V5 reverse primer
SV40 early promoter
RSV/5' LTR hybrid promoter
RSV promoter
aP2 promoter
EM7 promoter
bla promoter
HIV-1 Rev response element
pUC origin
f1 origin
splice acceptor
splice acceptor
splice donor
rb glob PA terminator
Xho I (40)
Xho I (6384)
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(4) TRE tight-LucGFP short aP2 rtTA advance 
 
 
 
 
 
 
 
 
 
 
 
Expression Clone/pLenti6-TRE Tight/Luc-GFP/sAP2/rtTA advance
12388 bp
3 stops
V5 epitope
Bsd(R)
Amp(R)
Orf frame 2
EGFP
HIV-1 3' LTR
HIV-1 5' LTR
deltaU3
deltaU3/3' LTR
HIV-1 psi packaging signal
miniCMV
TRE Tight
LucNrev primer
firefly Luciferase
EGFP N primer
EGFP C primer
bGlob int
sAP2
rtTA advance
SV40 pA
V5 reverse primer
SV40 early promoter
RSV/5' LTR hybrid promoter
RSV promoter
EM7 promoter
bla promoter
HIV-1 Rev response element
pUC origin
f1 origin
splice acceptor
splice acceptor
splice donor
rb glob PA terminator
PstI (6739)
PstI (11568)
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APPENDIX E - SEQUENCING RESULTS  
(1) Modified lentiviral backbone vectors 
 
pLenti TRE 
ttatcgtttcagacccacctcccaaccccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagaga
gacagagacagatccattcgattagtgaacggatctcgacggtatcgatgaaccccttcctcgagtttaccactccctatca
gtgatagagaaaagtgaaagtcgagtttaccactccctatcagtgatagagaaaagtgaaagtcgagtttaccactccct
atcagtgatagagaaaagtgaaagtcgagtttaccactccctatcagtgatagagaaaagtgaaagtcgagtttaccact
ccctatcagtgatagagaaaagtgaaagtcgagtttaccactccctatcagtgatagagaaaagtgaaagtcgagtttac
cactccctatcagtgatagagaaaagtgaaagtcgagctcggtacccgggtcgaggtaggcgtgtacggtgggaggcct
atataagcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacacc
gggaccgatccaactagtccagtgtggtggaattct 
The sequence underlined is TRE-CMV promoter. 
pLenti TRE tight 
ttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaaccccgaggg
gacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacgga
tctcgacggtatccccgggatcgatggccctttcgtcttcactcgagtttactccctatcagtgatagagaacgtatgtcgag
tttactccctatcagtgatagagaacgatgtcgagtttactccctatcagtgatagagaacgtatgtcgagtttactccctat
cagtgatagagaacgtatgtcgagtttactccctatcagtgatagagaacgtatgtcgagtttatccctatcagtgatagag
aacgtatgtcgagtttactccctatcagtgatagagaacgtatgtcgaggtaggcgtgtacggtgggaggcctatataagc
agagctcgtttagtgaaccgtcagatcgcactagtcccggggctagtccagtgtggtggaattctgcagatatcaacaagt
ttgtacaaaaaagctgaacgagaaacgtaaaatgatataaatatcaatatattaaattagattttgcataaaaaacagac
tacataatactgtaaaacaca 
The sequence underlined is TRE tight-CMV promoter. 
(2) Entry clones 
 
C/EBPɴ 
cagttccctactctcgcgttaacgctagcatggatctcgggccccaaataatgattttattttgactgatagtgacctgttcgt
tgcaacaaattgatgagcaatgcttttttataatgccaactttgtacaaaaaagcaggcttattgatagactcgagcggcc
gccactgtgctggatatctgcagaattcgcgccaccatggaagtggccaacttctactacgagcccgactgcctggcctac
ggggccaaggcggcccgcgccgcgccgcgcgcccccgccgccgagccggccattggcgagcacgagcgcgccatcgac
ttcagcccctacctggagccgctcgcgcccgccgcggacttcgccgcgcccgcgcccgcgcaccacgacttcctctccgac
ctcttcgccgacgactacggcgccaagccgagcaagaagccggccgactacggttacgtgagcctcggccgcgcgggcg
ccaaggccgcgccgcccgcctgcttcccgccgccgcctcccgcggcgctcaaggcggagccgggcttcgaacccgcggac
tgcaagcgcgcggacgacgcgcccgccatggcggccggtttcccgttcgccctgcgcgcctacctgggctaccaggcgac
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gccgagcggcagcagcggcagcctgtccacgtcgtcgtcgtccagcccgcccggcacgccgagccccgccgacgccaag
gccgcgcccgccgcctgcttcgcggggccgccggccgcgcccgccaaggccaaggccaagaagacggtggacaagctg
agcgacgagtacaagatgcggcgcgagcgcaacaacatcgcggtgcgcaagagccgcgacaaggccaagatgcgcaa
cctggagacgcagcacaaggtgctggagctgacggcggagaacgagcggctgcagaagaaggtggagcagctgtcgcg
agagctcagcaccctgcggaacttgttcaagcagctgcccgagccgctgctggcctcggcgggccactgctagcgcggcg
gtaccaagcttgtcgacgatatctctagagctgagaacttcagggtgagtttggggacccttgattgttctttctttttcgcta
ttgtaaaattcatgttatatggagggggcaaagttttcagggtgttgtttagaatgggaagatgtcccttgtatcaccatgg
accctcatgataattttgtttctttcactttctactctgttgacaaccattgtctcctcttattttcttttcattttctgtaacttttt
cgttaaactttagcttgcatttgtaacgaatttttaaattcacttttgtttatttgtcagattgtaagtactttctctaatcacttt
tttttcaaggcaatcagggtatattatattgtacttcagcacagttttagagaacaattgttataattaaatgataaggtaga
atatttctgcatataaattctggctggcgtggaaatattcttattggtagaaacaactacaccctggtcatcatcctgcctttc
tctttatggttacaatgatatacactgtttgagatgaggataaaatactctgagtccaaaccgggcccctctgctaaccatg
ttcatgccttcttctctttcctacagctcctgggcaacgtgctggttgttgtgctgtctcatcattttggcaaagaattcactcc
tcaggtgcaggctgcctatcagaaggtggtggctggtgtggccaatgccctggctcacaaataccactgagatctttttccc
tctgccaaaaattatggggacatcatgaagccccttgagcatctgacttctggctaataaaggaaatttattttcattgcaa
tagtgtgtgggaattttttgtgtctctcactcggaaggacatatgggagggcaaatcatttaaaacatcagaatgagtattt
ggtttagagtttggcaacatatgccatatgctggctgccatgaacaaaggtggctataaagaggtcatcagtatatgaaac
agccccctgctgtccattccttattccatagaaaagccttgacttgaggttagattttttttatattttgttttgtgttatttttttc
tttaacatccctaaaattttccttacatgttttactagccagatttttcctcctctcctgactactcccagtcatagctgtccctc
ttctccacccaacttttctatacaaagttggcattataagaaagcattgcttatcaatttgttgcaacgaacaggtcactatc
agtcaaaataaaatcattatttgccatccagctgcagctctggcccgtgtctcaaaatctctgatgttacattgcacaagat
aa 
The sequence underlined is C/EBPɴ-ɴGlob intron-polyA; the highlighted sequences 
before and after C/EBPɴ are attL1 and attL4 sites, respectively. 
LucGFP 
actgagcctttcgttttatttgatgcctggcagttccctactctcgcgttaacgctagcatggatctcgggccccaaataatg
attttattttgactgatagtgacctgttcgttgcaacaaattgatgagcaatgcttttttataatgccaactttgtacaaaaaa
gcaggctccaccatggaagacgccaaaaacataaagaaaggcccggcgccattctatccgctggaagatggaaccgctg
gagagcaactgcataaggctatgaagagatacgccctggttcctggaacaattgcttttacagatgcacatatcgaggtg
gacatcacttacgctgagtacttcgaaatgtccgttcggttggcagaagctatgaaacgatatgggctgaatacaaatcac
agaatcgtcgtatgcagtgaaaactctcttcaattctttatgccggtgttgggcgcgttatttatcggagttgcagttgcgcc
cgcgaacgacatttataatgaacgtgaattgctcaacagtatgggcatttcgcagcctaccgtggtgttcgtttccaaaaag
gggttgcaaaaaattttgaacgtgcaaaaaaagctcccaatcatccaaaaaattattatcatggattctaaaacggattac
cagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccggttttaatgaatacgattttgtgccagagtccttc
gatagggacaagacaattgcactgatcatgaactcctctggatctactggtctgcctaaaggtgtcgctctgcctcataga
actgcctgcgtgagattctcgcatgccagagatcctatttttggcaatcaaatcattccggatactgcgattttaagtgttgtt
ccattccatcacggttttggaatgtttactacactcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaa
gaagagctgtttctgaggagccttcaggattacaagattcaaagtgcgctgctggtgccaaccctattctccttcttcgcca
aaagcactctgattgacaaatacgatttatctaatttacacgaaattgcttctggtggcgctcccctctctaaggaagtcgg
233 
 
ggaagcggttgccaagaggttccatctgccaggtatcaggcaaggatatgggctcactgagactacatcagctattctgat
tacacccgagggggatgataaaccgggcgcggtcggtaaagttgttccattttttgaagcgaaggttgtggatctggatac
cgggaaaacgctgggcgttaatcaaagaggcgaactgtgtgtgagaggtcctatgattatgtccggttatgtaaacaatcc
ggaagcgaccaacgccttgattgacaaggatggatggctacattctggagacatagcttactgggacgaagacgaacac
ttcttcatcgttgaccgcctgaagtctctgattaagtacaaaggctatcaggtggctcccgctgaattggaatccatcttgct
ccaacaccccaacatcttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtgaacttcccgccgccgttgttgtt
ttggagcacggaaagacgatgacggaaaaagagatcgtggattacgtcgccagtcaagtaacaaccgcgaaaaagttg
cgcggaggagttgtgtttgtggacgaagtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatcagagagatcc
tcataaaggccaagaagggcggaaagatcgccgtgcgggatccaccggtcgccaccatggtgagcaagggcgaggagc
tgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggc
gagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccct
cgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgc
catgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaag
ttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcaca
agctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaa
gatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggcccc
gtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatgg
tcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaaagcggccgcatcgataag
cttgtcgacgatatctctagagctgagaacttcagggtgagtttggggacccttgattgttctttctttttcgctattgtaaaat
tcatgttatatggagggggcaaagttttcagggtgttgtttagaatgggaagatgtcccttgtatcaccatggaccctcatg
ataattttgtttctttcactttctactctgttgacaaccattgtctcctcttattttcttttcattttctgtaactttttcgttaaactt
tagcttgcatttgtaacgaatttttaaattcacttttgtttatttgtcagattgtaagtactttctctaatcacttttttttcaagg
caatcagggtatattatattgtacttcagcacagttttagagaacaattgttataattaaatgataaggtagaatatttctgc
atataaattctggctggcgtggaaatattcttattggtagaaacaactacaccctggtcatcatcctgcctttctctttatggt
tacaatgatatacactgtttgagatgaggataaaatactctgagtccaaaccgggcccctctgctaaccatgttcatgcctt
cttctctttcctacagctcctgggcaacgtgctggttgttgtgctgtctcatcattttggcaaagaattcactcctcaggtgca
ggctgcctatcagaaggtggtggctggtgtggccaatgccctggctcacaaataccactgagatctttttccctctgccaaa
aattatggggacatcatgaagccccttgagcatctgacttctggctaataaaggaaatttattttcattgcaatagtgtgtg
ggaattttttgtgtctctcactcggaaggacatatgggagggcaaatcatttaaaacatcagaatgagtatttggtttagag
tttggcaacatatgccatatgctggctgccatgaacaaaggtggctataaagaggtcatcagtatatgaaacagccccctg
ctgtccattccttattccatagaaaagccttgacttgaggttagattttttttatattttgttttgtgttatttttttctttaacatc
cctaaaattttccttacatgttttactagccagatttttcctcctctcctgactactcccagtcatagctgtccctcttctcaccc
aacttttctatacaaagttggcattataagaaagcattgcttatcaatttgttgcaacgaacaggtcactatcagtcaaaat
aaaatcattatttgccatccagctgcagctctggcccgtgtctcaaaatctctgatgttacattgcacaag 
The sequence underlined is LucGFP-ɴGlob intron-polyA; the highlighted sequences 
before and after LucGFP are attL1 and attL4 sites, respectively. 
CMV 
tccctactctcgcgttaacgctagcatggatctcgggcccctacaggtcactaataccatctaagtagttgattcatagtga
ctggatatgttgtgttttacagtattatgtagtctgttttttatgcaaaatctaatttaatatattgatatttatatcattttacgt
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ttctcgttcaacttttctatacaaagttgtattggctcatgtccaacattaccgccatgttgacattgattattgactagttatt
aatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcc
tggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttcca
ttgacgtcaatgggtggagtatttacgctaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccct
attgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtaca
tctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacgg
ggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgta
acaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctcacaactttgtat
aataaagttgaacgagaaacgtaaaatgatataaatatcaatatattaaattagattttgcataaaaaacagactacata
atactgtaaaacacaacatatccagtcactatgaatcaactacttagatggtattagtgacctgtactgcagctctggcccg
tgtctcaaaatctctgatgtt 
The sequence underlined is CMV promoter; the highlighted sequences before and 
after CMV are attR4 and attR3 sites, respectively. 
aP2 
aacgctagcatggatctcgggcccctacaggtcactaataccatctaagtagttgattcatagtgactggatatgttgtgttt
tacagtattatgtagtctgttttttatgcaaaatctaatttaatatattgatatttatatcattttacgtttctcgttcaacttttc
tatacaaagttgatatcgaattcccagcaggaatcaggtagctggagaatcgcacagagccatgcggattcttggcaagc
catgcgacaaaggcagaaatgcacatttcacccagagagaagggattgtagtcagcaggaagtcaccacccagagagc
aaatggagttcccagatgcctgacatttgccttcttactggatcagagttcactagtggaagtgtcacagcccaaacactcc
cccaaaggctcagcccttccttgccttgtaacaatcaagccgctcctggatgaactgctccgccctctgtctctttggcaggg
ttggagcccactgtggcctgagcgacttctatggctccctttctgtgattttcatggtttctgagctcttttcccccgctttatga
ttttctctttttgtctctctcttgctaaacctccttcgtatatgccctctcaggtttcatttctgaatcatctactgtgaactattcc
cattgtttgccagaagccccctggttcttccttctagaagttcaggccaggagtcagaaccataaccacccaccacaactgt
aatggacaaaaaaatgaagtgaaacccttggtctttaagtccagtcctaggctacaccctgtaaggctggtgattaaatac
attttacttactcagttcccgtttctgaaagcaggggctcaggttaaagcaagtgggggactcagagtgtctaagattacag
gcagagtggttccagtgtctgtttctagcctttctctggaaacccacacaagctgtttctcctactagaatgccaccgtttac
atagtggtggcctgatttctactttcagaacccttgagcagtttctgtatgccatgcccttgctgcgcgcccactgataaaag
ctctgtgaactggtttctcagagcatcccgtggttcttaagatcttttctgctttgttgtgttttgattttggttttggtttttatca
ggatggggtttctctggctgtcttgtaactctgtagactaggctggcctctaactcaagacctgaatgcacctgcttcaaata
catggccaccttccgactggttcttaagatctttatgacccgatagtgatctctgcagccctaacccttctgtcttaatatattt
aagacattagatatcttcaaatgctatgcctgtcctggctcagctctgagattccgagatatgtcctcagccccatatccga
aggcaaagccaggctgctcccattgtagtccttttctccctggctctgaggaaatactcagcctgctgtgtctgatttttttgc
ttgtttgtttttgtttatttgttgtctggctctttttaaaattttaacacagaacatcttttttttttttttttttttttttgtatctgca
catcactatgtaccaagcacaactggcacttactagggatttaatgtctttttttgtatttaggtctatttgtagaaagtaagt
tatatatgtactcaggcttaaaaatatataagatgcaagcagttgagatggtgaaagtaataagacacaaacagagcaa
atgtgaagtgtgtgtttgtgtgtgtttttgtgtgtgtgtgtgtgtgggtgtgtgggtgcacacacatgtgcttatgctcatgcat
gtgtgcttgtacgtggttgcatatctgccctcatggagatatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgttggca
ggggggttacatggtgcagctggcctgctggtaagttcttctctgcttttttctggtagagtgtcacctttgcttccacttaatt
cctgatgggtttgctttatgaaatgaagacaaagtaggtcacagtttatctgcagaaagcactttgaggtcccctcccccac
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cgtgggtccctgcttgcacaccctgagctatgtgtgaagaggttcttttatgagcaagaaggcaaatgaagaagttatcta
agagccttcaaagcactctcagtctgtctttacctgaggcagagtctgtggcttactcattctttgctaaacggttgccatctt
gagatcaaggagtcagtgcttagtcatcggaaccatgcatgtaaagaagaacatactggcctagctggacaggggacct
aggacagtcctggtaagtgacctcatcagggagagaaggaaaaaaaatgtgcctgcatttcctgttcagggctcacctta
cagttgccagcaagcacccgaatgcacttagaaagcagcattaacaaagtaagtttgcctccaataaaaggggatcctgg
atgtgaaccctcaccttagctggcctgtacaagctggaagctctccctgccaacggggctccgtcgttactcttcattatcta
gagtggggtctgtttcctcactaattaaaaattgtcagaaatgatattctcatttcctccgaaagaagtaaacacaggcaa
aggttagaaggatgcattccacagaaacggcccattgaggagcaaagtgcaaggcaaacagcctggaccagagggcct
gccctgtcagccctgagattctgagatgtgacctcagccccacatccccacagccaagccaggctgttcccactgcagacc
cttcccctcctccagctttcaggctgttcccactgcagacccttcccctcctccagctttcaggctgttcccactgcagaccct
tcccctcctccagctttcaggctgttcccactgcagacccttcccctcctccagctttcaggctgttcccattgcagacccttc
cccacggctctgaggaagtactcagccagctgtgtctgtgtggctgttgttgggcatcccaggttcttttgtaacttttaattt
ggagacacactcattgctaaattagctaggatggccttggactcactctgtggctcaggagagcagcgaacttaggggatt
ctcctggctcagcctcctgtggtgtttctttgtttgtttttgtttttactttgctttaacaggaccctcaggagcctggtctgttaa
gattcccttggtatatcttatgggatatccgattgtatctcatagtgaatgaatctggctaaaagttactgcctgacggttgg
tctttgcttactaggaacaaactcacacgtttgccctgatttacagataccccccatggccatagttgagtgaaattaactgc
acatggcactaagccagccatcttgtagttcctcggttccccagtgttgtggcggttgtcatctatcttcagctgacaattcct
ttgttctggaaggcccttctggtgtcatgtcagcttacattgtgcggatgctctggacagtgggtccctaactgtcccctgtac
accgtctttcccagtgtgggaaacatgttccttgctccgtggatccccagtggtcagcctgtgcctaaggcatgtgtgaata
aacgggtggacttggtgtcactgtgctgcgctaccagttccaagagaaacagagcacagagcacagagcacatgtgaaa
ttctagcaaccacattagaaaagtaaaaacaaacaaacaagcaaataaaaacaaattagttttagtaaaatatttcactt
ggcttgccttaattatggttattccaacatatattcaatgtaagaaattttcacgatgcattgcattttatattaacttcaactg
tgatacatactgtacactaacagtcatcttgagtcagactcttttttttgaaatacttgttcattatttaaagttcacaaaaatt
atagttaaaaaatttagattgatgaattcaagttgtttcacacattttatttttacatttaattaaagttgagctttcttgttata
ttagccacctgtcggaggcagaagtagttgtgtaagtgcagaagtttacatgggctggctctacagcacgtctaacccata
gcactataatccacatgcagtcagcacagcgggctaatcgcttgagaacatgtctaagttagggatcagcatacgtttcca
aataaaacaatttagaacattatcaaaattattcctgcattaaaatcgcttattttatttgagttgcaatccagggggtctta
tccagtaggaagcctgagtctgagagtagtccatagtgggtgaaagttgttcccctgacactagcagatgcgattaaaagt
tgttactgtgagttaaatttatcaaacttttacagtagcccattttcctacagaaaatatcatgtttcagagtctgtttcccca
gactttgggggctggtagggacttgggagcaggtacttctcagcgagcccctgtacagcagtccatctctctctaacaccct
gaaatgtgggtgtgctcgcaggcactggtgtacatgtgaacatctcccatcattctgctgtgaggcagggaggctgagaaa
ctggattactttataaaagctatctcagatgagtcactgtgtcaaagaagaaaacaggttttgataattcatgaccacatta
cttctgatcattcacataaacccacaatctttaggtctgcatgaaattaaaacttacaatatatttcaaaaatgaaatgagg
gacatattttgcattgggacccatttttgaagggtctgtaaaaatgagtactacatggctatttacgaatgggaagaataag
gcttaacttttaatgtaattaaatctgtgcactacattcctgagcaatgagcagaatgtattttaagtatgtattaaatatttg
aaattataaatctaggccgctgtagcccgcatccagaggcaggggcagctaggtttctttgagttagagaccagcctggtc
taggtagtaagttccaggactaccagagctgtgcagcgagactgtctcaaaaaccaaaccaaaccaaaacccaacccaa
accaaacaaagccaaacaacaacaacaaaaacaaaaaaacccaccaaaaaaaccaaggaaacaaaacaaccaaaa
atcaaaaaactaggctactttaaaatgtcattatttattttgttaaaattcctgagataaacactattctaacaaaagagcc
attaagactaagaatctctaagatagtttttatgttctcaaattcagaagaactaaacacattattgcagtattaataaaat
aaaaactcaagataagaaggtcaaatgtgtccaagataattgtctcctccacaatgaggcaaatccataaggaataatg
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gggggaagttcaatgcattagcttttgacagtcaaaacaggaacctttaaaatactctgttcatggttaaaaataatttgta
ctctaagtccagtgatcattgccagggagaaccaaagttgagaaatttctattaaaaacatgactcagaggaaaacatac
agggtctggtcatgaaggaaatgatctggcccccattggtcactcctacagtcacatggtcagggcatctttaaaagtgag
ctatctggacttcagaggctcatagcaccctcctgtgctgcagacaactttgtataataaagttgaacgagaaacgtaaaa
tgatataaatatcaatatattaaattagattttgcataaaaaacagactacataatactgtaaaacacaacatatccagtc
actatgaatcaactacttagatggtattagtgacctgtactgcagctctggcccgtgtctcaaaatctctgatgtta 
The sequence underlined is full length aP2 promoter; the highlighted sequences 
before and after aP2 are attR4 and attR3 sites, respectively. 
short aP2 
tctcgcgttaacgctagcatggatctcgggcccctacaggtcactaataccatctaagtagttgattcatagtgactggata
tgttgtgttttacagtattatgtagtctgttttttatgcaaaatctaatttaatatattgatatttatatcattttacgtttctcgtt
caacttttctatacaaagttgatatcgaattcccagcaggaatcaggtagctggagaatcgcacagagccatgcggattct
tggcaagccatgcgacaaaggcagaaatgcacatttcacccagagagaagggattgtagtcagcaggaagtcaccacc
cagagagcaaatggagttcccagatgcctgacatttgccttcttactggatcagagttcactagtggaagtgtcacagccc
aaacactcccccaaaggctcagcccttccttgccttgtaacaatcaagccgctcctggatgaactgctccgccctctgtctct
ttggcagggttggagcccactgtggcctgagcgacttctatggctccctttctgtgattttcatggtttctgagctcttttcccc
cgctttatgattttctctttttgtctctctcttgctaaacctccttcgtatatgccctctcaggtttcatttctgaatcatctactgt
gaactattcccattgtttgccagaagccccctggttcttccttctagaagttcaggccaggagtcagaacccccgggcggcc
gcgggcccgccggcgcccaacccaaaccaaacaaagccaaacaacaacaacaaaaacaaaaaaacccaccaaaaaa
accaaggaaacaaaacaaccaaaaatcaaaaaactaggctactttaaaatgtcattatttattttgttaaaattcctgaga
taaacactattctaacaaaagagccattaagactaagaatctctaagatagtttttatgttctcaaattcagaagaactaa
acacattattgcagtattaataaaataaaaactcaagataagaaggtcaaatgtgtccaagataattgtctcctccacaat
gaggcaaatccataaggaataatggggggaagttcaatgcattagcttttgacagtcaaaacaggaacctttaaaatact
ctgttcatggttaaaaataatttgtactctaagtccagtgatcattgccagggagaaccaaagttgagaaatttctattaaa
aacatgactcagaggaaaacatacagggtctggtcatgaaggaaatgatctggcccccattggtcactcctacagtcaca
tggtcagggcatctttaaaagtgagctatctggacttcagaggctcatagcaccctcctgtgctgcagacaactttgtataa
taaagttgaacgagaaacgtaaaatgatataaatatcaatatattaaattagattttgcataaaaaacagactacataat
actgtaaaacacaacatatccagtcactatgaatcaactacttagatggtattagtgacctgtactgcagctctggcccgtg
tctcaaaatctctg 
The sequence underlined is short aP2 promoter; the highlighted sequences before 
and after short aP2 are attR4 and attR3 sites, respectively. 
rtTA 
gtcttccgactgagcctttcgttttatttgatgcctggcagttccctactctcgcgttaacgctagcatggatctcgggcccca
aataatgattttattttgactgatagtgacctgttcgttgcaacaaattgatgagcaatgcttttttataatgccaactttgtat
aataaagttgatccagcctccgcggccccgaattcatatgtctagattagataaaagtaaagtgattaacagcgcattaga
gctgcttaatgaggtcggaatcgaaggtttaacaacccgtaaactcgcccagaagcttggtgtagagcagcctacactgt
attggcatgtaaaaaataagcgggctttgctcgacgccttagccattgagatgttagataggcaccatactcacttttgccc
tttaaaaggggaaagctggcaagattttttacgcaataacgctaaaagttttagatgtgctttactaagtcatcgcaatgga
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gcaaaagtacattcagatacacggcctacagaaaaacagtatgaaactctcgaaaatcaattagcctttttatgccaaca
aggtttttcactagagaacgcgttatatgcactcagcgctgtggggcattttactttaggttgcgtattggaagatcaagag
catcaagtcgctaaagaagaaagggaaacacctactactgatagtatgccgccattattacgacaagctatcgaattattt
gatcaccaaggtgcagagccagccttcttattcggccttgaattgatcatatgcggattagaaaaacaacttaaatgtgaa
agtgggtccgcgtacagccgcgcgcgtacgaaaaacaattacgggtctaccatcgagggcctgctcgatctcccggacga
cgacgcccccgaagaggcggggctggcggctccgcgcctgtcctttctccccgcgggacacacgcgcagactgtcgacgg
cccccccgaccgatgtcagcctgggggacgagctccacttagacggcgaggacgtggcgatggcgcatgccgacgcgct
agacgatttcgatctggacatgttgggggacggggattccccgggtccgggatttaccccccacgactccgccccctacgg
cgctctggatatggccgacttcgagtttgagcagatgtttaccgatgcccttggaattgacgagtacggtgggtagggggc
gcgaggatccagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaatgctttatt
tgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattcatttt
atgtttcaggttcagggggaggtgtgggaggttttttaaagcaagtaaaacctctacaaatgtggtatggctgattatgatc
ctgcaagcctcgtcgtctggccggaccacgctatctgtgcaaggtccccggacgcgcgctccatgagcagagcgcccgcc
gccgaggcaagactcgggcggcgccctgcccgtcccaccaggtcaacaggcggtaaccggcctcttcatcgggaatgcg
cgcgaccttcagcatcgccggcatgtcccctggcggacgggaagtatcagctcgaccaagccccagctttcttgtacaaag
ttggcattataagaaagcattgcttatcaatttgttgcaacgaacaggtcactatcagtcaaaataaaatcattatttgcca
tccagctgcagctctggcccgtgtctcaaaatctctgatgttacattgcacaagataaaaatat 
The sequence underlined is rtTA; the highlighted sequences before and after rtTA are 
attL3 and attL2 sites, respectively. 
rtTA advance 
agttccctactctcgcgttaacgctagcatggatctcgggccccaaataatgattttattttgactgatagtgacctgttcgtt
gcaacaaattgatgagcaatgcttttttataatgccaactttgtataataaagttgggggacaactttgtataataaagttg
gcaggcttcaccatgtctagactggacaagagcaaagtcataaacggcgctctggaattactcaatggagtcggtatcga
aggcctgacgacaaggaaactcgctcaaaagctgggagttgagcagcctaccctgtactggcacgtgaagaacaagcgg
gccctgctcgatgccctgccaatcgagatgctggacaggcatcatacccacttctgccccctggaaggcgagtcatggcaa
gactttctgcggaacaacgccaagtcattccgctgtgctctcctctcacatcgcgacggggctaaagtgcatctcggcaccc
gcccaacagagaaacagtacgaaaccctggaaaatcagctcgcgttcctgtgtcagcaaggcttctccctggagaacgca
ctgtacgctctgtccgccgtgggccactttacactgggctgcgtattggaggaacaggagcatcaagtagcaaaagagga
aagagagacacctaccaccgattctatgcccccacttctgagacaagcaattgagctgttcgaccggcagggagccgaac
ctgccttccttttcggcctggaactaatcatatgtggcctggagaaacagctaaagtgcgaaagcggcgggccggccgac
gcccttgacgattttgacttagacatgctcccagccgatgcccttgacgactttgaccttgatatgctgcctgctgacgctctt
gacgattttgaccttgacatgctccccgggtaactacccagctttcttgtacaaagttggcattataagaaagcattgcttat
caatttgttgcaacgaacaggtcactatcagtcaaaataaaatcattatttgccatccagctgcagctctggcccgtgtctc
aaaatctctgatgttacattgcacaagata 
The sequence underlined is rtTA advance; the highlighted sequences before and after 
rtTA advance are attL3 and attL2 sites, respectively. 
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Maps of pLP packaging plasmids for producing lentivirus 
The pLP packaging system consists of three different plasmids, pLP1 to express 
gag/pol protein, pLP2 to express Rev protein and pLP/VSVG to express envelope 
protein VSV-G.  
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(2) psPAX2 2-plasmid packaging system 
 
 
Map of psPAX2 packaging plasmid for producing lentivirus 
The psPAX2 plasmid contains a robust CAG promoter driving the efficient expression 
of the three packaging proteins: gag, pol and rev.  
There is another plasmid pCMV-VSVG in this packaging system, but no map of it was 
available from the people providing it. 
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